The	O
relationship	O
of	O
glycosylation	O
and	O
isoelectric	O
point	O
with	O
tumor	O
accumulation	O
of	O
avidin	S-Protein
.	O

Radiolabeled	O
avidin	S-Protein
markedly	O
accumulated	O
in	O
intraperitoneal	O
tumors	O
and	O
was	O
cleared	O
rapidly	O
from	O
circulation	O
when	O
given	O
intraperitoneally	O
.	O

This	O
study	O
investigated	O
the	O
mechanisms	O
of	O
the	O
tumor	O
localization	O
of	O
avidin	S-Protein
.	O

METHODS	O
:	O
Avidin	S-Protein
was	O
deglycosylated	O
through	O
endoglycosydase	B-Protein
-	I-Protein
H	E-Protein
digestion	O
and	O
/	O
or	O
neutralized	O
by	O
acetylation	O
of	O
its	O
lysine	O
amino	O
acids	O
with	O
acetic	O
acid	O
N	O
-	O
hydroxysuccinimide	O
ester	O
.	O

Avidin	S-Protein
and	O
modified	O
avidins	S-Protein
were	O
analyzed	O
using	O
sodium	O
dodecylsulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
/	O
PAGE	O
)	O
and	O
isoelectric	O
focusing	O
.	O

A	O
tumor	O
model	O
was	O
established	O
by	O
intraperitoneal	O
injection	O
of	O
human	O
colon	O
cancer	O
cells	O
,	O
LS180	O
,	O
in	O
nude	O
mice	O
.	O

Avidin	S-Protein
and	O
modified	O
avidins	S-Protein
were	O
labeled	O
with	O
111In	O
using	O
diethyleneamine	O
pentaacetic	O
acid	O
-	O
biotin	O
and	O
were	O
administered	O
intraperitoneally	O
into	O
the	O
tumor	O
-	O
bearing	O
mice	O
.	O

The	O
biodistribution	O
of	O
radioactivity	O
was	O
examined	O
2	O
and	O
24	O
h	O
postinjection	O
.	O

RESULTS	O
:	O
Deglycosylated	O
avidins	S-Protein
revealed	O
a	O
major	O
band	O
of	O
smaller	O
molecules	O
on	O
SDS	O
/	O
PAGE	O
.	O

The	O
isoelectric	O
point	O
of	O
neutralized	O
avidins	S-Protein
was	O
reduced	O
to	O
less	O
than	O
5	O
,	O
whereas	O
that	O
of	O
unneutralized	O
avidins	S-Protein
was	O
more	O
than	O
9	O
.	O
5	O
.	O

Biodistribution	O
study	O
demonstrated	O
that	O
liver	O
uptake	O
was	O
decreased	O
by	O
deglycosylation	O
and	O
kidney	O
accumulation	O
was	O
decreased	O
by	O
neutralization	O
,	O
respectively	O
.	O

The	O
blood	O
clearance	O
was	O
remarkably	O
slowed	O
by	O
combined	O
modification	O
of	O
deglycosylation	O
and	O
neutralization	O
.	O

The	O
tumor	O
uptake	O
of	O
radioactivity	O
was	O
reduced	O
by	O
either	O
deglycosylation	O
or	O
neutralization	O
and	O
was	O
further	O
decreased	O
with	O
combined	O
modification	O
.	O

CONCLUSION	O
:	O
Both	O
high	O
glycosylation	O
and	O
positive	O
charge	O
of	O
avidin	S-Protein
contributed	O
to	O
its	O
accumulation	O
in	O
tumor	O
.	O

This	O
study	O
may	O
facilitate	O
development	O
of	O
a	O
new	O
vehicle	O
for	O
the	O
delivery	O
of	O
therapeutic	O
agents	O
to	O
intraperitoneal	O
tumors	O
.	O

A	O
novel	O
aromatic	O
-	O
ring	O
-	O
hydroxylating	O
dioxygenase	O
from	O
the	O
diterpenoid	O
-	O
degrading	O
bacterium	O
Pseudomonas	O
abietaniphila	O
BKME	O
-	O
9	O
.	O

Pseudomonas	O
abietaniphila	O
BKME	O
-	O
9	O
is	O
able	O
to	O
degrade	O
dehydroabietic	O
acid	O
(	O
DhA	O
)	O
via	O
ring	O
hydroxylation	O
by	O
a	O
novel	O
dioxygenase	O
.	O

The	O
ditA1	S-Protein
,	O
ditA2	S-Protein
,	O
and	O
ditA3	S-Protein
genes	O
,	O
which	O
encode	O
the	O
alpha	O
and	O
beta	O
subunits	O
of	O
the	O
oxygenase	O
and	O
the	O
ferredoxin	O
of	O
the	O
diterpenoid	O
dioxygenase	O
,	O
respectively	O
,	O
were	O
isolated	O
and	O
sequenced	O
.	O

The	O
ferredoxin	O
gene	O
is	O
9	O
.	O

2	O
kb	O
upstream	O
of	O
the	O
oxygenase	O
genes	O
and	O
872	O
bp	O
upstream	O
of	O
a	O
putative	O
meta	O
ring	O
cleavage	O
dioxygenase	O
gene	O
,	O
ditC	S-Protein
.	O

A	O
Tn5	O
insertion	O
in	O
the	O
alpha	O
subunit	O
gene	O
,	O
ditA1	S-Protein
,	O
resulted	O
in	O
the	O
accumulation	O
by	O
the	O
mutant	O
strain	O
BKME	O
-	O
941	O
of	O
the	O
pathway	O
intermediate	O
,	O
7	O
-	O
oxoDhA	O
.	O

Disruption	O
of	O
the	O
ferredoxin	O
gene	O
,	O
ditA3	S-Protein
,	O
in	O
wild	O
-	O
type	O
BKME	O
-	O
9	O
by	O
mutant	O
-	O
allele	O
exchange	O
resulted	O
in	O
a	O
strain	O
(	O
BKME	O
-	O
91	O
)	O
with	O
a	O
phenotype	O
identical	O
to	O
that	O
of	O
the	O
mutant	O
strain	O
BKME	O
-	O
941	O
.	O

Sequence	O
analysis	O
of	O
the	O
putative	O
ferredoxin	O
indicated	O
that	O
it	O
is	O
likely	O
to	O
be	O
a	O
[	O
4Fe	O
-	O
4S	O
]	O
-	O
or	O
[	O
3Fe	O
-	O
4S	O
]	O
-	O
type	O
ferredoxin	O
and	O
not	O
a	O
[	O
2Fe	O
-	O
2S	O
]	O
-	O
type	O
ferredoxin	O
,	O
as	O
found	O
in	O
all	O
previously	O
described	O
ring	O
-	O
hydroxylating	O
dioxygenases	O
.	O

Expression	O
in	O
Escherichia	O
coli	O
of	O
ditA1A2A3	S-Protein
,	O
encoding	O
the	O
diterpenoid	O
dioxygenase	O
without	O
its	O
putative	O
reductase	O
component	O
,	O
resulted	O
in	O
a	O
functional	O
enzyme	O
.	O

The	O
diterpenoid	O
dioxygenase	O
attacks	O
7	O
-	O
oxoDhA	O
,	O
and	O
not	O
DhA	O
,	O
at	O
C	O
-	O
11	O
and	O
C	O
-	O
12	O
,	O
producing	O
7	O
-	O
oxo	O
-	O
11	O
,	O
12	O
-	O
dihydroxy	O
-	O
8	O
,	O
13	O
-	O
abietadien	O
acid	O
,	O
which	O
was	O
identified	O
by	O
1H	O
nuclear	O
magnetic	O
resonance	O
,	O
UV	O
-	O
visible	O
light	O
,	O
and	O
high	O
-	O
resolution	O
mass	O
spectrometry	O
.	O

The	O
organization	O
of	O
the	O
genes	O
encoding	O
the	O
various	O
components	O
of	O
the	O
diterpenoid	O
dioxygenase	O
,	O
the	O
phylogenetic	O
distinctiveness	O
of	O
both	O
the	O
alpha	O
subunit	O
and	O
the	O
ferredoxin	O
component	O
,	O
and	O
the	O
unusual	O
Fe	O
-	O
S	O
cluster	O
of	O
the	O
ferredoxin	O
all	O
suggest	O
that	O
this	O
enzyme	O
belongs	O
to	O
a	O
new	O
class	O
of	O
aromatic	O
ring	O
-	O
hydroxylating	O
dioxygenases	O
.	O

DNA	O
methylation	O
and	O
chromatin	O
modification	O
.	O

DNA	O
methylation	O
and	O
chromatin	O
modification	O
are	O
two	O
global	O
mechanisms	O
that	O
regulate	O
gene	O
expression	O
.	O

Recent	O
studies	O
provide	O
insight	O
into	O
the	O
mechanism	O
of	O
transcriptional	O
silencing	O
by	O
a	O
methyl	O
-	O
CpG	O
binding	O
protein	O
,	O
MeCP2	S-Protein
.	O

MeCP2	S-Protein
is	O
shown	O
to	O
interact	O
with	O
the	O
Sin3	S-Protein
/	O
histone	S-Protein
deacetylase	O
co	O
-	O
repressor	O
complex	O
.	O

Thus	O
,	O
this	O
interaction	O
can	O
provide	O
a	O
mechanistic	O
explanation	O
for	O
the	O
long	O
-	O
known	O
relationship	O
between	O
DNA	O
methylation	O
and	O
chromatin	O
structure	O
.	O

Moreover	O
,	O
several	O
studies	O
have	O
shown	O
that	O
inhibition	O
of	O
histone	S-Protein
deacetylases	O
by	O
specific	O
inhibitors	O
can	O
reactivate	O
endogenous	O
genes	O
or	O
reporter	O
constructs	O
previously	O
silenced	O
by	O
DNA	O
methylation	O
.	O

Taken	O
together	O
,	O
the	O
data	O
strongly	O
suggest	O
that	O
DNA	O
methylation	O
can	O
pattern	O
chromatin	O
modification	O
.	O

Cr	O
(	O
IV	O
)	O
causes	O
activation	O
of	O
nuclear	O
transcription	O
factor	O
-	O
kappa	O
B	O
,	O
DNA	O
strand	O
breaks	O
and	O
dG	O
hydroxylation	O
via	O
free	O
radical	O
reactions	O
.	O

Electrophoretic	O
mobility	O
shift	O
,	O
DNA	O
strand	O
breakage	O
assays	O
and	O
electron	O
spin	O
resonance	O
(	O
ESR	O
)	O
spin	O
trapping	O
were	O
used	O
to	O
investigate	O
the	O
activation	O
of	O
nuclear	O
transcription	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
,	O
DNA	O
strand	O
breakage	O
and	O
2	O
'	O
-	O
deoxyguanosine	O
hydroxylation	O
induced	O
by	O
Cr	O
(	O
IV	O
)	O
,	O
as	O
well	O
the	O
role	O
of	O
free	O
radical	O
reactions	O
in	O
these	O
processes	O
.	O

Incubation	O
of	O
synthesized	O
Cr	O
(	O
IV	O
)	O
-	O
glutathione	O
complex	O
with	O
cultured	O
Jurkat	O
cells	O
resulted	O
in	O
activation	O
of	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Cr	O
(	O
VI	O
)	O
is	O
also	O
able	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
activation	O
through	O
Cr	O
(	O
V	O
)	O
and	O
Cr	O
(	O
IV	O
)	O
intermediates	O
generated	O
during	O
the	O
reduction	O
of	O
Cr	O
(	O
VI	O
)	O
by	O
the	O
cells	O
.	O

Cr	O
(	O
III	O
)	O
did	O
not	O
cause	O
observable	O
NF	O
-	O
kappa	O
B	O
activation	O
due	O
to	O
its	O
inability	O
to	O
cross	O
cell	O
membranes	O
.	O

Cr	O
(	O
IV	O
)	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
dose	O
-	O
dependent	O
.	O

Catalase	S-Protein
inhibited	O
the	O
activation	O
while	O
superoxide	O
dismutase	O
enhanced	O
it	O
.	O

The	O
metal	O
chelator	O
,	O
deferoxamine	O
,	O
and	O
hydroxyl	O
(	O
.	O
OH	O
)	O
radical	O
scavengers	O
,	O
sodium	O
formate	O
and	O
aspirin	O
,	O
also	O
inhibited	O
the	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Electrophoretic	O
assays	O
using	O
lambda	O
Hind	O
III	O
linear	O
DNA	O
showed	O
that	O
,	O
in	O
the	O
presence	O
of	O
H2O2	O
,	O
Cr	O
(	O
IV	O
)	O
is	O
capable	O
of	O
causing	O
DNA	O
strand	O
breaks	O
.	O

Deferoxamine	O
,	O
sodium	O
formate	O
and	O
aspirin	O
inhibited	O
the	O
DNA	O
strand	O
breaks	O
.	O

HPLC	O
measurements	O
also	O
show	O
that	O
.	O
OH	O
radical	O
generated	O
by	O
the	O
Cr	O
(	O
IV	O
)	O
-	O
mediated	O
reaction	O
with	O
H2O2	O
was	O
capable	O
of	O
causing	O
2	O
'	O
-	O
deoxyguanosine	O
(	O
dG	O
)	O
hydroxylation	O
to	O
generate	O
8	O
-	O
hydroxyguanosine	O
(	O
8	O
-	O
OHdG	O
)	O
.	O

The	O
relative	O
magnitude	O
of	O
8	O
-	O
OHdG	O
formation	O
correlated	O
with	O
the	O
generation	O
of	O
.	O
OH	O
radicals	O
.	O

ESR	O
spin	O
trapping	O
measurements	O
showed	O
that	O
reaction	O
of	O
Cr	O
(	O
IV	O
)	O
with	O
H2O2	O
generated	O
.	O
OH	O
radicals	O
,	O
which	O
were	O
inhibited	O
by	O
deferoxamine	O
,	O
sodium	O
formate	O
and	O
aspirin	O
.	O

The	O
results	O
show	O
that	O
Cr	O
(	O
IV	O
)	O
can	O
cause	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
DNA	O
strand	O
breaks	O
and	O
dG	O
hydroxylation	O
through	O
.	O
OH	O
radical	O
-	O
initiated	O
reactions	O
.	O

This	O
reactive	O
chromium	O
intermediate	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
mechanism	O
of	O
Cr	O
(	O
VI	O
)	O
-	O
induced	O
carcinogenesis	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
Cr	O
(	O
IV	O
)	O
-	O
glutathione	O
complex	O
may	O
be	O
used	O
as	O
a	O
model	O
compound	O
to	O
study	O
the	O
role	O
of	O
Cr	O
(	O
IV	O
)	O
in	O
Cr	O
(	O
VI	O
)	O
carcinogenicity	O
.	O

Overhydroxylation	O
of	O
lysyl	O
residues	O
is	O
the	O
initial	O
step	O
for	O
altered	O
collagen	O
cross	O
-	O
links	O
and	O
fibril	O
architecture	O
in	O
fibrotic	O
skin	O
.	O

In	O
fibrotic	O
skin	O
of	O
lipodermatosclerosis	O
a	O
substantial	O
increase	O
of	O
the	O
cross	O
-	O
link	O
hydroxylysylpyridinoline	O
is	O
observed	O
.	O

Hydroxylysylpyridinoline	O
is	O
a	O
typical	O
cross	O
-	O
link	O
of	O
skeletal	O
tissue	O
and	O
is	O
thought	O
to	O
play	O
a	O
major	O
part	O
in	O
the	O
hardening	O
of	O
sclerotic	O
tissue	O
.	O

We	O
investigated	O
whether	O
the	O
increase	O
in	O
hydroxylysylpyridinoline	O
is	O
due	O
to	O
overhydroxylation	O
of	O
lysyl	O
residues	O
in	O
the	O
collagen	O
molecule	O
,	O
which	O
may	O
also	O
be	O
associated	O
with	O
an	O
increase	O
of	O
glycosylated	O
hydroxylysine	O
residues	O
.	O

Furthermore	O
,	O
we	O
determined	O
whether	O
the	O
collagen	O
fibrils	O
in	O
lipodermatosclerosis	O
showed	O
a	O
decrease	O
of	O
the	O
diameter	O
in	O
the	O
tissue	O
as	O
well	O
as	O
in	O
vitro	O
after	O
fibrillogenesis	O
of	O
pepsin	O
-	O
solubilized	O
collagens	O
.	O

Isolated	O
alpha	O
-	O
chains	O
of	O
pepsin	O
solubilized	O
collagen	O
I	O
showed	O
an	O
increase	O
in	O
lysyl	O
hydroxylation	O
(	O
hyl	O
/	O
(	O
hyl	O
+	O
lys	O
)	O
)	O
as	O
compared	O
with	O
normal	O
control	O
[	O
alpha1	O
(	O
I	O
)	O
:	O
lipodermatosclerosis	O
0	O
.	O
18	O
+	O
/	O
-	O
0	O
.	O
01	O
;	O
control	O
0	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
01	O
;	O
alpha2	O
(	O
I	O
)	O
:	O
lipodermatosclerosis	O
0	O
.	O
36	O
+	O
/	O
-	O
0	O
.	O
02	O
;	O
control	O
0	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
03	O
,	O
p	O
<	O
0	O
.	O
001	O
]	O
.	O

Furthermore	O
,	O
the	O
content	O
of	O
enzymatic	O
glycosylated	O
hydroxlysine	O
residues	O
increased	O
.	O

This	O
increase	O
is	O
associated	O
with	O
a	O
decrease	O
of	O
fibril	O
diameter	O
of	O
both	O
tissue	O
and	O
fibrils	O
formed	O
in	O
vitro	O
of	O
pepsin	O
-	O
solubilized	O
collagens	O
.	O

In	O
the	O
same	O
pool	O
of	O
collagens	O
an	O
increase	O
in	O
collagen	B-Protein
III	E-Protein
content	O
was	O
observed	O
as	O
compared	O
with	O
controls	O
(	O
lipodermatosclerosis	O
14	O
.	O
5	O
%	O
+	O
/	O
-	O
1	O
.	O
6	O
,	O
control	O
10	O
.	O
3	O
%	O
+	O
/	O
-	O
1	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Our	O
results	O
showed	O
that	O
the	O
overhydroxylation	O
of	O
lysyl	O
residues	O
,	O
which	O
is	O
required	O
for	O
the	O
generation	O
of	O
hydroxylysylpyridinoline	O
,	O
is	O
not	O
only	O
restricted	O
to	O
the	O
telopeptides	O
but	O
also	O
affects	O
the	O
helical	O
part	O
of	O
the	O
molecule	O
.	O

This	O
process	O
is	O
further	O
associated	O
with	O
an	O
increase	O
of	O
glycosylated	O
hydroxylysyl	O
residues	O
.	O

These	O
changes	O
along	O
with	O
the	O
increase	O
in	O
collagen	B-Protein
III	E-Protein
content	O
seem	O
to	O
be	O
responsible	O
for	O
the	O
observed	O
alteration	O
in	O
the	O
architecture	O
of	O
collagen	O
fibrils	O
in	O
sclerotic	O
skin	O
.	O

ER	O
/	O
Golgi	O
intermediates	O
acquire	O
Golgi	O
enzymes	O
by	O
brefeldin	O
A	O
-	O
sensitive	O
retrograde	O
transport	O
in	O
vitro	O
.	O

Secretory	O
proteins	O
exit	O
the	O
ER	O
in	O
transport	O
vesicles	O
that	O
fuse	O
to	O
form	O
vesicular	O
tubular	O
clusters	O
(	O
VTCs	O
)	O
which	O
move	O
along	O
microtubule	O
tracks	O
to	O
the	O
Golgi	O
apparatus	O
.	O

Using	O
the	O
well	O
-	O
characterized	O
in	O
vitro	O
approach	O
to	O
study	O
the	O
properties	O
of	O
Golgi	O
membranes	O
,	O
we	O
determined	O
whether	O
the	O
Golgi	O
enzyme	O
NAGT	B-Protein
I	E-Protein
is	O
transported	O
to	O
ER	O
/	O
Golgi	O
intermediates	O
.	O

Secretory	O
cargo	O
was	O
arrested	O
at	O
distinct	O
steps	O
of	O
the	O
secretory	O
pathway	O
of	O
a	O
glycosylation	O
mutant	O
cell	O
line	O
,	O
and	O
in	O
vitro	O
complementation	O
of	O
the	O
glycosylation	O
defect	O
was	O
determined	O
.	O

Complementation	O
yield	O
increased	O
after	O
ER	O
exit	O
of	O
secretory	O
cargo	O
and	O
was	O
optimal	O
when	O
transport	O
was	O
blocked	O
at	O
an	O
ER	O
/	O
Golgi	O
intermediate	O
step	O
.	O

The	O
rapid	O
drop	O
of	O
the	O
complementation	O
yield	O
as	O
secretory	O
cargo	O
progresses	O
into	O
the	O
stack	O
suggests	O
that	O
Golgi	O
enzymes	O
are	O
preferentially	O
targeted	O
to	O
ER	O
/	O
Golgi	O
intermediates	O
and	O
not	O
to	O
membranes	O
of	O
the	O
Golgi	O
stack	O
.	O

Two	O
mechanisms	O
for	O
in	O
vitro	O
complementation	O
could	O
be	O
distinguished	O
due	O
to	O
their	O
different	O
sensitivities	O
to	O
brefeldin	O
A	O
(	O
BFA	O
)	O
.	O

Transport	O
occurred	O
either	O
by	O
direct	O
fusion	O
of	O
preexisting	O
transport	O
intermediates	O
with	O
ER	O
/	O
Golgi	O
intermediates	O
,	O
or	O
it	O
occurred	O
as	O
a	O
BFA	O
-	O
sensitive	O
and	O
most	O
likely	O
COP	O
I	O
-	O
mediated	O
step	O
.	O

Direct	O
fusion	O
of	O
ER	O
/	O
Golgi	O
intermediates	O
with	O
cisternal	O
membranes	O
of	O
the	O
Golgi	O
stack	O
was	O
not	O
observed	O
under	O
these	O
conditions	O
.	O

Immunofluorescent	O
studies	O
of	O
human	O
chromosomes	O
with	O
antibodies	O
against	O
phosphorylated	O
H1	B-Protein
histone	E-Protein
.	O

One	O
of	O
the	O
prominent	O
cell	O
cycle	O
-	O
related	O
modifications	O
of	O
histone	S-Protein
proteins	O
whose	O
function	O
remains	O
unresolved	O
is	O
the	O
phosphorylation	O
of	O
linker	O
histone	B-Protein
H1	E-Protein
.	O

In	O
this	O
work	O
we	O
have	O
used	O
indirect	O
immunofluorescence	O
on	O
human	O
cells	O
with	O
antibodies	O
that	O
are	O
specific	O
for	O
phosphorylated	O
histone	B-Protein
H1	E-Protein
to	O
examine	O
the	O
cellular	O
distribution	O
and	O
chromosome	O
association	O
patterns	O
of	O
this	O
protein	O
.	O

With	O
confocal	O
microscopy	O
on	O
whole	O
cells	O
,	O
strong	O
immunofluorescence	O
was	O
seen	O
in	O
association	O
with	O
mitotic	O
chromosomes	O
as	O
well	O
as	O
a	O
prominent	O
punctate	O
pattern	O
of	O
labeling	O
throughout	O
the	O
mitotic	O
cell	O
,	O
whereas	O
interphase	O
cells	O
showed	O
very	O
little	O
,	O
if	O
any	O
,	O
specific	O
fluorescence	O
.	O

Multiple	O
patterns	O
of	O
fluorescence	O
distribution	O
were	O
detected	O
with	O
metaphase	O
chromosomes	O
,	O
ranging	O
from	O
apparent	O
tight	O
colocalization	O
with	O
the	O
DNA	O
to	O
expanded	O
"	O
puffy	O
"	O
mitotic	O
figures	O
to	O
an	O
amorphous	O
network	O
of	O
staining	O
.	O

It	O
was	O
also	O
shown	O
that	O
the	O
ability	O
to	O
label	O
chromosomes	O
could	O
vary	O
drastically	O
with	O
different	O
fixation	O
procedures	O
,	O
adding	O
further	O
complications	O
to	O
interpretation	O
of	O
the	O
potentially	O
complex	O
role	O
of	O
phosphorylated	O
histone	B-Protein
H1	E-Protein
in	O
chromatin	O
condensation	O
or	O
decondensation	O
.	O

Clinical	O
and	O
biochemical	O
characteristics	O
of	O
congenital	O
disorder	O
of	O
glycosylation	O
type	O
Ic	O
,	O
the	O
first	O
recognized	O
endoplasmic	O
reticulum	O
defect	O
in	O
N	O
-	O
glycan	O
synthesis	O
.	O

We	O
report	O
on	O
8	O
patients	O
with	O
a	O
recently	O
described	O
novel	O
subtype	O
of	O
congenital	O
disorder	O
of	O
glycosylation	O
type	O
Ic	O
(	O
CDG	O
-	O
Ic	O
)	O
.	O

Their	O
clinical	O
presentation	O
was	O
mainly	O
neurological	O
with	O
developmental	O
retardation	O
,	O
muscular	O
hypotonia	O
,	O
and	O
epilepsy	O
.	O

Several	O
symptoms	O
commonly	O
seen	O
in	O
CDG	O
-	O
Ia	O
such	O
as	O
inverted	O
nipples	O
,	O
abnormal	O
fat	O
distribution	O
,	O
and	O
cerebellar	O
hypoplasia	O
were	O
not	O
observed	O
.	O

The	O
clinical	O
course	O
is	O
milder	O
overall	O
,	O
with	O
a	O
better	O
neurological	O
outcome	O
,	O
than	O
in	O
CDG	O
-	O
Ia	O
.	O

The	O
isoelectric	O
focusing	O
pattern	O
of	O
serum	O
transferrin	S-Protein
in	O
CDG	O
-	O
Ia	O
and	O
CDG	O
-	O
Ic	O
is	O
indistinguishable	O
.	O

Interestingly	O
,	O
beta	B-Protein
-	I-Protein
trace	I-Protein
protein	E-Protein
in	O
cerebrospinal	O
fluid	O
derived	O
from	O
immunoblot	O
analysis	O
of	O
the	O
brain	O
showed	O
a	O
less	O
pronounced	O
hypoglycosylation	O
pattern	O
in	O
CDG	O
-	O
Ic	O
patients	O
than	O
in	O
CDG	O
-	O
Ia	O
patients	O
.	O

Analysis	O
of	O
lipid	O
-	O
linked	O
oligosaccharides	O
revealed	O
an	O
accumulation	O
of	O
Man9GlcNAc2	O
intermediates	O
due	O
to	O
dolichol	B-Protein
pyrophosphate	I-Protein
-	I-Protein
Man9GlcNAc2	I-Protein
alpha	I-Protein
-	I-Protein
1	I-Protein
,	I-Protein
3	I-Protein
glucosyltransferase	E-Protein
deficiency	O
.	O

All	O
patients	O
were	O
homozygous	O
for	O
an	O
A333V	O
mutation	O
.	O

Phosphorylation	O
of	O
RTP	S-Protein
,	O
an	O
ER	O
stress	O
-	O
responsive	O
cytoplasmic	O
protein	O
.	O

RTP	S-Protein
,	O
also	O
called	O
Drg1	S-Protein
/	O
Cap43	S-Protein
/	O
rit42	S-Protein
/	O
TDD5	S-Protein
/	O
Ndr1	S-Protein
,	O
was	O
originally	O
identified	O
as	O
a	O
homocysteine	O
-	O
responsive	O
gene	O
product	O
,	O
and	O
is	O
now	O
considered	O
to	O
be	O
involved	O
in	O
stress	O
responses	O
,	O
atherosclerosis	O
,	O
carcinogenesis	O
,	O
differentiation	O
,	O
androgen	O
responses	O
,	O
hypoxia	O
,	O
and	O
N	B-Protein
-	I-Protein
myc	E-Protein
pathways	O
.	O

We	O
raised	O
an	O
antiserum	O
against	O
a	O
recombinant	O
human	O
RTP	S-Protein
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
RTP	S-Protein
expression	O
was	O
induced	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
under	O
conditions	O
causing	O
endoplasmic	O
reticulum	O
stress	O
.	O

RTP	S-Protein
was	O
partially	O
phosphorylated	O
at	O
seven	O
or	O
more	O
sites	O
.	O

The	O
phosphorylation	O
was	O
reversible	O
,	O
and	O
was	O
enhanced	O
by	O
an	O
increased	O
level	O
of	O
intracellular	O
cAMP	O
and	O
inhibited	O
by	O
both	O
a	O
protein	O
kinase	O
A	O
inhibitor	O
and	O
a	O
calmodulin	O
kinase	O
inhibitor	O
.	O

Protein	O
kinase	O
A	O
directly	O
phosphorylated	O
recombinant	O
RTP	S-Protein
in	O
vitro	O
.	O

The	O
phosphorylated	O
forms	O
were	O
abundant	O
in	O
cells	O
at	O
the	O
early	O
log	O
phase	O
,	O
and	O
then	O
decreased	O
with	O
increasing	O
cell	O
density	O
.	O

These	O
data	O
demonstrated	O
that	O
RTP	S-Protein
is	O
a	O
phosphorylated	O
stress	O
-	O
responsive	O
protein	O
,	O
and	O
its	O
phosphorylation	O
may	O
be	O
related	O
to	O
cell	O
growth	O
.	O

A	O
method	O
for	O
determining	O
the	O
in	O
vivo	O
topology	O
of	O
yeast	O
polytopic	O
membrane	O
proteins	O
demonstrates	O
that	O
Gap1p	S-Protein
fully	O
integrates	O
into	O
the	O
membrane	O
independently	O
of	O
Shr3p	S-Protein
.	O

The	O
general	O
amino	O
acid	O
permease	O
(	O
Gap1p	S-Protein
)	O
of	O
Saccharomyces	O
cerevisiae	O
is	O
an	O
integral	O
membrane	O
protein	O
that	O
contains	O
12	O
hydrophobic	O
regions	O
predicted	O
to	O
be	O
membrane	O
-	O
spanning	O
segments	O
.	O

A	O
topological	O
reporter	O
construct	O
,	O
encoding	O
an	O
internal	O
53	O
-	O
amino	O
acid	O
peptide	O
of	O
invertase	O
(	O
Suc2p	S-Protein
)	O
containing	O
three	O
Asp	O
-	O
X	O
-	O
Ser	O
/	O
Thr	O
glycosylation	O
sites	O
,	O
was	O
inserted	O
in	O
-	O
frame	O
into	O
the	O
hydrophilic	O
NH	O
(	O
2	O
)	O
-	O
and	O
COOH	O
-	O
terminal	O
domains	O
and	O
each	O
of	O
the	O
11	O
hydrophilic	O
loops	O
that	O
separate	O
the	O
12	O
hydrophobic	O
segments	O
of	O
Gap1p	S-Protein
.	O

The	O
resulting	O
13	O
gene	O
sandwich	O
fusion	O
proteins	O
were	O
expressed	O
in	O
a	O
gap1Delta	S-Protein
null	O
mutant	O
strain	O
;	O
9	O
of	O
these	O
retain	O
amino	O
acid	O
transport	O
activity	O
and	O
are	O
folded	O
and	O
correctly	O
targeted	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
glycosylation	O
state	O
of	O
each	O
of	O
the	O
fusion	O
proteins	O
was	O
monitored	O
;	O
the	O
results	O
indicate	O
that	O
all	O
12	O
hydrophobic	O
segments	O
of	O
Gap1p	S-Protein
span	O
the	O
membrane	O
,	O
and	O
the	O
NH	O
(	O
2	O
)	O
and	O
COOH	O
termini	O
are	O
cytoplasmically	O
oriented	O
.	O

These	O
results	O
were	O
independently	O
tested	O
by	O
isolating	O
sealed	O
right	O
-	O
side	O
-	O
out	O
microsomes	O
from	O
sec12	O
-	O
1	O
strains	O
expressing	O
six	O
different	O
Gap1p	S-Protein
constructs	O
containing	O
functional	O
factor	O
Xa	O
protease	O
cleavage	O
sites	O
.	O

The	O
pattern	O
of	O
factor	O
Xa	O
protease	O
cleavage	O
was	O
found	O
to	O
be	O
consistent	O
with	O
the	O
presence	O
of	O
12	O
membrane	O
-	O
spanning	O
domains	O
.	O

Gap1p	S-Protein
exhibited	O
the	O
same	O
membrane	O
topology	O
in	O
strains	O
lacking	O
Shr3p	S-Protein
;	O
therefore	O
,	O
Gap1p	S-Protein
fully	O
integrates	O
into	O
the	O
ER	O
membrane	O
independently	O
of	O
this	O
permease	O
-	O
specific	O
packaging	O
chaperone	O
.	O

Exploring	O
the	O
glycan	O
repertoire	O
of	O
genetically	O
modified	O
mice	O
by	O
isolation	O
and	O
profiling	O
of	O
the	O
major	O
glycan	O
classes	O
and	O
nano	O
-	O
NMR	O
analysis	O
of	O
glycan	O
mixtures	O
.	O

The	O
production	O
of	O
mice	O
with	O
genetic	O
alterations	O
in	O
glycosyltransferases	O
has	O
highlighted	O
the	O
need	O
to	O
isolate	O
and	O
study	O
complex	O
mixtures	O
of	O
the	O
major	O
classes	O
of	O
oligosaccharides	O
(	O
glycans	O
)	O
from	O
intact	O
tissues	O
.	O

We	O
have	O
found	O
that	O
nano	O
-	O
NMR	O
spectroscopy	O
of	O
whole	O
mixtures	O
of	O
N	O
-	O
and	O
O	O
-	O
glycans	O
can	O
complement	O
HPLC	O
profiling	O
methods	O
for	O
elucidating	O
structural	O
details	O
.	O

Working	O
toward	O
obtaining	O
such	O
glycan	O
mixtures	O
from	O
mouse	O
tissues	O
,	O
we	O
decided	O
to	O
develop	O
an	O
approach	O
to	O
isolate	O
not	O
only	O
N	O
-	O
and	O
O	O
-	O
glycans	O
,	O
but	O
also	O
to	O
separate	O
out	O
glycosphingolipids	O
,	O
glycosaminoglycans	O
and	O
glycosylphosphatidylinositol	O
anchors	O
.	O

We	O
describe	O
here	O
a	O
comprehensive	O
Glycan	O
Isolation	O
Protocol	O
that	O
is	O
based	O
primarily	O
upon	O
the	O
physicochemical	O
characteristics	O
of	O
the	O
molecules	O
,	O
and	O
requires	O
only	O
commonly	O
available	O
reagents	O
and	O
equipment	O
.	O

Using	O
radiolabeled	O
internal	O
tracers	O
,	O
we	O
show	O
that	O
recovery	O
of	O
each	O
major	O
class	O
of	O
glycans	O
is	O
as	O
good	O
or	O
better	O
than	O
with	O
conventional	O
approaches	O
for	O
isolating	O
individual	O
classes	O
,	O
and	O
that	O
cross	O
-	O
contamination	O
is	O
minimal	O
.	O

The	O
recovered	O
glycans	O
are	O
of	O
sufficient	O
purity	O
to	O
provide	O
a	O
"	O
glycoprofile	O
"	O
of	O
a	O
cell	O
type	O
or	O
tissue	O
.	O

We	O
applied	O
this	O
approach	O
to	O
compare	O
the	O
N	O
-	O
and	O
O	O
-	O
glycans	O
from	O
wild	O
type	O
mouse	O
tissues	O
with	O
those	O
from	O
mice	O
genetically	O
deficient	O
in	O
glycosyltransferases	O
.	O

N	O
-	O
and	O
O	O
-	O
glycan	O
mixtures	O
from	O
organs	O
of	O
mice	O
deficient	O
in	O
ST6Gal	B-Protein
-	I-Protein
I	E-Protein
(	O
CMP	O
-	O
Sia	O
:	O
Galbeta1	O
-	O
4GlcNAc	O
alpha2	O
-	O
6	O
sialyltransferase	O
)	O
were	O
studied	O
by	O
the	O
nano	O
-	O
NMR	O
spectroscopy	O
approach	O
,	O
showing	O
no	O
detectable	O
alpha2	O
-	O
6	O
-	O
linked	O
sialic	O
acids	O
.	O

Thus	O
,	O
ST6Gal	B-Protein
-	I-Protein
I	E-Protein
is	O
likely	O
responsible	O
for	O
generating	O
most	O
or	O
all	O
of	O
these	O
residues	O
in	O
normal	O
mice	O
.	O

Similar	O
studies	O
indicate	O
that	O
this	O
linkage	O
is	O
very	O
rare	O
in	O
ganglioside	O
glycans	O
,	O
even	O
in	O
wild	O
-	O
type	O
tissues	O
.	O

In	O
mice	O
deficient	O
in	O
GalNAcT	B-Protein
-	I-Protein
8	E-Protein
(	O
UDP	B-Protein
-	I-Protein
GalNAc	I-Protein
:	I-Protein
polypeptide	I-Protein
O	I-Protein
-	I-Protein
Ser	I-Protein
/	I-Protein
Thr	I-Protein
GalNAc	I-Protein
transferase	I-Protein
8	E-Protein
)	O
,	O
HPLC	O
profiling	O
indicates	O
that	O
O	O
-	O
glycans	O
persist	O
in	O
the	O
thymus	O
in	O
large	O
amounts	O
,	O
without	O
a	O
major	O
change	O
in	O
overall	O
profile	O
,	O
suggesting	O
that	O
other	O
enzymes	O
can	O
synthesize	O
the	O
GalNAc	O
-	O
O	O
-	O
Ser	O
/	O
Thr	O
linkage	O
in	O
this	O
tissue	O
.	O

These	O
results	O
demonstrate	O
the	O
applicability	O
of	O
nano	O
-	O
NMR	O
spectroscopy	O
to	O
complex	O
glycan	O
mixtures	O
,	O
as	O
well	O
as	O
the	O
versatility	O
of	O
the	O
Glycan	O
Isolation	O
Protocol	O
,	O
which	O
makes	O
possible	O
the	O
concurrent	O
examination	O
of	O
multiple	O
glycan	O
classes	O
from	O
intact	O
vertebrate	O
tissues	O
.	O

Protein	O
N	O
-	O
arginine	O
methylation	O
in	O
subcellular	O
fractions	O
of	O
lymphoblastoid	O
cells	O
.	O

Arginine	O
methylation	O
in	O
RNA	O
-	O
binding	O
proteins	O
containing	O
arginine	O
-	O
and	O
glycine	O
-	O
rich	O
RGG	O
motifs	O
is	O
catalyzed	O
by	O
specific	O
protein	O
arginine	O
N	O
-	O
methyltransferase	O
in	O
cells	O
.	O

We	O
previously	O
showed	O
that	O
lymphoblastoid	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
an	O
indirect	O
methyltransferase	O
inhibitor	O
,	O
adenosine	O
dialdehyde	O
(	O
AdOx	O
)	O
,	O
accumulated	O
high	O
level	O
of	O
hypomethylated	O
protein	O
substrates	O
for	O
the	O
endogenous	O
protein	O
methyltransferases	O
or	O
recombinant	O
yeast	O
arginine	O
methyltransferase	O
[	O
Li	O
,	O
C	O
.	O
et	O
al	O
.	O
(	O
1998	O
)	O
Arch	O
.	O
Biochem	O
.	O
Biophys	O
.	O
351	O
,	O
53	O
-	O
59	O
]	O
.	O

In	O
this	O
study	O
we	O
fractionated	O
the	O
lymphoblastoid	O
cells	O
to	O
locate	O
the	O
methyltransferases	O
and	O
the	O
substrates	O
in	O
cells	O
.	O

Different	O
sets	O
of	O
hypomethylated	O
methyl	O
-	O
accepting	O
polypeptides	O
with	O
wide	O
range	O
of	O
molecular	O
masses	O
were	O
present	O
in	O
cytosolic	O
,	O
ribosomal	O
,	O
and	O
nucleus	O
fractions	O
.	O

The	O
methylated	O
amino	O
acid	O
residues	O
of	O
the	O
methyl	O
-	O
accepting	O
proteins	O
in	O
these	O
fractions	O
were	O
determined	O
.	O

In	O
all	O
three	O
fractions	O
,	O
dimethylarginine	O
was	O
the	O
most	O
abundant	O
methylated	O
amino	O
acid	O
.	O

The	O
protein	O
-	O
arginine	O
methyltransferase	O
activities	O
in	O
the	O
three	O
fractions	O
were	O
analyzed	O
using	O
recombinant	O
fibrillarin	S-Protein
(	O
a	O
nucleolar	O
RGG	O
protein	O
)	O
as	O
the	O
methyl	O
-	O
accepting	O
substrate	O
.	O

Fibrillarin	S-Protein
methylation	O
was	O
strongest	O
in	O
the	O
presence	O
of	O
the	O
cytosolic	O
fraction	O
,	O
followed	O
by	O
the	O
ribosomal	O
and	O
then	O
the	O
nucleus	O
fractions	O
.	O

The	O
results	O
demonstrated	O
that	O
protein	O
-	O
arginine	O
methyltransferases	O
as	O
well	O
as	O
their	O
methyl	O
-	O
accepting	O
substrates	O
were	O
widely	O
distributed	O
in	O
different	O
subcellular	O
fractions	O
of	O
lymphoblastoid	O
cells	O
.	O

Dynamic	O
associations	O
of	O
heterochromatin	O
protein	O
1	O
with	O
the	O
nuclear	O
envelope	O
.	O

To	O
study	O
the	O
dynamics	O
of	O
mammalian	O
HP1	O
proteins	O
we	O
have	O
microinjected	O
recombinant	O
forms	O
of	O
mHP1alpha	S-Protein
,	O
M31	S-Protein
and	O
M32	S-Protein
into	O
the	O
cytoplasm	O
of	O
living	O
cells	O
.	O

As	O
could	O
be	O
expected	O
from	O
previous	O
studies	O
,	O
the	O
three	O
fusion	O
proteins	O
were	O
efficiently	O
transported	O
into	O
the	O
nucleus	O
and	O
targeted	O
specific	O
chromatin	O
areas	O
.	O

However	O
,	O
before	O
incorporation	O
into	O
these	O
areas	O
the	O
exogenous	O
proteins	O
accumulated	O
in	O
a	O
peripheral	O
zone	O
and	O
associated	O
closely	O
with	O
the	O
nuclear	O
envelope	O
.	O

This	O
transient	O
association	O
did	O
not	O
occur	O
when	O
the	O
cells	O
were	O
treated	O
with	O
deacetylase	O
inhibitors	O
,	O
indicating	O
an	O
acetylation	O
-	O
inhibited	O
interaction	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
recombinant	O
HP1	O
proteins	O
exhibited	O
saturable	O
binding	O
to	O
purified	O
nuclear	O
envelopes	O
and	O
stained	O
the	O
nuclei	O
of	O
detergent	O
-	O
permeabilized	O
cells	O
in	O
a	O
rim	O
-	O
like	O
fashion	O
.	O

Competition	O
experiments	O
with	O
various	O
M31	S-Protein
mutants	O
allowed	O
mapping	O
of	O
the	O
nuclear	O
envelope	O
-	O
binding	O
site	O
within	O
an	O
N	O
-	O
terminal	O
region	O
that	O
includes	O
the	O
chromodomain	O
.	O

A	O
His	O
(	O
6	O
)	O
-	O
tagged	O
peptide	O
representing	O
this	O
region	O
inhibited	O
recruitment	O
of	O
LAP2beta	S-Protein
and	O
B	O
-	O
type	O
lamins	O
around	O
the	O
surfaces	O
of	O
condensed	O
chromosomes	O
,	O
suggesting	O
involvement	O
of	O
HP1	O
proteins	O
in	O
nuclear	O
envelope	O
reassembly	O
.	O

The	O
propeptide	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
superfamily	O
member	O
,	O
macrophage	B-Protein
inhibitory	I-Protein
cytokine	I-Protein
-	I-Protein
1	E-Protein
(	O
MIC	B-Protein
-	I-Protein
1	E-Protein
)	O
,	O
is	O
a	O
multifunctional	O
domain	O
that	O
can	O
facilitate	O
protein	O
folding	O
and	O
secretion	O
.	O

Macrophage	B-Protein
inhibitory	I-Protein
cytokine	I-Protein
-	I-Protein
1	E-Protein
(	O
MIC	B-Protein
-	I-Protein
1	E-Protein
)	O
is	O
a	O
divergent	O
member	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
superfamily	O
.	O

While	O
it	O
is	O
synthesized	O
in	O
a	O
pre	O
-	O
pro	O
form	O
,	O
it	O
is	O
unique	O
among	O
superfamily	O
members	O
because	O
it	O
does	O
not	O
require	O
its	O
propeptide	O
for	O
correct	O
folding	O
or	O
secretion	O
of	O
the	O
mature	O
peptide	O
.	O

To	O
investigate	O
factors	O
that	O
enable	O
these	O
propeptide	O
independent	O
events	O
to	O
occur	O
,	O
we	O
constructed	O
MIC	B-Protein
-	I-Protein
1	E-Protein
/	O
TGF	B-Protein
-	I-Protein
beta1	E-Protein
chimeras	O
,	O
both	O
with	O
and	O
without	O
a	O
propeptide	O
.	O

All	O
chimeras	O
without	O
a	O
propeptide	O
secreted	O
less	O
efficiently	O
compared	O
with	O
the	O
corresponding	O
constructs	O
with	O
propeptide	O
.	O

Folding	O
and	O
secretion	O
were	O
most	O
affected	O
after	O
replacement	O
of	O
the	O
predicted	O
major	O
alpha	O
-	O
helix	O
in	O
the	O
mature	O
protein	O
,	O
residues	O
56	O
-	O
68	O
.	O

Exchanging	O
the	O
human	O
propeptide	O
in	O
this	O
chimera	O
with	O
either	O
the	O
murine	O
MIC	B-Protein
-	I-Protein
1	E-Protein
or	O
TGF	B-Protein
-	I-Protein
beta1	E-Protein
propeptide	O
resulted	O
in	O
secretion	O
of	O
the	O
unprocessed	O
,	O
monomeric	O
chimera	O
,	O
suggesting	O
a	O
specific	O
interaction	O
between	O
the	O
human	O
MIC	B-Protein
-	I-Protein
1	E-Protein
propeptide	O
and	O
mature	O
peptide	O
.	O

Propeptide	O
deletion	O
mutants	O
enabled	O
identification	O
of	O
a	O
region	O
between	O
residues	O
56	O
and	O
78	O
,	O
which	O
is	O
important	O
for	O
the	O
interaction	O
between	O
the	O
propeptide	O
and	O
the	O
mature	O
peptide	O
.	O

Cotransfection	O
experiments	O
demonstrated	O
that	O
the	O
propeptide	O
must	O
be	O
in	O
cis	O
with	O
the	O
mature	O
peptide	O
for	O
this	O
phenomenon	O
to	O
occur	O
.	O

These	O
results	O
suggest	O
a	O
model	O
for	O
TGF	O
-	O
beta	O
superfamily	O
protein	O
folding	O
.	O

High	O
frequency	O
of	O
promoter	O
hypermethylation	O
of	O
RASSF1A	S-Protein
in	O
nasopharyngeal	O
carcinoma	O
.	O

We	O
have	O
investigated	O
the	O
genetic	O
and	O
epigenetic	O
changes	O
of	O
a	O
newly	O
isolated	O
tumor	O
suppressor	O
gene	O
on	O
3p21	O
.	O
3	O
,	O
RASSF1A	S-Protein
,	O
in	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O

Four	O
xenografts	O
,	O
four	O
cell	O
lines	O
and	O
21	O
primary	O
tumors	O
were	O
examined	O
.	O

Promoter	O
hypermethylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
RASSF1A	S-Protein
was	O
detected	O
in	O
4	O
of	O
4	O
(	O
100	O
%	O
)	O
xenografts	O
,	O
in	O
3	O
of	O
4	O
(	O
75	O
%	O
)	O
cell	O
lines	O
,	O
and	O
in	O
14	O
of	O
21	O
(	O
66	O
.	O
7	O
%	O
)	O
primary	O
tumors	O
but	O
not	O
in	O
the	O
normal	O
nasopharyngeal	O
epithelia	O
.	O

Mutations	O
were	O
found	O
in	O
2	O
of	O
21	O
(	O
9	O
.	O
5	O
%	O
)	O
primary	O
tumors	O
.	O

In	O
the	O
cell	O
lines	O
and	O
xenografts	O
with	O
extensive	O
methylation	O
,	O
no	O
RASSF1A	S-Protein
gene	O
expression	O
was	O
found	O
.	O

After	O
treatment	O
with	O
5	O
'	O
-	O
aza	O
-	O
2	O
'	O
deoxycytidine	O
,	O
reexpression	O
and	O
demethylation	O
of	O
the	O
RASSF1A	S-Protein
gene	O
were	O
detected	O
in	O
a	O
NPC	O
cell	O
line	O
.	O

These	O
findings	O
suggest	O
that	O
promoter	O
hypermethylation	O
may	O
participate	O
in	O
the	O
transcriptional	O
inactivation	O
of	O
the	O
RASSF1A	S-Protein
gene	O
in	O
NPC	O
.	O

The	O
high	O
incidence	O
of	O
RASSF1A	S-Protein
alterations	O
suggest	O
that	O
it	O
is	O
the	O
critical	O
target	O
gene	O
on	O
chromosome	O
3p21	O
.	O
3	O
involved	O
in	O
the	O
development	O
of	O
NPC	O
.	O

Cytosine	O
methylation	O
represses	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
P1	E-Protein
(	O
GSTP1	S-Protein
)	O
gene	O
expression	O
in	O
human	O
prostate	O
cancer	O
cells	O
.	O

Methylation	O
of	O
the	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
P1	E-Protein
(	O
GSTP1	S-Protein
)	O
gene	O
has	O
been	O
described	O
as	O
a	O
highly	O
specific	O
and	O
sensitive	O
biomarker	O
for	O
prostate	O
cancer	O
.	O

However	O
,	O
at	O
present	O
,	O
it	O
is	O
not	O
known	O
whether	O
methylation	O
represses	O
GSTP1	S-Protein
gene	O
expression	O
in	O
human	O
prostate	O
cancer	O
.	O

We	O
found	O
the	O
GSTP1	S-Protein
gene	O
promoter	O
to	O
be	O
completely	O
methylated	O
in	O
the	O
LNCaP	O
prostate	O
cancer	O
cell	O
line	O
,	O
where	O
this	O
gene	O
is	O
transcriptionally	O
inactive	O
.	O

In	O
contrast	O
,	O
Du145	O
and	O
PC3	O
prostate	O
cancer	O
cells	O
express	O
the	O
GSTP1	S-Protein
gene	O
and	O
exhibit	O
methylated	O
and	O
unmethylated	O
GSTP1	S-Protein
alleles	O
.	O

In	O
a	O
transient	O
transfection	O
assay	O
using	O
LNCaP	O
cells	O
,	O
methylation	O
of	O
the	O
GSTP1	S-Protein
promoter	O
-	O
driven	O
luciferase	S-Protein
reporter	O
vector	O
(	O
GSTP1	S-Protein
-	O
pGL3	O
)	O
resulted	O
in	O
a	O
>	O
20	O
-	O
fold	O
inhibition	O
of	O
transcription	O
,	O
and	O
this	O
repression	O
was	O
not	O
relieved	O
by	O
the	O
presence	O
of	O
a	O
histone	S-Protein
deacetylase	O
inhibitor	O
,	O
trichostatin	O
A	O
(	O
TSA	O
)	O
.	O

Treatment	O
of	O
LNCaP	O
cells	O
with	O
a	O
DNA	O
methyltransferase	O
inhibitor	O
,	O
5	O
-	O
Aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
,	O
resulted	O
in	O
demethylation	O
and	O
activation	O
of	O
the	O
GSTP1	S-Protein
gene	O
.	O

In	O
contrast	O
,	O
TSA	O
treatment	O
failed	O
to	O
demethylate	O
or	O
activate	O
the	O
GSTP1	S-Protein
gene	O
.	O

Fully	O
methylated	O
but	O
not	O
unmethylated	O
GSTP1	S-Protein
promoter	O
fragment	O
was	O
shown	O
to	O
bind	O
to	O
a	O
complex	O
similar	O
to	O
methyl	O
cytosine	O
-	O
binding	O
protein	O
complex	O
1	O
that	O
contains	O
methyl	B-Protein
-	I-Protein
CpG	I-Protein
-	I-Protein
binding	I-Protein
domain	I-Protein
2	I-Protein
protein	E-Protein
(	O
MBD2	S-Protein
)	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
LNCaP	O
cell	O
nuclear	O
extracts	O
.	O

These	O
data	O
demonstrate	O
that	O
cytosine	O
methylation	O
can	O
repress	O
GSTP1	S-Protein
gene	O
expression	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
and	O
that	O
this	O
effect	O
is	O
possibly	O
mediated	O
by	O
a	O
methyl	O
cytosine	O
-	O
binding	O
protein	O
complex	O
1	O
-	O
like	O
complex	O
.	O

Furthermore	O
,	O
these	O
data	O
also	O
support	O
the	O
notion	O
of	O
the	O
dominance	O
of	O
methylation	O
over	O
TSA	O
-	O
sensitive	O
histone	S-Protein
deacetylation	O
in	O
silencing	O
genes	O
with	O
a	O
high	O
CpG	O
density	O
in	O
the	O
promoter	O
region	O
.	O

Activation	O
of	O
the	O
maternally	O
preset	O
program	O
of	O
apoptosis	O
by	O
microinjection	O
of	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
and	O
5	O
-	O
methyl	O
-	O
2	O
'	O
-	O
deoxycytidine	O
-	O
5	O
'	O
-	O
triphosphate	O
in	O
Xenopus	O
laevis	O
embryos	O
.	O

The	O
present	O
study	O
examines	O
the	O
effects	O
on	O
embryogenesis	O
of	O
microinjecting	O
Xenopus	O
laevis	O
fertilized	O
eggs	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
Aza	O
-	O
CdR	O
)	O
,	O
which	O
induces	O
hypomethylation	O
of	O
DNA	O
,	O
and	O
5	O
-	O
methyl	O
-	O
2	O
'	O
-	O
deoxycytidine	O
-	O
5	O
'	O
-	O
triphosphate	O
(	O
5	O
-	O
methyl	O
-	O
dCTP	O
)	O
,	O
which	O
induces	O
hypermethylation	O
of	O
DNA	O
.	O

Embryos	O
injected	O
with	O
either	O
one	O
of	O
these	O
analogs	O
cleaved	O
normally	O
until	O
the	O
mid	O
-	O
blastula	O
stage	O
,	O
but	O
underwent	O
massive	O
cell	O
dissociation	O
and	O
stopped	O
development	O
at	O
the	O
early	O
gastrula	O
stage	O
.	O

Dissociated	O
cells	O
that	O
appeared	O
here	O
were	O
positive	O
by	O
terminal	O
deoxyribonucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	O
triphosphate	O
-	O
digoxigenin	O
nick	O
end	O
-	O
labeling	O
and	O
contained	O
fragmented	O
nuclei	O
with	O
condensed	O
chromatin	O
.	O

The	O
DNA	O
from	O
these	O
cells	O
formed	O
a	O
"	O
ladder	O
"	O
on	O
electrophoresis	O
.	O

Furthermore	O
,	O
the	O
induction	O
of	O
cell	O
dissociation	O
by	O
5	O
-	O
Aza	O
-	O
CdR	O
and	O
5	O
-	O
methyl	O
-	O
dCTP	O
was	O
postponed	O
by	O
2	O
-	O
3	O
h	O
by	O
co	O
-	O
injection	O
of	O
Bcl	B-Protein
-	I-Protein
2	E-Protein
mRNA	O
and	O
the	O
normal	O
metabolite	O
(	O
CdR	O
and	O
dCTP	O
,	O
respectively	O
)	O
.	O

Using	O
a	O
specific	O
antibody	O
against	O
5	O
-	O
methyl	O
-	O
cytosine	O
,	O
we	O
confirmed	O
that	O
5	O
-	O
Aza	O
-	O
CdR	O
induces	O
hypomethylation	O
,	O
whereas	O
5	O
-	O
methyl	O
-	O
dCTP	O
induces	O
hypermethylation	O
in	O
X	O
.	O
laevis	O
embryos	O
before	O
the	O
onset	O
of	O
cell	O
dissociation	O
.	O

Incorporation	O
of	O
radioactive	O
precursors	O
revealed	O
that	O
synthesis	O
of	O
DNA	O
,	O
and	O
also	O
RNA	O
,	O
is	O
inhibited	O
significantly	O
in	O
both	O
5	O
-	O
Aza	O
-	O
CdR	O
-	O
injected	O
and	O
5	O
-	O
methyl	O
-	O
dCTP	O
-	O
injected	O
embryos	O
.	O

These	O
results	O
show	O
that	O
5	O
-	O
Aza	O
-	O
CdR	O
and	O
5	O
-	O
methyl	O
-	O
dCTP	O
are	O
incorporated	O
into	O
DNA	O
and	O
induce	O
apoptosis	O
,	O
probably	O
through	O
alteration	O
of	O
DNA	O
methylation	O
coupled	O
with	O
inhibition	O
of	O
DNA	O
replication	O
and	O
/	O
or	O
transcription	O
.	O

Impairment	O
of	O
erythrocyte	O
viscoelasticity	O
is	O
correlated	O
with	O
levels	O
of	O
glycosylated	O
haemoglobin	O
in	O
diabetic	O
patients	O
.	O

Erythrocytes	O
from	O
diabetic	O
patients	O
exhibit	O
impaired	O
viscoelastic	O
properties	O
when	O
estimated	O
by	O
various	O
methods	O
.	O

We	O
determined	O
erythrocyte	O
filterability	O
through	O
5	O
-	O
microm	O
pores	O
,	O
in	O
51	O
patients	O
with	O
non	O
-	O
insulin	S-Protein
-	O
dependent	O
diabetes	O
mellitus	O
,	O
18	O
healthy	O
controls	O
,	O
15	O
patients	O
with	O
homozygous	O
beta	O
-	O
thalassemia	O
and	O
15	O
with	O
beta	O
-	O
thalassemia	O
traits	O
.	O

The	O
filtration	O
measurements	O
were	O
made	O
with	O
a	O
Hemorheometer	O
,	O
which	O
uses	O
the	O
"	O
initial	O
flow	O
rate	O
"	O
principle	O
.	O

To	O
determine	O
the	O
Index	O
of	O
Rigidity	O
(	O
IR	O
)	O
of	O
the	O
red	O
blood	O
cells	O
,	O
we	O
measured	O
the	O
passage	O
time	O
of	O
white	O
blood	O
cell	O
-	O
free	O
erythrocyte	O
suspensions	O
,	O
8	O
%	O
per	O
volume	O
,	O
through	O
the	O
filter	O
.	O

Diabetic	O
patients	O
had	O
significantly	O
increased	O
IR	O
in	O
comparison	O
to	O
healthy	O
controls	O
and	O
to	O
patients	O
with	O
beta	O
-	O
thalassemia	O
trait	O
,	O
but	O
not	O
at	O
the	O
level	O
found	O
in	O
patients	O
with	O
homozygous	O
beta	O
-	O
thalassemia	O
.	O

In	O
diabetic	O
patients	O
,	O
a	O
strong	O
correlation	O
between	O
IR	O
and	O
the	O
percentage	O
of	O
glycosylated	O
haemoglobin	O
was	O
found	O
(	O
r	O
=	O
0	O
.	O
737	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
a	O
weaker	O
one	O
with	O
serum	O
unconjugated	O
bilirubin	O
(	O
r	O
=	O
0	O
.	O
363	O
,	O
P	O
=	O
0	O
.	O
0097	O
)	O
and	O
serum	O
total	O
lipids	O
(	O
r	O
=	O
0	O
.	O
321	O
,	O
P	O
=	O
0	O
.	O
0286	O
)	O
.	O

Patients	O
with	O
severe	O
retinopathy	O
also	O
had	O
significantly	O
increased	O
IR	O
,	O
in	O
comparison	O
to	O
those	O
with	O
or	O
without	O
mild	O
retinopathy	O
.	O

Anaemic	O
diabetic	O
patients	O
,	O
especially	O
those	O
with	O
the	O
anaemia	O
of	O
chronic	O
disease	O
,	O
also	O
had	O
significantly	O
increased	O
IR	O
in	O
comparison	O
to	O
non	O
-	O
anaemic	O
diabetics	O
.	O

No	O
correlation	O
between	O
IR	O
,	O
MCV	O
,	O
MCH	O
,	O
MCHC	O
,	O
RDW	O
,	O
RBC	O
morphology	O
,	O
serum	O
LDH	O
or	O
the	O
presence	O
of	O
erythrocyte	O
inclusions	O
after	O
incubation	O
with	O
nitrous	O
sodium	O
solution	O
was	O
found	O
.	O

Our	O
findings	O
suggest	O
that	O
glycosylation	O
of	O
skeletal	O
proteins	O
probably	O
contributes	O
significantly	O
to	O
the	O
increased	O
membrane	O
rigidity	O
of	O
diabetic	O
erythrocytes	O
.	O

Characterization	O
of	O
the	O
secretable	O
ectodomain	O
of	O
thyrotropin	B-Protein
receptor	E-Protein
produced	O
by	O
the	O
recombinant	O
baculovirus	O
system	O
.	O

Thyrotropin	B-Protein
receptor	E-Protein
(	O
TSHR	S-Protein
)	O
is	O
a	O
member	O
of	O
the	O
glycoprotein	O
hormone	O
receptor	O
family	O
and	O
an	O
autoantigen	O
of	O
Graves	O
'	O
disease	O
.	O

Various	O
attempts	O
have	O
been	O
made	O
to	O
obtain	O
a	O
large	O
amount	O
of	O
soluble	O
ectodomain	O
of	O
TSHR	S-Protein
in	O
insect	O
or	O
mammalian	O
cells	O
,	O
but	O
most	O
of	O
them	O
failed	O
to	O
secrete	O
the	O
overexpressed	O
ectodomain	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
observed	O
that	O
about	O
one	O
-	O
third	O
of	O
the	O
ectodomain	O
protein	O
(	O
sTSHR	S-Protein
-	O
gp	O
)	O
,	O
in	O
which	O
the	O
signal	O
peptide	O
of	O
TSHR	S-Protein
was	O
replaced	O
by	O
the	O
baculovirus	O
-	O
encoded	O
glycoprotein	B-Protein
67	E-Protein
-	O
signal	O
peptide	O
,	O
was	O
secreted	O
into	O
the	O
culture	O
medium	O
and	O
the	O
remainder	O
stayed	O
within	O
cells	O
in	O
the	O
recombinant	O
baculovirus	O
system	O
.	O

Microsequencing	O
the	O
N	O
-	O
terminal	O
of	O
the	O
purified	O
protein	O
confirmed	O
that	O
the	O
baculovirus	O
signal	O
peptide	O
was	O
cleaved	O
at	O
the	O
expected	O
site	O
.	O

Carbohydrate	O
studies	O
using	O
several	O
glycosidases	O
and	O
lectins	O
revealed	O
that	O
the	O
secreted	O
form	O
of	O
the	O
ectodomain	O
had	O
biantennary	O
carbohydrate	O
,	O
whereas	O
the	O
non	O
-	O
secreted	O
form	O
had	O
high	O
-	O
mannose	O
.	O

Moreover	O
,	O
the	O
secreted	O
form	O
of	O
sTSHR	S-Protein
-	O
gp	O
exhibited	O
high	O
-	O
affinity	O
ligand	O
binding	O
,	O
whereas	O
the	O
non	O
-	O
secreted	O
form	O
did	O
not	O
show	O
any	O
significant	O
ligand	O
binding	O
.	O

Regarding	O
the	O
interactions	O
of	O
TSHR	S-Protein
ectodomains	O
with	O
anti	O
-	O
TSHR	S-Protein
antibodies	O
,	O
both	O
the	O
secreted	O
and	O
non	O
-	O
secreted	O
forms	O
of	O
sTSHR	S-Protein
-	O
gp	O
,	O
almost	O
completely	O
neutralized	O
the	O
stimulatory	O
and	O
inhibitory	O
anti	O
-	O
TSHR	S-Protein
antibody	O
activities	O
.	O

In	O
conclusion	O
,	O
we	O
succeeded	O
in	O
secreting	O
the	O
ectodomain	O
of	O
TSHR	S-Protein
into	O
culture	O
medium	O
,	O
which	O
was	O
capable	O
of	O
binding	O
to	O
TSH	O
and	O
neutralizing	O
anti	O
-	O
TSHR	S-Protein
antibody	O
activities	O
.	O

C	O
.	O
elegans	O
EGL	B-Protein
-	I-Protein
9	E-Protein
and	O
mammalian	O
homologs	O
define	O
a	O
family	O
of	O
dioxygenases	O
that	O
regulate	O
HIF	O
by	O
prolyl	O
hydroxylation	O
.	O

HIF	O
is	O
a	O
transcriptional	O
complex	O
that	O
plays	O
a	O
central	O
role	O
in	O
mammalian	O
oxygen	O
homeostasis	O
.	O

Recent	O
studies	O
have	O
defined	O
posttranslational	O
modification	O
by	O
prolyl	O
hydroxylation	O
as	O
a	O
key	O
regulatory	O
event	O
that	O
targets	O
HIF	O
-	O
alpha	O
subunits	O
for	O
proteasomal	O
destruction	O
via	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	E-Protein
ubiquitylation	O
complex	O
.	O

Here	O
,	O
we	O
define	O
a	O
conserved	O
HIF	O
-	O
VHL	S-Protein
-	O
prolyl	O
hydroxylase	O
pathway	O
in	O
C	O
.	O
elegans	O
,	O
and	O
use	O
a	O
genetic	O
approach	O
to	O
identify	O
EGL	B-Protein
-	I-Protein
9	E-Protein
as	O
a	O
dioxygenase	O
that	O
regulates	O
HIF	O
by	O
prolyl	O
hydroxylation	O
.	O

In	O
mammalian	O
cells	O
,	O
we	O
show	O
that	O
the	O
HIF	O
-	O
prolyl	O
hydroxylases	O
are	O
represented	O
by	O
a	O
series	O
of	O
isoforms	O
bearing	O
a	O
conserved	O
2	O
-	O
histidine	O
-	O
1	O
-	O
carboxylate	O
iron	O
coordination	O
motif	O
at	O
the	O
catalytic	O
site	O
.	O

Direct	O
modulation	O
of	O
recombinant	O
enzyme	O
activity	O
by	O
graded	O
hypoxia	O
,	O
iron	O
chelation	O
,	O
and	O
cobaltous	O
ions	O
mirrors	O
the	O
characteristics	O
of	O
HIF	O
induction	O
in	O
vivo	O
,	O
fulfilling	O
requirements	O
for	O
these	O
enzymes	O
being	O
oxygen	O
sensors	O
that	O
regulate	O
HIF	O
.	O

Biochemical	O
characterization	O
of	O
the	O
vanilloid	B-Protein
receptor	I-Protein
1	E-Protein
expressed	O
in	O
a	O
dorsal	O
root	O
ganglia	O
derived	O
cell	O
line	O
.	O

The	O
vanilloid	O
receptor	O
VR1	S-Protein
is	O
an	O
ion	O
channel	O
predominantly	O
expressed	O
by	O
primary	O
sensory	O
neurons	O
involved	O
in	O
nociception	O
.	O

Here	O
we	O
describe	O
its	O
biochemical	O
properties	O
and	O
assess	O
the	O
subcellular	O
localization	O
,	O
the	O
glycosylation	O
state	O
and	O
the	O
quaternary	O
structure	O
of	O
VR1	S-Protein
expressed	O
in	O
HEK293	O
cells	O
and	O
in	O
the	O
DRG	O
-	O
derived	O
cell	O
line	O
F	O
-	O
11	O
(	O
N18TG2	O
mouse	O
neuroblastoma	O
x	O
rat	O
dorsal	O
root	O
ganglia	O
,	O
hybridoma	O
)	O
.	O

VR1	S-Protein
was	O
found	O
to	O
be	O
glycosylated	O
in	O
both	O
cell	O
types	O
.	O

Of	O
the	O
five	O
potential	O
N	O
-	O
glycosylation	O
sites	O
,	O
the	O
predicted	O
transient	O
receptor	O
potential	O
channel	O
-	O
like	O
transmembrane	O
folding	O
proposes	O
N604	O
is	O
localized	O
extracellularly	O
.	O

We	O
used	O
site	O
-	O
directed	O
mutagenesis	O
to	O
mutate	O
the	O
Asn	O
at	O
position	O
604	O
to	O
Thr	O
.	O

This	O
mutated	O
VR1	S-Protein
was	O
not	O
glycosylated	O
,	O
confirming	O
the	O
extracellular	O
location	O
of	O
N604	O
and	O
its	O
role	O
as	O
the	O
exclusive	O
site	O
of	O
glycosylation	O
of	O
the	O
VR1	S-Protein
protein	O
.	O

VR1	S-Protein
occured	O
in	O
high	O
molecular	O
mass	O
complexes	O
as	O
assessed	O
by	O
blue	O
native	O
PAGE	O
.	O

In	O
the	O
presence	O
of	O
limited	O
amounts	O
of	O
SDS	O
dimers	O
,	O
trimers	O
and	O
tetramers	O
of	O
VR1	S-Protein
were	O
observed	O
,	O
consistent	O
with	O
the	O
predicted	O
tetrameric	O
quaternary	O
structure	O
of	O
the	O
receptor	O
.	O

Cross	O
-	O
linking	O
with	O
dimethyladipimidate	O
yielded	O
almost	O
exclusively	O
dimers	O
.	O

Whereas	O
VR1	S-Protein
localized	O
both	O
to	O
the	O
plasma	O
membrane	O
and	O
to	O
intracellular	O
membranes	O
in	O
HEK293	O
cells	O
,	O
it	O
localized	O
predominantly	O
to	O
the	O
plasma	O
membrane	O
in	O
F	O
-	O
11	O
cells	O
.	O

Using	O
confocal	O
laserscanning	O
microscopy	O
,	O
we	O
observed	O
an	O
enrichment	O
of	O
anti	O
-	O
VR1	S-Protein
immunoreactivity	O
in	O
neurite	O
-	O
like	O
structures	O
of	O
F	O
-	O
11	O
cells	O
.	O

In	O
the	O
light	O
of	O
conflicting	O
literature	O
data	O
on	O
biochemical	O
characteristics	O
of	O
VR1	S-Protein
,	O
our	O
data	O
suggest	O
that	O
dorsal	O
root	O
ganglion	O
-	O
derived	O
F	O
-	O
11	O
cells	O
provide	O
a	O
powerful	O
experimental	O
system	O
for	O
the	O
study	O
of	O
VR1	S-Protein
biochemistry	O
.	O

The	O
methylosome	O
,	O
a	O
20S	O
complex	O
containing	O
JBP1	S-Protein
and	O
pICln	S-Protein
,	O
produces	O
dimethylarginine	O
-	O
modified	O
Sm	O
proteins	O
.	O

snRNPs	O
,	O
integral	O
components	O
of	O
the	O
pre	O
-	O
mRNA	O
splicing	O
machinery	O
,	O
consist	O
of	O
seven	O
Sm	O
proteins	O
which	O
assemble	O
in	O
the	O
cytoplasm	O
as	O
a	O
ring	O
structure	O
on	O
the	O
snRNAs	O
U1	O
,	O
U2	O
,	O
U4	O
,	O
and	O
U5	O
.	O

The	O
survival	O
motor	O
neuron	O
(	O
SMN	O
)	O
protein	O
,	O
the	O
spinal	O
muscular	O
atrophy	O
disease	O
gene	O
product	O
,	O
is	O
crucial	O
for	O
snRNP	O
core	O
particle	O
assembly	O
in	O
vivo	O
.	O

SMN	O
binds	O
preferentially	O
and	O
directly	O
to	O
the	O
symmetrical	O
dimethylarginine	O
(	O
sDMA	O
)	O
-	O
modified	O
arginine	O
-	O
and	O
glycine	O
-	O
rich	O
(	O
RG	O
-	O
rich	O
)	O
domains	O
of	O
SmD1	S-Protein
and	O
SmD3	S-Protein
.	O

We	O
found	O
that	O
the	O
unmodified	O
,	O
but	O
not	O
the	O
sDMA	O
-	O
modified	O
,	O
RG	O
domains	O
of	O
SmD1	S-Protein
and	O
SmD3	S-Protein
associate	O
with	O
a	O
20S	O
methyltransferase	O
complex	O
,	O
termed	O
the	O
methylosome	O
,	O
that	O
contains	O
the	O
methyltransferase	O
JBP1	S-Protein
and	O
a	O
JBP1	S-Protein
-	O
interacting	O
protein	O
,	O
pICln	S-Protein
.	O

JBP1	S-Protein
binds	O
SmD1	S-Protein
and	O
SmD3	S-Protein
via	O
their	O
RG	O
domains	O
,	O
while	O
pICln	S-Protein
binds	O
the	O
Sm	O
domains	O
.	O

JBP1	S-Protein
produces	O
sDMAs	O
in	O
the	O
RG	O
domain	O
-	O
containing	O
Sm	O
proteins	O
.	O

We	O
further	O
demonstrate	O
the	O
existence	O
of	O
a	O
6S	O
complex	O
that	O
contains	O
pICln	S-Protein
,	O
SmD1	S-Protein
,	O
and	O
SmD3	S-Protein
but	O
not	O
JBP1	S-Protein
.	O

SmD3	S-Protein
from	O
the	O
methylosome	O
,	O
but	O
not	O
that	O
from	O
the	O
6S	O
complex	O
,	O
can	O
be	O
transferred	O
to	O
the	O
SMN	O
complex	O
in	O
vitro	O
.	O

Together	O
with	O
previous	O
results	O
,	O
these	O
data	O
indicate	O
that	O
methylation	O
of	O
Sm	O
proteins	O
by	O
the	O
methylosome	O
directs	O
Sm	O
proteins	O
to	O
the	O
SMN	O
complex	O
for	O
assembly	O
into	O
snRNP	O
core	O
particles	O
and	O
suggest	O
that	O
the	O
methylosome	O
can	O
regulate	O
snRNP	O
assembly	O
.	O

Methyl	O
CpG	O
-	O
binding	O
proteins	O
and	O
transcriptional	O
repression	O
.	O

Since	O
its	O
discovery	O
,	O
methylation	O
of	O
DNA	O
in	O
mammalian	O
cells	O
has	O
been	O
correlated	O
with	O
transcriptional	O
repression	O
and	O
with	O
specialized	O
chromatin	O
structures	O
.	O

Recently	O
,	O
considerable	O
progress	O
has	O
been	O
reported	O
in	O
the	O
identification	O
of	O
protein	O
factors	O
with	O
a	O
highly	O
conserved	O
DNA	O
interaction	O
surface	O
,	O
termed	O
the	O
methyl	O
CpG	O
-	O
binding	O
domain	O
or	O
MBD	O
.	O

A	O
subset	O
has	O
been	O
biochemically	O
linked	O
to	O
histone	S-Protein
deacetylases	O
,	O
suggesting	O
a	O
molecular	O
mechanism	O
for	O
the	O
functional	O
properties	O
of	O
methylated	O
DNA	O
.	O

Despite	O
several	O
obvious	O
attractions	O
,	O
the	O
connection	O
between	O
MBD	O
proteins	O
and	O
histone	S-Protein
deacetylases	O
fails	O
to	O
explain	O
all	O
the	O
existing	O
data	O
.	O

In	O
fact	O
,	O
the	O
biochemistry	O
and	O
DNA	O
-	O
binding	O
properties	O
of	O
most	O
MBD	O
family	O
members	O
have	O
not	O
been	O
adequately	O
described	O
and	O
considerable	O
evidence	O
exists	O
for	O
alternative	O
mechanisms	O
in	O
the	O
repression	O
of	O
methylated	O
loci	O
.	O

Null	O
mutations	O
have	O
been	O
generated	O
in	O
mice	O
for	O
several	O
MBD	O
family	O
members	O
,	O
the	O
phenotypes	O
of	O
the	O
mutant	O
animals	O
raise	O
important	O
questions	O
regarding	O
the	O
functions	O
of	O
the	O
MBD	O
family	O
.	O

Here	O
,	O
I	O
review	O
the	O
biochemistry	O
,	O
DNA	O
-	O
binding	O
properties	O
,	O
and	O
genetics	O
of	O
the	O
MBD	O
proteins	O
that	O
are	O
linked	O
to	O
transcriptional	O
repression	O
,	O
namely	O
,	O
MeCP2	S-Protein
,	O
MBD1	S-Protein
,	O
MBD2	S-Protein
,	O
and	O
MBD3	S-Protein
.	O

Several	O
models	O
to	O
account	O
for	O
the	O
functional	O
properties	O
of	O
methylated	O
DNA	O
are	O
presented	O
.	O

Molecular	O
and	O
immunohistochemical	O
study	O
of	O
the	O
inactivation	O
of	O
the	O
p16	S-Protein
gene	O
in	O
primary	O
hepatocellular	O
carcinoma	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
p16	S-Protein
gene	O
is	O
involved	O
in	O
the	O
genesis	O
of	O
primary	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

METHODS	O
:	O
Twenty	O
-	O
five	O
HCC	O
tumor	O
samples	O
with	O
corresponding	O
non	O
-	O
tumor	O
liver	O
tissue	O
specimens	O
were	O
examined	O
for	O
p16	S-Protein
gene	O
alterations	O
.	O

The	O
identification	O
of	O
deletion	O
of	O
exon	O
1	O
and	O
exon	O
2	O
in	O
p16	S-Protein
gene	O
was	O
performed	O
using	O
comparative	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analysis	O
.	O

The	O
point	O
mutation	O
of	O
exon	O
2	O
in	O
p16	S-Protein
gene	O
was	O
investigated	O
by	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
,	O
and	O
the	O
status	O
of	O
p16	S-Protein
gene	O
methylation	O
was	O
screened	O
using	O
a	O
PCR	O
based	O
methylation	O
analysis	O
.	O

35	O
parafin	O
-	O
embedded	O
specimens	O
of	O
HCC	O
with	O
corresponding	O
non	O
-	O
tumor	O
liver	O
tissues	O
,	O
including	O
the	O
25	O
cases	O
described	O
above	O
for	O
screening	O
p16	S-Protein
gene	O
alterations	O
,	O
were	O
investigated	O
for	O
p16	S-Protein
protein	O
expression	O
using	O
immunohistochemical	O
analysis	O
.	O

RESULTS	O
:	O
Among	O
25	O
cases	O
,	O
2	O
homozygous	O
deletions	O
and	O
1	O
hemizygous	O
deletion	O
were	O
found	O
in	O
HCC	O
samples	O
.	O

No	O
point	O
mutation	O
was	O
identified	O
in	O
the	O
remaining	O
22	O
tumor	O
samples	O
without	O
p16	S-Protein
gene	O
deletions	O
.	O

Hypermethylation	O
was	O
detected	O
in	O
24	O
%	O
(	O
6	O
/	O
25	O
)	O
of	O
tumor	O
samples	O
.	O

However	O
,	O
the	O
corresponding	O
non	O
-	O
tumor	O
liver	O
tissue	O
specimens	O
were	O
always	O
unmethylated	O
at	O
the	O
p16	S-Protein
locus	O
.	O

Loss	O
of	O
p16	S-Protein
protein	O
expression	O
occurred	O
in	O
16	O
of	O
35	O
(	O
45	O
.	O
7	O
%	O
)	O
tumor	O
samples	O
,	O
and	O
all	O
the	O
non	O
-	O
tumor	O
liver	O
tissue	O
specimens	O
showed	O
positive	O
p16	S-Protein
staining	O
.	O

For	O
the	O
25	O
cases	O
examined	O
for	O
p16	S-Protein
gene	O
alterations	O
,	O
the	O
loss	O
of	O
p16	S-Protein
protein	O
expression	O
was	O
observed	O
in	O
all	O
tumors	O
with	O
p16	S-Protein
gene	O
alterations	O
and	O
also	O
in	O
3	O
tumors	O
without	O
p16	S-Protein
gene	O
alterations	O
.	O

CONCLUSION	O
:	O
Inactivation	O
of	O
the	O
p16	S-Protein
gene	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
genesis	O
of	O
primary	O
hepatocellular	O
carcinoma	O
.	O

[	O
Hypermethylation	O
of	O
DAP	O
-	O
kinase	O
gene	O
CpG	O
Island	O
in	O
malignant	O
lymphoma	O
with	O
B	O
-	O
cell	O
phenotype	O
]	O

Death	O
-	O
associated	O
protein	O
-	O
kinase	O
(	O
DAP	O
-	O
Kinase	O
)	O
is	O
a	O
pro	O
-	O
apoptotic	O
serine	O
/	O
threonine	O
kinase	O
with	O
a	O
death	O
domain	O
,	O
which	O
is	O
involved	O
in	O
apoptosis	O
induced	O
by	O
interferon	B-Protein
-	I-Protein
gamma	E-Protein
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	E-Protein
,	O
and	O
Fas	B-Protein
ligand	E-Protein
.	O

Epigenetic	O
down	O
-	O
regulation	O
of	O
DAP	O
-	O
Kinase	O
gene	O
expression	O
by	O
hypermethylation	O
of	O
its	O
promoter	O
region	O
was	O
reported	O
in	O
certain	O
kinds	O
of	O
malignancies	O
.	O

Previous	O
patho	O
-	O
epidemiological	O
studies	O
indicated	O
that	O
thyroid	O
lymphoma	O
(	O
TL	O
)	O
evolves	O
among	O
active	O
lymphoid	O
cells	O
in	O
chronic	O
lymphocytic	O
thyroiditis	O
(	O
CLTH	O
)	O
.	O

With	O
the	O
use	O
of	O
methylation	O
specific	O
polymerase	O
chain	O
reaction	O
,	O
methylation	O
status	O
of	O
DAP	O
-	O
Kinase	O
CpG	O
island	O
was	O
examined	O
in	O
thyroid	O
lesions	O
of	O
19	O
cases	O
with	O
TL	O
and	O
9	O
with	O
CLTH	O
.	O

Frequency	O
of	O
methylation	O
was	O
higher	O
in	O
TL	O
cases	O
(	O
16	O
of	O
19	O
,	O
84	O
.	O
2	O
%	O
)	O
than	O
in	O
CLTH	O
cases	O
(	O
2	O
of	O
9	O
,	O
22	O
.	O
2	O
%	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

DNA	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
from	O
TL	O
and	O
CLTH	O
cases	O
never	O
showed	O
methylation	O
,	O
indicating	O
that	O
the	O
methylation	O
occurred	O
somatically	O
in	O
lesional	O
lymphocytes	O
in	O
the	O
thyroid	O
.	O

We	O
also	O
examined	O
the	O
methylation	O
status	O
of	O
DAP	O
-	O
kinase	O
gene	O
in	O
16	O
cases	O
of	O
T	O
-	O
cell	O
malignancies	O
including	O
eight	O
adult	O
T	O
-	O
cell	O
leukemia	O
/	O
lymphoma	O
and	O
24	O
NK	O
/	O
T	O
-	O
cell	O
,	O
34	O
B	O
-	O
cell	O
,	O
and	O
two	O
immunophenotypically	O
undetermined	O
lymphomas	O
.	O

Frequency	O
of	O
methylation	O
was	O
higher	O
in	O
B	O
-	O
cell	O
(	O
27	O
of	O
34	O
,	O
79	O
.	O
4	O
%	O
)	O
than	O
in	O
T	O
-	O
cell	O
malignancies	O
(	O
eight	O
of	O
16	O
,	O
50	O
%	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Fifteen	O
of	O
24	O
(	O
62	O
.	O
5	O
%	O
)	O
NK	O
/	O
T	O
-	O
cell	O
lymphomas	O
showed	O
DNA	O
methylation	O
.	O

Hematopoietic	O
cell	O
lines	O
with	O
a	O
methylated	O
gene	O
were	O
resistant	O
to	O
apoptosis	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
a	O
demethylating	O
agent	O
restored	O
apoptotic	O
cell	O
death	O
in	O
one	O
B	O
-	O
cell	O
lymphoma	O
cell	O
line	O
with	O
DNA	O
methylation	O
.	O

Our	O
results	O
suggested	O
that	O
suppression	O
of	O
DAP	O
-	O
Kinase	O
expression	O
by	O
DNA	O
methylation	O
might	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
B	O
-	O
cell	O
malignancies	O
.	O

Asparagine	O
hydroxylation	O
of	O
the	O
HIF	O
transactivation	O
domain	O
a	O
hypoxic	O
switch	O
.	O

The	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factors	I-Protein
(	I-Protein
HIFs	I-Protein
)	I-Protein
1alpha	E-Protein
and	O
2alpha	S-Protein
are	O
key	O
mammalian	O
transcription	O
factors	O
that	O
exhibit	O
dramatic	O
increases	O
in	O
both	O
protein	O
stability	O
and	O
intrinsic	O
transcriptional	O
potency	O
during	O
low	O
-	O
oxygen	O
stress	O
.	O

This	O
increased	O
stability	O
is	O
due	O
to	O
the	O
absence	O
of	O
proline	O
hydroxylation	O
,	O
which	O
in	O
normoxia	O
promotes	O
binding	O
of	O
HIF	O
to	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	E-Protein
(	O
VHL	B-Protein
tumor	I-Protein
suppressor	E-Protein
)	O
ubiquitin	S-Protein
ligase	O
.	O

We	O
now	O
show	O
that	O
hypoxic	O
induction	O
of	O
the	O
COOH	O
-	O
terminal	O
transactivation	O
domain	O
(	O
CAD	O
)	O
of	O
HIF	O
occurs	O
through	O
abrogation	O
of	O
hydroxylation	O
of	O
a	O
conserved	O
asparagine	O
in	O
the	O
CAD	O
.	O

Inhibitors	O
of	O
Fe	O
(	O
II	O
)	O
-	O
and	O
2	O
-	O
oxoglutarate	O
-	O
dependent	O
dioxygenases	O
prevented	O
hydroxylation	O
of	O
the	O
Asn	O
,	O
thus	O
allowing	O
the	O
CAD	O
to	O
interact	O
with	O
the	O
p300	S-Protein
transcription	O
coactivator	O
.	O

Replacement	O
of	O
the	O
conserved	O
Asn	O
by	O
Ala	O
resulted	O
in	O
constitutive	O
p300	S-Protein
interaction	O
and	O
strong	O
transcriptional	O
activity	O
.	O

Full	O
induction	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
-	B-Protein
2alpha	E-Protein
,	O
therefore	O
,	O
relies	O
on	O
the	O
abrogation	O
of	O
both	O
Pro	O
and	O
Asn	O
hydroxylation	O
,	O
which	O
during	O
normoxia	O
occur	O
at	O
the	O
degradation	O
and	O
COOH	O
-	O
terminal	O
transactivation	O
domains	O
,	O
respectively	O
.	O

Polymorphism	O
of	O
the	O
N	B-Protein
-	I-Protein
acetyltransferase	I-Protein
2	E-Protein
gene	O
as	O
a	O
susceptibility	O
risk	O
factor	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O

Antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
drug	O
-	O
induced	O
liver	O
injuries	O
.	O

Isoniazid	O
is	O
the	O
major	O
drug	O
incriminated	O
in	O
this	O
hepatotoxicity	O
.	O

Isoniazid	O
is	O
mainly	O
metabolized	O
to	O
hepatotoxic	O
intermediates	O
by	O
N	O
-	O
acetyltransferase	O
(	O
NAT	O
)	O
.	O

However	O
,	O
the	O
association	O
of	O
polymorphic	O
NAT	O
acetylator	O
status	O
and	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
is	O
debatable	O
.	O

To	O
determine	O
whether	O
acetylator	O
status	O
is	O
a	O
risk	O
factor	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
,	O
we	O
genotyped	O
NAT2	S-Protein
in	O
224	O
incident	O
tuberculosis	O
patients	O
who	O
received	O
antituberculosis	O
treatment	O
.	O

Antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
was	O
diagnosed	O
based	O
on	O
a	O
positive	O
isoniazid	O
rechallenge	O
test	O
and	O
exclusion	O
of	O
viral	O
hepatitis	O
.	O

Acetylator	O
status	O
was	O
determined	O
by	O
genotyping	O
NAT2	S-Protein
in	O
patients	O
using	O
a	O
polymerase	O
chain	O
reaction	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

Univariate	O
analysis	O
and	O
logistic	O
regression	O
analysis	O
were	O
used	O
to	O
evaluate	O
the	O
risk	O
factors	O
of	O
isoniazid	O
-	O
induced	O
hepatitis	O
.	O

Thirty	O
-	O
three	O
patients	O
(	O
14	O
.	O
7	O
%	O
)	O
were	O
diagnosed	O
with	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O

Slow	O
acetylators	O
had	O
a	O
higher	O
risk	O
of	O
hepatotoxicity	O
than	O
rapid	O
acetylators	O
(	O
26	O
.	O
4	O
%	O
vs	O
.	O
11	O
.	O
1	O
%	O
,	O
P	O
=	O
.	O
013	O
)	O
.	O

Among	O
patients	O
with	O
hepatotoxicity	O
,	O
slow	O
acetylators	O
had	O
significantly	O
higher	O
serum	O
aminotransferase	O
levels	O
than	O
rapid	O
acetylators	O
.	O

Logistic	O
regression	O
showed	O
that	O
slow	O
-	O
acetylator	O
status	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
3	O
.	O
66	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
58	O
-	O
8	O
.	O
49	O
;	O
P	O
=	O
.	O
003	O
)	O
and	O
age	O
(	O
OR	O
,	O
1	O
.	O
09	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
04	O
-	O
1	O
.	O
14	O
;	O
P	O
<	O
.	O
001	O
)	O
were	O
the	O
only	O
2	O
independent	O
risk	O
factors	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O

In	O
conclusion	O
,	O
slow	O
-	O
acetylator	O
status	O
of	O
NAT2	S-Protein
is	O
a	O
significant	O
susceptibility	O
risk	O
factor	O
for	O
antituberculosis	O
drug	O
-	O
induced	O
hepatitis	O
.	O

Additionally	O
,	O
slow	O
acetylators	O
are	O
prone	O
to	O
develop	O
more	O
severe	O
hepatotoxicity	O
than	O
rapid	O
acetylators	O
.	O

Regular	O
monitoring	O
of	O
serum	O
aminotransferase	O
levels	O
is	O
mandatory	O
in	O
patients	O
receiving	O
antituberculosis	O
treatment	O
,	O
especially	O
in	O
slow	O
acetylators	O
.	O

Reversal	O
of	O
tolerance	O
induced	O
by	O
transplantation	O
of	O
skin	O
expressing	O
the	O
immunodominant	O
T	O
cell	O
epitope	O
of	O
rat	O
type	B-Protein
II	I-Protein
collagen	E-Protein
entitles	O
development	O
of	O
collagen	O
-	O
induced	O
arthritis	O
but	O
not	O
graft	O
rejection	O
.	O

Collagen	O
-	O
induced	O
arthritis	O
(	O
CIA	O
)	O
is	O
induced	O
in	O
H	O
-	O
2	O
(	O
q	O
)	O
mice	O
after	O
immunization	O
with	O
rat	O
type	B-Protein
II	I-Protein
collagen	E-Protein
(	O
CII	S-Protein
)	O
.	O

The	O
immunodominant	O
T	O
cell	O
epitope	O
on	O
heterologous	O
CII	S-Protein
has	O
been	O
located	O
to	O
CII256	S-Protein
-	O
270	O
.	O

We	O
have	O
previously	O
shown	O
that	O
TSC	O
transgenic	O
mice	O
,	O
which	O
express	O
the	O
heterologous	O
epitope	O
in	O
type	O
I	O
collagen	O
(	O
CI	O
)	O
,	O
e	O
.	O
g	O
.	O
in	O
skin	O
,	O
are	O
tolerized	O
against	O
rat	O
CII	S-Protein
and	O
resistant	O
to	O
CIA	O
.	O

In	O
this	O
study	O
we	O
transplanted	O
skin	O
from	O
TSC	O
transgenic	O
mice	O
onto	O
non	O
-	O
transgenic	O
CIA	O
-	O
susceptible	O
littermates	O
to	O
investigate	O
whether	O
introduction	O
of	O
this	O
epitope	O
to	O
a	O
naive	O
immune	O
system	O
would	O
lead	O
to	O
T	O
cell	O
priming	O
and	O
graft	O
rejection	O
or	O
instead	O
to	O
tolerance	O
and	O
arthritis	O
protection	O
.	O

Interestingly	O
,	O
TSC	O
grafts	O
were	O
accepted	O
and	O
not	O
even	O
immunization	O
of	O
recipient	O
mice	O
with	O
CII	S-Protein
in	O
adjuvant	O
induced	O
graft	O
rejection	O
.	O

Instead	O
,	O
TSC	O
skin	O
recipients	O
displayed	O
a	O
reduced	O
T	O
and	O
B	O
cell	O
response	O
to	O
CII	S-Protein
and	O
were	O
also	O
protected	O
from	O
arthritis	O
.	O

However	O
,	O
additional	O
priming	O
could	O
break	O
arthritis	O
protection	O
and	O
was	O
accompanied	O
by	O
an	O
increased	O
T	O
cell	O
response	O
to	O
the	O
grafted	O
epitope	O
.	O

Strikingly	O
,	O
despite	O
the	O
regained	O
T	O
cell	O
response	O
,	O
development	O
of	O
arthritis	O
was	O
not	O
accompanied	O
by	O
graft	O
rejection	O
,	O
showing	O
that	O
these	O
immune	O
-	O
mediated	O
inflammatory	O
responses	O
involve	O
different	O
mechanisms	O
.	O

Glucocorticoid	O
regulation	O
and	O
glycosylation	O
of	O
mouse	O
intestinal	O
type	B-Protein
IIb	I-Protein
Na	I-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
cotransporter	E-Protein
during	O
ontogeny	O
.	O

We	O
sought	O
to	O
characterize	O
expression	O
of	O
an	O
apically	O
expressed	O
intestinal	O
Na	O
-	O
P	O
(	O
i	O
)	O
cotransporter	O
(	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	E-Protein
)	O
during	O
mouse	O
ontogeny	O
and	O
to	O
assess	O
the	O
effects	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
treatment	O
.	O

In	O
control	O
mice	O
,	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
by	O
intestinal	O
brush	O
-	O
border	O
membrane	O
vesicles	O
was	O
highest	O
at	O
14	O
days	O
of	O
age	O
,	O
lower	O
at	O
21	O
days	O
,	O
and	O
further	O
reduced	O
at	O
8	O
wk	O
and	O
8	O
-	O
9	O
mo	O
of	O
age	O
.	O

Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	E-Protein
mRNA	O
and	O
immunoreactive	O
protein	O
levels	O
in	O
14	O
-	O
day	O
-	O
old	O
animals	O
were	O
markedly	O
higher	O
than	O
in	O
older	O
groups	O
.	O

MP	O
treatment	O
significantly	O
decreased	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
and	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	E-Protein
mRNA	O
and	O
protein	O
expression	O
in	O
14	O
-	O
day	O
-	O
old	O
mice	O
.	O

Additionally	O
,	O
the	O
size	O
of	O
the	O
protein	O
was	O
smaller	O
in	O
14	O
-	O
day	O
-	O
old	O
mice	O
.	O

Deglycosylation	O
of	O
protein	O
from	O
14	O
-	O
day	O
-	O
old	O
and	O
8	O
-	O
wk	O
-	O
old	O
animals	O
with	O
peptide	O
N	O
-	O
glycosidase	O
reduced	O
the	O
molecular	O
weight	O
to	O
the	O
predicted	O
size	O
.	O

We	O
conclude	O
that	O
intestinal	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
and	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	E-Protein
expression	O
are	O
highest	O
at	O
14	O
days	O
and	O
decrease	O
with	O
age	O
.	O

Furthermore	O
,	O
MP	O
treatment	O
reduced	O
intestinal	O
Na	O
-	O
P	O
(	O
i	O
)	O
uptake	O
approximately	O
threefold	O
in	O
14	O
-	O
day	O
-	O
old	O
mice	O
and	O
this	O
reduction	O
correlates	O
with	O
reduced	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	E-Protein
mRNA	O
and	O
protein	O
expression	O
.	O

We	O
also	O
demonstrate	O
that	O
Na	B-Protein
-	I-Protein
P	I-Protein
(	I-Protein
i	I-Protein
)	I-Protein
-	I-Protein
IIb	E-Protein
is	O
an	O
N	O
-	O
linked	O
glycoprotein	O
and	O
that	O
glycosylation	O
is	O
age	O
dependent	O
.	O

The	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	E-Protein
protein	O
:	O
new	O
insights	O
into	O
oxygen	O
sensing	O
and	O
cancer	O
.	O

The	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	E-Protein
protein	O
(	O
pVHL	S-Protein
)	O
is	O
the	O
substrate	O
-	O
recognition	O
module	O
of	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
targets	O
the	O
alpha	O
subunits	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
for	O
degradation	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O

Recognition	O
of	O
HIF	O
by	O
pVHL	S-Protein
is	O
linked	O
to	O
enzymatic	O
hydroxylation	O
of	O
conserved	O
prolyl	O
residues	O
in	O
the	O
HIF	O
alpha	O
subunits	O
by	O
members	O
of	O
the	O
EGLN	O
family	O
.	O

Dysregulation	O
of	O
HIF	O
-	O
target	O
genes	O
such	O
as	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	E-Protein
and	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
alpha	E-Protein
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
renal	O
cell	O
carcinomas	O
and	O
of	O
hemangioblastomas	O
,	O
both	O
of	O
which	O
frequently	O
lack	O
pVHL	S-Protein
function	O
.	O

The	O
roles	O
of	O
supernumerical	O
X	O
chromosomes	O
and	O
XIST	S-Protein
expression	O
in	O
testicular	O
germ	O
cell	O
tumors	O
.	O

PURPOSE	O
:	O
An	O
overabundance	O
of	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumors	O
and	O
the	O
identification	O
of	O
the	O
candidate	O
testicular	O
germ	O
cell	O
tumor	O
susceptibility	O
gene	O
TGCT1	S-Protein
on	O
Xq27	O
highlight	O
the	O
potential	O
involvement	O
of	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumor	O
pathogenesis	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
shed	O
light	O
on	O
the	O
question	O
whether	O
the	O
multiple	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumor	O
are	O
active	O
or	O
inactive	O
through	O
a	O
complex	O
mechanism	O
of	O
X	O
chromosomal	O
gain	O
and	O
XIST	S-Protein
expression	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
analyzed	O
4	O
testicular	O
germ	O
cell	O
tumor	O
derived	O
cell	O
lines	O
and	O
20	O
primary	O
testicular	O
germ	O
cell	O
tumor	O
tissues	O
.	O

The	O
number	O
of	O
X	O
chromosomes	O
was	O
determined	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
using	O
the	O
X	O
chromosome	O
specific	O
probe	O
.	O

The	O
expression	O
patterns	O
of	O
XIST	S-Protein
and	O
the	O
3	O
X	O
-	O
linked	O
genes	O
androgen	B-Protein
receptor	E-Protein
(	O
AR	S-Protein
)	O
,	O
fragile	O
X	O
mental	O
retardation	O
(	O
FMR1	S-Protein
)	O
and	O
Glypican	B-Protein
3	E-Protein
(	O
GPC3	S-Protein
)	O
were	O
studied	O
by	O
reverse	B-Protein
transcriptase	E-Protein
-	O
polymerase	O
chain	O
reaction	O
.	O

Bisulfite	O
genomic	O
sequencing	O
was	O
used	O
to	O
analyze	O
the	O
methylation	O
patterns	O
of	O
the	O
AR	S-Protein
,	O
FMR1	S-Protein
and	O
GPC3	S-Protein
genes	O
.	O

The	O
relative	O
expression	O
levels	O
of	O
the	O
2	O
X	O
-	O
linked	O
proto	O
-	O
oncogenes	O
ARAF1	S-Protein
and	O
ELK1	S-Protein
were	O
assayed	O
by	O
quantitative	O
reverse	B-Protein
transcriptase	E-Protein
-	O
polymerase	O
chain	O
reaction	O
.	O

RESULTS	O
:	O
XIST	S-Protein
expression	O
was	O
common	O
in	O
seminomatous	O
testicular	O
germ	O
cell	O
tumors	O
(	O
2	O
of	O
2	O
or	O
100	O
%	O
of	O
seminoma	O
derived	O
cell	O
lines	O
and	O
10	O
of	O
12	O
or	O
83	O
%	O
of	O
seminomatous	O
testicular	O
germ	O
cell	O
tumor	O
tissues	O
)	O
but	O
not	O
in	O
nonseminomatous	O
testicular	O
germ	O
cell	O
tumors	O
(	O
0	O
of	O
2	O
or	O
0	O
%	O
nonseminoma	O
derived	O
cell	O
lines	O
and	O
2	O
of	O
8	O
or	O
25	O
%	O
of	O
nonseminomatous	O
testicular	O
germ	O
cell	O
tumor	O
tissues	O
)	O
.	O

However	O
,	O
X	O
chromosomal	O
gain	O
was	O
consistently	O
observed	O
in	O
the	O
2	O
types	O
of	O
tumors	O
.	O

XIST	S-Protein
expression	O
in	O
testicular	O
germ	O
cell	O
tumors	O
and	O
normal	O
testicular	O
parenchyma	O
was	O
not	O
associated	O
with	O
methylation	O
of	O
the	O
AR	S-Protein
,	O
FMR1	S-Protein
or	O
GPC3	S-Protein
genes	O
.	O

After	O
determining	O
the	O
expression	O
patterns	O
of	O
AR	S-Protein
,	O
FMR1	S-Protein
and	O
GPC3	S-Protein
in	O
testicular	O
germ	O
cell	O
tumor	O
samples	O
we	O
concluded	O
that	O
multiple	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumors	O
were	O
predominantly	O
hypomethylated	O
and	O
active	O
regardless	O
of	O
XIST	S-Protein
expression	O
.	O

The	O
biological	O
significance	O
of	O
excess	O
active	O
X	O
chromosomes	O
in	O
testicular	O
germ	O
cell	O
tumors	O
was	O
suggested	O
by	O
enhanced	O
expression	O
of	O
the	O
2	O
X	O
-	O
linked	O
oncogenes	O
ARAF1	S-Protein
and	O
ELK1	S-Protein
in	O
the	O
testicular	O
germ	O
cell	O
tumor	O
derived	O
cell	O
lines	O
.	O

CONCLUSIONS	O
:	O
The	O
current	O
data	O
may	O
suggest	O
the	O
potential	O
oncogenic	O
implications	O
of	O
X	O
chromosomal	O
gain	O
in	O
testicular	O
germ	O
cell	O
tumors	O
.	O

Cloning	O
and	O
sequence	O
analysis	O
of	O
FSH	O
and	O
LH	O
in	O
the	O
giant	O
panda	O
(	O
Ailuropoda	O
melanoleuca	O
)	O
.	O

The	O
giant	O
panda	O
(	O
Ailuropoda	O
melanoleuca	O
)	O
is	O
an	O
endangered	O
species	O
and	O
indigenous	O
to	O
China	O
.	O

It	O
has	O
been	O
proposed	O
that	O
it	O
has	O
a	O
highly	O
specialized	O
reproductive	O
pattern	O
with	O
low	O
fecundity	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
basic	O
reproductive	O
biology	O
at	O
the	O
molecular	O
level	O
.	O

In	O
this	O
report	O
the	O
genes	O
encoding	O
gonadotropin	B-Protein
subunits	I-Protein
alpha	E-Protein
,	O
follicle	B-Protein
-	I-Protein
stimulating	I-Protein
hormone	I-Protein
(	I-Protein
FSH	I-Protein
)	I-Protein
beta	E-Protein
and	O
luteinizing	B-Protein
hormone	I-Protein
(	I-Protein
LH	I-Protein
)	I-Protein
beta	E-Protein
of	O
the	O
giant	O
panda	O
were	O
amplified	O
for	O
the	O
first	O
time	O
by	O
RT	O
-	O
PCR	O
from	O
pituitary	O
total	O
RNA	O
,	O
and	O
were	O
cloned	O
,	O
sequenced	O
and	O
analyzed	O
.	O

The	O
results	O
revealed	O
that	O
the	O
open	O
reading	O
region	O
(	O
ORF	O
)	O
of	O
gonadotropin	B-Protein
subunits	I-Protein
alpha	E-Protein
,	O
FSH	B-Protein
beta	E-Protein
and	O
LH	B-Protein
beta	E-Protein
are	O
363	O
,	O
390	O
and	O
426	O
bp	O
long	O
,	O
respectively	O
.	O

They	O
displayed	O
a	O
reasonably	O
high	O
degree	O
(	O
74	O
-	O
94	O
,	O
85	O
-	O
93	O
,	O
75	O
-	O
91	O
%	O
,	O
for	O
alpha	O
,	O
FSH	B-Protein
beta	E-Protein
and	O
LH	B-Protein
beta	E-Protein
subunits	O
,	O
respectively	O
)	O
of	O
identity	O
when	O
deduced	O
amino	O
acids	O
were	O
compared	O
with	O
homologous	O
sequences	O
from	O
partial	O
available	O
mammals	O
including	O
human	O
,	O
cattle	O
,	O
sheep	O
,	O
pig	O
,	O
rat	O
,	O
mouse	O
.	O

Three	O
distinct	O
differences	O
were	O
found	O
at	O
the	O
site	O
of	O
59	O
aa	O
of	O
the	O
alpha	O
subunit	O
and	O
55	O
aa	O
,	O
68	O
aa	O
of	O
FSH	B-Protein
beta	E-Protein
subunit	O
.	O

Our	O
results	O
provide	O
an	O
insight	O
into	O
understanding	O
the	O
mechanism	O
of	O
reproduction	O
regulation	O
and	O
genetic	O
characteristics	O
of	O
giant	O
panda	O
which	O
will	O
make	O
an	O
actual	O
contribution	O
to	O
its	O
conservation	O
.	O

In	O
addition	O
they	O
lay	O
a	O
foundation	O
for	O
a	O
further	O
study	O
towards	O
producing	O
recombinant	O
panda	O
FSH	O
and	O
LH	O
which	O
can	O
be	O
used	O
in	O
artificial	O
breeding	O
aimed	O
to	O
increase	O
its	O
captive	O
reproductive	O
efficiency	O
.	O

Erasure	O
of	O
methylation	O
imprinting	O
of	O
Igf2r	S-Protein
during	O
mouse	O
primordial	O
germ	O
-	O
cell	O
development	O
.	O

During	O
germ	O
cell	O
differentiation	O
in	O
mice	O
,	O
the	O
genome	O
undergoes	O
specific	O
epigenetic	O
modifications	O
.	O

These	O
include	O
demethylation	O
of	O
imprinted	O
genes	O
and	O
subsequent	O
establishment	O
of	O
parental	O
allele	O
-	O
specific	O
methylation	O
.	O

The	O
mouse	O
Igf2r	S-Protein
gene	O
is	O
an	O
imprinted	O
gene	O
that	O
shows	O
maternal	O
-	O
specific	O
expression	O
.	O

Maternal	O
-	O
specific	O
methylation	O
of	O
differentially	O
methylated	O
region	O
2	O
(	O
DMR2	O
)	O
of	O
this	O
gene	O
may	O
be	O
necessary	O
for	O
its	O
maternal	O
-	O
specific	O
expression	O
.	O

Before	O
the	O
allele	O
-	O
specific	O
methylation	O
is	O
established	O
,	O
DMR2	O
is	O
demethylated	O
in	O
both	O
male	O
and	O
female	O
primordial	O
germ	O
cells	O
(	O
PGCs	O
)	O
by	O
13	O
.	O
5	O
days	O
post	O
coitum	O
(	O
dpc	O
)	O
,	O
indicating	O
that	O
the	O
demethylation	O
of	O
this	O
region	O
occurs	O
earlier	O
in	O
PGC	O
development	O
.	O

The	O
timing	O
of	O
the	O
demethylation	O
has	O
been	O
,	O
however	O
,	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
determine	O
the	O
timing	O
of	O
methylation	O
erasure	O
of	O
Igf2r	S-Protein
DMR2	O
in	O
developing	O
PGCs	O
,	O
using	O
transgenic	O
mice	O
expressing	O
green	B-Protein
fluorescent	I-Protein
protein	E-Protein
specifically	O
in	O
the	O
germ	O
line	O
.	O

We	O
purified	O
migrating	O
PGCs	O
from	O
the	O
transgenic	O
mice	O
and	O
examined	O
the	O
methylation	O
status	O
of	O
DMR2	O
.	O

The	O
results	O
show	O
that	O
some	O
CpG	O
sites	O
within	O
DMR2	O
start	O
demethylation	O
at	O
9	O
.	O
5	O
dpc	O
in	O
some	O
migrating	O
PGCs	O
,	O
before	O
the	O
cells	O
colonize	O
genital	O
ridges	O
,	O
and	O
the	O
progression	O
of	O
demethylation	O
is	O
rapid	O
after	O
colonization	O
of	O
the	O
genital	O
ridges	O
.	O

To	O
examine	O
whether	O
the	O
gonadal	O
environment	O
is	O
involved	O
in	O
demethylation	O
,	O
we	O
analyzed	O
the	O
methylation	O
of	O
DMR2	O
after	O
culturing	O
migrating	O
PGCs	O
in	O
the	O
absence	O
of	O
a	O
gonadal	O
environment	O
.	O

These	O
culture	O
experiments	O
support	O
the	O
idea	O
that	O
a	O
gonadal	O
environment	O
is	O
not	O
required	O
for	O
demethylation	O
of	O
the	O
region	O
in	O
at	O
least	O
a	O
fraction	O
of	O
PGCs	O
.	O

Inhibition	O
of	O
complex	O
glycosylation	O
increases	O
the	O
formation	O
of	O
PrPsc	S-Protein
.	O

N	O
-	O
linked	O
glycans	O
with	O
complex	O
structure	O
have	O
a	O
major	O
role	O
in	O
the	O
biological	O
activity	O
of	O
a	O
wide	O
variety	O
of	O
cell	O
surface	O
and	O
secreted	O
glycoproteins	O
.	O

Here	O
,	O
we	O
show	O
that	O
geldanamycin	O
,	O
an	O
inhibitor	O
of	O
Hsp90	O
,	O
interferes	O
with	O
the	O
formation	O
of	O
complex	O
glycosylated	O
mammalian	O
prion	B-Protein
protein	E-Protein
(	O
PrPC	S-Protein
)	O
.	O

Similarly	O
to	O
inhibitors	O
of	O
alpha	O
-	O
mannosidases	O
,	O
geldanamycin	O
stabilized	O
a	O
high	O
mannose	O
PrPC	S-Protein
glycoform	O
and	O
prevented	O
the	O
subsequent	O
processing	O
into	O
complex	O
structures	O
.	O

Moreover	O
,	O
a	O
PrP	S-Protein
/	O
Grp94	S-Protein
complex	O
could	O
be	O
isolated	O
from	O
geldanamycin	O
-	O
treated	O
cells	O
,	O
suggesting	O
that	O
Grp94	S-Protein
might	O
play	O
a	O
role	O
in	O
the	O
processing	O
of	O
PrPC	S-Protein
in	O
the	O
endoplasmic	O
reticulum	O
.	O

Inhibition	O
of	O
complex	O
glycosylation	O
did	O
not	O
interfere	O
with	O
the	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchor	O
attachment	O
and	O
cellular	O
trafficking	O
of	O
high	O
mannose	O
PrPC	S-Protein
to	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
.	O

In	O
scrapie	O
-	O
infected	O
neuroblastoma	O
cells	O
,	O
however	O
,	O
high	O
mannose	O
PrPC	S-Protein
glycoforms	O
were	O
preferred	O
substrates	O
for	O
the	O
formation	O
of	O
PrP	S-Protein
-	O
scrapie	O
(	O
PrPSc	S-Protein
)	O
.	O

Our	O
study	O
reveals	O
that	O
complex	O
glycosylation	O
is	O
dispensable	O
for	O
the	O
cellular	O
trafficking	O
of	O
PrPC	S-Protein
,	O
but	O
modulates	O
the	O
formation	O
of	O
PrPSc	S-Protein
.	O

Chromatin	O
-	O
dependent	O
regulation	O
of	O
the	O
MMTV	O
promoter	O
by	O
cAMP	O
signaling	O
is	O
mediated	O
through	O
distinct	O
pathways	O
.	O

The	O
nucleoprotein	O
structure	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
promoter	O
defines	O
its	O
response	O
to	O
cAMP	O
signaling	O
.	O

A	O
stably	O
replicating	O
MMTV	O
template	O
in	O
highly	O
organized	O
chromatin	O
is	O
repressed	O
in	O
the	O
presence	O
of	O
cAMP	O
,	O
whereas	O
a	O
transiently	O
transfected	O
template	O
with	O
a	O
disorganized	O
structure	O
is	O
activated	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
nature	O
of	O
the	O
cAMP	O
-	O
induced	O
signal	O
(	O
s	O
)	O
by	O
which	O
these	O
opposing	O
responses	O
occur	O
to	O
gain	O
insight	O
into	O
their	O
mechanism	O
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
changes	O
observed	O
at	O
both	O
templates	O
are	O
mediated	O
through	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

In	O
addition	O
,	O
the	O
MMTV	O
promoter	O
lacks	O
a	O
consensus	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
neither	O
template	O
requires	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
to	O
elicit	O
a	O
response	O
to	O
cAMP	O
signaling	O
.	O

However	O
,	O
the	O
responses	O
of	O
the	O
two	O
templates	O
differ	O
mechanistically	O
in	O
that	O
the	O
CREB	O
-	O
binding	O
protein	O
p300	S-Protein
potentiates	O
activation	O
from	O
the	O
transient	O
template	O
in	O
a	O
manner	O
dependent	O
on	O
its	O
Cys	O
/	O
His	O
-	O
rich	O
region	O
3	O
,	O
but	O
does	O
not	O
appear	O
to	O
affect	O
the	O
repression	O
of	O
the	O
replicating	O
chromatin	O
template	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
show	O
that	O
cAMP	O
treatment	O
results	O
in	O
a	O
decrease	O
in	O
acetylation	O
of	O
histone	B-Protein
H4	E-Protein
,	O
and	O
in	O
multiple	O
modifications	O
of	O
histone	B-Protein
H3	E-Protein
at	O
specific	O
nucleosomes	O
in	O
the	O
promoter	O
region	O
of	O
the	O
stable	O
MMTV	O
template	O
.	O

These	O
findings	O
suggest	O
novel	O
CREB	O
-	O
independent	O
,	O
chromatin	O
-	O
dependent	O
pathways	O
for	O
transcriptional	O
regulation	O
by	O
cAMP	O
.	O

Identification	O
of	O
the	O
ZPC	S-Protein
oligosaccharide	O
ligand	O
involved	O
in	O
sperm	O
binding	O
and	O
the	O
glycan	O
structures	O
of	O
Xenopus	O
laevis	O
vitelline	O
envelope	O
glycoproteins	O
.	O

The	O
Xenopus	O
laevis	O
egg	O
vitelline	O
envelope	O
is	O
composed	O
of	O
five	O
glycoproteins	O
(	O
ZPA	S-Protein
,	O
ZPB	S-Protein
,	O
ZPC	S-Protein
,	O
ZPD	S-Protein
,	O
and	O
ZPX	S-Protein
)	O
.	O

As	O
shown	O
previously	O
,	O
ZPC	S-Protein
is	O
the	O
primary	O
ligand	O
for	O
sperm	O
binding	O
to	O
the	O
egg	O
envelope	O
,	O
and	O
this	O
binding	O
involves	O
the	O
oligosaccharide	O
moieties	O
of	O
the	O
glycoprotein	O
(	O
Biol	O
.	O
Reprod	O
.	O
,	O
62	O
:	O
766	O
-	O
774	O
,	O
2000	O
)	O
.	O

To	O
understand	O
the	O
molecular	O
mechanism	O
of	O
sperm	O
-	O
egg	O
envelope	O
binding	O
,	O
we	O
characterized	O
the	O
N	O
-	O
linked	O
glycans	O
of	O
the	O
vitelline	O
envelope	O
(	O
VE	O
)	O
glycoproteins	O
.	O

The	O
N	O
-	O
linked	O
glycans	O
of	O
the	O
VE	O
were	O
composed	O
predominantly	O
of	O
a	O
heterogeneous	O
mixture	O
of	O
high	O
-	O
mannose	O
(	O
5	O
-	O
9	O
)	O
and	O
neutral	O
,	O
complex	O
oligosaccharides	O
primarily	O
derived	O
from	O
ZPC	S-Protein
(	O
the	O
dominant	O
glycoprotein	O
)	O
.	O

However	O
,	O
the	O
ZPA	S-Protein
N	O
-	O
linked	O
glycans	O
were	O
composed	O
of	O
acidic	O
-	O
complex	O
and	O
high	O
-	O
mannose	O
oligosaccharides	O
,	O
ZPX	S-Protein
had	O
only	O
high	O
-	O
mannose	O
oligosaccharides	O
,	O
and	O
ZPB	S-Protein
lacked	O
N	O
-	O
linked	O
oligosaccharides	O
.	O

The	O
consensus	O
sequence	O
for	O
N	O
-	O
linked	O
glycosylation	O
at	O
the	O
evolutionarily	O
conserved	O
residue	O
N113	O
of	O
the	O
ZPC	S-Protein
protein	O
sequence	O
was	O
glycosylated	O
solely	O
with	O
high	O
-	O
mannose	O
oligosaccharides	O
.	O

This	O
conserved	O
glycosylation	O
site	O
may	O
be	O
of	O
importance	O
to	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
ZPC	S-Protein
glycoproteins	O
.	O

One	O
of	O
the	O
complex	O
oligosaccharides	O
of	O
ZPC	S-Protein
possessed	O
terminal	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
glucosamine	O
residues	O
.	O

The	O
same	O
ZPC	S-Protein
oligosaccharide	O
species	O
isolated	O
from	O
the	O
activated	O
egg	O
envelopes	O
lacked	O
terminal	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
glucosamine	O
residues	O
.	O

We	O
previously	O
showed	O
that	O
the	O
cortical	O
granules	O
contain	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
glucosaminidase	O
(	O
J	O
.	O
Exp	O
.	O
Zool	O
.	O
,	O
235	O
:	O
335	O
-	O
340	O
,	O
1985	O
)	O
.	O

We	O
propose	O
that	O
an	O
alteration	O
in	O
the	O
oligosaccharide	O
structure	O
of	O
ZPC	S-Protein
by	O
glucosaminidase	O
released	O
from	O
the	O
cortical	O
granule	O
reaction	O
is	O
responsible	O
for	O
the	O
loss	O
of	O
sperm	O
binding	O
ligand	O
activity	O
at	O
fertilization	O
.	O

Set2	S-Protein
-	O
catalyzed	O
methylation	O
of	O
histone	B-Protein
H3	E-Protein
represses	O
basal	O
expression	O
of	O
GAL4	S-Protein
in	O
Saccharomyces	O
cerevisiae	O
.	O

Recent	O
work	O
has	O
shown	O
that	O
histone	S-Protein
methylation	O
is	O
an	O
important	O
regulator	O
of	O
transcription	O
.	O

While	O
much	O
is	O
known	O
about	O
the	O
roles	O
of	O
histone	O
methyltransferases	O
(	O
HMTs	O
)	O
in	O
the	O
establishment	O
of	O
heterochromatin	O
,	O
little	O
is	O
known	O
of	O
their	O
roles	O
in	O
the	O
regulation	O
of	O
actively	O
transcribed	O
genes	O
.	O

We	O
describe	O
an	O
in	O
vivo	O
role	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
HMT	O
,	O
Set2	S-Protein
.	O

We	O
identified	O
SET2	S-Protein
as	O
a	O
gene	O
necessary	O
for	O
repression	O
of	O
GAL4	S-Protein
basal	O
expression	O
and	O
show	O
that	O
the	O
evolutionarily	O
conserved	O
SACI	O
,	O
SACII	O
,	O
and	O
SET	O
domains	O
of	O
Set2	S-Protein
are	O
necessary	O
for	O
this	O
repression	O
.	O

We	O
confirm	O
that	O
Set2	S-Protein
catalyzes	O
methylation	O
of	O
lysine	O
36	O
on	O
the	O
N	O
-	O
terminal	O
tail	O
of	O
histone	B-Protein
H3	E-Protein
.	O

Conversion	O
of	O
lysine	O
36	O
to	O
an	O
unmethylatable	O
arginine	O
causes	O
a	O
decrease	O
in	O
the	O
repression	O
of	O
GAL4	S-Protein
transcription	O
,	O
as	O
does	O
a	O
Delta	O
set2	S-Protein
mutation	O
.	O

We	O
further	O
show	O
that	O
lysine	O
36	O
of	O
histone	B-Protein
H3	E-Protein
at	O
GAL4	S-Protein
is	O
methylated	O
and	O
that	O
this	O
methylation	O
is	O
dependent	O
upon	O
the	O
presence	O
of	O
SET2	S-Protein
.	O

A	O
possible	O
role	O
of	O
carbohydrate	O
moieties	O
in	O
prostaglandin	B-Protein
D2	E-Protein
and	O
prostaglandin	O
E2	O
receptor	O
proteins	O
from	O
the	O
porcine	O
temporal	O
cortex	O
.	O

The	O
binding	O
activities	O
of	O
prostaglandins	O
(	O
PGs	O
)	O
D2	O
and	O
E2	O
were	O
measured	O
after	O
deglycosylation	O
of	O
P2	O
membranes	O
prepared	O
from	O
the	O
porcine	O
temporal	O
cortex	O
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
carbohydrate	O
moieties	O
in	O
the	O
receptor	O
binding	O
.	O

PGD2	O
and	O
PGE2	O
binding	O
activities	O
were	O
significantly	O
decreased	O
by	O
pretreatment	O
with	O
various	O
exoglycosidases	O
,	O
such	O
as	O
neuraminidase	O
for	O
PGE2	O
binding	O
,	O
alpha	O
-	O
mannosidase	O
and	O
beta	O
-	O
galactosidase	O
for	O
PGD2	O
binding	O
,	O
and	O
beta	O
-	O
N	O
-	O
acetylhexosaminidase	O
for	O
both	O
.	O

Further	O
,	O
peptide	O
N	O
-	O
glycohydrolase	O
F	O
and	O
endo	B-Protein
-	I-Protein
alpha	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminidase	E-Protein
,	O
which	O
are	O
specific	O
for	O
the	O
cleavage	O
of	O
N	O
-	O
glycan	O
and	O
O	O
-	O
glycan	O
linkages	O
,	O
respectively	O
,	O
in	O
glycoproteins	O
were	O
used	O
.	O

Pretreatment	O
with	O
either	O
of	O
them	O
also	O
reduced	O
both	O
PGD2	O
and	O
PGE2	O
binding	O
activities	O
.	O

The	O
reduction	O
was	O
dependent	O
on	O
the	O
pretreatment	O
time	O
and	O
enzyme	O
concentration	O
.	O

The	O
time	O
courses	O
of	O
the	O
reduction	O
were	O
typically	O
characterized	O
by	O
a	O
marked	O
increase	O
in	O
the	O
nonspecific	O
bindings	O
.	O

Scatchard	O
plot	O
analysis	O
revealed	O
that	O
the	O
reduction	O
was	O
caused	O
by	O
a	O
decrease	O
in	O
the	O
affinity	O
rather	O
than	O
one	O
in	O
the	O
maximal	O
binding	O
capacity	O
.	O

The	O
specificity	O
of	O
the	O
binding	O
sites	O
thereby	O
shifted	O
to	O
be	O
more	O
nonspecific	O
without	O
affecting	O
the	O
order	O
of	O
the	O
relative	O
affinities	O
among	O
PGs	O
for	O
the	O
binding	O
sites	O
.	O

These	O
results	O
suggest	O
that	O
the	O
carbohydrate	O
moieties	O
on	O
PG	O
receptor	O
proteins	O
of	O
the	O
brain	O
are	O
essential	O
for	O
the	O
expression	O
of	O
their	O
binding	O
activities	O
.	O

Sequence	O
analysis	O
of	O
the	O
membrane	O
protein	O
gene	O
of	O
human	O
coronavirus	O
OC43	O
and	O
evidence	O
for	O
O	O
-	O
glycosylation	O
.	O

The	O
gene	O
encoding	O
the	O
membrane	O
(	O
M	S-Protein
)	O
protein	O
of	O
the	O
OC43	O
strain	O
of	O
human	O
coronavirus	O
(	O
HCV	O
-	O
OC43	O
)	O
was	O
amplified	O
by	O
a	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
of	O
viral	O
RNA	O
with	O
HCV	O
-	O
OC43	O
-	O
and	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
-	O
specific	O
primers	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
cloned	O
1	O
.	O
5	O
kb	O
fragment	O
revealed	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
690	O
nucleotides	O
which	O
was	O
identified	O
as	O
the	O
M	S-Protein
protein	O
gene	O
from	O
its	O
homology	O
to	O
BCV	O
.	O

This	O
ORF	O
encodes	O
a	O
protein	O
of	O
230	O
amino	O
acids	O
with	O
an	O
M	O
(	O
r	O
)	O
of	O
26416	O
.	O

The	O
gene	O
is	O
preceded	O
by	O
the	O
motif	O
UCCAAAC	O
,	O
analogous	O
to	O
the	O
consensus	O
coronavirus	O
transcription	O
initiation	O
sequence	O
.	O

The	O
M	S-Protein
protein	O
of	O
HCV	O
-	O
OC43	O
shows	O
features	O
typical	O
of	O
all	O
coronavirus	O
M	S-Protein
proteins	O
studied	O
:	O
a	O
hydrophilic	O
,	O
presumably	O
external	O
N	O
terminus	O
including	O
about	O
10	O
%	O
of	O
the	O
protein	O
,	O
and	O
a	O
potential	O
N	O
-	O
glycosylation	O
site	O
followed	O
by	O
three	O
major	O
hydrophobic	O
transmembrane	O
domains	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
M	S-Protein
protein	O
of	O
HCV	O
-	O
OC43	O
has	O
94	O
%	O
identity	O
with	O
that	O
of	O
the	O
Mebus	O
strain	O
of	O
BCV	O
,	O
and	O
also	O
contains	O
six	O
potential	O
O	O
-	O
glycosylation	O
sites	O
in	O
the	O
exposed	O
N	O
-	O
terminal	O
domain	O
.	O

Indeed	O
,	O
the	O
glycosylation	O
of	O
the	O
M	S-Protein
protein	O
was	O
not	O
inhibited	O
in	O
the	O
presence	O
of	O
tunicamycin	O
,	O
which	O
is	O
indicative	O
of	O
O	O
-	O
glycosylation	O
,	O
as	O
previously	O
reported	O
for	O
BCV	O
and	O
murine	O
hepatitis	O
virus	O
.	O

Virions	O
released	O
from	O
tunicamycin	O
-	O
treated	O
cells	O
contained	O
the	O
M	S-Protein
glycoprotein	O
but	O
were	O
devoid	O
of	O
both	O
peplomer	S-Protein
(	O
S	S-Protein
)	O
and	O
haemagglutinin	B-Protein
-	I-Protein
esterase	E-Protein
(	O
HE	S-Protein
)	O
proteins	O
.	O

Thus	O
,	O
inhibition	O
of	O
the	O
N	O
-	O
glycosylation	O
of	O
the	O
S	S-Protein
and	O
HE	S-Protein
structural	O
proteins	O
prevented	O
their	O
incorporation	O
into	O
progeny	O
virions	O
,	O
an	O
indication	O
that	O
they	O
are	O
dispensable	O
for	O
virion	O
morphogenesis	O
,	O
unlike	O
the	O
M	S-Protein
protein	O
.	O

Production	O
and	O
secretion	O
of	O
high	O
levels	O
of	O
recombinant	O
human	O
acetylcholinesterase	S-Protein
in	O
cultured	O
cell	O
lines	O
:	O
microheterogeneity	O
of	O
the	O
catalytic	O
subunit	O
.	O

To	O
allow	O
for	O
structural	O
analysis	O
of	O
the	O
human	O
acetylcholinesterase	S-Protein
(	O
hAChE	S-Protein
)	O
subunit	O
,	O
a	O
series	O
of	O
eukaryotic	O
vectors	O
was	O
designed	O
for	O
efficient	O
expression	O
.	O

Several	O
eukaryotic	O
multicistronic	O
expression	O
vectors	O
were	O
tested	O
in	O
various	O
mammalian	O
cell	O
lines	O
.	O

All	O
expression	O
vectors	O
contained	O
the	O
selectable	O
neo	O
gene	O
under	O
control	O
of	O
a	O
weak	O
promoter	O
,	O
while	O
the	O
hAChE	S-Protein
cDNA	O
was	O
under	O
control	O
of	O
the	O
cytomegalovirus	O
(	O
CMV	O
)	O
immediate	O
-	O
early	O
or	O
Rous	O
sarcoma	O
virus	O
long	O
terminal	O
repeat	O
(	O
RSV	O
LTR	O
)	O
or	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
early	O
promoters	O
.	O

Optimal	O
production	O
and	O
secretion	O
of	O
recombinant	O
hAChE	S-Protein
(	O
rehAChE	S-Protein
)	O
was	O
achieved	O
in	O
the	O
embryonal	O
kidney	O
293	O
cell	O
line	O
transfected	O
either	O
with	O
the	O
RSV	O
-	O
hAChE	S-Protein
or	O
with	O
CMV	O
-	O
hAChE	S-Protein
expression	O
vectors	O
.	O

Clones	O
expressing	O
and	O
secreting	O
as	O
much	O
as	O
5	O
-	O
25	O
pg	O
of	O
enzyme	O
per	O
cell	O
per	O
24	O
h	O
were	O
obtained	O
without	O
resorting	O
to	O
coamplification	O
techniques	O
or	O
continuous	O
maintenance	O
of	O
cells	O
under	O
selective	O
pressure	O
.	O

The	O
purified	O
(	O
specific	O
activity	O
of	O
6000	O
units	O
per	O
mg	O
protein	O
)	O
homodimer	O
and	O
tetramer	O
enzyme	O
molecules	O
displayed	O
typical	O
AChE	S-Protein
biochemical	O
properties	O
:	O
a	O
Km	O
value	O
of	O
120	O
microM	O
for	O
acetylthiocholine	O
;	O
a	O
kcat	O
value	O
of	O
3	O
.	O
9	O
x	O
10	O
(	O
5	O
)	O
/	O
min	O
,	O
and	O
selective	O
by	O
AChE	S-Protein
-	O
specific	O
inhibitors	O
.	O

Catalytic	O
subunit	O
dimers	O
(	O
130	O
kDa	O
)	O
exhibit	O
differential	O
N	O
-	O
glycosylation	O
patterns	O
,	O
and	O
upon	O
reduction	O
resolve	O
into	O
67	O
-	O
and	O
70	O
-	O
kDa	O
monomeric	O
subunits	O
.	O

These	O
two	O
forms	O
appear	O
as	O
a	O
single	O
discrete	O
62	O
-	O
kDa	O
band	O
following	O
deglycosylation	O
by	O
N	B-Protein
-	I-Protein
glycanase	E-Protein
.	O

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
of	O
the	O
purified	O
mature	O
enzyme	O
suggests	O
the	O
existence	O
of	O
two	O
alternative	O
cleavage	O
sites	O
for	O
the	O
removal	O
of	O
the	O
signal	O
peptide	O
,	O
in	O
which	O
the	O
'	O
mature	O
'	O
position	O
1	O
is	O
either	O
Ala31	O
or	O
Gly33	O
.	O

Both	O
of	O
these	O
positions	O
conform	O
with	O
the	O
consensus	O
signal	O
peptide	O
recognition	O
sequences	O
and	O
demonstrate	O
bidirected	O
processing	O
of	O
signal	O
peptides	O
on	O
a	O
native	O
molecule	O
.	O

Evaluation	O
of	O
CD44	S-Protein
variant	O
6	O
expression	O
and	O
clinicopathological	O
factors	O
in	O
pulmonary	O
metastases	O
from	O
colon	O
carcinoma	O
.	O

Although	O
relatively	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
underlying	O
tumor	O
progression	O
,	O
recently	O
CD44	S-Protein
glycoproteins	O
and	O
the	O
c	B-Protein
-	I-Protein
Met	E-Protein
receptor	O
tyrosine	O
kinase	O
have	O
been	O
identified	O
as	O
potentially	O
important	O
components	O
of	O
the	O
metastatic	O
cascade	O
.	O

CD44	S-Protein
is	O
a	O
family	O
of	O
transmembrane	O
receptors	O
generated	O
from	O
a	O
single	O
gene	O
by	O
alternative	O
splicing	O
and	O
differential	O
glycosylation	O
.	O

Important	O
biological	O
processes	O
involving	O
CD44	S-Protein
glycoproteins	O
include	O
cell	O
adhesion	O
,	O
lymphocyte	O
homing	O
,	O
hematopoiesis	O
,	O
tumor	O
progression	O
and	O
metastasis	O
.	O

The	O
precise	O
mechanism	O
via	O
which	O
CD44	S-Protein
promotes	O
tumorigenesis	O
have	O
not	O
yet	O
been	O
elucidated	O
.	O

We	O
evaluated	O
the	O
expression	O
of	O
adhesion	O
molecule	O
CD44	S-Protein
variant	O
6	O
in	O
pulmonary	O
metastases	O
from	O
colorectal	O
carcinomas	O
and	O
its	O
correlation	O
with	O
clinicopathological	O
parameters	O
.	O

Twenty	O
patients	O
were	O
randomly	O
selected	O
from	O
the	O
patients	O
who	O
had	O
undergone	O
a	O
resection	O
of	O
pulmonary	O
metastasis	O
from	O
colorectal	O
cancer	O
.	O

Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
archival	O
specimens	O
of	O
tumor	O
tissues	O
and	O
adjacent	O
normal	O
mucosa	O
from	O
these	O
patients	O
were	O
the	O
subjects	O
of	O
the	O
present	O
study	O
.	O

Immunoreactivity	O
for	O
CD44	S-Protein
was	O
quantified	O
.	O

Specimens	O
were	O
considered	O
positive	O
if	O
almost	O
25	O
%	O
of	O
the	O
neoplastic	O
cells	O
were	O
stained	O
.	O

CD44	S-Protein
v6	O
expression	O
was	O
related	O
to	O
the	O
interval	O
between	O
colon	O
resection	O
and	O
metastases	O
diagnosis	O
,	O
the	O
number	O
of	O
pulmonary	O
metastases	O
,	O
and	O
the	O
survival	O
after	O
lung	O
resection	O
.	O

No	O
statistical	O
correlation	O
was	O
found	O
between	O
CD44	S-Protein
v6	O
positivity	O
and	O
disease	O
-	O
free	O
interval	O
after	O
colon	O
resection	O
,	O
number	O
of	O
metastases	O
or	O
2	O
-	O
year	O
survival	O
after	O
lung	O
resection	O
.	O

Probably	O
CD44	S-Protein
v6	O
is	O
necessary	O
and	O
sufficient	O
to	O
confer	O
metastatic	O
potential	O
to	O
carcinoma	O
cells	O
increasing	O
the	O
migration	O
capacity	O
and	O
participating	O
in	O
invasion	O
via	O
changes	O
in	O
adhesion	O
to	O
the	O
extracellular	O
ligands	O
,	O
but	O
is	O
not	O
necessary	O
to	O
modify	O
the	O
clinical	O
history	O
of	O
the	O
metastases	O
.	O

Therefore	O
the	O
evaluation	O
of	O
CD44	S-Protein
v6	O
expression	O
in	O
lung	O
metastases	O
does	O
not	O
influence	O
the	O
therapeutic	O
scheme	O
.	O

Promoter	O
-	O
restricted	O
H3	S-Protein
Lys	O
4	O
di	O
-	O
methylation	O
is	O
an	O
epigenetic	O
mark	O
for	O
monoallelic	O
expression	O
.	O

Methylation	O
of	O
histone	S-Protein
tails	O
has	O
been	O
implicated	O
in	O
long	O
-	O
term	O
epigenetic	O
memory	O
.	O

Methylated	O
H3	S-Protein
Lys	O
4	O
(	O
K4	O
)	O
is	O
a	O
generally	O
conserved	O
mark	O
for	O
euchromatic	O
,	O
transcriptionally	O
active	O
regions	O
,	O
although	O
the	O
effect	O
of	O
this	O
modification	O
is	O
likely	O
also	O
to	O
depend	O
on	O
its	O
distribution	O
both	O
within	O
the	O
euchromatic	O
region	O
and	O
more	O
specifically	O
within	O
a	O
given	O
gene	O
.	O

Here	O
we	O
describe	O
a	O
profile	O
of	O
H3K4	S-Protein
di	O
-	O
methylation	O
that	O
is	O
specific	O
for	O
monoallelically	O
expressed	O
genes	O
.	O

Both	O
X	O
-	O
linked	O
genes	O
subject	O
to	O
X	O
-	O
inactivation	O
and	O
autosomal	O
imprinted	O
genes	O
have	O
di	O
-	O
methylated	O
H3K4	S-Protein
restricted	O
to	O
their	O
promoter	O
regions	O
.	O

In	O
contrast	O
,	O
high	O
levels	O
of	O
H3K4	S-Protein
di	O
-	O
methylation	O
are	O
found	O
in	O
both	O
promoters	O
and	O
exonic	O
parts	O
of	O
autosomal	O
genes	O
and	O
of	O
X	O
-	O
linked	O
genes	O
that	O
escape	O
X	O
-	O
inactivation	O
.	O

We	O
suggest	O
that	O
this	O
pattern	O
of	O
promoter	O
restricted	O
H3	S-Protein
Lys	O
4	O
di	O
-	O
methylation	O
,	O
already	O
present	O
in	O
totipotent	O
cells	O
,	O
is	O
causally	O
related	O
to	O
the	O
long	O
-	O
term	O
programming	O
of	O
allelic	O
expression	O
and	O
provides	O
an	O
epigenetic	O
mark	O
for	O
monoallelically	O
expressed	O
genes	O
.	O

Inhibition	O
of	O
histone	S-Protein
deacetylase	O
increases	O
cytotoxicity	O
to	O
anticancer	O
drugs	O
targeting	O
DNA	O
.	O

Several	O
anticancer	O
drugs	O
target	O
DNA	O
or	O
enzymes	O
acting	O
on	O
the	O
DNA	O
.	O

Because	O
chromatin	O
DNA	O
is	O
tightly	O
compacted	O
,	O
accessibility	O
to	O
the	O
drug	O
target	O
may	O
reduce	O
the	O
efficiency	O
of	O
these	O
anticancer	O
drugs	O
.	O

We	O
thus	O
treated	O
four	O
human	O
cancer	O
cell	O
lines	O
and	O
two	O
normal	O
epithelial	O
cell	O
lines	O
with	O
either	O
trichostatin	O
A	O
(	O
TSA	O
)	O
or	O
SAHA	O
,	O
two	O
histone	S-Protein
deacetylase	O
inhibitors	O
,	O
before	O
exposing	O
the	O
cells	O
to	O
VP	O
-	O
16	O
,	O
ellipticine	O
,	O
camptothecin	O
,	O
doxorubicin	O
,	O
cisplatin	O
,	O
5	O
-	O
fluorouracil	O
,	O
or	O
cyclophosmamide	O
.	O

Pretreatment	O
with	O
TSA	O
or	O
SAHA	O
increased	O
the	O
killing	O
efficiency	O
of	O
VP	O
-	O
16	O
,	O
ellipticine	O
,	O
doxorubicin	O
,	O
and	O
cisplatin	O
.	O

The	O
magnitude	O
of	O
sensitization	O
is	O
cell	O
type	O
specific	O
and	O
is	O
>	O
10	O
-	O
fold	O
for	O
VP	O
-	O
16	O
in	O
D54	O
,	O
a	O
brain	O
tumor	O
cell	O
line	O
intrinsically	O
resistant	O
to	O
topoisomerase	O
II	O
inhibitors	O
.	O

Topoisomerase	O
II	O
levels	O
and	O
activity	O
were	O
not	O
affected	O
by	O
this	O
treatment	O
,	O
but	O
p53	S-Protein
,	O
p21	S-Protein
,	O
and	O
Gadd45	S-Protein
protein	O
levels	O
were	O
markedly	O
induced	O
.	O

Moreover	O
,	O
pretreatment	O
with	O
TSA	O
also	O
increased	O
VP	O
-	O
16	O
-	O
induced	O
apoptosis	O
in	O
a	O
p53	S-Protein
-	O
dependent	O
and	O
-	O
independent	O
manner	O
.	O

Treating	O
the	O
cells	O
in	O
the	O
reverse	O
order	O
(	O
anticancer	O
drug	O
first	O
,	O
followed	O
by	O
TSA	O
or	O
SAHA	O
)	O
had	O
no	O
more	O
cytotoxic	O
effect	O
than	O
the	O
drug	O
alone	O
.	O

These	O
data	O
suggest	O
that	O
loosening	O
-	O
up	O
the	O
chromatin	O
structure	O
by	O
histone	S-Protein
acetylation	O
can	O
increase	O
the	O
efficiency	O
of	O
several	O
anticancer	O
drugs	O
targeting	O
DNA	O
.	O

This	O
may	O
be	O
advantageous	O
for	O
treating	O
tumors	O
intrinsically	O
resistant	O
to	O
these	O
drugs	O
.	O

Epigenetic	O
regulation	O
of	O
telomere	O
length	O
in	O
mammalian	O
cells	O
by	O
the	O
Suv39h1	S-Protein
and	O
Suv39h2	S-Protein
histone	S-Protein
methyltransferases	O
.	O

Telomeres	O
are	O
capping	O
structures	O
at	O
the	O
ends	O
of	O
eukaryotic	O
chromosomes	O
composed	O
of	O
TTAGGG	O
repeats	O
bound	O
to	O
an	O
array	O
of	O
specialized	O
proteins	O
.	O

Telomeres	O
are	O
heterochromatic	O
regions	O
.	O

Yeast	O
and	O
flies	O
with	O
defects	O
in	O
activities	O
that	O
modify	O
the	O
state	O
of	O
chromatin	O
also	O
have	O
abnormal	O
telomere	O
function	O
,	O
but	O
the	O
putative	O
role	O
of	O
chromatin	O
-	O
modifying	O
activities	O
in	O
regulating	O
telomeres	O
in	O
mammals	O
is	O
unknown	O
.	O

Here	O
we	O
report	O
on	O
telomere	O
length	O
and	O
function	O
in	O
mice	O
null	O
with	O
respect	O
to	O
both	O
the	O
histone	S-Protein
methyltransferases	O
(	O
HMTases	O
)	O
Suv39h1	S-Protein
and	O
Suv39h2	S-Protein
(	O
called	O
SUV39DN	O
mice	O
)	O
.	O

Suv39h1	S-Protein
and	O
Suv39h2	S-Protein
govern	O
methylation	O
of	O
histone	B-Protein
H3	E-Protein
Lys9	O
(	O
H3	S-Protein
-	O
Lys9	O
)	O
in	O
heterochromatic	O
regions	O
.	O

We	O
show	O
that	O
primary	O
cells	O
derived	O
from	O
SUV39DN	O
mice	O
have	O
abnormally	O
long	O
telomeres	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
analysis	O
,	O
we	O
found	O
that	O
telomeres	O
were	O
enriched	O
in	O
di	O
-	O
and	O
trimethylated	O
H3	S-Protein
-	O
Lys9	O
but	O
that	O
telomeres	O
of	O
SUV39DN	O
cells	O
had	O
less	O
dimethylated	O
and	O
trimethylated	O
H3	S-Protein
-	O
Lys9	O
but	O
more	O
monomethylated	O
H3	S-Protein
-	O
Lys9	O
.	O

Concomitant	O
with	O
the	O
decrease	O
in	O
H3	S-Protein
-	O
Lys9	O
methylation	O
,	O
telomeres	O
in	O
SUV39DN	O
cells	O
had	O
reduced	O
binding	O
of	O
the	O
chromobox	O
proteins	O
Cbx1	S-Protein
,	O
Cbx3	S-Protein
and	O
Cbx5	S-Protein
,	O
homologs	O
of	O
Drosophila	O
melanogaster	O
heterochromatin	B-Protein
protein	I-Protein
1	E-Protein
(	O
HP1	S-Protein
)	O
.	O

These	O
findings	O
indicate	O
substantial	O
changes	O
in	O
the	O
state	O
of	O
telomeric	O
heterochromatin	O
in	O
SUV39DN	O
cells	O
,	O
which	O
are	O
associated	O
with	O
abnormal	O
telomere	O
elongation	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
epigenetic	O
regulation	O
of	O
telomere	O
length	O
in	O
mammals	O
by	O
Suv39h1	S-Protein
and	O
Suv39h2	S-Protein
.	O

Role	O
of	O
glycosylation	O
in	O
the	O
organic	O
anion	O
transporter	O
OAT1	S-Protein
.	O

Organic	O
anion	O
transporters	O
(	O
OAT	O
)	O
play	O
essential	O
roles	O
in	O
the	O
body	O
disposition	O
of	O
clinically	O
important	O
anionic	O
drugs	O
,	O
including	O
antiviral	O
drugs	O
,	O
antitumor	O
drugs	O
,	O
antibiotics	O
,	O
antihypertensives	O
,	O
and	O
anti	O
-	O
inflammatories	O
.	O

We	O
reported	O
previously	O
(	O
Kuze	O
,	O
K	O
.	O
,	O
Graves	O
,	O
P	O
.	O
,	O
Leahy	O
,	O
A	O
.	O
,	O
Wilson	O
,	O
P	O
.	O
,	O
Stuhlmann	O
,	O
H	O
.	O
,	O
and	O
You	O
,	O
G	O
.	O
(	O
1999	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
274	O
,	O
1519	O
-	O
1524	O
)	O
that	O
tunicamycin	O
,	O
an	O
inhibitor	O
of	O
asparagine	O
-	O
linked	O
glycosylation	O
,	O
significantly	O
inhibited	O
organic	O
anion	O
transport	O
in	O
COS	O
-	O
7	O
cells	O
expressing	O
a	O
mouse	O
organic	O
anion	O
transporter	O
(	O
mOAT1	S-Protein
)	O
,	O
suggesting	O
an	O
important	O
role	O
of	O
glycosylation	O
in	O
mOAT1	S-Protein
function	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
disrupting	O
putative	O
glycosylation	O
sites	O
in	O
mOAT1	S-Protein
as	O
well	O
as	O
its	O
human	O
counterpart	O
,	O
hOAT1	S-Protein
,	O
by	O
mutating	O
asparagine	O
to	O
glutamine	O
and	O
assessing	O
mutant	O
transporters	O
in	O
HeLa	O
cells	O
.	O

We	O
showed	O
that	O
the	O
putative	O
glycosylation	O
site	O
Asp	O
-	O
39	O
in	O
mOAT1	S-Protein
was	O
not	O
glycosylated	O
but	O
the	O
corresponding	O
site	O
(	O
Asp	O
-	O
39	O
)	O
in	O
hOAT1	S-Protein
was	O
glycosylated	O
.	O

Disrupting	O
Asp	O
-	O
39	O
resulted	O
in	O
a	O
complete	O
loss	O
of	O
transport	O
activity	O
in	O
both	O
mOAT1	S-Protein
and	O
hOAT1	S-Protein
without	O
affecting	O
their	O
cell	O
surface	O
expression	O
,	O
suggesting	O
that	O
the	O
loss	O
of	O
function	O
is	O
not	O
because	O
of	O
deglycosylation	O
of	O
Asp	O
-	O
39	O
per	O
se	O
but	O
rather	O
is	O
likely	O
because	O
of	O
the	O
change	O
of	O
this	O
important	O
amino	O
acid	O
critically	O
involved	O
in	O
the	O
substrate	O
binding	O
.	O

Single	O
replacement	O
of	O
asparagines	O
at	O
other	O
sites	O
had	O
no	O
effect	O
on	O
transport	O
activity	O
indicating	O
that	O
glycosylation	O
at	O
individual	O
sites	O
is	O
not	O
essential	O
for	O
OAT	O
function	O
.	O

In	O
contrast	O
,	O
a	O
simultaneous	O
replacement	O
of	O
all	O
asparagines	O
in	O
both	O
mOAT1	S-Protein
and	O
hOAT1	S-Protein
impaired	O
the	O
trafficking	O
of	O
the	O
transporters	O
to	O
the	O
plasma	O
membrane	O
.	O

In	O
summary	O
,	O
we	O
provided	O
the	O
evidence	O
that	O
1	O
)	O
Asp	O
-	O
39	O
is	O
crucially	O
involved	O
in	O
substrate	O
recognition	O
of	O
OAT1	S-Protein
,	O
2	O
)	O
glycosylation	O
at	O
individual	O
sites	O
is	O
not	O
required	O
for	O
OAT1	S-Protein
function	O
,	O
and	O
3	O
)	O
glycosylation	O
plays	O
an	O
important	O
role	O
in	O
the	O
targeting	O
of	O
OAT1	S-Protein
onto	O
the	O
plasma	O
membrane	O
.	O

This	O
study	O
is	O
the	O
first	O
molecular	O
identification	O
and	O
characterization	O
of	O
glycosylation	O
of	O
OAT1	S-Protein
and	O
may	O
provide	O
important	O
insights	O
into	O
the	O
structure	O
-	O
function	O
relationships	O
of	O
the	O
organic	O
anion	O
transporter	O
family	O
.	O

Cytochrome	O
P450	O
isoenzymes	O
involved	O
in	O
rat	O
liver	O
microsomal	O
metabolism	O
of	O
californine	O
and	O
protopine	O
.	O

Studies	O
are	O
described	O
on	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
isoenzyme	O
dependence	O
of	O
the	O
main	O
metabolic	O
steps	O
of	O
the	O
Eschscholtzia	O
californica	O
alkaloids	O
californine	O
and	O
protopine	O
using	O
rat	O
liver	O
microsomes	O
.	O

Preparations	O
of	O
E	O
.	O
californica	O
are	O
in	O
use	O
as	O
phytopharmaceuticals	O
and	O
as	O
herbal	O
drugs	O
of	O
abuse	O
.	O

CYP	O
isoenzyme	O
dependences	O
were	O
studied	O
using	O
specific	O
chemical	O
inhibitors	O
for	O
CYP1A2	S-Protein
,	O
CYP2D1	S-Protein
,	O
and	O
CYP3A2	S-Protein
(	O
alpha	O
-	O
naphthoflavone	O
,	O
quinine	O
,	O
and	O
ketoconazole	O
,	O
respectively	O
)	O
.	O

CYP2C11	S-Protein
was	O
inhibited	O
by	O
specific	O
antibodies	O
for	O
lack	O
of	O
specific	O
chemical	O
inhibitors	O
.	O

Californine	O
N	O
-	O
demethylation	O
was	O
mainly	O
catalyzed	O
by	O
CYP3A2	S-Protein
and	O
to	O
a	O
minor	O
extent	O
by	O
CYP1A2	S-Protein
and	O
CYP2D1	S-Protein
,	O
but	O
not	O
by	O
CYP2C11	S-Protein
.	O

CYP2D1	S-Protein
and	O
CYP2C11	S-Protein
were	O
shown	O
to	O
be	O
mainly	O
involved	O
in	O
demethylenation	O
of	O
both	O
,	O
californine	O
and	O
protopine	O
,	O
while	O
CYP1A2	S-Protein
and	O
CYP3A2	S-Protein
showed	O
only	O
minor	O
contribution	O
.	O

Kinetic	O
parameters	O
of	O
the	O
reactions	O
were	O
established	O
.	O

K	O
(	O
m	O
)	O
and	O
V	O
(	O
max	O
)	O
values	O
for	O
the	O
californine	O
N	O
-	O
demethylation	O
were	O
4	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
7	O
microM	O
and	O
22	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
7	O
min	O
/	O
mg	O
protein	O
(	O
high	O
affinity	O
)	O
and	O
161	O
.	O
3	O
+	O
/	O
-	O
16	O
.	O
7	O
microM	O
and	O
311	O
.	O
8	O
+	O
/	O
-	O
39	O
.	O
4	O
min	O
/	O
mg	O
protein	O
(	O
low	O
affinity	O
)	O
,	O
respectively	O
.	O

Californine	O
demethylenation	O
and	O
protopine	O
demethylenation	O
showed	O
substrate	O
inhibition	O
and	O
K	O
(	O
m	O
)	O
and	O
V	O
(	O
max	O
)	O
values	O
were	O
5	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
5	O
and	O
7	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
6	O
microM	O
and	O
83	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
and	O
160	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
0	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
.	O

Expression	O
and	O
methylation	O
status	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
can	O
characterize	O
the	O
different	O
histological	O
features	O
of	O
ovarian	O
cancer	O
.	O

We	O
hypothesize	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
expression	O
and	O
its	O
regulation	O
by	O
methylation	O
can	O
characterize	O
histological	O
types	O
of	O
primary	O
human	O
epithelial	O
ovarian	O
cancer	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
ovarian	O
cancer	O
cell	O
lines	O
and	O
54	O
ovarian	O
cancer	O
tissue	O
samples	O
were	O
analyzed	O
for	O
expression	O
and	O
methylation	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
using	O
methylation	O
specific	O
PCR	O
.	O

The	O
results	O
of	O
our	O
experiments	O
demonstrate	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
was	O
methylated	O
and	O
inactivated	O
in	O
ES	O
-	O
2	O
ovarian	O
cell	O
line	O
,	O
which	O
was	O
derived	O
from	O
clear	O
cell	O
adenocarcinoma	O
.	O

Treatment	O
of	O
this	O
cell	O
line	O
with	O
demethylating	O
agent	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
restored	O
the	O
expression	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
.	O

In	O
human	O
ovarian	O
cancer	O
tissues	O
,	O
the	O
expression	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
protein	O
was	O
inactivated	O
in	O
most	O
of	O
the	O
ovarian	O
clear	O
cell	O
carcinoma	O
tissues	O
.	O

Interestingly	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
protein	O
expression	O
was	O
positive	O
in	O
significantly	O
higher	O
percentages	O
of	O
serous	O
(	O
89	O
.	O
5	O
%	O
)	O
,	O
endometrioid	O
(	O
90	O
%	O
)	O
,	O
and	O
mucinous	O
(	O
81	O
.	O
8	O
%	O
)	O
ovarian	O
adenocarcinoma	O
tissues	O
.	O

The	O
ovarian	O
clear	O
cell	O
carcinoma	O
samples	O
with	O
inactivated	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
protein	O
were	O
highly	O
methylated	O
,	O
suggesting	O
that	O
inactivation	O
of	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
is	O
through	O
DNA	O
methylation	O
.	O

Using	O
direct	O
DNA	O
sequencing	O
,	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
methylation	O
on	O
all	O
the	O
17	O
CpG	O
sites	O
was	O
significantly	O
higher	O
in	O
ovarian	O
clear	O
cell	O
carcinoma	O
as	O
compared	O
to	O
other	O
histological	O
types	O
of	O
ovarian	O
cancer	O
(	O
serous	O
,	O
endometrioid	O
,	O
and	O
mucinous	O
)	O
.	O

This	O
is	O
the	O
first	O
report	O
suggesting	O
that	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3	I-Protein
sigma	E-Protein
gene	O
expression	O
and	O
methylation	O
status	O
can	O
characterize	O
histological	O
features	O
of	O
different	O
types	O
of	O
ovarian	O
cancer	O
.	O

Thrombophilic	O
dysfibrinogen	O
Tokyo	O
V	O
with	O
the	O
amino	O
acid	O
substitution	O
of	O
gammaAla327Thr	O
:	O
formation	O
of	O
fragile	O
but	O
fibrinolysis	O
-	O
resistant	O
fibrin	O
clots	O
and	O
its	O
relevance	O
to	O
arterial	O
thromboembolism	O
.	O

Thrombophilic	O
dysfibrinogen	O
Tokyo	O
V	O
was	O
identified	O
in	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
with	O
recurrent	O
thromboembolism	O
.	O

Based	O
on	O
analyses	O
of	O
the	O
patient	O
fibrinogen	O
genes	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
aberrant	O
fibrinogen	O
peptide	O
,	O
and	O
deglycosylation	O
experiments	O
,	O
fibrinogen	O
Tokyo	O
V	O
was	O
shown	O
to	O
have	O
an	O
amino	O
acid	O
substitution	O
of	O
gamma	O
Ala327Thr	O
and	O
possibly	O
extra	O
glycosylation	O
at	O
gamma	O
Asn325	O
because	O
the	O
mutation	O
confers	O
the	O
N	O
-	O
linked	O
glycosylation	O
consensus	O
sequence	O
Asn	O
-	O
X	O
-	O
Thr	O
.	O

The	O
mutation	O
resulted	O
in	O
impaired	O
function	O
and	O
hypofibrinogenemia	O
(	O
hypodysfibrinogen	O
)	O
.	O

Polymerization	O
of	O
fibrin	O
monomers	O
derived	O
from	O
patient	O
fibrinogen	O
was	O
severely	O
impaired	O
with	O
a	O
partial	O
correction	O
in	O
the	O
presence	O
of	O
calcium	O
,	O
resulting	O
in	O
very	O
low	O
clottability	O
.	O

Additionally	O
,	O
a	O
large	O
amount	O
of	O
soluble	O
cross	O
-	O
linked	O
fibrin	O
was	O
formed	O
upon	O
thrombin	O
treatment	O
in	O
the	O
presence	O
of	O
factor	O
XIII	O
and	O
calcium	O
.	O

However	O
,	O
Tokyo	O
V	O
-	O
derived	O
fibrin	O
was	O
resistant	O
to	O
degradation	O
by	O
tissue	B-Protein
plasminogen	I-Protein
activator	E-Protein
(	O
tPA	S-Protein
)	O
-	O
catalyzed	O
plasmin	S-Protein
digestion	O
.	O

The	O
structure	O
of	O
Tokyo	O
V	O
fibrin	O
appeared	O
severely	O
perturbed	O
,	O
since	O
there	O
are	O
large	O
pores	O
inside	O
the	O
tangled	O
fibrin	O
networks	O
and	O
fiber	O
ends	O
at	O
the	O
boundaries	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
Tokyo	O
V	O
fibrin	O
clots	O
are	O
fragile	O
,	O
so	O
that	O
fibrinolysis	O
-	O
resistant	O
insoluble	O
fibrin	O
and	O
soluble	O
fibrin	O
polymers	O
may	O
be	O
released	O
to	O
the	O
circulation	O
,	O
partly	O
accounting	O
for	O
the	O
recurrent	O
embolic	O
episodes	O
in	O
the	O
patient	O
.	O

Tracking	O
global	O
patterns	O
of	O
N	O
-	O
linked	O
glycosylation	O
site	O
variation	O
in	O
highly	O
variable	O
viral	O
glycoproteins	O
:	O
HIV	O
,	O
SIV	O
,	O
and	O
HCV	O
envelopes	O
and	O
influenza	O
hemagglutinin	S-Protein
.	O

Human	O
and	O
simian	O
immunodeficiency	O
viruses	O
(	O
HIV	O
and	O
SIV	O
)	O
,	O
influenza	O
virus	O
,	O
and	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
have	O
heavily	O
glycosylated	O
,	O
highly	O
variable	O
surface	O
proteins	O
.	O

Here	O
we	O
explore	O
N	O
-	O
linked	O
glycosylation	O
site	O
(	O
sequon	O
)	O
variation	O
at	O
the	O
population	O
level	O
in	O
these	O
viruses	O
,	O
using	O
a	O
new	O
Web	O
-	O
based	O
program	O
developed	O
to	O
facilitate	O
the	O
sequon	O
tracking	O
and	O
to	O
define	O
patterns	O
(	O
www	O
.	O
hiv	O
.	O
lanl	O
.	O
gov	O
)	O
.	O

This	O
tool	O
allowed	O
rapid	O
visualization	O
of	O
the	O
two	O
distinctive	O
patterns	O
of	O
sequon	O
variation	O
found	O
in	O
HIV	O
-	O
1	O
,	O
HIV	O
-	O
2	O
,	O
and	O
SIV	O
CPZ	O
.	O

The	O
first	O
pattern	O
(	O
fixed	O
)	O
describes	O
readily	O
aligned	O
sites	O
that	O
are	O
either	O
simply	O
present	O
or	O
absent	O
.	O

These	O
sites	O
tend	O
to	O
be	O
occupied	O
by	O
high	O
-	O
mannose	O
glycans	O
.	O

The	O
second	O
pattern	O
(	O
shifting	O
)	O
refers	O
to	O
sites	O
embedded	O
in	O
regions	O
of	O
extreme	O
local	O
length	O
variation	O
and	O
is	O
characterized	O
by	O
shifts	O
in	O
terms	O
of	O
the	O
relative	O
position	O
and	O
local	O
density	O
of	O
sequons	O
;	O
these	O
sites	O
tend	O
to	O
be	O
populated	O
by	O
complex	O
carbohydrates	O
.	O

HIV	O
,	O
with	O
its	O
extreme	O
variation	O
in	O
number	O
and	O
precise	O
location	O
of	O
sequons	O
,	O
does	O
not	O
have	O
a	O
net	O
increase	O
in	O
the	O
number	O
of	O
sites	O
over	O
time	O
at	O
the	O
population	O
level	O
.	O

Primate	O
lentiviral	O
lineages	O
have	O
host	O
species	O
-	O
dependent	O
levels	O
of	O
sequon	O
shifting	O
,	O
with	O
HIV	O
-	O
1	O
in	O
humans	O
the	O
most	O
extreme	O
.	O

HCV	O
E1	S-Protein
and	O
E2	S-Protein
proteins	O
,	O
despite	O
evolving	O
extremely	O
rapidly	O
through	O
point	O
mutation	O
,	O
show	O
limited	O
sequon	O
variation	O
,	O
although	O
two	O
shifting	O
sites	O
were	O
identified	O
.	O

Human	O
influenza	O
A	O
hemagglutinin	S-Protein
H3	O
HA1	S-Protein
is	O
accumulating	O
sequons	O
over	O
time	O
,	O
but	O
this	O
trend	O
is	O
not	O
evident	O
in	O
any	O
other	O
avian	O
or	O
human	O
influenza	O
A	O
serotypes	O
.	O

Redox	O
state	O
regulates	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
its	O
DNA	O
binding	O
and	O
phosphorylation	O
in	O
salmonid	O
cells	O
.	O

Rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
a	O
heterodimeric	O
transcription	O
factor	O
structurally	O
similar	O
to	O
mammalian	O
HIF	O
-	O
1	O
.	O

It	O
consists	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
HIF	B-Protein
-	I-Protein
1beta	E-Protein
subunits	O
,	O
of	O
which	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
subunit	O
confers	O
the	O
hypoxia	O
sensitivity	O
.	O

HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
rapidly	O
degraded	O
by	O
a	O
proteasome	O
under	O
normal	O
oxygen	O
(	O
21	O
%	O
O2	O
)	O
conditions	O
,	O
mainly	O
as	O
a	O
result	O
of	O
prolyl	O
hydroxylation	O
needed	O
for	O
protein	O
destabilization	O
.	O

Although	O
prolyl	O
hydroxylation	O
at	O
conserved	O
proline	O
residues	O
is	O
a	O
major	O
factor	O
controlling	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
stability	O
,	O
the	O
redox	O
state	O
of	O
the	O
cells	O
may	O
,	O
in	O
addition	O
,	O
influence	O
the	O
function	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
like	O
proteins	O
by	O
influencing	O
their	O
stability	O
,	O
DNA	O
binding	O
and	O
phosphorylation	O
.	O

Sensitivity	O
of	O
the	O
protein	O
to	O
oxidation	O
/	O
reduction	O
may	O
be	O
due	O
to	O
cysteine	O
residues	O
at	O
critical	O
positions	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
rainbow	O
trout	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
contains	O
several	O
unique	O
cysteine	O
residues	O
,	O
notably	O
in	O
the	O
DNA	O
-	O
binding	O
area	O
at	O
position	O
28	O
and	O
in	O
the	O
transactivation	O
domain	O
of	O
the	O
molecule	O
in	O
the	O
vicinity	O
of	O
the	O
conserved	O
proline	O
residue	O
at	O
position	O
564	O
of	O
mammalian	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
investigated	O
if	O
the	O
redox	O
state	O
influences	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
stability	O
,	O
DNA	O
binding	O
and	O
phosphorylation	O
in	O
two	O
established	O
salmonid	O
cell	O
lines	O
RTG	O
-	O
2	O
and	O
CHSE	O
-	O
214	O
.	O

The	O
results	O
indicate	O
that	O
reducing	O
conditions	O
,	O
achieved	O
using	O
N	O
-	O
propylgallate	O
(	O
nPG	O
)	O
or	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
,	O
stabilize	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
,	O
facilitate	O
its	O
DNA	O
binding	O
,	O
and	O
increase	O
its	O
phosphorylation	O
even	O
under	O
normal	O
oxygen	O
conditions	O
.	O

On	O
the	O
other	O
hand	O
,	O
oxidizing	O
conditions	O
,	O
achieved	O
using	O
L	O
-	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
dampen	O
the	O
hypoxia	O
response	O
.	O

Furthermore	O
,	O
the	O
hypoxia	O
-	O
like	O
effect	O
of	O
cobalt	O
is	O
increased	O
in	O
the	O
presence	O
of	O
the	O
reducing	O
agent	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
suggest	O
that	O
redox	O
state	O
influences	O
the	O
accessibility	O
of	O
the	O
conserved	O
prolyl	O
residues	O
to	O
oxygen	O
-	O
dependent	O
hydroxylation	O
and	O
the	O
accessibility	O
of	O
the	O
residues	O
involved	O
in	O
the	O
phosphorylation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

Induction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
activity	O
by	O
muscarinic	O
acetylcholine	O
receptor	O
signaling	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
a	O
master	O
regulator	O
of	O
cellular	O
adaptive	O
responses	O
to	O
hypoxia	O
.	O

Levels	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
subunit	O
increase	O
under	O
hypoxic	O
conditions	O
.	O

Exposure	O
of	O
cells	O
to	O
growth	O
factors	O
,	O
prostaglandin	O
,	O
and	O
certain	O
nitric	O
oxide	O
donors	O
also	O
induces	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
expression	O
under	O
non	O
-	O
hypoxic	O
conditions	O
.	O

We	O
demonstrate	O
that	O
muscarinic	O
acetylcholine	O
signals	O
induce	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
expression	O
and	O
transcriptional	O
activity	O
in	O
a	O
receptor	O
subtype	O
-	O
specific	O
manner	O
using	O
HEK293	O
cells	O
transiently	O
overexpressing	O
each	O
of	O
M1	S-Protein
-	O
M4	B-Protein
muscarinic	I-Protein
acetylcholine	I-Protein
receptors	E-Protein
.	O

The	O
muscarinic	O
signaling	O
pathways	O
inhibited	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
hydroxylation	O
and	O
degradation	O
and	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
protein	O
synthesis	O
that	O
was	O
confirmed	O
by	O
pulse	O
labeling	O
studies	O
.	O

Muscarinic	O
signal	O
-	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
protein	O
and	O
HIF	O
-	O
1	O
-	O
dependent	O
gene	O
expression	O
were	O
blocked	O
by	O
treating	O
cells	O
with	O
inhibitors	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
,	O
MAP	O
kinase	O
kinase	O
,	O
or	O
tyrosine	O
kinase	O
signaling	O
pathways	O
.	O

Dominant	O
-	O
negative	O
forms	O
of	O
Ras	O
and	O
/	O
or	O
Rac	B-Protein
-	I-Protein
1	E-Protein
significantly	O
suppressed	O
HIF	O
-	O
1	O
activation	O
by	O
muscarinic	O
signaling	O
.	O

Signaling	O
via	O
M1	B-Protein
-	E-Protein
and	O
M3	B-Protein
-	E-Protein
but	O
not	O
M2	B-Protein
-	E-Protein
or	O
M4	B-Protein
-	I-Protein
AchRs	E-Protein
promote	O
accumulation	O
and	O
transcriptional	O
activation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

We	O
conclude	O
that	O
muscarinic	O
acetylcholine	O
signals	O
activate	O
HIF	O
-	O
1	O
by	O
both	O
stabilization	O
and	O
synthesis	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
by	O
inducing	O
the	O
transcriptional	O
activity	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

Protein	B-Protein
C	I-Protein
inhibitor	E-Protein
as	O
an	O
anti	O
-	O
disseminated	O
intravascular	O
coagulation	O
agent	O
-	O
-	O
mechanism	O
and	O
modification	O
.	O

Gram	O
-	O
negative	O
sepsis	O
is	O
associated	O
with	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
)	O
due	O
to	O
endothelial	O
damage	O
,	O
which	O
is	O
induced	O
by	O
inflammatory	O
mediators	O
released	O
from	O
phagocytes	O
activated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

DIC	O
is	O
a	O
systemic	O
hemorrhagic	O
syndrome	O
,	O
which	O
results	O
from	O
the	O
consumption	O
of	O
coagulation	O
factors	O
for	O
the	O
formation	O
of	O
multiple	O
thrombi	O
in	O
the	O
systemic	O
microvessels	O
;	O
it	O
is	O
associated	O
with	O
multiple	O
organ	O
failure	O
.	O

Therefore	O
,	O
not	O
only	O
the	O
systemic	O
activation	O
of	O
coagulation	O
but	O
also	O
the	O
inflammatory	O
response	O
has	O
been	O
perceived	O
as	O
the	O
therapeutic	O
target	O
for	O
DIC	O
in	O
sepsis	O
.	O

We	O
gave	O
attention	O
that	O
protein	B-Protein
C	I-Protein
inhibitor	E-Protein
(	O
PCI	S-Protein
)	O
acts	O
as	O
an	O
inhibitor	O
of	O
both	O
plasma	O
kallikrein	O
and	O
thrombin	S-Protein
,	O
which	O
are	O
known	O
to	O
act	O
not	O
only	O
as	O
procoagulant	O
proteases	O
but	O
also	O
as	O
chemotactic	O
factors	O
toward	O
phagocytes	O
.	O

Then	O
,	O
we	O
hypothesized	O
that	O
PCI	S-Protein
possibly	O
acts	O
as	O
an	O
anti	O
-	O
DIC	O
agent	O
rather	O
than	O
an	O
inhibitor	O
of	O
the	O
protein	B-Protein
C	E-Protein
anticoagulant	O
pathway	O
under	O
the	O
pathophysiology	O
of	O
DIC	O
,	O
accompanied	O
by	O
the	O
decrease	O
in	O
the	O
thrombomodulin	S-Protein
expression	O
on	O
endothelial	O
cells	O
.	O

Our	O
studies	O
have	O
suggested	O
that	O
PCI	S-Protein
purified	O
from	O
human	O
urine	O
(	O
uPCI	S-Protein
)	O
improves	O
the	O
pathophysiology	O
of	O
DIC	O
through	O
the	O
inhibition	O
of	O
activities	O
of	O
plasma	O
kallikrein	O
and	O
thrombin	S-Protein
,	O
and	O
the	O
activities	O
of	O
PCI	S-Protein
are	O
regulated	O
by	O
N	O
-	O
glycans	O
.	O

This	O
review	O
introduces	O
the	O
anti	O
-	O
DIC	O
action	O
of	O
PCI	S-Protein
and	O
about	O
the	O
modification	O
of	O
N	O
-	O
glycosylation	O
site	O
(	O
s	O
)	O
of	O
PCI	S-Protein
to	O
heighten	O
the	O
value	O
of	O
PCI	S-Protein
as	O
an	O
anti	O
-	O
DIC	O
agent	O
.	O

In	O
vitro	O
effects	O
of	O
high	O
glucose	O
concentrations	O
on	O
membrane	O
protein	O
oxidation	O
,	O
G	O
-	O
actin	O
and	O
deformability	O
of	O
human	O
erythrocytes	O
.	O

The	O
object	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
elevated	O
in	O
vitro	O
glucose	O
concentrations	O
on	O
protein	O
modification	O
and	O
functional	O
changes	O
in	O
human	O
erythrocytes	O
.	O

Groups	O
were	O
exposed	O
to	O
5	O
-	O
45	O
mM	O
glucose	O
concentrations	O
.	O

The	O
time	O
effect	O
of	O
any	O
changes	O
was	O
also	O
evaluated	O
.	O

In	O
erythrocyte	O
ghosts	O
,	O
protein	O
glycation	O
and	O
oxidation	O
were	O
evaluated	O
using	O
spectrophotometric	O
methods	O
.	O

G	O
-	O
actin	O
was	O
measured	O
by	O
a	O
DNase	B-Protein
I	E-Protein
inhibition	O
assay	O
in	O
cell	O
lysates	O
.	O

Erythrocyte	O
deformability	O
was	O
assessed	O
using	O
a	O
cell	O
transit	O
analyser	O
.	O

At	O
24	O
h	O
,	O
a	O
significant	O
protein	O
oxidation	O
(	O
at	O
25	O
and	O
45	O
mM	O
glucose	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
G	O
-	O
actin	O
increase	O
was	O
observed	O
for	O
all	O
concentrations	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
48	O
h	O
,	O
a	O
significant	O
increase	O
in	O
glycation	O
(	O
25	O
and	O
45	O
mM	O
glucose	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
protein	O
oxidation	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
G	O
-	O
actin	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
was	O
observed	O
in	O
all	O
groups	O
.	O

A	O
significant	O
positive	O
correlation	O
was	O
observed	O
between	O
glucose	O
/	O
protein	O
oxidation	O
,	O
glucose	O
/	O
G	O
-	O
actin	O
and	O
protein	O
oxidation	O
/	O
G	O
-	O
actin	O
at	O
24	O
and	O
48	O
h	O
.	O

Our	O
findings	O
show	O
that	O
the	O
oxidative	O
effect	O
of	O
glucose	O
on	O
erythrocytes	O
depends	O
on	O
concentration	O
and	O
incubation	O
time	O
.	O

We	O
also	O
present	O
the	O
first	O
evidence	O
of	O
increased	O
G	O
-	O
actin	O
in	O
human	O
erythrocytes	O
exposed	O
to	O
high	O
glucose	O
concentrations	O
as	O
a	O
diabetes	O
model	O
.	O

Determination	O
and	O
comparison	O
of	O
specific	O
activity	O
of	O
the	O
HIF	O
-	O
prolyl	O
hydroxylases	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
transcriptional	O
complex	O
that	O
is	O
regulated	O
by	O
oxygen	O
sensitive	O
hydroxylation	O
of	O
its	O
alpha	O
subunits	O
by	O
the	O
prolyl	O
hydroxylases	O
PHD1	S-Protein
,	O
2	S-Protein
and	O
3	S-Protein
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
these	O
enzymes	O
in	O
directing	O
cellular	O
responses	O
to	O
hypoxia	O
,	O
we	O
derived	O
an	O
assay	O
to	O
determine	O
their	O
specific	O
activity	O
in	O
both	O
native	O
cell	O
extracts	O
and	O
recombinant	O
sources	O
of	O
enzyme	O
.	O

We	O
show	O
that	O
all	O
three	O
are	O
capable	O
of	O
high	O
rates	O
of	O
catalysis	O
,	O
in	O
the	O
order	O
PHD2	S-Protein
=	O
PHD3	S-Protein
>	O
PHD1	S-Protein
,	O
using	O
substrate	O
peptides	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
degradation	O
domain	O
of	O
HIF	O
-	O
alpha	O
subunits	O
,	O
and	O
that	O
each	O
demonstrates	O
similar	O
and	O
remarkable	O
sensitivity	O
to	O
oxygen	O
,	O
commensurate	O
with	O
a	O
common	O
role	O
in	O
signaling	O
hypoxia	O
.	O

Many	O
amino	O
acid	O
substitutions	O
in	O
a	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
transcription	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
-	I-Protein
1alpha	E-Protein
-	O
like	O
peptide	O
cause	O
only	O
minor	O
changes	O
in	O
its	O
hydroxylation	O
by	O
the	O
HIF	O
prolyl	O
4	O
-	O
hydroxylases	O
:	O
substitution	O
of	O
3	O
,	O
4	O
-	O
dehydroproline	O
or	O
azetidine	O
-	O
2	O
-	O
carboxylic	O
acid	O
for	O
the	O
proline	O
leads	O
to	O
a	O
high	O
rate	O
of	O
uncoupled	O
2	O
-	O
oxoglutarate	O
decarboxylation	O
.	O

Three	O
human	O
prolyl	O
4	O
-	O
hydroxylases	O
(	O
P4Hs	O
)	O
regulate	O
the	O
hypoxia	O
-	O
inducible	O
transcription	O
factors	O
(	O
HIFs	O
)	O
by	O
hydroxylating	O
a	O
Leu	O
-	O
Xaa	O
-	O
Xaa	O
-	O
Leu	O
-	O
Ala	O
-	O
Pro	O
motif	O
.	O

We	O
report	O
here	O
that	O
the	O
two	O
leucines	O
in	O
the	O
Leu	O
-	O
Glu	O
-	O
Met	O
-	O
Leu	O
-	O
Ala	O
-	O
Pro	O
core	O
motif	O
of	O
a	O
20	O
-	O
residue	O
peptide	O
corresponding	O
to	O
the	O
sequence	O
around	O
Pro	O
(	O
564	O
)	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
can	O
be	O
replaced	O
by	O
many	O
residues	O
with	O
no	O
or	O
only	O
a	O
modest	O
decrease	O
in	O
its	O
substrate	O
properties	O
or	O
in	O
some	O
cases	O
even	O
a	O
slight	O
increase	O
.	O

The	O
glutamate	O
and	O
methionine	O
could	O
be	O
substituted	O
by	O
almost	O
any	O
residue	O
,	O
eight	O
amino	O
acids	O
in	O
the	O
former	O
position	O
and	O
four	O
in	O
the	O
latter	O
being	O
even	O
better	O
for	O
HIF	B-Protein
-	I-Protein
P4H	I-Protein
-	I-Protein
3	E-Protein
than	O
the	O
wild	O
-	O
type	O
residues	O
.	O

Alanine	O
was	O
by	O
far	O
the	O
strictest	O
requirement	O
,	O
because	O
no	O
residue	O
could	O
fully	O
substitute	O
for	O
it	O
in	O
the	O
case	O
of	O
HIF	B-Protein
-	I-Protein
P4H	I-Protein
-	I-Protein
1	E-Protein
,	O
and	O
only	O
serine	O
or	O
isoleucine	O
,	O
valine	O
,	O
and	O
serine	O
did	O
this	O
in	O
the	O
cases	O
of	O
HIF	B-Protein
-	I-Protein
P4Hs	I-Protein
2	E-Protein
and	O
3	S-Protein
.	O

Peptides	O
with	O
more	O
than	O
one	O
substitution	O
,	O
having	O
the	O
core	O
sequences	O
Trp	O
-	O
Glu	O
-	O
Met	O
-	O
Val	O
-	O
Ala	O
-	O
Pro	O
,	O
Tyr	O
-	O
Glu	O
-	O
Met	O
-	O
Ile	O
-	O
Ala	O
-	O
Pro	O
,	O
Ile	O
-	O
Glu	O
-	O
Met	O
-	O
Ile	O
-	O
Ala	O
-	O
Pro	O
,	O
Trp	O
-	O
Glu	O
-	O
Met	O
-	O
Val	O
-	O
Ser	O
-	O
Pro	O
,	O
and	O
Trp	O
-	O
Glu	O
-	O
Ala	O
-	O
Val	O
-	O
Ser	O
-	O
Pro	O
were	O
in	O
most	O
cases	O
equally	O
as	O
good	O
or	O
almost	O
as	O
good	O
substrates	O
as	O
the	O
wild	O
-	O
type	O
peptide	O
.	O

The	O
acidic	O
residues	O
present	O
in	O
the	O
20	O
-	O
residue	O
peptide	O
also	O
played	O
a	O
distinct	O
role	O
,	O
but	O
alanine	O
substitution	O
for	O
any	O
six	O
of	O
them	O
,	O
and	O
in	O
some	O
combinations	O
even	O
three	O
of	O
them	O
,	O
had	O
no	O
negative	O
effects	O
.	O

Substitution	O
of	O
the	O
proline	O
by	O
3	O
,	O
4	O
-	O
dehydroproline	O
or	O
l	O
-	O
azetidine	O
-	O
2	O
-	O
carboxylic	O
acid	O
,	O
but	O
not	O
any	O
other	O
residue	O
,	O
led	O
to	O
a	O
high	O
rate	O
of	O
uncoupled	O
2	O
-	O
oxoglutarate	O
decarboxylation	O
with	O
no	O
hydroxylation	O
.	O

The	O
data	O
obtained	O
for	O
the	O
three	O
HIF	O
-	O
P4Hs	O
in	O
various	O
experiments	O
were	O
in	O
most	O
cases	O
similar	O
,	O
but	O
in	O
some	O
cases	O
HIF	B-Protein
-	I-Protein
P4H	I-Protein
-	I-Protein
3	E-Protein
showed	O
distinctly	O
different	O
properties	O
.	O

Genetics	O
and	O
epigenetics	O
in	O
flower	O
pigmentation	O
associated	O
with	O
transposable	O
elements	O
in	O
morning	O
glories	O
.	O

Among	O
the	O
genus	O
Ipomoea	O
,	O
three	O
morning	O
glories	O
,	O
I	O
.	O
nil	O
(	O
the	O
Japanese	O
morning	O
glory	O
)	O
,	O
I	O
.	O
purpurea	O
(	O
the	O
common	O
morning	O
glory	O
)	O
,	O
and	O
I	O
.	O
tricolor	O
,	O
were	O
domesticated	O
well	O
for	O
floricultural	O
plants	O
,	O
and	O
many	O
spontaneous	O
mutants	O
displaying	O
various	O
flower	O
pigmentation	O
patterns	O
were	O
isolated	O
.	O

Most	O
of	O
these	O
spontaneous	O
mutations	O
were	O
found	O
to	O
be	O
caused	O
by	O
the	O
insertion	O
of	O
DNA	O
transposable	O
elements	O
in	O
the	O
genes	O
for	O
the	O
anthocyanin	O
pigmentation	O
in	O
flowers	O
,	O
and	O
many	O
of	O
them	O
exhibited	O
variegated	O
flowers	O
,	O
such	O
as	O
white	O
flowers	O
with	O
pigmented	O
spots	O
and	O
sectors	O
.	O

Here	O
,	O
we	O
describe	O
the	O
historical	O
background	O
of	O
the	O
mutants	O
displaying	O
variegated	O
flowers	O
and	O
review	O
the	O
genetic	O
and	O
epigenetic	O
regulation	O
in	O
flower	O
pigmentation	O
associated	O
with	O
transposable	O
elements	O
of	O
these	O
morning	O
glories	O
.	O

The	O
flecked	O
,	O
speckled	O
,	O
r	O
-	O
1	O
,	O
and	O
purple	O
mutations	O
in	O
I	O
.	O
nil	O
were	O
caused	O
by	O
insertions	O
of	O
Tpn1	O
and	O
its	O
relatives	O
in	O
the	O
En	O
/	O
Spm	O
superfamily	O
,	O
Tpn2	O
,	O
Tpn3	O
,	O
and	O
Tpn4	O
,	O
into	O
the	O
genes	O
for	O
anthocyanin	O
coloration	O
in	O
flowers	O
,	O
i	O
.	O
e	O
.	O
,	O
DFR	B-Protein
-	I-Protein
B	E-Protein
,	O
CHI	S-Protein
,	O
CHS	B-Protein
-	I-Protein
D	E-Protein
,	O
and	O
InNHX1	S-Protein
,	O
respectively	O
.	O

Similarly	O
,	O
the	O
flaked	O
and	O
pink	O
mutants	O
of	O
I	O
.	O
purpurea	O
have	O
distantly	O
related	O
elements	O
,	O
Tip100	O
and	O
Tip201	O
,	O
in	O
the	O
Ac	O
/	O
Ds	O
superfamily	O
inserted	O
into	O
the	O
CHS	B-Protein
-	I-Protein
D	E-Protein
and	O
F3	B-Protein
'	I-Protein
H	E-Protein
genes	O
,	O
respectively	O
.	O

The	O
flower	O
variegation	O
patterns	O
can	O
be	O
determined	O
by	O
the	O
frequency	O
and	O
timing	O
of	O
the	O
excision	O
of	O
these	O
transposons	O
,	O
and	O
their	O
stable	O
insertions	O
produce	O
plain	O
color	O
flowers	O
without	O
generating	O
pigmented	O
spots	O
or	O
sectors	O
;	O
furthermore	O
,	O
both	O
genetic	O
and	O
epigenetic	O
regulation	O
appeared	O
to	O
play	O
important	O
roles	O
in	O
determining	O
the	O
frequency	O
and	O
timing	O
of	O
the	O
excision	O
of	O
the	O
transposons	O
.	O

However	O
,	O
flower	O
variegation	O
is	O
not	O
always	O
associated	O
with	O
the	O
excision	O
of	O
an	O
integrated	O
DNA	O
transposon	O
from	O
one	O
of	O
the	O
genes	O
for	O
anthocyanin	O
pigmentation	O
.	O

The	O
mutant	O
Flying	O
Saucers	O
of	O
I	O
.	O
tricolor	O
displaying	O
variegated	O
flowers	O
was	O
found	O
to	O
have	O
the	O
transposon	O
ItMULE1	O
inserted	O
into	O
the	O
DFR	B-Protein
-	I-Protein
B	E-Protein
promoter	O
region	O
,	O
but	O
no	O
excision	O
of	O
ItMULE1	O
from	O
the	O
DFR	B-Protein
-	I-Protein
B	E-Protein
could	O
be	O
detected	O
in	O
the	O
variegated	O
flower	O
lines	O
.	O

The	O
instable	O
pearly	O
-	O
vrg	O
allele	O
in	O
cv	O
.	O

Flying	O
Saucers	O
is	O
likely	O
to	O
be	O
an	O
epiallele	O
because	O
the	O
DNA	O
methylation	O
in	O
the	O
DFR	B-Protein
-	I-Protein
B	E-Protein
promoter	O
appeared	O
to	O
be	O
associated	O
with	O
flower	O
pigmentation	O
.	O

Characterization	O
of	O
a	O
second	O
Arabidopsis	O
thaliana	O
prolyl	O
4	O
-	O
hydroxylase	O
with	O
distinct	O
substrate	O
specificity	O
.	O

4	O
-	O
Hydroxyproline	O
is	O
found	O
in	O
collagens	O
,	O
collagen	O
-	O
like	O
proteins	O
,	O
elastin	S-Protein
,	O
and	O
the	O
hypoxia	O
-	O
inducible	O
transcription	O
factor	O
in	O
animals	O
and	O
in	O
many	O
hydroxyproline	O
-	O
rich	O
glycoproteins	O
in	O
plants	O
.	O

We	O
report	O
here	O
on	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
second	O
plant	O
P4H	O
(	O
prolyl	O
4	O
-	O
hydroxylase	O
)	O
,	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
,	O
from	O
Arabidopsis	O
thaliana	O
.	O

It	O
consists	O
of	O
299	O
amino	O
acids	O
and	O
shows	O
33	O
%	O
sequence	O
identity	O
to	O
the	O
first	O
characterized	O
isoenzyme	O
,	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	E-Protein
.	O

A	O
characteristic	O
feature	O
of	O
the	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
polypeptide	O
is	O
a	O
49	O
-	O
amino	O
-	O
acid	O
C	O
-	O
terminal	O
toxin	O
homology	O
domain	O
with	O
6	O
cysteines	O
that	O
is	O
not	O
found	O
in	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	E-Protein
but	O
is	O
present	O
in	O
a	O
putative	O
rice	O
P4H	O
homologue	O
.	O

At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
differed	O
distinctly	O
from	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	E-Protein
in	O
its	O
substrate	O
specificity	O
.	O

Recombinant	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
hydroxylated	O
poly	O
(	O
L	O
-	O
proline	O
)	O
and	O
extensin	O
and	O
arabinogalactan	O
-	O
like	O
peptides	O
effectively	O
but	O
with	O
much	O
higher	O
Km	O
values	O
than	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	E-Protein
,	O
suggesting	O
different	O
roles	O
for	O
the	O
two	O
At	O
-	O
P4Hs	O
in	O
the	O
plant	O
cell	O
.	O

Unlike	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	E-Protein
,	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
hydroxylated	O
collagen	O
-	O
like	O
peptides	O
only	O
very	O
inefficiently	O
and	O
did	O
not	O
hydroxylate	O
hypoxia	O
-	O
inducible	O
transcription	O
factor	O
alpha	O
-	O
like	O
peptides	O
at	O
all	O
.	O

All	O
the	O
peptides	O
efficiently	O
hydroxylated	O
by	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
had	O
at	O
least	O
3	O
consecutive	O
prolines	O
,	O
suggesting	O
that	O
these	O
may	O
represent	O
a	O
minimum	O
requirement	O
for	O
efficient	O
hydroxylation	O
by	O
this	O
isoenzyme	O
.	O

N	O
-	O
terminal	O
sequencing	O
of	O
an	O
extensin	O
-	O
like	O
peptide	O
SPPPVYKSPPPPVKHYSPPPV	O
indicated	O
that	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
preferentially	O
hydroxylated	O
the	O
3rd	O
proline	O
in	O
the	O
C	O
-	O
terminal	O
PPP	O
triplet	O
.	O

The	O
Km	O
values	O
of	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
for	O
the	O
reaction	O
cosubstrates	O
Fe2	O
+	O
,	O
2	O
-	O
oxoglutarate	O
,	O
and	O
ascorbate	O
were	O
similar	O
to	O
those	O
of	O
At	O
-	O
P4H	B-Protein
-	I-Protein
1	E-Protein
with	O
the	O
exception	O
that	O
the	O
Km	O
for	O
iron	O
was	O
about	O
3	O
-	O
fold	O
lower	O
.	O

Pyridine	O
-	O
2	O
,	O
4	O
-	O
dicarboxylate	O
and	O
pyridine	O
-	O
2	O
,	O
5	O
-	O
dicarboxylate	O
,	O
well	O
known	O
competitive	O
inhibitors	O
of	O
the	O
vertebrate	O
P4Hs	O
with	O
respect	O
to	O
2	O
-	O
oxoglutarate	O
,	O
were	O
also	O
competitive	O
inhibitors	O
of	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
but	O
with	O
Ki	O
values	O
5	O
-	O
100	O
-	O
fold	O
higher	O
than	O
those	O
of	O
human	O
type	O
I	O
collagen	O
P4H	O
.	O

It	O
thus	O
seems	O
that	O
there	O
are	O
some	O
distinct	O
differences	O
in	O
the	O
structure	O
of	O
the	O
2	O
-	O
oxoglutarate	O
-	O
binding	O
site	O
between	O
At	O
-	O
P4H	B-Protein
-	I-Protein
2	E-Protein
and	O
the	O
animal	O
collagen	O
P4Hs	O
.	O

The	O
role	O
of	O
protein	O
kinase	O
A	O
pathway	O
and	O
cAMP	O
responsive	O
element	O
-	O
binding	O
protein	O
in	O
androgen	B-Protein
receptor	E-Protein
-	O
mediated	O
transcription	O
at	O
the	O
prostate	B-Protein
-	I-Protein
specific	I-Protein
antigen	E-Protein
locus	O
.	O

Androgen	O
-	O
independent	O
prostate	O
cancer	O
is	O
a	O
lethal	O
form	O
of	O
the	O
disease	O
that	O
is	O
marked	O
by	O
metastasis	O
and	O
rapid	O
proliferation	O
in	O
its	O
final	O
stages	O
.	O

As	O
no	O
effective	O
therapy	O
for	O
this	O
aggressive	O
tumor	O
currently	O
exists	O
,	O
it	O
is	O
imperative	O
to	O
elucidate	O
and	O
target	O
the	O
mechanisms	O
involved	O
in	O
the	O
progression	O
to	O
androgen	O
independence	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
aberrant	O
activation	O
of	O
androgen	B-Protein
receptor	E-Protein
(	O
AR	S-Protein
)	O
via	O
signal	O
transduction	O
pathways	O
,	O
AR	S-Protein
gene	O
mutation	O
and	O
/	O
or	O
amplification	O
,	O
and	O
/	O
or	O
coregulator	O
alterations	O
may	O
contribute	O
to	O
the	O
progression	O
of	O
prostate	O
cancer	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signaling	O
and	O
its	O
downstream	O
factors	O
on	O
AR	S-Protein
activity	O
at	O
the	O
prostate	B-Protein
-	I-Protein
specific	I-Protein
antigen	E-Protein
(	O
PSA	S-Protein
)	O
gene	O
were	O
tested	O
.	O

Activation	O
of	O
PKA	O
by	O
forskolin	O
resulted	O
in	O
enhanced	O
androgen	O
-	O
induced	O
expression	O
of	O
the	O
PSA	S-Protein
gene	O
,	O
an	O
effect	O
that	O
was	O
blocked	O
by	O
the	O
AR	S-Protein
antagonist	O
,	O
bicalutamide	O
.	O

Interestingly	O
,	O
when	O
either	O
p300	S-Protein
or	O
CBP	S-Protein
was	O
overexpressed	O
,	O
PKA	O
activation	O
was	O
sufficient	O
to	O
stimulate	O
PSA	S-Protein
promoter	O
-	O
driven	O
transcription	O
in	O
the	O
absence	O
of	O
androgen	O
,	O
which	O
was	O
not	O
inhibited	O
by	O
bicalutamide	O
.	O

PKA	O
activation	O
did	O
not	O
significantly	O
alter	O
AR	S-Protein
protein	O
levels	O
but	O
significantly	O
increased	O
the	O
phosphorylated	O
form	O
of	O
its	O
downstream	O
effector	O
,	O
cAMP	O
responsive	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
in	O
the	O
presence	O
of	O
androgen	O
.	O

Furthermore	O
,	O
chromatin	O
immunoprecipitation	O
showed	O
that	O
the	O
combination	O
of	O
androgen	O
and	O
forskolin	O
increased	O
phosphorylated	O
CREB	O
occupancy	O
,	O
which	O
was	O
accompanied	O
by	O
histone	S-Protein
acetylation	O
,	O
at	O
the	O
putative	O
cAMP	O
responsive	O
element	O
located	O
in	O
the	O
5	O
'	O
upstream	O
regulatory	O
region	O
of	O
the	O
PSA	S-Protein
gene	O
.	O

Remarkably	O
,	O
mammalian	O
two	O
-	O
hybrid	O
assay	O
indicated	O
that	O
p300	S-Protein
/	O
CBP	S-Protein
may	O
bridge	O
the	O
interaction	O
between	O
AR	S-Protein
and	O
CREB	O
,	O
suggesting	O
a	O
novel	O
enhanceosomal	O
cooperation	O
.	O

These	O
results	O
demonstrate	O
an	O
intriguing	O
interplay	O
between	O
a	O
signal	O
transduction	O
pathway	O
,	O
coactivator	O
overexpression	O
and	O
AR	S-Protein
signaling	O
as	O
a	O
possible	O
combined	O
mechanism	O
of	O
progression	O
to	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

Oxidative	O
stress	O
is	O
involved	O
in	O
inhibition	O
of	O
copper	O
on	O
histone	S-Protein
acetylation	O
in	O
cells	O
.	O

Our	O
previous	O
study	O
demonstrates	O
that	O
copper	O
induces	O
histone	S-Protein
hypoacetylation	O
by	O
inhibiting	O
histone	S-Protein
acetyltransferase	O
(	O
HAT	O
)	O
activity	O
.	O

However	O
,	O
it	O
lacks	O
direct	O
evidences	O
whether	O
copper	O
-	O
inhibited	O
histone	S-Protein
acetylation	O
right	O
contributes	O
to	O
the	O
toxicity	O
of	O
copper	O
.	O

Exposure	O
of	O
human	O
leukemia	O
cells	O
(	O
HL	O
-	O
60	O
)	O
to	O
Cu2	O
+	O
resulted	O
in	O
cell	O
proliferation	O
arrest	O
and	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
decrease	O
of	O
histone	S-Protein
acetylation	O
.	O

At	O
the	O
same	O
time	O
,	O
Cu2	O
+	O
-	O
induced	O
significant	O
increase	O
of	O
H2O2	O
and	O
O2	O
.	O
-	O
generation	O
via	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
too	O
.	O

The	O
histone	S-Protein
acetylation	O
was	O
efficiently	O
suppressed	O
by	O
exogenous	O
H2O2	O
,	O
and	O
enhanced	O
by	O
superoxide	O
dismutase	O
(	O
the	O
scavenger	O
of	O
O2	O
.	O
-	O
)	O
,	O
catalase	S-Protein
(	O
the	O
scavenger	O
of	O
H2O2	O
)	O
or	O
the	O
combination	O
of	O
both	O
,	O
indicating	O
that	O
Cu2	O
+	O
at	O
least	O
partially	O
inhibited	O
histone	S-Protein
acetylation	O
through	O
triggering	O
oxidative	O
stress	O
.	O

Further	O
studies	O
found	O
that	O
sodium	O
butyrate	O
,	O
the	O
inhibitor	O
of	O
histone	S-Protein
deacetylase	O
(	O
HDAC	O
)	O
,	O
which	O
had	O
no	O
obvious	O
effect	O
on	O
oxidative	O
stress	O
but	O
increased	O
histone	S-Protein
acetylation	O
at	O
the	O
concentration	O
of	O
50	O
microM	O
,	O
attenuated	O
Cu2	O
+	O
-	O
inhibited	O
cell	O
proliferation	O
,	O
indicating	O
that	O
histone	S-Protein
acetylation	O
inhibition	O
is	O
simultaneously	O
involved	O
in	O
the	O
cytotoxicity	O
of	O
Cu2	O
+	O
.	O

Considering	O
the	O
important	O
role	O
of	O
histone	S-Protein
acetylation	O
in	O
gene	O
transcription	O
and	O
regulation	O
of	O
cell	O
fate	O
,	O
the	O
present	O
study	O
may	O
open	O
a	O
new	O
door	O
to	O
further	O
understand	O
the	O
mechanism	O
of	O
Cu2	O
+	O
-	O
induced	O
toxicity	O
.	O

DNA	O
methylation	O
-	O
related	O
chromatin	O
modification	O
in	O
the	O
regulation	O
of	O
mouse	O
delta	B-Protein
-	I-Protein
opioid	I-Protein
receptor	E-Protein
gene	O
.	O

DNA	O
methylation	O
plays	O
critical	O
roles	O
in	O
gene	O
-	O
silencing	O
through	O
chromatin	O
modification	O
.	O

We	O
reported	O
previously	O
that	O
promoter	O
-	O
region	O
CpG	O
methylation	O
repressed	O
mouse	O
delta	B-Protein
-	I-Protein
opioid	I-Protein
receptor	E-Protein
(	O
mDOR	S-Protein
)	O
gene	O
expression	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
methylation	O
of	O
mDOR	S-Protein
gene	O
promoter	O
is	O
correlated	O
with	O
a	O
repressive	O
chromatin	O
structure	O
that	O
has	O
less	O
HaeIII	S-Protein
and	O
MspI	S-Protein
nuclear	O
accessibility	O
and	O
more	O
deacetylated	O
histone	B-Protein
H3	E-Protein
and	O
H4	S-Protein
than	O
that	O
of	O
unmethylated	O
mDOR	S-Protein
promoter	O
.	O

Chromatin	O
immunoprecipitation	O
analysis	O
showed	O
the	O
association	O
of	O
a	O
methyl	B-Protein
-	I-Protein
CpG	I-Protein
-	I-Protein
binding	I-Protein
domain	I-Protein
protein	I-Protein
2	E-Protein
(	O
MBD2	S-Protein
)	O
with	O
methylated	O
mDOR	S-Protein
promoter	O
.	O

Transient	O
expression	O
of	O
MBD2	S-Protein
enhanced	O
the	O
repression	O
of	O
partially	O
methylated	O
mDOR	S-Protein
promoter	O
activity	O
,	O
and	O
this	O
repression	O
was	O
partially	O
reversed	O
by	O
treatment	O
of	O
trichostatin	O
A	O
,	O
a	O
specific	O
histone	S-Protein
deacetylase	O
inhibitor	O
,	O
indicating	O
that	O
MBD2	S-Protein
may	O
mediate	O
DNA	O
methylation	O
-	O
related	O
chromatin	O
modification	O
through	O
recruiting	O
histone	O
deacetylases	O
to	O
mDOR	S-Protein
promoter	O
region	O
.	O

In	O
addition	O
,	O
trichostatin	O
A	O
treatment	O
increased	O
both	O
methylated	O
mDOR	S-Protein
promoter	O
activity	O
in	O
a	O
transient	O
transfection	O
assay	O
and	O
endogenous	O
mDOR	S-Protein
mRNA	O
level	O
in	O
Neuro2A	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
mDOR	S-Protein
gene	O
expression	O
is	O
regulated	O
by	O
DNA	O
methylation	O
-	O
related	O
chromatin	O
modification	O
,	O
especially	O
histone	S-Protein
acetylation	O
and	O
deacetylation	O
.	O

The	O
potential	O
of	O
Pseudozyma	O
yeastlike	O
epiphytes	O
for	O
the	O
production	O
of	O
heterologous	O
recombinant	O
proteins	O
.	O

Although	O
Basidiomycetes	O
represent	O
the	O
most	O
evolved	O
class	O
of	O
fungi	O
,	O
they	O
have	O
been	O
neglected	O
with	O
regard	O
to	O
recombinant	O
gene	O
expression	O
.	O

In	O
this	O
work	O
,	O
basidiomycetous	O
yeasts	O
belonging	O
to	O
Pseudozyma	O
spp	O
.	O
were	O
studied	O
with	O
respect	O
to	O
their	O
amenability	O
to	O
heterologous	O
protein	O
production	O
.	O

Single	O
plasmid	O
or	O
cotransformation	O
experiments	O
routinely	O
afforded	O
100	O
to	O
200	O
independent	O
transformants	O
for	O
the	O
two	O
tested	O
species	O
of	O
Pseudozyma	O
.	O

Green	B-Protein
fluorescent	I-Protein
protein	E-Protein
(	O
GFP	S-Protein
)	O
was	O
expressed	O
in	O
the	O
correctly	O
folded	O
conformation	O
,	O
as	O
demonstrated	O
by	O
fluorescence	O
microscopy	O
,	O
and	O
hen	O
egg	O
white	O
lysozyme	S-Protein
(	O
HEWL	O
)	O
was	O
expressed	O
in	O
its	O
active	O
form	O
,	O
as	O
revealed	O
by	O
its	O
lytic	O
activity	O
on	O
Micrococcus	O
lysodeikticus	O
cells	O
.	O

Protease	O
analysis	O
established	O
that	O
Pseudozyma	O
spp	O
.	O
contained	O
equivalent	O
or	O
less	O
extracellular	O
protease	O
activity	O
than	O
yeasts	O
and	O
far	O
less	O
protease	O
activity	O
than	O
ascomycetous	O
filamentous	O
fungi	O
in	O
similar	O
culture	O
conditions	O
.	O

This	O
proteolytic	O
activity	O
was	O
inhibited	O
by	O
over	O
97	O
%	O
with	O
a	O
combination	O
of	O
PMSF	O
and	O
Pepstatin	O
A	O
.	O

N	O
-	O
glycosylation	O
patterns	O
of	O
native	O
Pseudozyma	O
flocculosa	O
secreted	O
proteins	O
were	O
comprised	O
of	O
one	O
or	O
a	O
few	O
short	O
glycan	O
chains	O
that	O
possess	O
a	O
classic	O
eukaryotic	O
structure	O
typical	O
of	O
higher	O
fungi	O
and	O
animal	O
cells	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
Basidiomycete	O
that	O
possesses	O
multiple	O
intrinsic	O
characteristics	O
necessary	O
for	O
use	O
as	O
a	O
heterologous	O
gene	O
expression	O
system	O
.	O

Interactions	O
of	O
whey	O
proteins	O
during	O
heat	O
treatment	O
of	O
oil	O
-	O
in	O
-	O
water	O
emulsions	O
formed	O
with	O
whey	O
protein	O
isolate	O
and	O
hydroxylated	O
lecithin	O
.	O

The	O
interactions	O
of	O
proteins	O
during	O
the	O
heat	O
treatment	O
of	O
whey	O
-	O
protein	O
-	O
isolate	O
(	O
WPI	O
)	O
-	O
based	O
oil	O
-	O
in	O
-	O
water	O
emulsions	O
with	O
and	O
without	O
added	O
hydroxylated	O
lecithin	O
were	O
studied	O
by	O
examining	O
the	O
changes	O
in	O
droplet	O
size	O
distribution	O
and	O
the	O
quantity	O
and	O
type	O
of	O
adsorbed	O
and	O
unadsorbed	O
proteins	O
.	O

Heat	O
treatment	O
at	O
90	O
degrees	O
C	O
of	O
WPI	O
emulsions	O
resulted	O
in	O
an	O
increase	O
in	O
total	O
adsorbed	O
protein	O
;	O
unadsorbed	O
beta	B-Protein
-	I-Protein
lactoglobulin	E-Protein
(	O
beta	B-Protein
-	I-Protein
lg	E-Protein
)	O
was	O
the	O
main	O
protein	O
interacting	O
with	O
the	O
adsorbed	O
proteins	O
during	O
the	O
first	O
10	O
min	O
of	O
heating	O
,	O
but	O
after	O
this	O
time	O
,	O
unadsorbed	O
alpha	B-Protein
-	I-Protein
lactalbumin	E-Protein
(	O
alpha	B-Protein
-	I-Protein
la	E-Protein
)	O
also	O
associated	O
with	O
the	O
adsorbed	O
protein	O
.	O

In	O
emulsions	O
containing	O
hydroxylated	O
lecithin	O
,	O
the	O
increase	O
in	O
total	O
adsorbed	O
protein	O
during	O
heat	O
treatment	O
was	O
much	O
lower	O
and	O
the	O
unadsorbed	O
beta	B-Protein
-	I-Protein
lg	E-Protein
did	O
not	O
appear	O
to	O
interact	O
with	O
the	O
adsorbed	O
proteins	O
during	O
heating	O
.	O

However	O
,	O
the	O
behavior	O
of	O
alpha	B-Protein
-	I-Protein
la	E-Protein
during	O
heat	O
treatment	O
of	O
these	O
emulsions	O
was	O
similar	O
to	O
that	O
observed	O
in	O
the	O
emulsions	O
containing	O
no	O
hydroxylated	O
lecithin	O
.	O

In	O
the	O
presence	O
of	O
NaCl	O
,	O
the	O
particle	O
size	O
of	O
the	O
emulsion	O
droplets	O
and	O
the	O
quantities	O
of	O
adsorbed	O
protein	O
increased	O
markedly	O
during	O
heating	O
.	O

Emulsions	O
containing	O
hydroxylated	O
lecithin	O
were	O
less	O
sensitive	O
to	O
the	O
addition	O
of	O
NaCl	O
.	O

These	O
results	O
suggest	O
that	O
the	O
binding	O
of	O
hydroxylated	O
lecithin	O
to	O
unfolded	O
monomers	O
or	O
intermediate	O
products	O
of	O
beta	B-Protein
-	I-Protein
lg	E-Protein
reduces	O
the	O
extent	O
of	O
heat	O
-	O
induced	O
aggregation	O
of	O
beta	B-Protein
-	I-Protein
lg	E-Protein
and	O
consequently	O
decreases	O
the	O
interactions	O
between	O
unadsorbed	O
beta	B-Protein
-	I-Protein
lg	E-Protein
and	O
adsorbed	O
protein	O
.	O

This	O
was	O
confirmed	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
of	O
heated	O
whey	O
protein	O
and	O
hydroxylated	O
lecithin	O
solutions	O
.	O

Dynamic	O
lysine	O
methylation	O
on	O
histone	B-Protein
H3	E-Protein
defines	O
the	O
regulatory	O
phase	O
of	O
gene	O
transcription	O
.	O

Covalent	O
modifications	O
to	O
histones	S-Protein
are	O
key	O
epigenetic	O
marks	O
that	O
control	O
gene	O
transcription	O
.	O

Multiple	O
lysine	O
residues	O
on	O
histone	B-Protein
H3	E-Protein
are	O
methylated	O
(	O
me	O
)	O
,	O
but	O
their	O
functions	O
are	O
unclear	O
.	O

Here	O
,	O
we	O
demonstrate	O
two	O
phases	O
of	O
combinatorial	O
and	O
dynamic	O
H3	S-Protein
methylation	O
during	O
induction	O
of	O
transcription	O
at	O
MET16	S-Protein
in	O
yeast	O
.	O

K4me3	O
with	O
K36me2	O
/	O
3	O
define	O
a	O
postinitiation	O
regulatory	O
phase	O
and	O
precede	O
the	O
appearance	O
of	O
K4me2	O
with	O
K79me2	O
at	O
the	O
onset	O
of	O
transcript	O
elongation	O
.	O

The	O
Isw1	S-Protein
ATPase	O
delays	O
the	O
release	O
of	O
initiated	O
RNA	O
polymerase	O
II	O
(	O
RNAPII	O
)	O
into	O
elongation	O
to	O
facilitate	O
chromatin	O
modifications	O
.	O

The	O
Spp1	S-Protein
subunit	O
of	O
complex	O
associated	O
with	O
Set1	S-Protein
(	O
COMPASS	O
)	O
and	O
Set2	S-Protein
,	O
determining	O
K4me3	O
and	O
K36me2	O
/	O
3	O
,	O
respectively	O
,	O
are	O
required	O
for	O
transient	O
NuA4	O
-	O
dependent	O
H4K8ac	O
.	O

This	O
releases	O
RNAPII	O
from	O
Isw1	S-Protein
control	O
and	O
promotes	O
controlled	O
transcription	O
elongation	O
and	O
termination	O
.	O

We	O
propose	O
that	O
newly	O
initiated	O
RNAPII	O
is	O
under	O
epigenetic	O
control	O
.	O

Proline	O
hydroxylation	O
and	O
gene	O
expression	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
master	O
transcriptional	O
regulator	O
of	O
hypoxia	O
-	O
inducible	O
genes	O
and	O
consists	O
of	O
a	O
labile	O
alpha	O
subunit	O
(	O
such	O
as	O
HIF1alpha	S-Protein
)	O
and	O
a	O
stable	O
beta	O
subunit	O
(	O
such	O
as	O
HIF1beta	S-Protein
or	O
ARNT	S-Protein
)	O
.	O

In	O
the	O
presence	O
of	O
oxygen	O
,	O
HIFalpha	O
family	O
members	O
are	O
hydroxylated	O
on	O
one	O
of	O
two	O
conserved	O
prolyl	O
residues	O
by	O
members	O
of	O
the	O
egg	O
-	O
laying	O
-	O
defective	O
nine	O
(	O
EGLN	O
)	O
family	O
.	O

Prolyl	O
hydroxylation	O
generates	O
a	O
binding	O
site	O
for	O
a	O
ubiquitin	S-Protein
ligase	O
complex	O
containing	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumor	I-Protein
suppressor	E-Protein
protein	O
,	O
which	O
results	O
in	O
HIFalpha	O
destruction	O
.	O

In	O
addition	O
,	O
the	O
HIFalpha	O
transcriptional	O
activation	O
function	O
is	O
modulated	O
further	O
by	O
asparagine	O
hydroxylation	O
by	O
FIH	S-Protein
(	O
factor	B-Protein
-	I-Protein
inhibiting	I-Protein
HIF	E-Protein
)	O
,	O
which	O
affects	O
recruitment	O
of	O
the	O
coactivators	O
p300	S-Protein
and	O
CBP	S-Protein
.	O

These	O
findings	O
provide	O
new	O
mechanistic	O
insights	O
into	O
oxygen	O
sensing	O
by	O
metazoans	O
and	O
are	O
the	O
first	O
examples	O
of	O
protein	O
hydroxylation	O
being	O
used	O
in	O
intracellular	O
signaling	O
.	O

The	O
existence	O
of	O
three	O
human	O
EGLN	O
family	O
members	O
,	O
as	O
well	O
as	O
other	O
putative	O
hydroxylases	O
,	O
raises	O
the	O
possibility	O
that	O
this	O
signal	O
is	O
used	O
in	O
other	O
contexts	O
by	O
other	O
proteins	O
.	O

Histone	S-Protein
acetyltransferase	O
activity	O
of	O
p300	S-Protein
is	O
required	O
for	O
transcriptional	O
repression	O
by	O
the	O
promyelocytic	O
leukemia	O
zinc	O
finger	O
protein	O
.	O

Histone	S-Protein
acetyltransferase	O
(	O
HAT	O
)	O
activities	O
of	O
proteins	O
such	O
as	O
p300	S-Protein
,	O
CBP	S-Protein
,	O
and	O
P	B-Protein
/	I-Protein
CAF	E-Protein
play	O
important	O
roles	O
in	O
activation	O
of	O
gene	O
expression	O
.	O

We	O
now	O
show	O
that	O
the	O
HAT	O
activity	O
of	O
p300	S-Protein
can	O
also	O
be	O
required	O
for	O
down	O
-	O
regulation	O
of	O
transcription	O
by	O
a	O
DNA	O
binding	O
repressor	O
protein	O
.	O

Promyelocytic	B-Protein
leukemia	I-Protein
zinc	I-Protein
finger	E-Protein
(	O
PLZF	S-Protein
)	O
,	O
originally	O
identified	O
as	O
a	O
fusion	O
with	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
alpha	E-Protein
in	O
rare	O
cases	O
of	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
-	O
resistant	O
acute	O
promyelocytic	O
leukemia	O
,	O
is	O
a	O
transcriptional	O
repressor	O
that	O
recruits	O
histone	S-Protein
deacetylase	O
-	O
containing	O
corepressor	O
complexes	O
to	O
specific	O
DNA	O
binding	O
sites	O
.	O

PLZF	S-Protein
associates	O
with	O
p300	S-Protein
in	O
vivo	O
,	O
and	O
its	O
ability	O
to	O
repress	O
transcription	O
is	O
specifically	O
dependent	O
on	O
HAT	O
activity	O
of	O
p300	S-Protein
and	O
acetylation	O
of	O
lysines	O
in	O
its	O
C	O
-	O
terminal	O
C2	O
-	O
H2	O
zinc	O
finger	O
motif	O
.	O

An	O
acetylation	O
site	O
mutant	O
of	O
PLZF	S-Protein
does	O
not	O
repress	O
transcription	O
and	O
is	O
functionally	O
deficient	O
in	O
a	O
colony	O
suppression	O
assay	O
despite	O
retaining	O
its	O
abilities	O
to	O
interact	O
with	O
corepressor	O
/	O
histone	S-Protein
deacetylase	O
complexes	O
.	O

This	O
is	O
due	O
to	O
the	O
fact	O
that	O
acetylation	O
of	O
PLZF	S-Protein
activates	O
its	O
ability	O
to	O
bind	O
specific	O
DNA	O
sequences	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
a	O
histone	S-Protein
deacetylase	O
-	O
dependent	O
transcriptional	O
repressor	O
can	O
be	O
positively	O
regulated	O
through	O
acetylation	O
and	O
point	O
to	O
an	O
unexpected	O
role	O
of	O
a	O
coactivator	O
protein	O
in	O
transcriptional	O
repression	O
.	O

Coordinate	O
regulation	O
of	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domains	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1	I-Protein
alpha	E-Protein
.	O

Oxygen	O
-	O
dependent	O
proteolysis	O
is	O
the	O
primary	O
means	O
of	O
regulating	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
family	O
of	O
transcription	O
factors	O
.	O

The	O
alpha	O
-	O
subunit	O
of	O
HIF	O
factor	O
1	O
(	O
HIF	O
-	O
1	O
)	O
contains	O
two	O
highly	O
conserved	O
oxygen	O
-	O
dependent	O
degradation	O
domains	O
(	O
402	O
ODD	O
and	O
564	O
ODD	O
)	O
,	O
each	O
of	O
which	O
includes	O
a	O
proline	O
that	O
is	O
hydroxylated	O
in	O
the	O
presence	O
of	O
oxygen	O
,	O
allowing	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	E-Protein
(	O
VHL	S-Protein
)	O
E3	O
ubiquitin	S-Protein
ligase	O
to	O
interact	O
and	O
target	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

Mutation	O
of	O
either	O
proline	O
is	O
sufficient	O
to	O
partially	O
stabilize	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
under	O
conditions	O
of	O
normoxia	O
,	O
but	O
the	O
specific	O
contributions	O
of	O
each	O
hydroxylation	O
event	O
to	O
the	O
regulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
are	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
the	O
two	O
ODDs	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
have	O
independent	O
yet	O
interactive	O
roles	O
in	O
the	O
regulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
protein	O
turnover	O
,	O
with	O
the	O
relative	O
involvement	O
of	O
each	O
ODD	O
depending	O
on	O
the	O
levels	O
of	O
oxygen	O
.	O

Using	O
hydroxylation	O
-	O
specific	O
antibodies	O
,	O
we	O
found	O
that	O
under	O
conditions	O
of	O
normoxia	O
proline	O
564	O
is	O
hydroxylated	O
prior	O
to	O
proline	O
402	O
,	O
and	O
mutation	O
of	O
proline	O
564	O
results	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
hydroxylation	O
of	O
proline	O
402	O
.	O

Mutation	O
of	O
proline	O
402	O
,	O
however	O
,	O
has	O
little	O
effect	O
on	O
the	O
hydroxylation	O
of	O
proline	O
564	O
.	O

To	O
determine	O
whether	O
the	O
more	O
rapid	O
hydroxylation	O
of	O
the	O
proline	O
564	O
under	O
conditions	O
of	O
normoxia	O
is	O
due	O
to	O
a	O
preference	O
for	O
the	O
particular	O
sequence	O
surrounding	O
proline	O
564	O
or	O
for	O
that	O
site	O
within	O
the	O
protein	O
,	O
we	O
exchanged	O
the	O
degradation	O
domains	O
within	O
the	O
full	O
-	O
length	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
protein	O
.	O

In	O
these	O
domain	O
-	O
swapping	O
experiments	O
,	O
prolyl	O
hydroxylase	O
domain	O
1	O
(	O
PHD1	O
)	O
and	O
PHD2	O
preferentially	O
hydroxylated	O
the	O
proline	O
located	O
in	O
the	O
site	O
of	O
the	O
original	O
564	O
ODD	O
,	O
while	O
PHD3	O
preferred	O
the	O
proline	O
564	O
sequence	O
,	O
regardless	O
of	O
its	O
location	O
.	O

At	O
limiting	O
oxygen	O
tensions	O
,	O
we	O
found	O
that	O
proline	O
402	O
exhibits	O
an	O
oxygen	O
-	O
dependent	O
decrease	O
in	O
hydroxylation	O
at	O
higher	O
oxygen	O
tensions	O
relative	O
to	O
proline	O
564	O
hydroxylation	O
.	O

These	O
results	O
indicate	O
that	O
hydroxylation	O
of	O
proline	O
402	O
is	O
highly	O
responsive	O
to	O
physiologic	O
changes	O
in	O
oxygen	O
and	O
,	O
therefore	O
,	O
plays	O
a	O
more	O
important	O
role	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
regulation	O
under	O
conditions	O
of	O
hypoxia	O
than	O
under	O
conditions	O
of	O
normoxia	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
each	O
hydroxylated	O
proline	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
has	O
a	O
distinct	O
activity	O
in	O
controlling	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
stability	O
in	O
response	O
to	O
different	O
levels	O
of	O
oxygenation	O
.	O

Carboxyl	O
-	O
terminal	O
extensions	O
beyond	O
the	O
conserved	O
pentapeptide	O
reduce	O
rates	O
of	O
chemoreceptor	O
adaptational	O
modification	O
.	O

Sensory	O
adaptation	O
in	O
bacterial	O
chemotaxis	O
is	O
mediated	O
by	O
covalent	O
modification	O
of	O
chemoreceptors	O
.	O

Specific	O
glutamyl	O
residues	O
are	O
methylated	O
and	O
demethylated	O
in	O
reactions	O
catalyzed	O
by	O
methyltransferase	O
CheR	S-Protein
and	O
methylesterase	O
CheB	S-Protein
.	O

In	O
the	O
well	O
-	O
characterized	O
chemosensory	O
systems	O
of	O
Escherichia	O
coli	O
and	O
Salmonella	O
spp	O
.	O
,	O
efficient	O
modification	O
by	O
either	O
enzyme	O
is	O
dependent	O
on	O
a	O
conserved	O
pentapeptide	O
sequence	O
,	O
NWETF	O
or	O
NWESF	O
,	O
present	O
at	O
the	O
extreme	O
carboxyl	O
terminus	O
of	O
high	O
-	O
abundance	O
chemoreceptors	O
.	O

To	O
what	O
extent	O
is	O
position	O
at	O
the	O
extreme	O
carboxyl	O
terminus	O
important	O
for	O
pentapeptide	O
-	O
mediated	O
enhancement	O
of	O
adaptational	O
modification	O
?	O

Is	O
this	O
position	O
equally	O
important	O
for	O
enhancement	O
of	O
both	O
enzyme	O
activities	O
?	O

To	O
address	O
these	O
questions	O
,	O
we	O
created	O
forms	O
of	O
high	O
-	O
abundance	O
receptor	O
Tsr	S-Protein
or	O
Tar	S-Protein
carrying	O
one	O
,	O
six	O
,	O
or	O
eight	O
additional	O
amino	O
acids	O
extending	O
beyond	O
the	O
pentapeptide	O
at	O
their	O
carboxyl	O
termini	O
and	O
assayed	O
methylation	O
,	O
demethylation	O
,	O
deamidation	O
,	O
and	O
ability	O
to	O
mediate	O
chemotaxis	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
,	O
all	O
three	O
carboxyl	O
-	O
terminal	O
extensions	O
reduced	O
pentapeptide	O
-	O
mediated	O
enhancement	O
of	O
rates	O
of	O
adaptational	O
modification	O
.	O

CheB	S-Protein
-	O
catalyzed	O
reactions	O
were	O
more	O
affected	O
than	O
CheR	S-Protein
-	O
catalyzed	O
reactions	O
.	O

Effects	O
were	O
less	O
severe	O
for	O
the	O
complete	O
sensory	O
system	O
in	O
vivo	O
than	O
for	O
the	O
minimal	O
system	O
of	O
receptor	O
and	O
modification	O
enzymes	O
in	O
vitro	O
.	O

Notably	O
,	O
extended	O
receptors	O
mediated	O
chemotaxis	O
as	O
efficiently	O
as	O
wild	O
-	O
type	O
receptors	O
,	O
providing	O
a	O
striking	O
example	O
of	O
robustness	O
in	O
chemotactic	O
systems	O
.	O

This	O
could	O
reflect	O
compensatory	O
reductions	O
of	O
rates	O
for	O
both	O
modification	O
reactions	O
,	O
mitigation	O
of	O
effects	O
of	O
slower	O
reactions	O
by	O
the	O
intertwined	O
circuitry	O
of	O
signaling	O
and	O
adaptation	O
,	O
or	O
tolerance	O
of	O
a	O
range	O
of	O
reactions	O
rates	O
for	O
adaptational	O
modification	O
.	O

No	O
matter	O
what	O
the	O
mechanism	O
,	O
the	O
observations	O
provide	O
a	O
challenging	O
test	O
for	O
mathematical	O
models	O
of	O
chemotaxis	O
.	O

Dimethylation	O
of	O
histone	B-Protein
H3	E-Protein
at	O
lysine	O
36	O
demarcates	O
regulatory	O
and	O
nonregulatory	O
chromatin	O
genome	O
-	O
wide	O
.	O

Set2p	S-Protein
,	O
which	O
mediates	O
histone	B-Protein
H3	E-Protein
lysine	O
36	O
dimethylation	O
(	O
H3K36me2	S-Protein
)	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
has	O
been	O
shown	O
to	O
associate	O
with	O
RNA	O
polymerase	O
II	O
(	O
RNAP	O
II	O
)	O
at	O
individual	O
loci	O
.	O

Here	O
,	O
chromatin	O
immunoprecipitation	O
-	O
microarray	O
experiments	O
normalized	O
to	O
general	O
nucleosome	O
occupancy	O
reveal	O
that	O
nucleosomes	O
within	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
and	O
downstream	O
noncoding	O
chromatin	O
were	O
highly	O
dimethylated	O
at	O
H3K36	S-Protein
and	O
that	O
Set2p	S-Protein
activity	O
begins	O
at	O
a	O
stereotypic	O
distance	O
from	O
the	O
initiation	O
of	O
transcription	O
genome	O
-	O
wide	O
.	O

H3K36me2	S-Protein
is	O
scarce	O
in	O
regions	O
upstream	O
of	O
divergently	O
transcribed	O
genes	O
,	O
telomeres	O
,	O
silenced	O
mating	O
loci	O
,	O
and	O
regions	O
transcribed	O
by	O
RNA	O
polymerase	O
III	O
,	O
providing	O
evidence	O
that	O
the	O
enzymatic	O
activity	O
of	O
Set2p	S-Protein
is	O
restricted	O
to	O
its	O
association	O
with	O
RNAP	O
II	O
.	O

The	O
presence	O
of	O
H3K36me2	S-Protein
within	O
ORFs	O
correlated	O
with	O
the	O
"	O
on	O
"	O
or	O
"	O
off	O
"	O
state	O
of	O
transcription	O
,	O
but	O
the	O
degree	O
of	O
H3K36	S-Protein
dimethylation	O
within	O
ORFs	O
did	O
not	O
correlate	O
with	O
transcription	O
frequency	O
.	O

This	O
provides	O
evidence	O
that	O
H3K36me2	S-Protein
is	O
established	O
during	O
the	O
initial	O
instances	O
of	O
gene	O
transcription	O
,	O
with	O
subsequent	O
transcription	O
having	O
at	O
most	O
a	O
maintenance	O
role	O
.	O

Accordingly	O
,	O
newly	O
activated	O
genes	O
acquire	O
H3K36me2	S-Protein
in	O
a	O
manner	O
that	O
does	O
not	O
correlate	O
with	O
gene	O
transcript	O
levels	O
.	O

Finally	O
,	O
nucleosomes	O
dimethylated	O
at	O
H3K36	S-Protein
appear	O
to	O
be	O
refractory	O
to	O
loss	O
from	O
highly	O
transcribed	O
chromatin	O
.	O

Thus	O
,	O
H3K36me2	S-Protein
,	O
which	O
is	O
highly	O
conserved	O
throughout	O
eukaryotic	O
evolution	O
,	O
provides	O
a	O
stable	O
molecular	O
mechanism	O
for	O
establishing	O
chromatin	O
context	O
throughout	O
the	O
genome	O
by	O
distinguishing	O
potential	O
regulatory	O
regions	O
from	O
transcribed	O
chromatin	O
.	O

Versatile	O
peroxidase	O
oxidation	O
of	O
high	O
redox	O
potential	O
aromatic	O
compounds	O
:	O
site	O
-	O
directed	O
mutagenesis	O
,	O
spectroscopic	O
and	O
crystallographic	O
investigation	O
of	O
three	O
long	O
-	O
range	O
electron	O
transfer	O
pathways	O
.	O

Versatile	O
peroxidases	O
(	O
VP	O
)	O
,	O
a	O
recently	O
described	O
family	O
of	O
ligninolytic	O
peroxidases	O
,	O
show	O
a	O
hybrid	O
molecular	O
architecture	O
combining	O
different	O
oxidation	O
sites	O
connected	O
to	O
the	O
heme	O
cofactor	O
.	O

High	O
-	O
resolution	O
crystal	O
structures	O
as	O
well	O
as	O
homology	O
models	O
of	O
VP	O
isoenzymes	O
from	O
the	O
fungus	O
Pleurotus	O
eryngii	O
revealed	O
three	O
possibilities	O
for	O
long	O
-	O
range	O
electron	O
transfer	O
for	O
the	O
oxidation	O
of	O
high	O
redox	O
potential	O
aromatic	O
compounds	O
.	O

The	O
possible	O
pathways	O
would	O
start	O
either	O
at	O
Trp164	O
or	O
His232	O
of	O
isoenzyme	O
VPL	O
,	O
and	O
at	O
His82	O
or	O
Trp170	O
of	O
isoenzyme	O
VPS1	S-Protein
.	O

These	O
residues	O
are	O
exposed	O
,	O
and	O
less	O
than	O
11	O
A	O
apart	O
from	O
the	O
heme	O
.	O

With	O
the	O
purpose	O
of	O
investigating	O
their	O
functionality	O
,	O
two	O
single	O
mutations	O
(	O
W164S	O
and	O
H232F	O
)	O
and	O
one	O
double	O
mutation	O
(	O
W164S	O
/	O
P76H	O
)	O
were	O
introduced	O
in	O
VPL	O
that	O
:	O
(	O
i	O
)	O
removed	O
the	O
two	O
pathways	O
in	O
this	O
isoenzyme	O
;	O
and	O
(	O
ii	O
)	O
incorporated	O
the	O
absent	O
putative	O
pathway	O
.	O

Analysis	O
of	O
the	O
variants	O
showed	O
that	O
Trp164	O
is	O
required	O
for	O
oxidation	O
of	O
two	O
high	O
redox	O
potential	O
model	O
substrates	O
(	O
veratryl	O
alcohol	O
and	O
Reactive	O
Black	O
5	O
)	O
,	O
whereas	O
the	O
two	O
other	O
pathways	O
(	O
starting	O
at	O
His232	O
and	O
His82	O
)	O
are	O
not	O
involved	O
in	O
long	O
-	O
range	O
electron	O
transfer	O
(	O
LRET	O
)	O
.	O

None	O
of	O
the	O
mutations	O
affected	O
Mn2	O
+	O
oxidation	O
,	O
which	O
would	O
take	O
place	O
at	O
the	O
opposite	O
side	O
of	O
the	O
enzyme	O
.	O

Substitution	O
of	O
Trp164	O
by	O
His	O
also	O
resulted	O
in	O
an	O
inactive	O
variant	O
,	O
indicating	O
that	O
an	O
indole	O
side	O
-	O
chain	O
is	O
required	O
for	O
activity	O
.	O

It	O
is	O
proposed	O
that	O
substrate	O
oxidation	O
occurs	O
via	O
a	O
protein	O
-	O
based	O
radical	O
.	O

For	O
the	O
first	O
time	O
in	O
a	O
ligninolytic	O
peroxidase	O
such	O
an	O
intermediate	O
species	O
could	O
be	O
detected	O
by	O
low	O
-	O
temperature	O
electron	O
paramagnetic	O
resonance	O
of	O
H2O2	O
-	O
activated	O
VP	O
,	O
and	O
was	O
found	O
to	O
exist	O
at	O
Trp164	O
as	O
a	O
neutral	O
radical	O
.	O

The	O
H2O2	O
-	O
activated	O
VP	O
was	O
self	O
-	O
reduced	O
in	O
the	O
absence	O
of	O
reducing	O
substrates	O
.	O

Trp164	O
is	O
also	O
involved	O
in	O
this	O
reaction	O
,	O
which	O
in	O
the	O
W164S	O
variant	O
was	O
blocked	O
at	O
the	O
level	O
of	O
compound	O
II	O
.	O

When	O
analyzing	O
VP	O
crystal	O
structures	O
close	O
to	O
atomic	O
resolution	O
,	O
no	O
hydroxylation	O
of	O
the	O
Trp164	O
Cbeta	O
atom	O
was	O
observed	O
(	O
even	O
after	O
addition	O
of	O
several	O
equivalents	O
of	O
H2O2	O
)	O
.	O

This	O
is	O
in	O
contrast	O
to	O
lignin	O
peroxidase	O
Trp171	O
.	O

Analysis	O
of	O
the	O
crystal	O
structures	O
of	O
both	O
peroxidases	O
showed	O
differences	O
in	O
the	O
environment	O
of	O
the	O
protein	O
radical	O
-	O
forming	O
residue	O
that	O
could	O
affect	O
its	O
reactivity	O
.	O

These	O
variations	O
would	O
also	O
explain	O
differences	O
found	O
for	O
the	O
oxidation	O
of	O
some	O
high	O
redox	O
potential	O
aromatic	O
substrates	O
.	O

Promoter	O
hypermethylation	O
profile	O
of	O
RASSF1A	S-Protein
,	O
FHIT	S-Protein
,	O
and	O
sFRP1	S-Protein
in	O
intracranial	O
primitive	O
neuroectodermal	O
tumors	O
.	O

Medulloblastomas	O
(	O
MBs	O
)	O
and	O
supratentorial	O
primitive	O
neuroectodermal	O
tumors	O
(	O
SPNETs	O
)	O
are	O
histologically	O
alike	O
intracranial	O
PNETs	O
found	O
in	O
different	O
anatomical	O
locations	O
of	O
the	O
brain	O
.	O

Current	O
evidence	O
suggests	O
that	O
hypermethylation	O
of	O
promoter	O
CpG	O
islands	O
is	O
a	O
common	O
epigenetic	O
event	O
in	O
a	O
variety	O
of	O
human	O
cancers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
promoter	O
hypermethylation	O
of	O
putative	O
tumor	O
suppressor	O
genes	O
was	O
involved	O
in	O
both	O
types	O
of	O
intracranial	O
PNETs	O
.	O

We	O
examined	O
the	O
methylation	O
status	O
at	O
promoter	O
regions	O
of	O
RASSF1A	S-Protein
,	O
FHIT	S-Protein
,	O
and	O
sFRP1	S-Protein
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
in	O
a	O
cohort	O
of	O
25	O
primary	O
MBs	O
,	O
9	O
primary	O
SPNETs	O
,	O
and	O
3	O
MB	O
and	O
2	O
SPNET	O
cell	O
lines	O
.	O

Our	O
results	O
revealed	O
no	O
promoter	O
hypermethylation	O
of	O
RASSF1A	S-Protein
,	O
FHIT	S-Protein
,	O
and	O
sFRP1	S-Protein
in	O
2	O
normal	O
cerebellar	O
and	O
5	O
normal	O
cerebral	O
tissue	O
specimens	O
examined	O
.	O

In	O
contrast	O
,	O
promoter	O
hypermethylation	O
of	O
RASSF1A	S-Protein
was	O
detected	O
in	O
100	O
%	O
of	O
primary	O
MBs	O
,	O
67	O
%	O
(	O
6	O
/	O
9	O
)	O
of	O
primary	O
SPNETs	O
,	O
and	O
all	O
PNET	O
cell	O
lines	O
.	O

The	O
frequency	O
of	O
promoter	O
hypermethylation	O
of	O
RASSF1A	S-Protein
was	O
significantly	O
lower	O
in	O
SPNETs	O
than	O
in	O
MBs	O
(	O
Fisher	O
exact	O
test	O
,	O
P	O
=	O
.	O
014	O
)	O
.	O

Treatment	O
of	O
RASSF1A	S-Protein
-	O
deficient	O
PNET	O
cell	O
lines	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
deoxycytidine	O
,	O
a	O
demethylating	O
agent	O
,	O
restored	O
RASSF1A	S-Protein
expression	O
,	O
providing	O
evidence	O
that	O
promoter	O
hypermethylation	O
contributes	O
to	O
transcriptional	O
silencing	O
.	O

In	O
addition	O
,	O
promoter	O
hypermethylation	O
of	O
FHIT	S-Protein
and	O
sFRP1	S-Protein
was	O
detected	O
in	O
22	O
%	O
(	O
2	O
/	O
9	O
)	O
and	O
11	O
%	O
(	O
1	O
/	O
9	O
)	O
of	O
SPNETs	O
,	O
respectively	O
,	O
but	O
not	O
in	O
any	O
MBs	O
studied	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
demonstrates	O
that	O
promoter	O
hypermethylation	O
of	O
RASSF1A	S-Protein
is	O
a	O
common	O
event	O
in	O
intracranial	O
PNETs	O
,	O
whereas	O
FHIT	S-Protein
and	O
sFRP1	S-Protein
are	O
epigenetically	O
affected	O
in	O
a	O
fraction	O
of	O
SPNETs	O
.	O

Macroprolactin	S-Protein
(	O
s	O
)	O
:	O
composition	O
and	O
reactivity	O
in	O
immunoassays	O
and	O
laboratory	O
interpretation	O
of	O
results	O
of	O
an	O
unusual	O
patient	O
serum	O
.	O

BACKGROUND	O
:	O
Macroprolactin	S-Protein
is	O
a	O
high	O
molecular	O
mass	O
complex	O
of	O
prolactin	S-Protein
that	O
may	O
be	O
the	O
cause	O
of	O
elevated	O
serum	O
prolactin	S-Protein
as	O
determined	O
by	O
immunoassay	O
.	O

The	O
composition	O
of	O
macroprolactin	S-Protein
and	O
its	O
reactivity	O
in	O
immunoassays	O
are	O
variable	O
but	O
the	O
complex	O
has	O
minimal	O
bioactivity	O
in	O
vivo	O
.	O

Hyperprolactinaemia	O
due	O
to	O
unrecognized	O
macroprolactinaemia	O
can	O
lead	O
to	O
misdiagnosis	O
and	O
mistreatment	O
.	O

METHODS	O
:	O
Serum	O
from	O
a	O
patient	O
with	O
an	O
unusual	O
pattern	O
of	O
immunoreactivity	O
was	O
distributed	O
to	O
three	O
users	O
of	O
each	O
of	O
the	O
most	O
popular	O
immunoassays	O
represented	O
in	O
the	O
UK	O
National	O
External	O
Quality	O
Assessment	O
Scheme	O
(	O
NEQAS	O
)	O
for	O
prolactin	S-Protein
.	O

Clinical	O
details	O
were	O
provided	O
and	O
participating	O
centres	O
were	O
invited	O
to	O
investigate	O
the	O
prolactin	S-Protein
content	O
of	O
the	O
specimen	O
according	O
to	O
their	O
local	O
protocol	O
,	O
and	O
to	O
comment	O
on	O
their	O
results	O
.	O

The	O
nature	O
of	O
the	O
macroprolactin	S-Protein
in	O
the	O
specimen	O
was	O
investigated	O
in	O
detail	O
by	O
gel	O
filtration	O
chromatography	O
of	O
the	O
native	O
serum	O
and	O
of	O
the	O
serum	O
after	O
adsorption	O
of	O
IgG	O
with	O
protein	O
A	O
,	O
and	O
by	O
affinity	O
chromatography	O
with	O
concanavalin	B-Protein
A	E-Protein
.	O

RESULTS	O
:	O
Gel	O
filtration	O
studies	O
revealed	O
two	O
peaks	O
of	O
macroprolactin	S-Protein
in	O
this	O
serum	O
.	O

These	O
macroprolactins	S-Protein
were	O
shown	O
to	O
be	O
different	O
in	O
their	O
IgG	O
content	O
and	O
degree	O
of	O
glycosylation	O
.	O

All	O
eight	O
immunoassays	O
reacted	O
strongly	O
with	O
the	O
macroprolactin	S-Protein
present	O
.	O

The	O
majority	O
(	O
78	O
%	O
)	O
of	O
centres	O
that	O
interpreted	O
their	O
results	O
either	O
demonstrated	O
the	O
presence	O
of	O
macroprolactin	S-Protein
in	O
the	O
specimen	O
,	O
or	O
suggested	O
it	O
as	O
a	O
likely	O
cause	O
of	O
the	O
hyperprolactinaemia	O
.	O

However	O
,	O
two	O
centres	O
inappropriately	O
excluded	O
macroprolactinaemia	O
as	O
the	O
cause	O
of	O
the	O
elevated	O
prolactin	S-Protein
,	O
and	O
a	O
further	O
two	O
did	O
not	O
consider	O
it	O
at	O
all	O
.	O

Data	O
from	O
previous	O
UK	O
NEQAS	O
distributions	O
(	O
between	O
1996	O
and	O
2003	O
)	O
of	O
macroprolactin	S-Protein
containing	O
sera	O
are	O
presented	O
which	O
suggest	O
that	O
the	O
frequency	O
of	O
recognition	O
of	O
macroprolactin	S-Protein
as	O
a	O
possible	O
cause	O
of	O
hyperprolactinaemia	O
has	O
increased	O
over	O
time	O
.	O

CONCLUSIONS	O
:	O
Very	O
high	O
molecular	O
mass	O
forms	O
of	O
prolactin	S-Protein
and	O
the	O
presence	O
of	O
multiple	O
molecular	O
mass	O
forms	O
,	O
as	O
detected	O
in	O
the	O
case	O
presented	O
here	O
,	O
are	O
uncommon	O
.	O

Also	O
,	O
the	O
pattern	O
of	O
immunoreactivity	O
reported	O
in	O
this	O
specimen	O
was	O
unusual	O
as	O
most	O
macroprolactins	S-Protein
studied	O
previously	O
react	O
less	O
strongly	O
in	O
,	O
for	O
example	O
,	O
the	O
Bayer	O
ADVIA	O
Centaur	O
assay	O
compared	O
to	O
the	O
Roche	O
E170	O
assay	O
.	O

Both	O
peaks	O
of	O
macroprolactin	S-Protein
in	O
this	O
serum	O
reacted	O
in	O
all	O
assays	O
tested	O
.	O

This	O
case	O
highlights	O
the	O
variable	O
nature	O
and	O
immunoreactive	O
behaviour	O
of	O
macroprolactin	S-Protein
species	O
.	O

Sodium	O
butyrate	O
ameliorates	O
histone	S-Protein
hypoacetylation	O
and	O
neurodegenerative	O
phenotypes	O
in	O
a	O
mouse	O
model	O
for	O
DRPLA	O
.	O

Dentatorubral	O
-	O
pallidoluysian	O
atrophy	O
(	O
DRPLA	O
)	O
is	O
a	O
progressive	O
neurodegenerative	O
disease	O
caused	O
by	O
polyglutamine	O
expansion	O
within	O
the	O
Atrophin	B-Protein
-	I-Protein
1	E-Protein
protein	O
.	O

To	O
study	O
the	O
mechanism	O
of	O
this	O
disease	O
and	O
to	O
test	O
potential	O
therapeutic	O
methods	O
,	O
we	O
established	O
Atro	O
-	O
118Q	O
transgenic	O
mice	O
,	O
which	O
express	O
in	O
neurons	O
a	O
mutant	O
human	O
Atrophin	B-Protein
-	I-Protein
1	E-Protein
protein	O
that	O
contains	O
an	O
expanded	O
stretch	O
of	O
118	O
glutamines	O
.	O

Consistent	O
with	O
the	O
results	O
from	O
previous	O
studies	O
on	O
transgenic	O
mice	O
that	O
expressed	O
mutant	O
Atrophin	B-Protein
-	I-Protein
1	E-Protein
with	O
65	O
glutamines	O
,	O
Atro	O
-	O
118Q	O
mice	O
exhibited	O
several	O
neurodegenerative	O
phenotypes	O
that	O
are	O
commonly	O
seen	O
in	O
DRPLA	O
patients	O
,	O
including	O
ataxia	O
,	O
tremors	O
,	O
and	O
other	O
motor	O
defects	O
.	O

Overexpression	O
of	O
wild	O
-	O
type	O
human	O
Atrophin	B-Protein
-	I-Protein
1	E-Protein
could	O
not	O
rescue	O
the	O
motor	O
and	O
survival	O
defects	O
in	O
Atro	O
-	O
118Q	O
mice	O
,	O
indicating	O
that	O
the	O
mutant	O
protein	O
with	O
polyglutamine	O
expansion	O
does	O
not	O
simply	O
function	O
in	O
a	O
dominant	O
negative	O
manner	O
.	O

Biochemical	O
analysis	O
of	O
Atro	O
-	O
118Q	O
mice	O
revealed	O
hypoacetylation	O
of	O
histone	B-Protein
H3	E-Protein
in	O
brain	O
tissues	O
and	O
thus	O
suggested	O
that	O
global	O
gene	O
repression	O
is	O
an	O
underlying	O
mechanism	O
for	O
neurodegeneration	O
in	O
this	O
mouse	O
model	O
.	O

We	O
further	O
show	O
that	O
intraperitoneal	O
administration	O
of	O
sodium	O
butyrate	O
,	O
a	O
histone	S-Protein
deacetylase	O
inhibitor	O
,	O
ameliorated	O
the	O
histone	S-Protein
acetylation	O
defects	O
,	O
significantly	O
improved	O
motor	O
performance	O
,	O
and	O
extended	O
the	O
average	O
life	O
span	O
of	O
Atro	O
-	O
118Q	O
mice	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
transcription	O
deregulation	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
polyglutamine	O
expansion	O
diseases	O
and	O
suggest	O
that	O
reversion	O
of	O
transcription	O
repression	O
with	O
small	O
molecules	O
such	O
as	O
sodium	O
butyrate	O
is	O
a	O
feasible	O
approach	O
to	O
treating	O
DRPLA	O
symptoms	O
.	O

Changes	O
in	O
liver	O
and	O
plasma	O
acetylcholinesterase	S-Protein
in	O
rats	O
with	O
cirrhosis	O
induced	O
by	O
bile	O
duct	O
ligation	O
.	O

Classical	O
studies	O
of	O
cholinesterase	O
activity	O
during	O
liver	O
dysfunction	O
have	O
focused	O
on	O
butyrylcholinesterase	S-Protein
(	O
BuChE	S-Protein
)	O
,	O
whereas	O
acetylcholinesterase	S-Protein
(	O
AChE	S-Protein
)	O
has	O
not	O
received	O
much	O
attention	O
.	O

In	O
the	O
current	O
study	O
,	O
liver	O
and	O
plasma	O
AChE	S-Protein
levels	O
were	O
investigated	O
in	O
rats	O
with	O
cirrhosis	O
induced	O
after	O
3	O
weeks	O
of	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
.	O

BDL	O
rats	O
showed	O
a	O
pronounced	O
decrease	O
in	O
liver	O
AChE	S-Protein
levels	O
(	O
approximately	O
50	O
%	O
)	O
compared	O
with	O
sham	O
-	O
operated	O
(	O
non	O
-	O
ligated	O
,	O
NL	O
)	O
controls	O
;	O
whereas	O
liver	O
BuChE	S-Protein
appeared	O
unaffected	O
.	O

A	O
selective	O
loss	O
of	O
tetrameric	O
(	O
G4	O
)	O
AChE	S-Protein
was	O
detected	O
in	O
BDL	O
rats	O
,	O
an	O
effect	O
also	O
observed	O
in	O
rats	O
with	O
carbon	O
tetrachloride	O
-	O
induced	O
cirrhosis	O
.	O

In	O
accordance	O
,	O
SDS	O
-	O
PAGE	O
analysis	O
showed	O
that	O
the	O
major	O
55	O
-	O
kd	O
immunoreactive	O
AChE	S-Protein
band	O
was	O
decreased	O
in	O
BDL	O
as	O
compared	O
with	O
NL	O
.	O

A	O
65	O
-	O
kd	O
band	O
,	O
attributed	O
in	O
part	O
to	O
inactive	O
AChE	S-Protein
,	O
was	O
increased	O
as	O
became	O
the	O
most	O
abundant	O
AChE	S-Protein
subunit	O
in	O
BDL	O
liver	O
.	O

The	O
overall	O
decrease	O
in	O
AChE	S-Protein
activity	O
in	O
BDL	O
liver	O
was	O
not	O
accompanied	O
by	O
a	O
reduction	O
of	O
AChE	S-Protein
transcripts	O
.	O

The	O
loss	O
of	O
G4	O
was	O
also	O
reflected	O
by	O
changes	O
observed	O
in	O
AChE	S-Protein
glycosylation	O
pattern	O
attributable	O
to	O
different	O
liver	O
AChE	S-Protein
forms	O
being	O
differentially	O
glycosylated	O
.	O

BDL	O
affects	O
AChE	S-Protein
levels	O
in	O
both	O
hepatocytes	O
and	O
Kupffer	O
cells	O
;	O
however	O
,	O
altered	O
AChE	S-Protein
expression	O
was	O
mainly	O
reflected	O
in	O
an	O
alteration	O
in	O
hepatocyte	O
AChE	S-Protein
pattern	O
.	O

Plasma	O
from	O
BDL	O
rats	O
had	O
approximately	O
45	O
%	O
lower	O
AChE	S-Protein
activity	O
than	O
controls	O
,	O
displaying	O
decreased	O
G4	O
levels	O
and	O
altered	O
lectin	O
-	O
binding	O
patterns	O
.	O

In	O
conclusion	O
,	O
the	O
liver	O
is	O
an	O
important	O
source	O
of	O
serum	O
AChE	S-Protein
;	O
altered	O
AChE	S-Protein
levels	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
liver	O
cirrhosis	O
.	O

NF	O
-	O
kappaB	O
activation	O
upregulates	O
fibroblast	B-Protein
growth	I-Protein
factor	I-Protein
8	E-Protein
expression	O
in	O
prostate	O
cancer	O
cells	O
.	O

BACKGROUND	O
:	O
Fibroblast	B-Protein
growth	I-Protein
factor	I-Protein
8	E-Protein
(	O
FGF8	S-Protein
)	O
is	O
over	O
-	O
expressed	O
in	O
prostate	O
cancer	O
(	O
CaP	O
)	O
correlating	O
with	O
high	O
-	O
grade	O
disease	O
and	O
reduced	O
survival	O
.	O

The	O
role	O
of	O
acetylation	O
in	O
transcriptional	O
regulation	O
of	O
FGF8	S-Protein
was	O
investigated	O
using	O
the	O
histone	S-Protein
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
Trichostatin	O
A	O
(	O
TSA	O
)	O
.	O

METHODS	O
:	O
FGF8	S-Protein
transcriptional	O
response	O
to	O
TSA	O
was	O
investigated	O
by	O
gene	O
reporter	O
assays	O
,	O
RT	O
-	O
PCR	O
,	O
and	O
Western	O
blotting	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
were	O
also	O
performed	O
.	O

RESULTS	O
:	O
FGF8	S-Protein
is	O
upregulated	O
in	O
response	O
to	O
TSA	O
treatment	O
along	O
with	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
.	O

Over	O
-	O
expression	O
of	O
p65	S-Protein
activated	O
FGF8	S-Protein
transcription	O
.	O

ChIP	O
assays	O
revealed	O
p65	S-Protein
recruitment	O
to	O
the	O
fgf8	S-Protein
promoter	O
,	O
containing	O
putative	O
NF	O
-	O
kappaB	O
binding	O
sites	O
,	O
post	O
TSA	O
stimulation	O
.	O

PI	O
-	O
3K	O
activity	O
is	O
required	O
for	O
TSA	O
mediated	O
FGF8	S-Protein
upregulation	O
.	O

CONCLUSION	O
:	O
Using	O
TSA	O
treatment	O
in	O
prostate	O
cancer	O
cells	O
,	O
a	O
requirement	O
of	O
PI	O
-	O
3K	O
activity	O
in	O
mediating	O
TSA	O
function	O
is	O
demonstrated	O
and	O
a	O
novel	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
regulation	O
of	O
FGF8	S-Protein
expression	O
is	O
uncovered	O
.	O

Epigenetics	O
of	O
gene	O
expression	O
in	O
human	O
hepatoma	O
cells	O
:	O
expression	O
profiling	O
the	O
response	O
to	O
inhibition	O
of	O
DNA	O
methylation	O
and	O
histone	S-Protein
deacetylation	O
.	O

BACKGROUND	O
:	O
DNA	O
methylation	O
and	O
histone	S-Protein
deacetylation	O
are	O
epigenetic	O
mechanisms	O
that	O
play	O
major	O
roles	O
in	O
eukaryotic	O
gene	O
regulation	O
.	O

We	O
hypothesize	O
that	O
many	O
genes	O
in	O
the	O
human	O
hepatoma	O
cell	O
line	O
HepG2	O
are	O
regulated	O
by	O
DNA	O
methylation	O
and	O
histone	S-Protein
deacetylation	O
.	O

Treatment	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
aza	O
-	O
dC	O
)	O
to	O
inhibit	O
DNA	O
methylation	O
with	O
and	O
/	O
or	O
Trichostatin	O
A	O
(	O
TSA	O
)	O
to	O
inhibit	O
histone	S-Protein
deacetylation	O
should	O
allow	O
us	O
to	O
identify	O
genes	O
that	O
are	O
regulated	O
epigenetically	O
in	O
hepatoma	O
cells	O
.	O

RESULTS	O
:	O
5	O
-	O
aza	O
-	O
dC	O
had	O
a	O
much	O
larger	O
effect	O
on	O
gene	O
expression	O
in	O
HepG2	O
cells	O
than	O
did	O
TSA	O
,	O
as	O
measured	O
using	O
Affymetrix	O
HG	O
-	O
U133	O
Plus	O
2	O
.	O
0	O
microarrays	O
.	O

The	O
expression	O
of	O
1504	O
probe	O
sets	O
was	O
affected	O
by	O
5	O
-	O
aza	O
-	O
dC	O
(	O
at	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
535	O
probe	O
sets	O
by	O
TSA	O
,	O
and	O
1929	O
probe	O
sets	O
by	O
the	O
combination	O
of	O
5	O
-	O
aza	O
-	O
dC	O
and	O
TSA	O
.	O

5	O
-	O
aza	O
-	O
dC	O
treatment	O
turned	O
on	O
the	O
expression	O
of	O
211	O
probe	O
sets	O
that	O
were	O
not	O
detectably	O
expressed	O
in	O
its	O
absence	O
.	O

Expression	O
of	O
imprinted	O
genes	O
regulated	O
by	O
DNA	O
methylation	O
,	O
such	O
as	O
H19	S-Protein
and	O
NNAT	S-Protein
,	O
was	O
turned	O
on	O
or	O
greatly	O
increased	O
in	O
response	O
to	O
5	O
-	O
aza	O
-	O
dC	O
.	O

Genes	O
involved	O
in	O
liver	O
processes	O
such	O
as	O
xenobiotic	O
metabolism	O
(	O
CYP3A4	S-Protein
,	O
CYP3A5	S-Protein
,	O
and	O
CYP3A7	S-Protein
)	O
and	O
steroid	O
biosynthesis	O
(	O
CYP17A1	S-Protein
and	O
CYP19A1	S-Protein
)	O
,	O
and	O
genes	O
encoding	O
CCAAT	O
element	O
-	O
binding	O
proteins	O
(	O
C	B-Protein
/	I-Protein
EBPalpha	E-Protein
,	O
C	B-Protein
/	I-Protein
EBPbeta	E-Protein
,	O
and	O
C	B-Protein
/	I-Protein
EBPgamma	E-Protein
)	O
were	O
affected	O
by	O
5	O
-	O
aza	O
-	O
dC	O
or	O
the	O
combination	O
.	O

Many	O
of	O
the	O
genes	O
that	O
fall	O
within	O
these	O
groups	O
are	O
also	O
expressed	O
in	O
the	O
developing	O
fetal	O
liver	O
and	O
adult	O
liver	O
.	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
confirmed	O
selected	O
gene	O
expression	O
changes	O
seen	O
in	O
microarray	O
analyses	O
.	O

CONCLUSION	O
:	O
Epigenetics	O
play	O
a	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
genes	O
involved	O
in	O
essential	O
liver	O
processes	O
such	O
as	O
xenobiotic	O
metabolism	O
and	O
steroid	O
biosynthesis	O
in	O
HepG2	O
cells	O
.	O

Many	O
genes	O
whose	O
expression	O
is	O
normally	O
silenced	O
in	O
these	O
hepatoma	O
cells	O
were	O
re	O
-	O
expressed	O
by	O
5	O
-	O
aza	O
-	O
dC	O
treatment	O
.	O

DNA	O
methylation	O
may	O
be	O
a	O
factor	O
in	O
restricting	O
the	O
expression	O
of	O
fetal	O
genes	O
during	O
liver	O
development	O
and	O
in	O
shutting	O
down	O
expression	O
in	O
hepatoma	O
cells	O
.	O

Epigenetic	O
regulation	O
of	O
the	O
imprinted	O
U2af1	B-Protein
-	I-Protein
rs1	E-Protein
gene	O
during	O
retinoic	O
acid	O
-	O
induced	O
differentiation	O
of	O
embryonic	O
stem	O
cells	O
.	O

Epigenetic	O
modifications	O
such	O
as	O
DNA	O
methylation	O
and	O
changes	O
in	O
chromatin	O
structure	O
are	O
changes	O
in	O
the	O
chemical	O
composition	O
or	O
structure	O
of	O
DNA	O
that	O
work	O
by	O
regulating	O
gene	O
expression	O
.	O

Their	O
mechanisms	O
of	O
action	O
have	O
been	O
generally	O
studied	O
in	O
imprinted	O
genes	O
.	O

The	O
present	O
work	O
analyzes	O
the	O
involvement	O
of	O
these	O
mechanisms	O
in	O
the	O
expression	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	E-Protein
imprinted	O
gene	O
during	O
the	O
differentiation	O
process	O
of	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
induced	O
by	O
retinoic	O
acid	O
.	O

By	O
DNA	O
digestion	O
with	O
methylation	O
-	O
dependent	O
or	O
independent	O
restriction	O
enzymes	O
and	O
consecutive	O
Southern	O
blot	O
,	O
we	O
have	O
found	O
that	O
methylation	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	E-Protein
gene	O
increases	O
in	O
differentiated	O
ES	O
cells	O
and	O
in	O
embryoid	O
bodies	O
.	O

However	O
,	O
northern	O
blot	O
and	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
showed	O
a	O
higher	O
expression	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	E-Protein
gene	O
in	O
differentiated	O
ES	O
cells	O
and	O
in	O
embryoid	O
bodies	O
than	O
in	O
undifferentiated	O
ones	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
sensitivity	O
to	O
DNase	B-Protein
-	I-Protein
I	E-Protein
assay	O
demonstrated	O
an	O
open	O
chromatin	O
conformation	O
for	O
differentiated	O
cells	O
with	O
regard	O
to	O
undifferentiated	O
ES	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
the	O
U2af1	B-Protein
-	I-Protein
rs1	E-Protein
gene	O
would	O
be	O
regulated	O
by	O
changes	O
in	O
chromatin	O
structure	O
rather	O
than	O
by	O
DNA	O
methylation	O
during	O
the	O
RA	O
-	O
induced	O
process	O
of	O
differentiation	O
of	O
ES	O
cells	O
.	O

The	O
Yng1p	S-Protein
plant	O
homeodomain	O
finger	O
is	O
a	O
methyl	O
-	O
histone	S-Protein
binding	O
module	O
that	O
recognizes	O
lysine	O
4	O
-	O
methylated	O
histone	B-Protein
H3	E-Protein
.	O

The	O
ING	O
(	O
inhibitor	O
of	O
growth	O
)	O
protein	O
family	O
includes	O
a	O
group	O
of	O
homologous	O
nuclear	O
proteins	O
that	O
share	O
a	O
highly	O
conserved	O
plant	O
homeodomain	O
(	O
PHD	O
)	O
finger	O
domain	O
at	O
their	O
carboxyl	O
termini	O
.	O

Members	O
of	O
this	O
family	O
are	O
found	O
in	O
multiprotein	O
complexes	O
that	O
posttranslationally	O
modify	O
histones	S-Protein
,	O
suggesting	O
that	O
these	O
proteins	O
serve	O
a	O
general	O
role	O
in	O
permitting	O
various	O
enzymatic	O
activities	O
to	O
interact	O
with	O
nucleosomes	O
.	O

There	O
are	O
three	O
members	O
of	O
the	O
ING	O
family	O
in	O
Saccharomyces	O
cerevisiae	O
:	O
Yng1p	S-Protein
,	O
Yng2p	S-Protein
,	O
and	O
Pho23p	S-Protein
.	O

Yng1p	S-Protein
is	O
a	O
component	O
of	O
the	O
NuA3	O
histone	S-Protein
acetyltransferase	O
complex	O
and	O
is	O
required	O
for	O
the	O
interaction	O
of	O
NuA3	O
with	O
chromatin	O
.	O

To	O
gain	O
insight	O
into	O
the	O
function	O
of	O
the	O
ING	O
proteins	O
,	O
we	O
made	O
use	O
of	O
a	O
genetic	O
strategy	O
to	O
identify	O
genes	O
required	O
for	O
the	O
binding	O
of	O
Yng1p	S-Protein
to	O
histones	S-Protein
.	O

Using	O
the	O
toxicity	O
of	O
YNG1	S-Protein
overexpression	O
as	O
a	O
tool	O
,	O
we	O
showed	O
that	O
Yng1p	S-Protein
interacts	O
with	O
the	O
amino	O
-	O
terminal	O
tail	O
of	O
histone	B-Protein
H3	E-Protein
and	O
that	O
this	O
interaction	O
can	O
be	O
disrupted	O
by	O
loss	O
of	O
lysine	O
4	O
methylation	O
within	O
this	O
tail	O
.	O

Additionally	O
,	O
we	O
mapped	O
the	O
region	O
of	O
Yng1p	S-Protein
required	O
for	O
overexpression	O
of	O
toxicity	O
to	O
the	O
PHD	O
finger	O
,	O
showed	O
that	O
this	O
region	O
capable	O
of	O
binding	O
lysine	O
4	O
-	O
methylated	O
histone	B-Protein
H3	E-Protein
in	O
vitro	O
,	O
and	O
demonstrated	O
that	O
mutations	O
of	O
the	O
PHD	O
finger	O
that	O
abolish	O
binding	O
in	O
vitro	O
are	O
no	O
longer	O
toxic	O
in	O
vivo	O
.	O

These	O
results	O
identify	O
a	O
novel	O
function	O
for	O
the	O
Yng1p	S-Protein
PHD	O
finger	O
in	O
promoting	O
stabilization	O
of	O
the	O
NuA3	O
complex	O
at	O
chromatin	O
through	O
recognition	O
of	O
histone	B-Protein
H3	E-Protein
lysine	O
4	O
methylation	O
.	O

Clioquinol	O
,	O
a	O
Cu	O
(	O
II	O
)	O
/	O
Zn	O
(	O
II	O
)	O
chelator	O
,	O
inhibits	O
both	O
ubiquitination	O
and	O
asparagine	O
hydroxylation	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	E-Protein
,	O
leading	O
to	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
erythropoietin	S-Protein
in	O
normoxic	O
cells	O
.	O

We	O
found	O
that	O
the	O
Cu	O
(	O
II	O
)	O
and	O
Zn	O
(	O
II	O
)	O
-	O
specific	O
chelator	O
Clioquinol	O
(	O
10	O
-	O
50	O
microM	O
)	O
increased	O
functional	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	E-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
)	O
protein	O
,	O
leading	O
to	O
increased	O
expression	O
of	O
its	O
target	O
genes	O
,	O
vascular	O
endothelial	O
growth	O
factors	O
and	O
erythropoietin	S-Protein
,	O
in	O
SH	O
-	O
SY5Y	O
cells	O
and	O
HepG2	O
cells	O
.	O

Clioquinol	O
inhibited	O
ubiquitination	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
in	O
a	O
Cu	O
(	O
II	O
)	O
-	O
and	O
Zn	O
(	O
II	O
)	O
-	O
dependent	O
manner	O
.	O

It	O
prevents	O
FIH	B-Protein
-	I-Protein
1	E-Protein
from	O
hydroxylating	O
the	O
asparagine	O
residue	O
(	O
803	O
)	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
in	O
a	O
Cu	O
(	O
II	O
)	O
-	O
and	O
Zn	O
(	O
II	O
)	O
-	O
independent	O
fashion	O
.	O

Therefore	O
,	O
it	O
leads	O
to	O
the	O
accumulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
that	O
is	O
prolyl	O
but	O
not	O
asparaginyl	O
hydroxylated	O
.	O

Consistent	O
with	O
this	O
,	O
co	O
-	O
immunoprecipitation	O
assays	O
showed	O
that	O
Clioquinol	O
-	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
interacted	O
with	O
cAMP	O
-	O
responsive	O
element	O
-	O
binding	O
protein	O
in	O
normoxic	O
cells	O
,	O
implying	O
that	O
Clioquinol	O
stabilizes	O
the	O
trans	O
-	O
active	O
form	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

Our	O
results	O
indicate	O
that	O
Clioquinol	O
could	O
be	O
useful	O
as	O
an	O
inducer	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
and	O
its	O
target	O
genes	O
in	O
ischemic	O
diseases	O
.	O

Interaction	O
of	O
HIV	O
-	O
1	O
with	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	E-Protein
-	O
expressing	O
cells	O
is	O
influenced	O
by	O
gp120	S-Protein
envelope	O
modifications	O
associated	O
with	O
disease	O
progression	O
.	O

Dendritic	O
cells	O
can	O
enhance	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
CD4	S-Protein
(	O
+	O
)	O
lymphocytes	O
through	O
the	O
interaction	O
of	O
the	O
gp120	S-Protein
envelope	O
protein	O
with	O
such	O
molecules	O
as	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	E-Protein
.	O

The	O
variable	O
loops	O
of	O
gp120	S-Protein
have	O
previously	O
been	O
shown	O
to	O
modulate	O
the	O
interaction	O
of	O
HIV	O
-	O
1	O
with	O
its	O
principal	O
receptor	O
CD4	S-Protein
and	O
its	O
various	O
coreceptors	O
,	O
namely	O
CCR5	S-Protein
and	O
CXCR4	S-Protein
.	O

Here	O
,	O
we	O
utilized	O
a	O
panel	O
of	O
molecular	O
cloned	O
viruses	O
to	O
identify	O
whether	O
gp120	S-Protein
modifications	O
can	O
influence	O
the	O
virus	O
interaction	O
with	O
immature	O
dendritic	O
cells	O
or	O
a	O
cell	O
line	O
expressing	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	E-Protein
(	O
Raji	O
-	O
DC	B-Protein
-	I-Protein
SIGN	E-Protein
)	O
.	O

The	O
viruses	O
encompass	O
the	O
R5	O
,	O
R5X4	O
and	O
X4	O
phenotypes	O
,	O
and	O
are	O
based	O
upon	O
V1V2	O
and	O
V3	O
sequences	O
from	O
a	O
patient	O
with	O
disease	O
progression	O
.	O

We	O
found	O
that	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	E-Protein
enhancement	O
of	O
virus	O
replication	O
can	O
be	O
modulated	O
by	O
the	O
V1V2	O
length	O
,	O
the	O
overall	O
V3	O
charge	O
and	O
N	O
-	O
linked	O
glycosylation	O
patterns	O
;	O
similar	O
results	O
were	O
observed	O
with	O
immature	O
dendritic	O
cells	O
.	O

Viruses	O
with	O
higher	O
V3	O
charges	O
are	O
more	O
readily	O
transferred	O
to	O
CD4	S-Protein
(	O
+	O
)	O
lymphocytes	O
when	O
the	O
V1V2	O
region	O
is	O
longer	O
and	O
contains	O
an	O
additional	O
N	O
-	O
linked	O
glycosylation	O
site	O
,	O
whereas	O
transfer	O
of	O
viruses	O
with	O
lower	O
V3	O
charges	O
is	O
greater	O
when	O
the	O
V1V2	O
region	O
is	O
shorter	O
.	O

Viruses	O
differing	O
in	O
the	O
V1V2	O
and	O
V3	O
regions	O
also	O
demonstrated	O
differential	O
capture	O
by	O
Raji	O
-	O
DC	B-Protein
-	I-Protein
SIGN	E-Protein
cells	O
in	O
the	O
presence	O
of	O
mannan	O
.	O

These	O
results	O
indicate	O
that	O
the	O
interaction	O
between	O
HIV	O
-	O
1	O
and	O
immature	O
dendritic	O
cells	O
via	O
such	O
molecules	O
as	O
dendritic	B-Protein
cell	I-Protein
-	I-Protein
specific	I-Protein
intercellular	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
grabbing	I-Protein
nonintegrin	E-Protein
may	O
have	O
a	O
role	O
in	O
selecting	O
viruses	O
undergoing	O
transmission	O
and	O
evolution	O
during	O
disease	O
progression	O
.	O

Knockdown	O
of	O
ALR	S-Protein
(	O
MLL2	S-Protein
)	O
reveals	O
ALR	S-Protein
target	O
genes	O
and	O
leads	O
to	O
alterations	O
in	O
cell	O
adhesion	O
and	O
growth	O
.	O

ALR	S-Protein
(	O
MLL2	S-Protein
)	O
is	O
a	O
member	O
of	O
the	O
human	O
MLL	O
family	O
,	O
which	O
belongs	O
to	O
a	O
larger	O
SET1	O
family	O
of	O
histone	S-Protein
methyltransferases	O
.	O

We	O
found	O
that	O
ALR	S-Protein
is	O
present	O
within	O
a	O
stable	O
multiprotein	O
complex	O
containing	O
a	O
cohort	O
of	O
proteins	O
shared	O
with	O
other	O
SET1	O
family	O
complexes	O
and	O
several	O
unique	O
components	O
,	O
such	O
as	O
PTIP	S-Protein
and	O
the	O
jumonji	O
family	O
member	O
UTX	S-Protein
.	O

Like	O
other	O
complexes	O
formed	O
by	O
SET1	O
family	O
members	O
,	O
the	O
ALR	S-Protein
complex	O
exhibited	O
strong	O
H3K4	S-Protein
methyltransferase	O
activity	O
,	O
conferred	O
by	O
the	O
ALR	S-Protein
SET	O
domain	O
.	O

By	O
generating	O
ALR	S-Protein
knockdown	O
cell	O
lines	O
and	O
comparing	O
their	O
expression	O
profiles	O
to	O
that	O
of	O
control	O
cells	O
,	O
we	O
identified	O
a	O
set	O
of	O
genes	O
whose	O
expression	O
is	O
activated	O
by	O
ALR	S-Protein
.	O

Some	O
of	O
these	O
genes	O
were	O
identified	O
by	O
chromatin	O
immunoprecipitation	O
as	O
direct	O
ALR	S-Protein
targets	O
.	O

The	O
ALR	S-Protein
complex	O
was	O
found	O
to	O
associate	O
in	O
an	O
ALR	S-Protein
-	O
dependent	O
fashion	O
with	O
promoters	O
and	O
transcription	O
initiation	O
sites	O
of	O
target	O
genes	O
and	O
to	O
induce	O
H3K4	S-Protein
trimethylation	O
.	O

The	O
most	O
characteristic	O
features	O
of	O
the	O
ALR	S-Protein
knockdown	O
cells	O
were	O
changes	O
in	O
the	O
dynamics	O
and	O
mode	O
of	O
cell	O
spreading	O
/	O
polarization	O
,	O
reduced	O
migration	O
capacity	O
,	O
impaired	O
anchorage	O
-	O
dependent	O
and	O
-	O
independent	O
growth	O
,	O
and	O
decreased	O
tumorigenicity	O
in	O
mice	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
ALR	S-Protein
is	O
a	O
transcriptional	O
activator	O
that	O
induces	O
the	O
transcription	O
of	O
target	O
genes	O
by	O
covalent	O
histone	O
modification	O
.	O

ALR	S-Protein
appears	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
adhesion	O
-	O
related	O
cytoskeletal	O
events	O
,	O
which	O
might	O
affect	O
cell	O
growth	O
and	O
survival	O
.	O

Glycogen	O
synthase	O
kinase	O
3	O
phosphorylates	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	E-Protein
and	O
mediates	O
its	O
destabilization	O
in	O
a	O
VHL	O
-	O
independent	O
manner	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
transcription	I-Protein
factor	I-Protein
1alpha	E-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
)	O
is	O
a	O
key	O
player	O
in	O
the	O
response	O
to	O
hypoxia	O
.	O

Additionally	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
responds	O
to	O
growth	O
factors	O
and	O
hormones	O
which	O
can	O
act	O
via	O
protein	B-Protein
kinase	I-Protein
B	E-Protein
(	O
Akt	S-Protein
)	O
.	O

However	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
is	O
not	O
a	O
direct	O
substrate	O
for	O
this	O
kinase	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
the	O
protein	B-Protein
kinase	I-Protein
B	E-Protein
target	O
glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK	O
-	O
3	O
)	O
may	O
have	O
an	O
impact	O
on	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

We	O
found	O
that	O
the	O
inhibition	O
or	O
depletion	O
of	O
GSK	O
-	O
3	O
induced	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
whereas	O
the	O
overexpression	O
of	O
GSK	B-Protein
-	I-Protein
3beta	E-Protein
reduced	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

These	O
effects	O
were	O
mediated	O
via	O
three	O
amino	O
acid	O
residues	O
in	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
.	O

In	O
addition	O
,	O
mutation	O
analyses	O
and	O
experiments	O
with	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	E-Protein
(	O
VHL	S-Protein
)	O
-	O
defective	O
cells	O
indicated	O
that	O
GSK	O
-	O
3	O
mediates	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
degradation	O
in	O
a	O
VHL	S-Protein
-	O
independent	O
manner	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
the	O
inhibition	O
of	O
the	O
proteasome	O
reversed	O
the	O
GSK	O
-	O
3	O
effects	O
,	O
indicating	O
that	O
GSK	O
-	O
3	O
may	O
target	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
to	O
the	O
proteasome	O
by	O
phosphorylation	O
.	O

Thus	O
,	O
the	O
direct	O
regulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	E-Protein
stability	O
by	O
GSK	O
-	O
3	O
may	O
influence	O
physiological	O
processes	O
or	O
pathophysiological	O
situations	O
such	O
as	O
metabolic	O
diseases	O
or	O
tumors	O
.	O

Kinetic	O
manifestation	O
of	O
processivity	O
during	O
multiple	O
methylations	O
catalyzed	O
by	O
SET	O
domain	O
protein	O
methyltransferases	O
.	O

Processive	O
versus	O
distributive	O
methyl	O
group	O
transfer	O
was	O
assessed	O
for	O
pea	O
Rubisco	B-Protein
large	I-Protein
subunit	I-Protein
methyltransferase	E-Protein
,	O
a	O
SET	O
domain	O
protein	O
lysine	O
methyltransferase	O
catalyzing	O
the	O
formation	O
of	O
trimethyllysine	O
-	O
14	O
in	O
the	O
large	O
subunit	O
of	O
Rubisco	O
.	O

Catalytically	O
competent	O
complexes	O
between	O
an	O
immobilized	O
form	O
of	O
des	O
(	O
methyl	O
)	O
Rubisco	O
and	O
Rubisco	B-Protein
large	I-Protein
subunit	I-Protein
methyltransferase	E-Protein
were	O
used	O
to	O
demonstrate	O
enzyme	O
release	O
that	O
was	O
co	O
-	O
incident	O
with	O
and	O
dependent	O
on	O
formation	O
of	O
trimethyllysine	O
.	O

Catalytic	O
rate	O
constants	O
determined	O
for	O
formation	O
of	O
trimethyllysine	O
were	O
considerably	O
lower	O
(	O
approximately	O
10	O
-	O
fold	O
)	O
than	O
rate	O
constants	O
determined	O
for	O
total	O
radiolabel	O
incorporation	O
from	O
[	O
3H	O
-	O
methyl	O
]	O
-	O
S	O
-	O
adenosylmethionine	O
.	O

Double	O
-	O
reciprocal	O
velocity	O
plots	O
under	O
catalytic	O
conditions	O
favoring	O
monomethyllysine	O
indicated	O
a	O
random	O
or	O
ordered	O
reaction	O
mechanism	O
,	O
while	O
conditions	O
favoring	O
trimethyllysine	O
suggested	O
a	O
hybrid	O
ping	O
-	O
pong	O
mechanism	O
.	O

These	O
results	O
were	O
compared	O
with	O
double	O
-	O
reciprocal	O
velocity	O
plots	O
and	O
product	O
analyses	O
obtained	O
for	O
HsSET7	B-Protein
/	I-Protein
9	E-Protein
(	O
a	O
monomethyltransferase	O
)	O
and	O
SpCLR4	S-Protein
(	O
a	O
dimethyltransferase	O
)	O
and	O
suggest	O
a	O
predictive	O
ability	O
of	O
double	O
-	O
reciprocal	O
velocity	O
plots	O
for	O
single	O
versus	O
multiple	O
methyl	O
group	O
transfers	O
by	O
SET	O
domain	O
protein	O
lysine	O
methyltransferases	O
.	O

A	O
model	O
is	O
proposed	O
for	O
SET	O
domain	O
protein	O
lysine	O
methyltransferases	O
in	O
which	O
initial	O
binding	O
of	O
polypeptide	O
substrate	O
and	O
S	O
-	O
adenosylmethionine	O
is	O
random	O
,	O
with	O
polypeptide	O
binding	O
followed	O
by	O
deprotonation	O
of	O
the	O
epsilon	O
-	O
amine	O
of	O
the	O
target	O
lysyl	O
residue	O
and	O
subsequent	O
methylation	O
.	O

Following	O
methyl	O
group	O
transfer	O
,	O
S	O
-	O
adenosylhomocysteine	O
and	O
monomethylated	O
polypeptide	O
dissociate	O
from	O
monomethyltransferases	O
,	O
but	O
di	O
-	O
and	O
trimethyltransferases	O
begin	O
a	O
successive	O
and	O
catalytically	O
obligatory	O
deprotonation	O
of	O
enzyme	O
-	O
bound	O
methylated	O
lysyl	O
intermediates	O
,	O
which	O
along	O
with	O
binding	O
and	O
release	O
of	O
S	O
-	O
adenosylmethionine	O
and	O
S	O
-	O
adenosylhomocysteine	O
is	O
manifested	O
as	O
a	O
hybrid	O
ping	O
-	O
pong	O
-	O
like	O
reaction	O
mechanism	O
.	O

Aberrant	O
hypermethylation	O
of	O
p14ARF	S-Protein
and	O
O6	B-Protein
-	I-Protein
methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
methyltransferase	E-Protein
genes	O
in	O
astrocytoma	O
progression	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
elucidate	O
genetic	O
alterations	O
that	O
are	O
critically	O
involved	O
in	O
astrocytoma	O
progression	O
.	O

We	O
characterized	O
27	O
World	O
Health	O
Organization	O
grade	O
II	O
fibrillary	O
astrocytomas	O
which	O
later	O
underwent	O
recurrence	O
or	O
progression	O
,	O
paying	O
specific	O
attention	O
to	O
the	O
CpG	O
island	O
methylation	O
status	O
of	O
critical	O
growth	O
regulatory	O
genes	O
.	O

p14	S-Protein
(	O
ARF	S-Protein
)	O
and	O
O	B-Protein
(	I-Protein
6	I-Protein
)	I-Protein
-	I-Protein
methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
methyltransferase	E-Protein
(	O
MGMT	S-Protein
)	O
hypermethylation	O
represented	O
frequent	O
events	O
(	O
26	O
%	O
and	O
63	O
%	O
,	O
respectively	O
)	O
,	O
which	O
were	O
mutually	O
exclusive	O
except	O
in	O
one	O
case	O
,	O
with	O
alternate	O
or	O
simultaneous	O
methylation	O
of	O
these	O
two	O
genes	O
occurring	O
in	O
85	O
%	O
of	O
our	O
tumor	O
series	O
.	O

Seventeen	O
tumors	O
(	O
63	O
%	O
)	O
contained	O
TP53	S-Protein
mutations	O
,	O
which	O
were	O
closely	O
related	O
to	O
the	O
presence	O
of	O
MGMT	S-Protein
methylation	O
.	O

Methylation	O
of	O
the	O
p21	S-Protein
(	O
Waf1	S-Protein
/	O
Cip1	S-Protein
)	O
,	O
p27	S-Protein
(	O
Kip1	S-Protein
)	O
and	O
p73	S-Protein
genes	O
and	O
homozygous	O
deletion	O
of	O
the	O
p16	S-Protein
(	O
INK4a	S-Protein
)	O
,	O
p15	S-Protein
(	O
INK4b	S-Protein
)	O
and	O
p14	S-Protein
(	O
ARF	S-Protein
)	O
genes	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
primary	O
low	O
-	O
grade	O
tumors	O
.	O

The	O
presence	O
of	O
p14	S-Protein
(	O
ARF	S-Protein
)	O
methylation	O
at	O
first	O
biopsy	O
was	O
associated	O
with	O
shorter	O
patient	O
survival	O
,	O
whereas	O
the	O
presence	O
of	O
MGMT	S-Protein
methylation	O
carried	O
a	O
better	O
clinical	O
outcome	O
after	O
salvage	O
therapy	O
.	O

Examination	O
of	O
20	O
cases	O
whose	O
histological	O
data	O
for	O
recurrent	O
tumors	O
were	O
available	O
revealed	O
that	O
malignant	O
progression	O
occurred	O
in	O
all	O
of	O
the	O
tumors	O
with	O
p14	S-Protein
(	O
ARF	S-Protein
)	O
methylation	O
but	O
less	O
frequently	O
(	O
50	O
%	O
)	O
in	O
the	O
lesions	O
with	O
MGMT	S-Protein
methylation	O
.	O

On	O
analysis	O
of	O
their	O
respective	O
recurrent	O
tumors	O
,	O
five	O
of	O
six	O
patients	O
whose	O
primary	O
low	O
-	O
grade	O
tumors	O
carried	O
p14	S-Protein
(	O
ARF	S-Protein
)	O
methylation	O
exhibited	O
homozygous	O
co	O
-	O
deletions	O
of	O
the	O
p14	S-Protein
(	O
ARF	S-Protein
)	O
,	O
p15	S-Protein
(	O
INK4b	S-Protein
)	O
and	O
p16	S-Protein
(	O
INK4a	S-Protein
)	O
genes	O
,	O
which	O
were	O
restricted	O
to	O
glioblastoma	O
as	O
the	O
most	O
malignant	O
end	O
point	O
.	O

Our	O
findings	O
suggest	O
that	O
p14	S-Protein
(	O
ARF	S-Protein
)	O
hypermethylation	O
and	O
MGMT	S-Protein
hypermethylation	O
constitute	O
distinct	O
molecular	O
pathways	O
of	O
astrocytoma	O
progression	O
,	O
which	O
could	O
differ	O
in	O
biological	O
behavior	O
and	O
clinical	O
outcome	O
.	O

Mechanisms	O
of	O
ceramide	O
-	O
mediated	O
repression	O
of	O
the	O
human	O
telomerase	B-Protein
reverse	I-Protein
transcriptase	E-Protein
promoter	O
via	O
deacetylation	O
of	O
Sp3	S-Protein
by	O
histone	B-Protein
deacetylase	I-Protein
1	E-Protein
.	O

In	O
this	O
study	O
,	O
distinct	O
roles	O
of	O
de	O
novo	O
-	O
generated	O
endogenous	O
ceramides	O
and	O
mechanisms	O
by	O
which	O
deacetylated	O
Sp3	S-Protein
regulates	O
the	O
hTERT	S-Protein
promoter	O
activity	O
in	O
response	O
to	O
ceramide	O
signaling	O
were	O
explored	O
.	O

The	O
generation	O
of	O
C18	O
-	O
ceramide	O
via	O
the	O
expression	O
of	O
ceramide	B-Protein
synthase	I-Protein
1	E-Protein
(	O
CerS1	S-Protein
)	O
,	O
and	O
not	O
C16	O
-	O
ceramide	O
by	O
CerS5	S-Protein
or	O
CerS6	S-Protein
expression	O
,	O
resulted	O
in	O
repression	O
of	O
the	O
hTERT	S-Protein
promoter	O
via	O
deacetylation	O
of	O
Sp3	S-Protein
by	O
histone	B-Protein
deacetylase	I-Protein
1	E-Protein
(	O
HDAC1	S-Protein
)	O
in	O
A549	O
human	O
lung	O
adenocarcinoma	O
cells	O
.	O

Then	O
roles	O
and	O
mechanisms	O
of	O
action	O
of	O
ceramide	O
-	O
mediated	O
deacetylation	O
of	O
Sp3	S-Protein
in	O
inhibiting	O
the	O
hTERT	S-Protein
promoter	O
were	O
determined	O
using	O
constitutively	O
deacetylated	O
or	O
acetylated	O
Sp3	S-Protein
mutants	O
at	O
lysine	O
(	O
K	O
)	O
551	O
.	O

Expression	O
of	O
the	O
deacetylated	O
Sp3	S-Protein
mutant	O
resulted	O
in	O
repression	O
,	O
whereas	O
its	O
acetylated	O
mutant	O
induced	O
basal	O
hTERT	S-Protein
promoter	O
activity	O
in	O
Drosophila	O
S2	O
cells	O
,	O
which	O
do	O
not	O
express	O
any	O
endogenous	O
Sp3	S-Protein
,	O
and	O
in	O
A549	O
cells	O
.	O

Remarkably	O
,	O
chromatin	O
immunoprecipitation	O
data	O
revealed	O
that	O
acetylated	O
Sp3	S-Protein
mutant	O
(	O
K551Q	O
-	O
Sp3	S-Protein
)	O
did	O
not	O
bind	O
whereas	O
deacetylated	O
Sp3	S-Protein
(	O
K551R	O
-	O
Sp3	S-Protein
)	O
mutant	O
bound	O
strongly	O
to	O
the	O
promoter	O
DNA	O
,	O
resulting	O
in	O
the	O
recruitment	O
of	O
histone	B-Protein
deacetylase	I-Protein
1	E-Protein
(	O
HDAC1	S-Protein
)	O
and	O
inhibition	O
of	O
the	O
association	O
of	O
RNA	O
polymerase	O
II	O
with	O
the	O
promoter	O
.	O

Mechanistically	O
,	O
increased	O
generation	O
of	O
C18	O
-	O
ceramide	O
by	O
hCerS1	S-Protein
expression	O
,	O
but	O
not	O
by	O
its	O
catalytically	O
inactive	O
mutant	O
,	O
mediated	O
the	O
association	O
and	O
recruitment	O
of	O
the	O
deacetylated	O
Sp3	S-Protein
/	O
HDAC1	S-Protein
complex	O
to	O
the	O
hTERT	S-Protein
promoter	O
DNA	O
,	O
resulting	O
in	O
the	O
local	O
histone	B-Protein
H3	E-Protein
deacetylation	O
and	O
repression	O
of	O
the	O
promoter	O
.	O

Drosophila	O
dSet2	S-Protein
functions	O
in	O
H3	S-Protein
-	O
K36	O
methylation	O
and	O
is	O
required	O
for	O
development	O
.	O

Lysine	O
methylation	O
has	O
important	O
functions	O
in	O
biological	O
processes	O
that	O
range	O
from	O
heterochromatin	O
formation	O
to	O
transcription	O
regulation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
Drosophila	O
dSet2	S-Protein
encodes	O
a	O
developmentally	O
essential	O
histone	B-Protein
H3	E-Protein
lysine	O
36	O
(	O
K36	O
)	O
methyltransferase	O
.	O

Larvae	O
subjected	O
to	O
RNA	O
interference	O
-	O
mediated	O
(	O
RNAi	O
)	O
suppression	O
of	O
dSet2	S-Protein
lack	O
dSet2	S-Protein
expression	O
and	O
H3	S-Protein
-	O
K36	O
methylation	O
,	O
indicating	O
that	O
dSet2	S-Protein
is	O
the	O
sole	O
enzyme	O
responsible	O
for	O
this	O
modification	O
in	O
Drosophila	O
melanogaster	O
.	O

dSet2	S-Protein
RNAi	O
blocks	O
puparium	O
formation	O
and	O
adult	O
development	O
,	O
and	O
causes	O
partial	O
(	O
blister	O
)	O
separation	O
of	O
the	O
dorsal	O
and	O
ventral	O
wing	O
epithelia	O
,	O
defects	O
suggesting	O
a	O
failure	O
of	O
the	O
ecdysone	O
-	O
controlled	O
genetic	O
program	O
.	O

A	O
transheterozygous	O
EcR	S-Protein
null	O
mutation	O
/	O
dSet2	S-Protein
RNAi	O
combination	O
produces	O
a	O
complete	O
(	O
balloon	O
)	O
separation	O
of	O
the	O
wing	O
surfaces	O
,	O
revealing	O
a	O
genetic	O
interaction	O
between	O
EcR	S-Protein
and	O
dSet2	S-Protein
.	O

Using	O
immunoprecipitation	O
,	O
we	O
demonstrate	O
that	O
dSet2	S-Protein
associates	O
with	O
the	O
hyperphosphorylated	O
form	O
of	O
RNA	O
polymerase	O
II	O
(	O
RNAPII	O
)	O
.	O

VIPL	S-Protein
has	O
sugar	O
-	O
binding	O
activity	O
specific	O
for	O
high	O
-	O
mannose	O
-	O
type	O
N	O
-	O
glycans	O
,	O
and	O
glucosylation	O
of	O
the	O
alpha1	O
,	O
2	O
mannotriosyl	O
branch	O
blocks	O
its	O
binding	O
.	O

VIP36	B-Protein
-	I-Protein
like	I-Protein
protein	E-Protein
(	O
VIPL	S-Protein
)	O
was	O
identified	O
as	O
an	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
resident	O
protein	O
with	O
homology	O
to	O
VIP36	S-Protein
,	O
a	O
cargo	O
receptor	O
involved	O
in	O
the	O
transport	O
of	O
glycoproteins	O
within	O
cells	O
.	O

Although	O
VIPL	S-Protein
is	O
structurally	O
similar	O
to	O
VIP36	S-Protein
,	O
VIPL	S-Protein
is	O
thought	O
not	O
to	O
be	O
a	O
lectin	O
,	O
because	O
its	O
sugar	O
-	O
binding	O
activity	O
has	O
not	O
been	O
detected	O
in	O
several	O
experiments	O
.	O

Here	O
,	O
recombinant	O
soluble	O
VIPL	S-Protein
proteins	O
(	O
sVIPL	S-Protein
)	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
biotinylated	O
with	O
biotin	B-Protein
ligase	E-Protein
and	O
oligomerized	O
with	O
R	O
-	O
phycoerythrin	O
(	O
PE	O
)	O
-	O
labeled	O
streptavidin	S-Protein
(	O
SA	S-Protein
)	O
.	O

As	O
measured	O
with	O
flow	O
cytometry	O
,	O
PE	O
-	O
labeled	O
sVIPL	S-Protein
-	O
SA	S-Protein
bound	O
to	O
deoxymannojirimycin	O
(	O
DMJ	O
)	O
-	O
or	O
kifunensine	O
(	O
KIF	O
)	O
-	O
but	O
not	O
to	O
swainsonine	O
(	O
SW	O
)	O
-	O
treated	O
HeLaS3	O
cells	O
in	O
the	O
presence	O
of	O
calcium	O
.	O

A	O
surface	O
plasmon	O
resonance	O
analysis	O
showed	O
that	O
the	O
avidity	O
of	O
sVIPL	S-Protein
was	O
enhanced	O
after	O
it	O
formed	O
a	O
complex	O
with	O
SA	S-Protein
.	O

The	O
binding	O
of	O
PE	O
-	O
labeled	O
sVIPL	S-Protein
-	O
SA	S-Protein
was	O
abrogated	O
by	O
endo	B-Protein
beta	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminidase	I-Protein
H	E-Protein
treatment	O
of	O
the	O
DMJ	O
-	O
or	O
KIF	O
-	O
treated	O
cells	O
.	O

Competition	O
with	O
several	O
high	O
-	O
mannose	O
-	O
type	O
N	O
-	O
glycans	O
inhibited	O
VIPL	S-Protein
binding	O
,	O
and	O
indicated	O
that	O
VIPL	S-Protein
recognizes	O
the	O
Manalpha1	O
-	O
2Manalpha1	O
-	O
2Man	O
sequence	O
.	O

Glucosylation	O
of	O
the	O
outer	O
mannose	O
residue	O
of	O
this	O
portion	O
decreased	O
the	O
binding	O
.	O

Although	O
the	O
biochemical	O
characteristics	O
of	O
VIPL	S-Protein
are	O
similar	O
to	O
those	O
of	O
VIP36	S-Protein
,	O
the	O
sugar	O
-	O
binding	O
activity	O
of	O
VIPL	S-Protein
was	O
stronger	O
at	O
neutral	O
pH	O
,	O
corresponding	O
to	O
the	O
pH	O
in	O
the	O
lumen	O
of	O
the	O
ER	O
,	O
than	O
under	O
acidic	O
conditions	O
.	O

The	O
transcription	O
factor	O
snail	O
mediates	O
epithelial	O
to	O
mesenchymal	O
transitions	O
by	O
repression	O
of	O
estrogen	B-Protein
receptor	I-Protein
-	I-Protein
alpha	E-Protein
.	O

The	O
estrogen	B-Protein
receptor	I-Protein
(	I-Protein
ER	I-Protein
)	I-Protein
-	I-Protein
alpha	E-Protein
(	O
ESR1	S-Protein
)	O
is	O
a	O
key	O
regulatory	O
molecule	O
in	O
mammary	O
epithelial	O
cell	O
development	O
.	O

Loss	O
of	O
ER	B-Protein
-	I-Protein
alpha	E-Protein
in	O
breast	O
cancer	O
is	O
correlated	O
with	O
poor	O
prognosis	O
,	O
increased	O
recurrence	O
after	O
treatment	O
,	O
and	O
an	O
elevated	O
incidence	O
of	O
metastasis	O
.	O

A	O
proposed	O
molecular	O
pathway	O
by	O
which	O
ER	B-Protein
-	I-Protein
alpha	E-Protein
acts	O
to	O
constrain	O
invasive	O
growth	O
in	O
breast	O
cancer	O
cells	O
involves	O
direct	O
,	O
ER	B-Protein
-	I-Protein
alpha	E-Protein
-	O
dependent	O
expression	O
of	O
metastasis	O
-	O
associated	O
protein	O
3	O
,	O
a	O
cell	O
-	O
type	O
-	O
specific	O
component	O
of	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
chromatin	O
remodeling	O
complex	O
.	O

MTA3	S-Protein
in	O
turn	O
represses	O
expression	O
of	O
Snail	O
,	O
a	O
transcription	O
factor	O
linked	O
to	O
epithelial	O
to	O
mesenchymal	O
transition	O
and	O
cancer	O
metastasis	O
.	O

To	O
elucidate	O
its	O
role	O
(	O
s	O
)	O
in	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
we	O
expressed	O
Snail	O
in	O
the	O
noninvasive	O
,	O
ER	B-Protein
-	I-Protein
alpha	E-Protein
-	O
positive	O
MCF	O
-	O
7	O
cell	O
line	O
.	O

Snail	O
expression	O
led	O
to	O
decreased	O
cell	O
-	O
cell	O
adhesion	O
and	O
increased	O
cell	O
invasiveness	O
.	O

Furthermore	O
,	O
we	O
observed	O
loss	O
of	O
ER	B-Protein
-	I-Protein
alpha	E-Protein
expression	O
at	O
both	O
the	O
RNA	O
and	O
protein	O
level	O
that	O
was	O
accompanied	O
by	O
direct	O
interaction	O
of	O
Snail	O
with	O
regulatory	O
DNA	O
sequences	O
at	O
the	O
ESR1	S-Protein
locus	O
.	O

A	O
consequence	O
of	O
loss	O
of	O
ER	B-Protein
-	I-Protein
alpha	E-Protein
function	O
in	O
this	O
system	O
was	O
the	O
increased	O
abundance	O
of	O
key	O
components	O
of	O
the	O
TGF	O
-	O
beta	O
signaling	O
pathway	O
.	O

Thus	O
,	O
cross	O
-	O
talk	O
among	O
ER	B-Protein
-	I-Protein
alpha	E-Protein
,	O
Snail	O
,	O
and	O
the	O
TGF	O
-	O
beta	O
pathway	O
appears	O
to	O
control	O
critical	O
phenotypic	O
properties	O
of	O
breast	O
cancer	O
cells	O
.	O

DNA	O
stool	O
test	O
for	O
colorectal	O
cancer	O
:	O
hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
gene	O
.	O

PURPOSE	O
:	O
To	O
investigate	O
a	O
potential	O
mode	O
of	O
noninvasive	O
screening	O
for	O
colorectal	O
cancer	O
,	O
we	O
evaluated	O
the	O
hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
gene	O
promoter	O
in	O
human	O
stool	O
DNA	O
.	O

METHODS	O
:	O
In	O
stool	O
samples	O
from	O
36	O
patients	O
with	O
colorectal	O
neoplasia	O
(	O
7	O
adenoma	O
,	O
29	O
colorectal	O
cancer	O
)	O
and	O
17	O
healthy	O
control	O
subjects	O
,	O
isolated	O
DNA	O
was	O
treated	O
with	O
sodium	O
bisulfite	O
and	O
analyzed	O
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
with	O
primers	O
specific	O
for	O
methylated	O
or	O
unmethylated	O
promoter	O
sequences	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
gene	O
.	O

RESULTS	O
:	O
Hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
promoter	O
was	O
present	O
in	O
the	O
stool	O
DNA	O
of	O
patients	O
with	O
adenoma	O
and	O
colorectal	O
cancer	O
.	O

A	O
sensitivity	O
of	O
89	O
percent	O
and	O
specificity	O
of	O
86	O
percent	O
were	O
achieved	O
in	O
the	O
detection	O
of	O
colorectal	O
neoplasia	O
.	O

The	O
difference	O
in	O
hypermethylation	O
status	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
promoter	O
between	O
the	O
patients	O
with	O
colorectal	O
neoplasia	O
and	O
the	O
control	O
group	O
was	O
statistically	O
highly	O
significant	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Adenoma	O
and	O
early	O
tumor	O
Stage	O
I	O
(	O
International	O
Union	O
Against	O
Cancer	O
)	O
displayed	O
both	O
unmethylated	O
and	O
methylated	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
promoter	O
sequences	O
,	O
whereas	O
advanced	O
tumor	O
stages	O
showed	O
only	O
methylated	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
indicate	O
that	O
this	O
DNA	O
stool	O
test	O
of	O
hypermethylation	O
of	O
the	O
secreted	B-Protein
frizzled	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
-	I-Protein
1	E-Protein
promoter	O
is	O
a	O
sensitive	O
and	O
specific	O
method	O
.	O

It	O
has	O
the	O
potential	O
of	O
a	O
clinically	O
useful	O
test	O
for	O
the	O
early	O
detection	O
of	O
colorectal	O
cancer	O
.	O

Characterization	O
of	O
a	O
novel	O
Cullin5	S-Protein
binding	O
domain	O
in	O
HIV	O
-	O
1	O
Vif	S-Protein
.	O

Human	O
immunodeficiency	O
virus	O
tyoe	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Vif	O
counteracts	O
host	O
restriction	O
cytidine	O
deaminase	O
(	O
APOBEC3G	S-Protein
)	O
A3G	S-Protein
by	O
co	O
-	O
opting	O
the	O
cellular	O
ubiquitin	S-Protein
-	O
proteasome	O
machinery	O
.	O

Vif	S-Protein
utilizes	O
a	O
viral	O
-	O
specific	O
BC	O
-	O
box	O
to	O
recruit	O
ElonginB	S-Protein
-	O
ElonginC	S-Protein
and	O
a	O
novel	O
zinc	O
-	O
binding	O
HCCH	O
motif	O
to	O
recruit	O
Cullin5	S-Protein
(	O
Cul5	S-Protein
)	O
to	O
form	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
targeting	O
A3G	S-Protein
for	O
polyubiquitination	O
and	O
subsequently	O
proteasomal	O
degradation	O
.	O

To	O
determine	O
the	O
structural	O
requirements	O
in	O
HIV	O
-	O
1	O
Vif	O
HCCH	O
motif	O
for	O
Cul5	S-Protein
binding	O
and	O
Vif	S-Protein
function	O
,	O
we	O
investigated	O
the	O
arrangement	O
of	O
the	O
His	O
and	O
Cys	O
residues	O
,	O
the	O
role	O
of	O
the	O
spacing	O
between	O
them	O
,	O
and	O
the	O
requirement	O
for	O
the	O
conserved	O
residues	O
.	O

Our	O
data	O
demonstrate	O
that	O
exchanging	O
Cys	O
for	O
His	O
and	O
vice	O
versa	O
in	O
the	O
highly	O
conserved	O
Zn	O
-	O
coordinating	O
HCCH	O
motif	O
disrupted	O
Vif	S-Protein
function	O
and	O
interaction	O
with	O
Cul5	S-Protein
.	O

Moreover	O
,	O
the	O
maintenance	O
of	O
both	O
conserved	O
residues	O
and	O
spacing	O
within	O
the	O
HCCH	O
motif	O
is	O
critical	O
for	O
Vif	S-Protein
function	O
.	O

We	O
have	O
identified	O
a	O
"	O
viral	O
Cul5	S-Protein
box	O
"	O
with	O
consensus	O
Hx2YFxCFx4Phix2APhix7	O
-	O
8Cx5H	O
that	O
is	O
required	O
for	O
Cul5	S-Protein
selection	O
and	O
subsequent	O
A3G	S-Protein
degradation	O
.	O

This	O
novel	O
motif	O
may	O
represent	O
a	O
potential	O
new	O
target	O
for	O
anti	O
-	O
viral	O
drug	O
development	O
.	O

Splicing	O
determines	O
the	O
glycosylation	O
state	O
of	O
ameloblastin	S-Protein
.	O

In	O
developing	O
porcine	O
enamel	O
,	O
the	O
space	O
between	O
enamel	O
rods	O
selectively	O
binds	O
lectins	O
and	O
ameloblastin	S-Protein
(	O
Ambn	S-Protein
)	O
N	O
-	O
terminal	O
antibodies	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
ameloblastin	S-Protein
N	O
-	O
terminal	O
cleavage	O
products	O
are	O
glycosylated	O
.	O

Assorted	O
Ambn	S-Protein
cleavage	O
products	O
showed	O
positive	O
lectin	O
staining	O
by	O
peanut	O
agglutinin	S-Protein
(	O
PNA	S-Protein
)	O
,	O
Maclura	O
pomifera	O
agglutinin	O
(	O
MPA	O
)	O
,	O
and	O
Limulus	O
polyphemus	O
agglutinin	O
(	O
LPA	O
)	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
O	O
-	O
linked	O
glycosylation	O
containing	O
galactose	O
(	O
Gal	O
)	O
,	O
N	O
-	O
acetylgalactosamine	O
(	O
GalNAc	O
)	O
,	O
and	O
sialic	O
acid	O
.	O

Edman	O
sequencing	O
of	O
the	O
lectin	O
-	O
positive	O
bands	O
gave	O
the	O
Ambn	S-Protein
N	O
-	O
terminal	O
sequence	O
:	O
VPAFPRQPGTXGVASLXLE	O
.	O

The	O
blank	O
cycles	O
for	O
Pro	O
(	O
11	O
)	O
and	O
Ser	O
(	O
17	O
)	O
confirmed	O
that	O
these	O
residues	O
are	O
hydroxylated	O
and	O
phosphorylated	O
,	O
respectively	O
.	O

The	O
O	O
-	O
glycosylation	O
site	O
was	O
determined	O
by	O
Edman	O
sequencing	O
of	O
pronase	O
-	O
digested	O
Ambn	S-Protein
,	O
which	O
gave	O
HPPPLPXQPS	O
,	O
indicating	O
that	O
Ser	O
(	O
86	O
)	O
is	O
the	O
site	O
of	O
the	O
O	O
-	O
linked	O
glycosylation	O
.	O

This	O
modification	O
is	O
within	O
the	O
15	O
-	O
amino	O
-	O
acid	O
segment	O
(	O
73	O
-	O
YEYSLPVHPPPLPSQ	O
-	O
87	O
)	O
deleted	O
by	O
splicing	O
in	O
the	O
mRNA	O
encoding	O
the	O
380	O
-	O
amino	O
-	O
acid	O
Ambn	S-Protein
isoform	O
.	O

We	O
conclude	O
that	O
only	O
the	O
N	O
-	O
terminal	O
Ambn	S-Protein
products	O
derived	O
from	O
the	O
395	O
-	O
Ambn	S-Protein
isoform	O
are	O
glycosylated	O
.	O

Chemical	O
genetic	O
interrogation	O
of	O
natural	O
variation	O
uncovers	O
a	O
molecule	O
that	O
is	O
glycoactivated	O
.	O

Natural	O
variation	O
in	O
human	O
drug	O
metabolism	O
and	O
target	O
genes	O
can	O
cause	O
pharmacogenetic	O
or	O
interindividual	O
variation	O
in	O
drug	O
sensitivity	O
.	O

We	O
reasoned	O
that	O
natural	O
pharmacogenetic	O
variation	O
in	O
model	O
organisms	O
could	O
be	O
systematically	O
exploited	O
to	O
facilitate	O
the	O
characterization	O
of	O
new	O
small	O
molecules	O
.	O

To	O
test	O
this	O
,	O
we	O
subjected	O
multiple	O
Arabidopsis	O
thaliana	O
accessions	O
to	O
chemical	O
genetic	O
screens	O
and	O
discovered	O
12	O
accession	O
-	O
selective	O
hit	O
molecules	O
.	O

As	O
a	O
model	O
for	O
understanding	O
this	O
variation	O
,	O
we	O
characterized	O
natural	O
resistance	O
to	O
hypostatin	O
,	O
a	O
new	O
inhibitor	O
of	O
cell	O
expansion	O
.	O

Map	O
-	O
based	O
cloning	O
identified	O
HYR1	S-Protein
,	O
a	O
UDP	O
glycosyltransferase	O
(	O
UGT	O
)	O
,	O
as	O
causative	O
for	O
hypostatin	O
resistance	O
.	O

Multiple	O
lines	O
of	O
evidence	O
demonstrate	O
that	O
HYR1	S-Protein
glucosylates	O
hypostatin	O
in	O
vivo	O
to	O
form	O
a	O
bioactive	O
glucoside	O
.	O

Additionally	O
,	O
we	O
delineated	O
a	O
HYR1	S-Protein
substrate	O
motif	O
and	O
used	O
it	O
to	O
identify	O
another	O
molecule	O
modulated	O
by	O
glucosylation	O
.	O

Our	O
results	O
demonstrate	O
that	O
natural	O
variation	O
can	O
be	O
exploited	O
to	O
inform	O
the	O
biology	O
of	O
new	O
small	O
molecules	O
,	O
and	O
that	O
UGT	O
sequence	O
variation	O
affects	O
xenobiotic	O
sensitivity	O
across	O
biological	O
kingdoms	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
herpesvirus	O
-	O
encoded	O
latency	B-Protein
-	I-Protein
associated	I-Protein
nuclear	I-Protein
antigen	E-Protein
stabilizes	O
intracellular	O
activated	O
Notch	O
by	O
targeting	O
the	O
Sel10	S-Protein
protein	O
.	O

Deregulation	O
of	O
the	O
evolutionarily	O
conserved	O
Notch	O
signaling	O
is	O
highly	O
correlated	O
with	O
oncogenesis	O
.	O

Intracellular	O
activated	O
Notch	O
(	O
ICN	O
)	O
is	O
a	O
protooncogene	O
linked	O
to	O
the	O
transcription	O
activation	O
of	O
a	O
number	O
of	O
cellular	O
genes	O
involved	O
in	O
cell	O
cycle	O
regulation	O
,	O
differentiation	O
,	O
and	O
proliferation	O
.	O

Stability	O
of	O
ICN	O
is	O
tightly	O
regulated	O
by	O
the	O
Sel10	S-Protein
-	O
mediated	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
.	O

Sel10	S-Protein
can	O
function	O
as	O
a	O
negative	O
regulator	O
of	O
Notch	O
and	O
exhibits	O
activities	O
of	O
a	O
tumor	O
-	O
suppressor	O
protein	O
.	O

This	O
article	O
shows	O
that	O
the	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
latency	B-Protein
-	I-Protein
associated	I-Protein
nuclear	I-Protein
antigen	E-Protein
(	O
LANA	S-Protein
)	O
directly	O
interacts	O
with	O
Sel10	S-Protein
and	O
forms	O
a	O
complex	O
in	O
KSHV	O
-	O
infected	O
cells	O
.	O

This	O
results	O
in	O
suppression	O
of	O
ICN	O
ubiquitination	O
and	O
degradation	O
.	O

The	O
carboxyl	O
terminus	O
of	O
LANA	S-Protein
interacts	O
with	O
the	O
F	O
-	O
box	O
and	O
WD40	O
domains	O
of	O
Sel10	S-Protein
and	O
competes	O
with	O
ICN	O
for	O
binding	O
to	O
Sel10	S-Protein
.	O

This	O
elevated	O
level	O
of	O
ICN	O
is	O
also	O
critical	O
for	O
maintaining	O
the	O
enhanced	O
proliferation	O
of	O
KSHV	O
-	O
infected	O
tumor	O
cells	O
.	O

These	O
findings	O
describe	O
a	O
mechanism	O
by	O
which	O
the	O
KSHV	O
-	O
encoded	O
LANA	S-Protein
protein	O
regulates	O
ubiquitination	O
of	O
ICN	O
mediated	O
by	O
the	O
F	O
-	O
box	O
component	O
of	O
the	O
E3	O
ligase	O
Sel10	S-Protein
,	O
leading	O
to	O
proliferation	O
of	O
the	O
virus	O
-	O
infected	O
cells	O
.	O

The	O
initiation	O
and	O
pattern	O
of	O
spread	O
of	O
histone	B-Protein
H4	E-Protein
acetylation	O
parallel	O
the	O
order	O
of	O
transcriptional	O
activation	O
of	O
genes	O
in	O
the	O
aflatoxin	O
cluster	O
.	O

The	O
27	O
genes	O
involved	O
in	O
aflatoxin	O
biosynthesis	O
are	O
clustered	O
within	O
a	O
70	O
kb	O
region	O
in	O
the	O
Aspergillus	O
parasiticus	O
genome	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
,	O
we	O
demonstrated	O
a	O
positive	O
correlation	O
between	O
the	O
initiation	O
and	O
spread	O
of	O
histone	B-Protein
H4	E-Protein
acetylation	O
in	O
aflatoxin	O
promoters	O
and	O
the	O
onset	O
of	O
accumulation	O
of	O
aflatoxin	O
proteins	O
and	O
aflatoxin	O
.	O

Histone	B-Protein
H4	E-Protein
acetylation	O
in	O
the	O
pksA	S-Protein
(	O
encodes	O
an	O
'	O
early	O
'	O
biosynthetic	O
pathway	O
enzyme	O
)	O
promoter	O
peaked	O
at	O
30	O
h	O
,	O
prior	O
to	O
the	O
increased	O
acetylation	O
in	O
the	O
omtA	S-Protein
and	O
ordA	S-Protein
(	O
encode	O
'	O
late	O
'	O
enzymes	O
)	O
promoters	O
detected	O
at	O
40	O
h	O
.	O

The	O
specific	O
order	O
in	O
which	O
pksA	S-Protein
,	O
ver	B-Protein
-	I-Protein
1	E-Protein
(	O
encodes	O
a	O
'	O
middle	O
'	O
enzyme	O
)	O
and	O
omtA	S-Protein
transcripts	O
accumulated	O
in	O
cells	O
paralleled	O
the	O
pattern	O
of	O
spread	O
of	O
histone	B-Protein
H4	E-Protein
acetylation	O
.	O

Binding	O
of	O
AflR	S-Protein
,	O
a	O
positive	O
regulator	O
of	O
aflatoxin	O
biosynthesis	O
,	O
to	O
the	O
ordA	S-Protein
promoter	O
showed	O
a	O
positive	O
correlation	O
with	O
the	O
spread	O
of	O
histone	B-Protein
H4	E-Protein
acetylation	O
.	O

The	O
data	O
suggest	O
that	O
the	O
order	O
of	O
genes	O
within	O
the	O
aflatoxin	O
cluster	O
determines	O
the	O
timing	O
and	O
order	O
of	O
transcriptional	O
activation	O
,	O
and	O
that	O
the	O
site	O
of	O
initiation	O
and	O
spread	O
of	O
histone	B-Protein
H4	E-Protein
acetylation	O
mediate	O
this	O
process	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
aflatoxin	O
and	O
adjacent	O
sugar	O
utilization	O
clusters	O
are	O
part	O
of	O
a	O
larger	O
'	O
regulatory	O
unit	O
'	O
.	O

Correlation	O
of	O
DNA	O
methylation	O
with	O
histone	S-Protein
modifications	O
across	O
the	O
HNRPA2B1	S-Protein
-	O
CBX3	S-Protein
ubiquitously	O
-	O
acting	O
chromatin	O
open	O
element	O
(	O
UCOE	O
)	O
.	O

The	O
methylation	O
-	O
free	O
CpG	O
island	O
encompassing	O
the	O
divergently	O
transcribed	O
promoters	O
of	O
the	O
HNRPA2B1	S-Protein
and	O
CBX3	S-Protein
housekeeping	O
genes	O
possesses	O
a	O
dominant	O
ubiquitously	O
-	O
acting	O
chromatin	O
opening	O
element	O
(	O
UCOE	O
)	O
capability	O
.	O

This	O
element	O
allows	O
reproducible	O
and	O
stable	O
transgene	O
expression	O
including	O
from	O
within	O
centromeric	O
heterochromatin	O
.	O

We	O
present	O
an	O
investigation	O
of	O
DNA	O
methylation	O
and	O
histone	S-Protein
modification	O
marks	O
across	O
the	O
HNRPA2B1	S-Protein
-	O
CBX3	S-Protein
locus	O
in	O
primary	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
to	O
characterise	O
the	O
chromatin	O
structure	O
that	O
underlies	O
UCOE	O
activity	O
.	O

The	O
CpG	O
methylation	O
-	O
free	O
region	O
associated	O
with	O
the	O
UCOE	O
extends	O
into	O
the	O
central	O
areas	O
of	O
HNRPA2B1	S-Protein
and	O
CBX3	S-Protein
,	O
with	O
a	O
total	O
length	O
of	O
approximately	O
5	O
kb	O
.	O

However	O
,	O
the	O
DNA	O
in	O
the	O
3	O
'	O
half	O
of	O
both	O
genes	O
is	O
methylated	O
.	O

Histone	B-Protein
H4	E-Protein
lysine	O
(	O
K	O
)	O
acetylation	O
shows	O
a	O
broad	O
distribution	O
across	O
both	O
genes	O
,	O
whilst	O
histone	B-Protein
H3	E-Protein
lysine	O
acetylation	O
peaks	O
around	O
the	O
transcriptional	O
start	O
sites	O
and	O
drops	O
to	O
background	O
levels	O
at	O
the	O
3	O
'	O
ends	O
.	O

Higher	O
levels	O
of	O
H3K4	S-Protein
di	O
-	O
methylation	O
are	O
present	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
genes	O
in	O
contrast	O
to	O
H3K4	S-Protein
tri	O
-	O
methylation	O
which	O
peaks	O
around	O
the	O
transcriptional	O
start	O
sites	O
.	O

Therefore	O
,	O
methylated	O
DNA	O
in	O
transcribed	O
regions	O
of	O
these	O
genes	O
has	O
been	O
shown	O
here	O
to	O
co	O
-	O
exist	O
with	O
active	O
histone	S-Protein
modification	O
marks	O
,	O
indicating	O
that	O
these	O
functionally	O
opposing	O
epigenetic	O
signatures	O
can	O
overlap	O
.	O

This	O
suggests	O
that	O
an	O
extended	O
large	O
region	O
of	O
unmethylated	O
DNA	O
in	O
combination	O
with	O
distinct	O
histone	S-Protein
modification	O
patterns	O
are	O
at	O
the	O
basis	O
of	O
UCOE	O
function	O
.	O

Cdc42	S-Protein
regulates	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
ubiquitination	O
and	O
degradation	O
through	O
an	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	E-Protein
to	O
Src	S-Protein
-	O
mediated	O
pathway	O
.	O

E	B-Protein
-	I-Protein
cadherins	E-Protein
play	O
an	O
essential	O
role	O
in	O
maintaining	O
epithelial	O
polarity	O
by	O
forming	O
Ca2	O
+	O
-	O
dependent	O
adherens	O
junctions	O
between	O
epithelial	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
Ca2	O
+	O
depletion	O
induces	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
ubiquitination	O
and	O
lysosomal	O
degradation	O
and	O
that	O
Cdc42	S-Protein
plays	O
an	O
important	O
role	O
in	O
regulating	O
this	O
process	O
.	O

We	O
demonstrate	O
that	O
Ca2	O
+	O
depletion	O
induces	O
activation	O
of	O
Cdc42	S-Protein
.	O

This	O
in	O
turn	O
up	O
-	O
regulates	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	E-Protein
(	O
EGFR	S-Protein
)	O
signaling	O
to	O
mediate	O
Src	S-Protein
activation	O
,	O
leading	O
to	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
ubiquitination	O
and	O
lysosomal	O
degradation	O
.	O

Silencing	O
Cdc42	S-Protein
blocks	O
activation	O
of	O
EGFR	S-Protein
and	O
Src	S-Protein
induced	O
by	O
Ca2	O
+	O
depletion	O
,	O
resulting	O
in	O
a	O
reduction	O
in	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
degradation	O
.	O

The	O
role	O
of	O
Cdc42	S-Protein
in	O
regulating	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
ubiquitination	O
and	O
degradation	O
is	O
underscored	O
by	O
the	O
fact	O
that	O
constitutively	O
active	O
Cdc42	S-Protein
(	O
F28L	S-Protein
)	O
increases	O
the	O
activity	O
of	O
EGFR	S-Protein
and	O
Src	S-Protein
and	O
significantly	O
enhances	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
ubiquitination	O
and	O
lysosomal	O
degradation	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
GTP	O
-	O
dependent	O
binding	O
of	O
Cdc42	S-Protein
to	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
is	O
critical	O
for	O
Cdc42	S-Protein
to	O
induce	O
the	O
dissolution	O
of	O
adherens	O
junctions	O
.	O

Our	O
data	O
support	O
a	O
model	O
that	O
activation	O
of	O
Cdc42	S-Protein
contributes	O
to	O
mesenchyme	O
-	O
like	O
phenotype	O
by	O
targeting	O
of	O
E	B-Protein
-	I-Protein
cadherin	E-Protein
for	O
lysosomal	O
degradation	O
.	O

A	O
conserved	O
SET	O
domain	O
methyltransferase	O
,	O
Set11	S-Protein
,	O
modifies	O
ribosomal	O
protein	O
Rpl12	S-Protein
in	O
fission	O
yeast	O
.	O

SET	O
domain	O
-	O
containing	O
methyltransferases	O
post	O
-	O
translationally	O
modify	O
a	O
variety	O
of	O
cellular	O
proteins	O
,	O
such	O
as	O
histones	S-Protein
,	O
cytochrome	B-Protein
c	E-Protein
,	O
ribulose	O
-	O
bisphosphate	O
carboxylase	O
/	O
oxygenase	O
,	O
and	O
ribosomal	O
proteins	O
.	O

In	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
,	O
at	O
least	O
13	O
SET	O
domain	O
-	O
containing	O
proteins	O
have	O
been	O
identified	O
in	O
the	O
genome	O
,	O
four	O
of	O
which	O
are	O
involved	O
in	O
transcriptional	O
regulation	O
through	O
their	O
modification	O
of	O
histone	S-Protein
tails	O
.	O

However	O
,	O
the	O
roles	O
played	O
by	O
the	O
other	O
SET	O
domain	O
proteins	O
in	O
cellular	O
processes	O
and	O
their	O
physiological	O
substrates	O
remain	O
unresolved	O
.	O

We	O
show	O
here	O
that	O
S	O
.	O
pombe	O
Set11	S-Protein
,	O
a	O
SET	O
domain	O
-	O
containing	O
protein	O
encoded	O
by	O
SPCC1223	O
.	O
04c	O
,	O
specifically	O
modifies	O
Rpl12	S-Protein
(	O
ribosomal	B-Protein
protein	I-Protein
L12	E-Protein
)	O
.	O

Recombinant	O
Set11	S-Protein
prepared	O
from	O
Escherichia	O
coli	O
had	O
catalytic	O
activity	O
and	O
methylated	O
a	O
17	O
-	O
kDa	O
polypeptide	O
in	O
cellular	O
extracts	O
of	O
set11	S-Protein
mutant	O
cells	O
.	O

The	O
methylated	O
protein	O
was	O
isolated	O
by	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
or	O
by	O
reverse	O
-	O
phase	O
chromatography	O
and	O
was	O
identified	O
as	O
Rpl12	S-Protein
by	O
mass	O
spectrometry	O
.	O

In	O
vitro	O
methylation	O
experiments	O
using	O
wild	O
-	O
type	O
and	O
mutant	O
Rpl12	S-Protein
proteins	O
verified	O
that	O
Set11	S-Protein
modified	O
recombinant	O
Rpl12	S-Protein
and	O
suggested	O
that	O
its	O
potential	O
target	O
site	O
was	O
lysine	O
3	O
.	O

The	O
methylation	O
site	O
modified	O
by	O
Set11	S-Protein
was	O
also	O
confirmed	O
by	O
mass	O
spectrometric	O
analysis	O
,	O
which	O
also	O
revealed	O
other	O
unique	O
methylation	O
sites	O
of	O
Rpl12	S-Protein
.	O

Finally	O
,	O
we	O
found	O
that	O
Set11	S-Protein
predominantly	O
localized	O
to	O
the	O
nucleolus	O
and	O
that	O
the	O
overproduction	O
of	O
Set11	S-Protein
caused	O
a	O
severe	O
growth	O
defect	O
.	O

These	O
results	O
suggest	O
that	O
Rpl12	S-Protein
methylation	O
occurs	O
during	O
the	O
ribosomal	O
assembly	O
processes	O
and	O
that	O
control	O
of	O
the	O
Set11	S-Protein
expression	O
level	O
is	O
important	O
for	O
its	O
cellular	O
function	O
.	O

Yeast	O
Chfr	S-Protein
homologs	O
retard	O
cell	O
cycle	O
at	O
G1	O
and	O
G2	O
/	O
M	O
via	O
Ubc4	S-Protein
and	O
Ubc13	S-Protein
/	O
Mms2	S-Protein
-	O
dependent	O
ubiquitination	O
.	O

Checkpoint	B-Protein
with	I-Protein
forkhead	I-Protein
-	I-Protein
associated	I-Protein
and	I-Protein
RING	E-Protein
(	O
Chfr	S-Protein
)	O
is	O
a	O
ubiquitin	S-Protein
ligase	O
(	O
E3	O
)	O
that	O
establishes	O
an	O
antephase	O
or	O
prometaphase	O
checkpoint	O
in	O
response	O
to	O
mitotic	O
stress	O
.	O

Though	O
ubiquitination	O
is	O
essential	O
for	O
checkpoint	O
function	O
,	O
the	O
sites	O
,	O
linkages	O
and	O
ubiquitin	S-Protein
conjugating	O
enzyme	O
(	O
E2	O
)	O
specificity	O
are	O
controversial	O
.	O

Here	O
we	O
dissect	O
the	O
function	O
of	O
the	O
two	O
Chfr	S-Protein
homologs	O
in	O
S	O
.	O
cerevisiae	O
,	O
Chf1	S-Protein
and	O
Chf2	S-Protein
,	O
overexpression	O
of	O
which	O
retard	O
cell	O
cycle	O
at	O
both	O
G	O
(	O
1	O
)	O
and	O
G	O
(	O
2	O
)	O
.	O

Using	O
a	O
genetic	O
assay	O
,	O
we	O
establish	O
that	O
Ubc4	S-Protein
is	O
required	O
for	O
Chf2	S-Protein
-	O
dependent	O
G	O
(	O
1	O
)	O
cell	O
cycle	O
delay	O
and	O
Chf	O
protein	O
turnover	O
.	O

In	O
contrast	O
,	O
Ubc13	S-Protein
/	O
Mms2	S-Protein
is	O
required	O
for	O
G	O
(	O
2	O
)	O
delay	O
and	O
does	O
not	O
contribute	O
to	O
Chf	O
protein	O
turnover	O
.	O

By	O
reconstituting	O
cis	O
and	O
trans	O
-	O
ubiquitination	O
activities	O
of	O
Chf	O
proteins	O
in	O
purified	O
systems	O
and	O
characterizing	O
sites	O
modified	O
and	O
linkages	O
formed	O
by	O
tandem	O
mass	O
spectrometry	O
,	O
we	O
discovered	O
that	O
Ubc13	S-Protein
/	O
Mms2	S-Protein
-	O
dependent	O
modifications	O
are	O
a	O
distinct	O
subset	O
of	O
those	O
catalyzed	O
by	O
Ubc4	S-Protein
.	O

Mutagenesis	O
of	O
Lys	O
residues	O
identified	O
in	O
vitro	O
indicates	O
that	O
site	O
-	O
specific	O
Ubc4	S-Protein
-	O
dependent	O
Chf	O
protein	O
autoubiquitination	O
is	O
responsible	O
for	O
Chf	O
protein	O
turnover	O
.	O

Thus	O
,	O
combined	O
genetic	O
and	O
biochemical	O
analyses	O
indicate	O
that	O
Chf	O
proteins	O
have	O
dual	O
E2	O
specificity	O
accounting	O
for	O
different	O
functions	O
in	O
the	O
cell	O
cycle	O
.	O

The	O
histone	S-Protein
-	O
like	O
NF	O
-	O
Y	O
is	O
a	O
bifunctional	O
transcription	O
factor	O
.	O

NF	O
-	O
Y	O
is	O
a	O
trimeric	O
transcription	O
factor	O
containing	O
H2A	S-Protein
/	O
H2B	S-Protein
-	O
like	O
subunits	O
,	O
which	O
specifically	O
binds	O
to	O
the	O
CCAAT	O
box	O
,	O
a	O
common	O
eukaryotic	O
promoter	O
element	O
.	O

To	O
gain	O
insights	O
into	O
NF	O
-	O
Y	O
-	O
dependent	O
transcriptional	O
regulation	O
,	O
we	O
assessed	O
its	O
relationships	O
with	O
positive	O
histone	S-Protein
marks	O
by	O
chromatin	O
immunoprecipitation	O
-	O
on	O
-	O
chip	O
and	O
correlative	O
-	O
profiling	O
studies	O
.	O

Unbiased	O
identification	O
of	O
binding	O
sites	O
shows	O
that	O
the	O
majority	O
of	O
genes	O
are	O
bound	O
by	O
NF	O
-	O
Y	O
in	O
the	O
promoter	O
and	O
/	O
or	O
within	O
the	O
coding	O
region	O
.	O

Parallel	O
analysis	O
of	O
H3K9	S-Protein
-	O
14ac	O
and	O
H3K4me3	S-Protein
sites	O
indicates	O
that	O
NF	O
-	O
Y	O
loci	O
can	O
be	O
divided	O
in	O
two	O
distinct	O
clusters	O
:	O
(	O
i	O
)	O
a	O
large	O
cohort	O
contains	O
H3K9	S-Protein
-	O
14ac	O
and	O
H3K4me3	S-Protein
marks	O
and	O
correlates	O
with	O
expression	O
and	O
(	O
ii	O
)	O
a	O
sizeable	O
group	O
is	O
devoid	O
of	O
these	O
marks	O
and	O
is	O
found	O
on	O
transcriptionally	O
silent	O
genes	O
.	O

Within	O
this	O
class	O
,	O
we	O
find	O
that	O
NF	O
-	O
Y	O
binding	O
is	O
associated	O
with	O
negative	O
histone	O
marks	O
,	O
such	O
as	O
H4K20me3	S-Protein
and	O
H3K27me3	S-Protein
.	O

NF	O
-	O
Y	O
removal	O
by	O
a	O
dominant	O
negative	O
NF	B-Protein
-	I-Protein
YA	E-Protein
leads	O
to	O
a	O
decrease	O
in	O
the	O
transcription	O
of	O
expressed	O
genes	O
associated	O
with	O
H3K4me3	S-Protein
and	O
H3K9	S-Protein
-	O
14ac	O
,	O
while	O
increasing	O
the	O
levels	O
of	O
many	O
inactive	O
genes	O
.	O

These	O
data	O
indicate	O
that	O
NF	O
-	O
Y	O
is	O
embedded	O
in	O
positive	O
as	O
well	O
as	O
in	O
negative	O
methyl	O
histone	S-Protein
marks	O
,	O
serving	O
a	O
dual	O
function	O
in	O
transcriptional	O
regulation	O
,	O
as	O
an	O
activator	O
or	O
as	O
a	O
repressor	O
.	O

Role	O
of	O
S3	O
and	O
S4	O
transmembrane	O
domain	O
charged	O
amino	O
acids	O
in	O
channel	O
biogenesis	O
and	O
gating	O
of	O
KCa2	B-Protein
.	I-Protein
3	E-Protein
and	O
KCa3	B-Protein
.	I-Protein
1	E-Protein
.	O

The	O
role	O
of	O
positively	O
charged	O
arginines	O
in	O
the	O
fourth	O
transmembrane	O
domain	O
(	O
S4	O
)	O
and	O
a	O
single	O
negatively	O
charged	O
amino	O
acid	O
in	O
the	O
third	O
transmembrane	O
domain	O
(	O
S3	O
)	O
on	O
channel	O
biogenesis	O
and	O
gating	O
of	O
voltage	O
-	O
gated	O
K	O
(	O
+	O
)	O
channels	O
(	O
Kv	O
)	O
has	O
been	O
well	O
established	O
.	O

Both	O
intermediate	O
(	O
KCa3	B-Protein
.	I-Protein
1	E-Protein
)	O
and	O
small	O
(	O
KCa2	O
.	O
x	O
)	O
conductance	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-	O
activated	O
K	O
(	O
+	O
)	O
channels	O
have	O
two	O
conserved	O
arginines	O
in	O
S4	O
and	O
a	O
single	O
conserved	O
glutamic	O
acid	O
in	O
S3	O
,	O
although	O
these	O
channels	O
are	O
voltage	O
-	O
independent	O
.	O

We	O
demonstrate	O
that	O
mutation	O
of	O
any	O
of	O
these	O
charged	O
amino	O
acids	O
in	O
KCa3	B-Protein
.	I-Protein
1	E-Protein
or	O
KCa2	B-Protein
.	I-Protein
3	E-Protein
to	O
alanine	O
,	O
glutamine	O
,	O
or	O
charge	O
reversal	O
mutations	O
results	O
in	O
a	O
rapid	O
degradation	O
(	O
<	O
30	O
min	O
)	O
of	O
total	O
protein	O
,	O
confirming	O
the	O
critical	O
role	O
of	O
these	O
amino	O
acids	O
in	O
channel	O
biogenesis	O
.	O

Mutation	O
of	O
the	O
S4	O
arginine	O
closest	O
to	O
the	O
cytosolic	O
side	O
of	O
KCa3	B-Protein
.	I-Protein
1	E-Protein
to	O
histidine	O
resulted	O
in	O
expression	O
at	O
the	O
cell	O
surface	O
.	O

Excised	O
patch	O
clamp	O
experiments	O
revealed	O
that	O
this	O
Arg	O
/	O
His	O
mutation	O
had	O
a	O
dramatically	O
reduced	O
open	O
probability	O
(	O
P	O
(	O
o	O
)	O
)	O
,	O
relative	O
to	O
wild	O
type	O
channels	O
.	O

Additionally	O
,	O
we	O
demonstrate	O
,	O
using	O
a	O
combination	O
of	O
short	O
hairpin	O
RNA	O
,	O
dominant	O
negative	O
,	O
and	O
co	O
-	O
immunoprecipitation	O
studies	O
,	O
that	O
both	O
KCa3	B-Protein
.	I-Protein
1	E-Protein
and	O
KCa2	B-Protein
.	I-Protein
3	E-Protein
are	O
translocated	O
out	O
of	O
the	O
endoplasmic	O
reticulum	O
associated	O
with	O
Derlin	B-Protein
-	I-Protein
1	E-Protein
.	O

These	O
misfolded	O
channels	O
are	O
poly	O
-	O
ubiquitylated	O
,	O
recognized	O
by	O
p97	S-Protein
,	O
and	O
targeted	O
for	O
proteasomal	O
degradation	O
.	O

Our	O
results	O
suggest	O
that	O
S3	O
and	O
S4	O
charged	O
amino	O
acids	O
play	O
an	O
evolutionarily	O
conserved	O
role	O
in	O
the	O
biogenesis	O
and	O
gating	O
of	O
KCa	O
channels	O
.	O

Furthermore	O
,	O
these	O
improperly	O
folded	O
K	O
(	O
+	O
)	O
channels	O
are	O
translocated	O
out	O
of	O
the	O
endoplasmic	O
reticulum	O
in	O
a	O
Derlin	B-Protein
-	I-Protein
1	E-Protein
-	O
and	O
p97	S-Protein
-	O
dependent	O
fashion	O
,	O
poly	O
-	O
ubiquitylated	O
,	O
and	O
targeted	O
for	O
proteasomal	O
degradation	O
.	O

Role	O
and	O
regulation	O
of	O
prolyl	O
hydroxylase	O
domain	O
proteins	O
.	O

Oxygen	O
-	O
dependent	O
hydroxylation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
alpha	O
subunits	O
by	O
prolyl	O
hydroxylase	O
domain	O
(	O
PHD	O
)	O
proteins	O
signals	O
their	O
polyubiquitination	O
and	O
proteasomal	O
degradation	O
,	O
and	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
HIF	O
abundance	O
and	O
oxygen	O
homeostasis	O
.	O

While	O
oxygen	O
concentration	O
plays	O
a	O
major	O
role	O
in	O
determining	O
the	O
efficiency	O
of	O
PHD	O
-	O
catalyzed	O
hydroxylation	O
reactions	O
,	O
many	O
other	O
environmental	O
and	O
intracellular	O
factors	O
also	O
significantly	O
modulate	O
PHD	O
activities	O
.	O

In	O
addition	O
,	O
PHDs	O
may	O
also	O
employ	O
hydroxylase	O
-	O
independent	O
mechanisms	O
to	O
modify	O
HIF	O
activity	O
.	O

Interestingly	O
,	O
while	O
PHDs	O
regulate	O
HIF	O
-	O
alpha	O
protein	O
stability	O
,	O
PHD2	S-Protein
and	O
PHD3	S-Protein
themselves	O
are	O
subject	O
to	O
feedback	O
upregulation	O
by	O
HIFs	O
.	O

Functionally	O
,	O
different	O
PHD	O
isoforms	O
may	O
differentially	O
contribute	O
to	O
specific	O
pathophysiological	O
processes	O
,	O
including	O
angiogenesis	O
,	O
erythropoiesis	O
,	O
tumorigenesis	O
,	O
and	O
cell	O
growth	O
,	O
differentiation	O
and	O
survival	O
.	O

Because	O
of	O
diverse	O
roles	O
of	O
PHDs	O
in	O
many	O
different	O
processes	O
,	O
loss	O
of	O
PHD	O
expression	O
or	O
function	O
triggers	O
multi	O
-	O
faceted	O
pathophysiological	O
changes	O
as	O
has	O
been	O
shown	O
in	O
mice	O
lacking	O
different	O
PHD	O
isoforms	O
.	O

Future	O
investigations	O
are	O
needed	O
to	O
explore	O
in	O
vivo	O
specificity	O
of	O
PHDs	O
over	O
different	O
HIF	O
-	O
alpha	O
subunits	O
and	O
differential	O
roles	O
of	O
PHD	O
isoforms	O
in	O
different	O
biological	O
processes	O
.	O

Characterization	O
of	O
the	O
molecular	O
interaction	O
between	O
tropoelastin	S-Protein
and	O
DANCE	S-Protein
/	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
.	O

Fibulin	B-Protein
-	I-Protein
5	E-Protein
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
elastic	O
fiber	O
formation	O
.	O

The	O
present	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
molecular	O
interaction	O
between	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
and	O
tropoelastin	S-Protein
.	O

Our	O
data	O
showed	O
that	O
the	O
divalent	O
cations	O
of	O
Ca	O
(	O
2	O
+	O
)	O
,	O
Ba	O
(	O
2	O
+	O
)	O
and	O
Mg	O
(	O
2	O
+	O
)	O
significantly	O
enhanced	O
the	O
binding	O
of	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
to	O
tropoelastin	S-Protein
.	O

In	O
addition	O
,	O
N	O
-	O
linked	O
glycosylation	O
of	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
does	O
not	O
require	O
for	O
the	O
binding	O
to	O
tropoelastin	S-Protein
.	O

To	O
address	O
the	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
binding	O
site	O
on	O
tropoelastin	S-Protein
constructs	O
containing	O
,	O
exons	O
2	O
-	O
15	O
and	O
exons	O
16	O
-	O
36	O
,	O
of	O
tropoelastin	S-Protein
were	O
used	O
.	O

Fibulin	B-Protein
-	I-Protein
5	E-Protein
binding	O
was	O
significantly	O
reduced	O
to	O
either	O
fragment	O
and	O
also	O
to	O
a	O
mixture	O
of	O
the	O
two	O
fragments	O
.	O

These	O
results	O
suggested	O
that	O
the	O
whole	O
molecule	O
of	O
tropoelastin	S-Protein
was	O
required	O
for	O
the	O
interaction	O
with	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
.	O

In	O
co	O
-	O
immunoprecipitation	O
experiments	O
,	O
tropoelastin	S-Protein
binding	O
to	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
was	O
enhanced	O
by	O
an	O
increase	O
of	O
temperature	O
and	O
sodium	O
chloride	O
concentration	O
,	O
conditions	O
that	O
enhance	O
the	O
coacervation	O
of	O
tropoelastin	S-Protein
.	O

The	O
binding	O
of	O
tropoelastin	S-Protein
fragments	O
to	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
was	O
directly	O
proportional	O
to	O
their	O
propensity	O
to	O
coacervate	O
.	O

Furthermore	O
,	O
the	O
addition	O
of	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
to	O
tropoelastin	S-Protein
facilitated	O
coacervation	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
shows	O
that	O
fibulin	B-Protein
-	I-Protein
5	E-Protein
enhances	O
elastic	O
fiber	O
formation	O
in	O
part	O
by	O
improving	O
the	O
self	O
-	O
association	O
properties	O
of	O
tropoelastin	S-Protein
.	O

E3	O
ubiquitin	S-Protein
ligase	O
SIAH1	S-Protein
mediates	O
ubiquitination	O
and	O
degradation	O
of	O
TRB3	S-Protein
.	O

Tribbles	B-Protein
3	I-Protein
homolog	E-Protein
(	O
TRB3	S-Protein
)	O
is	O
recently	O
identified	O
as	O
a	O
scaffold	O
-	O
like	O
regulator	O
of	O
various	O
signal	O
transducers	O
and	O
has	O
been	O
implicated	O
in	O
several	O
processes	O
including	O
insulin	S-Protein
signaling	O
,	O
NF	O
-	O
kappaB	O
signaling	O
,	O
lipid	O
metabolism	O
and	O
BMP	O
signaling	O
.	O

To	O
further	O
understand	O
cellular	O
mechanisms	O
of	O
TRB3	S-Protein
regulation	O
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
to	O
identify	O
novel	O
TRB3	O
interacting	O
proteins	O
and	O
totally	O
obtained	O
ten	O
in	O
-	O
frame	O
fused	O
preys	O
.	O

Candidate	O
interactions	O
were	O
validated	O
by	O
co	O
-	O
immunoprecipitation	O
assays	O
in	O
mammalian	O
cells	O
.	O

We	O
further	O
characterized	O
the	O
identified	O
proteins	O
sorted	O
by	O
Gene	O
Ontology	O
Annotation	O
.	O

Its	O
interaction	O
with	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
SIAH1	S-Protein
was	O
further	O
investigated	O
.	O

SIAH1	S-Protein
could	O
interact	O
with	O
TRB3	S-Protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Importantly	O
,	O
SIAH1	S-Protein
targeted	O
TRB3	S-Protein
for	O
proteasome	O
-	O
dependent	O
degradation	O
.	O

Cotransfection	O
of	O
SIAH1	S-Protein
could	O
withdraw	O
up	O
-	O
regulation	O
of	O
TGF	O
-	O
beta	O
signaling	O
by	O
TRB3	S-Protein
,	O
suggesting	O
SIAH1	S-Protein
-	O
induced	O
degradation	O
of	O
TRB3	S-Protein
represents	O
a	O
potential	O
regulatory	O
mechanism	O
for	O
TGF	O
-	O
beta	O
signaling	O
.	O

Histone	B-Protein
deacetylase	I-Protein
3	E-Protein
localizes	O
to	O
the	O
mitotic	O
spindle	O
and	O
is	O
required	O
for	O
kinetochore	O
-	O
microtubule	O
attachment	O
.	O

Protein	O
acetylation	O
and	O
deacetylation	O
play	O
key	O
roles	O
in	O
multiple	O
physiological	O
functions	O
.	O

Histone	B-Protein
deacetylase	I-Protein
3	E-Protein
(	O
HDAC3	S-Protein
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitously	O
expressed	O
protein	O
that	O
forms	O
multiprotein	O
corepressor	O
complexes	O
to	O
repress	O
gene	O
transcription	O
.	O

Recent	O
studies	O
show	O
that	O
HDAC3	S-Protein
may	O
play	O
a	O
role	O
in	O
cell	O
proliferation	O
.	O

Altered	O
HDAC3	S-Protein
level	O
increases	O
G	O
(	O
2	O
)	O
/	O
M	O
cells	O
,	O
but	O
the	O
mechanism	O
remains	O
unknown	O
.	O

Here	O
we	O
show	O
for	O
the	O
first	O
time	O
,	O
to	O
our	O
knowledge	O
,	O
that	O
the	O
HDAC3	S-Protein
complex	O
,	O
including	O
nuclear	O
receptor	O
corepressor	O
(	O
N	O
-	O
CoR	O
)	O
,	O
transducin	O
-	O
beta	O
-	O
like	O
protein	O
1	O
(	O
TBL1	O
)	O
,	O
and	O
TBL1	B-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
1	E-Protein
(	O
TBLR1	S-Protein
)	O
,	O
is	O
localized	O
on	O
the	O
mitotic	O
spindle	O
.	O

Knockdown	O
of	O
HDAC3	S-Protein
or	O
N	O
-	O
CoR	O
resulted	O
in	O
a	O
collapsed	O
mitotic	O
spindle	O
that	O
was	O
surrounded	O
by	O
chromosomes	O
arranged	O
in	O
a	O
dome	O
-	O
like	O
configuration	O
.	O

Treatment	O
of	O
mitotic	O
cells	O
with	O
Trichostatin	O
A	O
,	O
an	O
HDAC	O
inhibitor	O
,	O
resulted	O
in	O
similar	O
spindle	O
defects	O
independent	O
of	O
transcriptional	O
regulation	O
.	O

In	O
addition	O
,	O
wild	O
-	O
type	O
HDAC3	S-Protein
but	O
not	O
a	O
deacetylase	O
-	O
dead	O
mutant	O
HDAC3	S-Protein
rescued	O
the	O
phenotypes	O
of	O
HDAC3	S-Protein
-	O
depleted	O
cells	O
,	O
suggesting	O
that	O
the	O
enzymatic	O
activity	O
of	O
HDAC3	S-Protein
is	O
important	O
for	O
proper	O
spindle	O
function	O
.	O

Whereas	O
the	O
kinetochores	O
and	O
the	O
spindle	O
assembly	O
checkpoint	O
appeared	O
intact	O
in	O
HDAC3	S-Protein
-	O
deficient	O
cells	O
,	O
kinetochore	O
-	O
microtubule	O
attachments	O
were	O
impaired	O
because	O
spindle	O
microtubules	O
were	O
unstable	O
in	O
response	O
to	O
cold	O
treatment	O
.	O

These	O
data	O
suggest	O
that	O
the	O
HDAC3	S-Protein
complex	O
is	O
involved	O
in	O
the	O
formation	O
of	O
functional	O
mitotic	O
spindles	O
and	O
proper	O
kinetochore	O
-	O
microtubule	O
attachment	O
.	O

The	O
level	O
or	O
distribution	O
of	O
acetylated	O
alpha	O
-	O
tubulin	O
was	O
not	O
altered	O
in	O
HDAC3	S-Protein
-	O
deficient	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
raise	O
the	O
interesting	O
possibility	O
that	O
acetylation	O
-	O
deacetylation	O
of	O
mitotic	O
spindle	O
components	O
may	O
be	O
essential	O
for	O
mitotic	O
spindle	O
function	O
.	O

VprBP	S-Protein
targets	O
Merlin	S-Protein
to	O
the	O
Roc1	S-Protein
-	O
Cul4A	S-Protein
-	O
DDB1	S-Protein
E3	O
ligase	O
complex	O
for	O
degradation	O
.	O

Inactivation	O
of	O
the	O
neurofibromatosis	B-Protein
type	I-Protein
2	E-Protein
(	O
NF2	S-Protein
)	O
tumor	O
suppressor	O
gene	O
function	O
has	O
been	O
observed	O
not	O
only	O
in	O
familial	O
schwannomas	O
and	O
other	O
central	O
nervous	O
system	O
tumors	O
,	O
but	O
also	O
in	O
malignant	O
tumors	O
unrelated	O
to	O
the	O
NF2	S-Protein
syndrome	O
,	O
indicating	O
a	O
broader	O
role	O
of	O
NF2	S-Protein
in	O
human	O
tumorigenesis	O
.	O

The	O
NF2	S-Protein
-	O
encoded	O
protein	O
Merlin	S-Protein
is	O
closely	O
related	O
to	O
the	O
Ezrin	S-Protein
-	O
Radixin	S-Protein
-	O
Moesin	S-Protein
family	O
of	O
membrane	O
/	O
cytoskeleton	O
linker	O
proteins	O
,	O
and	O
has	O
been	O
demonstrated	O
to	O
suppress	O
tumor	O
growth	O
by	O
inhibiting	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
and	O
Rac1	S-Protein
activation	O
.	O

Interestingly	O
,	O
serum	O
deprivation	O
has	O
been	O
shown	O
to	O
regulate	O
Merlin	S-Protein
at	O
the	O
protein	O
level	O
,	O
however	O
,	O
exactly	O
how	O
such	O
condition	O
affects	O
Merlin	S-Protein
remains	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
provide	O
evidence	O
to	O
show	O
that	O
Merlin	S-Protein
is	O
regulated	O
in	O
a	O
Roc1	S-Protein
-	O
Cullin4A	S-Protein
-	O
DDB1	S-Protein
-	O
dependent	O
manner	O
.	O

Following	O
serum	O
stimulation	O
,	O
Merlin	S-Protein
is	O
recruited	O
to	O
the	O
E3	O
ligase	O
complex	O
through	O
a	O
direct	O
interaction	O
with	O
the	O
WD40	O
-	O
containing	O
adaptor	O
protein	O
VprBP	S-Protein
.	O

Loading	O
of	O
Merlin	S-Protein
to	O
the	O
E3	O
ubiquitin	S-Protein
ligase	O
complex	O
resulted	O
in	O
its	O
polyubiquitination	O
,	O
and	O
consequently	O
its	O
proteasome	O
-	O
mediated	O
degradation	O
.	O

Consistently	O
,	O
VprBP	S-Protein
depletion	O
abolished	O
the	O
in	O
vivo	O
interaction	O
of	O
Merlin	S-Protein
and	O
Roc1	S-Protein
-	O
Cullin4A	S-Protein
-	O
DDB1	S-Protein
,	O
which	O
resulted	O
in	O
Merlin	S-Protein
stabilization	O
and	O
inhibited	O
ERK	O
and	O
Rac	O
activation	O
.	O

Together	O
,	O
our	O
data	O
revealed	O
a	O
novel	O
regulatory	O
mechanism	O
for	O
the	O
tumor	O
suppressor	O
function	O
of	O
Merlin	S-Protein
.	O

The	O
novel	O
gene	O
LRP15	S-Protein
is	O
regulated	O
by	O
DNA	O
methylation	O
and	O
confers	O
increased	O
efficiency	O
of	O
DNA	O
repair	O
of	O
ultraviolet	O
-	O
induced	O
DNA	O
damage	O
.	O

LRP15	S-Protein
is	O
a	O
novel	O
gene	O
cloned	O
from	O
lymphocytic	O
cells	O
,	O
and	O
its	O
function	O
is	O
still	O
unknown	O
.	O

Bioinformatic	O
data	O
showed	O
that	O
LRP15	S-Protein
might	O
be	O
regulated	O
by	O
DNA	O
methylation	O
and	O
had	O
an	O
important	O
role	O
in	O
DNA	O
repair	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
whether	O
the	O
expression	O
of	O
LRP15	S-Protein
is	O
regulated	O
by	O
DNA	O
methylation	O
,	O
and	O
whether	O
overexpression	O
of	O
LRP15	S-Protein
increases	O
efficiency	O
of	O
DNA	O
repair	O
of	O
UV	O
-	O
induced	O
DNA	O
damage	O
in	O
HeLa	O
cells	O
.	O

The	O
results	O
showed	O
(	O
1	O
)	O
the	O
promoter	O
of	O
LRP15	S-Protein
was	O
hypermethylated	O
in	O
HeLa	O
cells	O
,	O
resulting	O
a	O
silence	O
of	O
its	O
expression	O
.	O

Gene	O
expression	O
was	O
restored	O
by	O
a	O
demethylating	O
agent	O
,	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
,	O
but	O
not	O
by	O
a	O
histone	S-Protein
deacetylase	O
inhibitor	O
,	O
trichostatin	O
A	O
;	O
(	O
2	O
)	O
overexpression	O
of	O
LRP15	S-Protein
inhibited	O
HeLa	O
cell	O
proliferation	O
,	O
and	O
the	O
numbers	O
of	O
cells	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
cells	O
transfected	O
with	O
LRP15	S-Protein
increased	O
about	O
10	O
%	O
compared	O
with	O
controls	O
;	O
(	O
3	O
)	O
cyclin	O
B1	O
level	O
was	O
much	O
lower	O
in	O
cells	O
overexpressing	O
LRP15	S-Protein
than	O
in	O
control	O
cells	O
;	O
and	O
(	O
4	O
)	O
after	O
exposure	O
to	O
UV	O
radiation	O
,	O
the	O
LRP15	S-Protein
-	O
positive	O
cells	O
showed	O
shorter	O
comet	O
tails	O
compared	O
with	O
the	O
LRP15	S-Protein
-	O
negative	O
cells	O
.	O

From	O
these	O
results	O
we	O
conclude	O
that	O
the	O
expression	O
of	O
LRP15	S-Protein
is	O
controlled	O
by	O
methylation	O
in	O
its	O
promoter	O
in	O
HeLa	O
cells	O
,	O
and	O
LRP15	S-Protein
confers	O
resistance	O
to	O
UV	O
damage	O
and	O
accelerates	O
the	O
DNA	O
repair	O
rate	O
.	O

Enzymatic	O
mechanism	O
and	O
product	O
specificity	O
of	O
SET	O
-	O
domain	O
protein	O
lysine	O
methyltransferases	O
.	O

Molecular	O
dynamics	O
and	O
hybrid	O
quantum	O
mechanics	O
/	O
molecular	O
mechanics	O
have	O
been	O
used	O
to	O
investigate	O
the	O
mechanisms	O
of	O
(	O
+	O
)	O
AdoMet	O
methylation	O
of	O
protein	O
-	O
Lys	O
-	O
NH	O
(	O
2	O
)	O
catalyzed	O
by	O
the	O
lysine	O
methyltransferase	O
enzymes	O
:	O
histone	O
lysine	O
monomethyltransferase	O
SET7	B-Protein
/	I-Protein
9	E-Protein
,	O
Rubisco	O
large	O
-	O
subunit	O
dimethyltransferase	O
,	O
viral	O
histone	O
lysine	O
trimethyltransferase	O
,	O
and	O
the	O
Tyr245Phe	O
mutation	O
of	O
SET7	B-Protein
/	I-Protein
9	E-Protein
.	O

At	O
neutrality	O
in	O
aqueous	O
solution	O
,	O
primary	O
amines	O
are	O
protonated	O
.	O

The	O
enzyme	O
reacts	O
with	O
Lys	O
-	O
NH	O
(	O
3	O
)	O
(	O
+	O
)	O
and	O
(	O
+	O
)	O
AdoMet	O
species	O
to	O
provide	O
an	O
Enz	O
.	O
Lys	O
-	O
NH	O
(	O
3	O
)	O
(	O
+	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
complex	O
.	O

The	O
close	O
positioning	O
of	O
two	O
positive	O
charges	O
lowers	O
the	O
pK	O
(	O
a	O
)	O
of	O
the	O
Lys	O
-	O
NH	O
(	O
3	O
)	O
(	O
+	O
)	O
entity	O
,	O
a	O
water	O
channel	O
appears	O
,	O
and	O
the	O
proton	O
escapes	O
to	O
the	O
aqueous	O
solvent	O
;	O
then	O
the	O
reaction	O
Enz	O
.	O
Lys	O
-	O
NH	O
(	O
2	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
-	O
-	O
>	O
Enz	O
.	O
Lys	O
-	O
N	O
(	O
Me	O
)	O
H	O
(	O
2	O
)	O
(	O
+	O
)	O
.	O
AdoHcy	O
occurs	O
.	O

Repeat	O
of	O
the	O
sequence	O
provides	O
dimethylated	O
lysine	O
,	O
and	O
another	O
repeat	O
yields	O
a	O
trimethylated	O
lysine	O
.	O

The	O
sequence	O
is	O
halted	O
at	O
monomethylation	O
when	O
the	O
conformation	O
of	O
the	O
Enz	O
.	O
Lys	O
-	O
N	O
(	O
Me	O
)	O
H	O
(	O
2	O
)	O
(	O
+	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
has	O
the	O
methyl	O
positioned	O
to	O
block	O
formation	O
of	O
a	O
water	O
channel	O
.	O

The	O
sequence	O
of	O
reactions	O
stops	O
at	O
dimethylation	O
if	O
the	O
conformation	O
of	O
Enz	O
.	O
Lys	O
-	O
N	O
(	O
Me	O
)	O
(	O
2	O
)	O
H	O
(	O
+	O
)	O
.	O
(	O
+	O
)	O
AdoMet	O
has	O
a	O
methyl	O
in	O
position	O
,	O
which	O
forbids	O
the	O
formation	O
of	O
the	O
water	O
channel	O
.	O

Cdc34p	S-Protein
ubiquitin	S-Protein
-	O
conjugating	O
enzyme	O
is	O
a	O
component	O
of	O
the	O
tombusvirus	O
replicase	O
complex	O
and	O
ubiquitinates	O
p33	S-Protein
replication	O
protein	O
.	O

To	O
identify	O
host	O
proteins	O
interacting	O
with	O
Tomato	O
bushy	O
stunt	O
virus	O
(	O
TBSV	O
)	O
replication	O
proteins	O
in	O
a	O
genome	O
-	O
wide	O
scale	O
,	O
we	O
have	O
used	O
a	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
proteome	O
microarray	O
carrying	O
4	O
,	O
088	O
purified	O
proteins	O
.	O

This	O
approach	O
led	O
to	O
the	O
identification	O
of	O
58	O
yeast	O
proteins	O
that	O
interacted	O
with	O
p33	S-Protein
replication	O
protein	O
.	O

The	O
identified	O
host	O
proteins	O
included	O
protein	O
chaperones	O
,	O
ubiquitin	S-Protein
-	O
associated	O
proteins	O
,	O
translation	O
factors	O
,	O
RNA	O
-	O
modifying	O
enzymes	O
,	O
and	O
other	O
proteins	O
with	O
yet	O
-	O
unknown	O
functions	O
.	O

We	O
confirmed	O
that	O
19	O
of	O
the	O
identified	O
host	O
proteins	O
bound	O
to	O
p33	S-Protein
in	O
vitro	O
or	O
in	O
a	O
split	O
-	O
ubiquitin	S-Protein
-	O
based	O
two	O
-	O
hybrid	O
assay	O
.	O

Further	O
analysis	O
of	O
Cdc34p	S-Protein
E2	O
ubiquitin	S-Protein
-	O
conjugating	O
enzyme	O
,	O
which	O
is	O
one	O
of	O
the	O
host	O
proteins	O
interacting	O
with	O
p33	S-Protein
,	O
revealed	O
that	O
Cdc34p	S-Protein
is	O
a	O
novel	O
component	O
of	O
the	O
purified	O
viral	O
replicase	O
.	O

Downregulation	O
of	O
Cdc34p	S-Protein
expression	O
in	O
yeast	O
,	O
which	O
supports	O
replication	O
of	O
a	O
TBSV	O
replicon	O
RNA	O
(	O
repRNA	O
)	O
,	O
reduced	O
repRNA	O
accumulation	O
and	O
the	O
activity	O
of	O
the	O
tombusvirus	O
replicase	O
by	O
up	O
to	O
fivefold	O
.	O

Overexpression	O
of	O
wild	O
-	O
type	O
Cdc34p	S-Protein
,	O
but	O
not	O
that	O
of	O
an	O
E2	O
-	O
defective	O
mutant	O
of	O
Cdc34p	S-Protein
,	O
increased	O
repRNA	O
accumulation	O
,	O
suggesting	O
a	O
significant	O
role	O
for	O
the	O
ubiquitin	S-Protein
-	O
conjugating	O
enzyme	O
function	O
of	O
Cdc34p	S-Protein
in	O
TBSV	O
replication	O
.	O

Also	O
,	O
Cdc34p	S-Protein
was	O
able	O
to	O
ubiquitinate	O
p33	S-Protein
in	O
vitro	O
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
p33	S-Protein
becomes	O
ubiquitinated	O
in	O
vivo	O
.	O

We	O
propose	O
that	O
ubiquitination	O
of	O
p33	S-Protein
likely	O
alters	O
its	O
function	O
or	O
affects	O
the	O
recruitment	O
of	O
host	O
factors	O
during	O
TBSV	O
replication	O
.	O

O6	B-Protein
-	I-Protein
Methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
-	I-Protein
methyltransferase	E-Protein
in	O
recurring	O
anaplastic	O
ependymomas	O
:	O
PCR	O
and	O
immunohistochemistry	O
.	O

Ependymomas	O
are	O
the	O
third	O
most	O
common	O
brain	O
tumor	O
in	O
children	O
.	O

The	O
post	O
surgical	O
management	O
is	O
controversial	O
.	O

There	O
are	O
no	O
convincing	O
data	O
on	O
an	O
effective	O
role	O
for	O
chemotherapy	O
.	O

O	B-Protein
(	I-Protein
6	I-Protein
)	I-Protein
-	I-Protein
Methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
-	I-Protein
Methyltransferase	E-Protein
(	O
MGMT	S-Protein
)	O
is	O
a	O
DNA	O
repair	O
protein	O
considered	O
to	O
be	O
a	O
chemosensitivity	O
predictor	O
.	O

Hypermethylation	O
of	O
the	O
MGMT	S-Protein
gene	O
promoter	O
is	O
an	O
important	O
cause	O
of	O
MGMT	S-Protein
inactivation	O
.	O

We	O
evaluated	O
the	O
MGMT	S-Protein
gene	O
promoter	O
methylation	O
and	O
the	O
immunohistochemical	O
MGMT	S-Protein
protein	O
expression	O
in	O
12	O
recurrent	O
anaplastic	O
ependymomas	O
affecting	O
children	O
.	O

Our	O
purpose	O
was	O
to	O
investigate	O
the	O
molecular	O
rationale	O
of	O
the	O
administration	O
of	O
alkylating	O
agents	O
to	O
children	O
affected	O
by	O
recurrent	O
anaplastic	O
ependymomas	O
.	O

All	O
ependymomas	O
lacked	O
MGMT	S-Protein
promoter	O
hypermethylation	O
and	O
9	O
(	O
75	O
%	O
)	O
showed	O
high	O
MGMT	S-Protein
protein	O
expression	O
(	O
>	O
50	O
%	O
tumoral	O
cells	O
)	O
.	O

Differences	O
between	O
different	O
recurrences	O
in	O
the	O
same	O
patient	O
were	O
not	O
observed	O
.	O

These	O
results	O
may	O
indicate	O
MGMT	S-Protein
as	O
a	O
factor	O
of	O
chemoresistance	O
to	O
alkylating	O
drugs	O
in	O
anaplastic	O
ependymomas	O
and	O
support	O
the	O
uncertainties	O
regarding	O
the	O
actual	O
benefit	O
of	O
chemotherapy	O
for	O
patients	O
with	O
anaplastic	O
ependymomas	O
.	O

The	O
aggresome	O
pathway	O
as	O
a	O
target	O
for	O
therapy	O
in	O
hematologic	O
malignancies	O
.	O

Misfolded	O
or	O
unfolded	O
proteins	O
are	O
often	O
refolded	O
with	O
the	O
help	O
of	O
chaperones	O
or	O
degraded	O
by	O
the	O
26S	O
proteasome	O
.	O

An	O
alternative	O
fate	O
of	O
these	O
proteins	O
is	O
the	O
aggresome	O
pathway	O
.	O

The	O
microtubule	O
-	O
organizing	O
center	O
(	O
MTOC	O
)	O
transports	O
unfolded	O
proteins	O
to	O
lysosomes	O
and	O
are	O
degraded	O
through	O
autophagy	O
.	O

Histone	B-Protein
deacetylase	I-Protein
6	E-Protein
(	O
HDAC6	S-Protein
)	O
deacetylates	O
alpha	O
-	O
tubulin	O
,	O
which	O
is	O
thought	O
to	O
be	O
a	O
component	O
of	O
the	O
MTOC	O
.	O

Recently	O
,	O
two	O
small	O
molecule	O
inhibitors	O
of	O
the	O
aggresome	O
pathway	O
and	O
HDAC6	S-Protein
have	O
been	O
described	O
.	O

One	O
inhibitor	O
,	O
tubacin	O
,	O
prevents	O
deacetylation	O
of	O
alpha	O
-	O
tubulin	O
and	O
produces	O
accumulation	O
of	O
polyubiquitinated	O
proteins	O
and	O
apoptosis	O
.	O

Tubacin	O
acts	O
synergistically	O
with	O
the	O
proteasome	O
inhibitor	O
,	O
bortezomib	O
,	O
to	O
induce	O
cytotoxicity	O
in	O
one	O
type	O
of	O
hematologic	O
malignancy	O
,	O
multiple	O
myeloma	O
.	O

The	O
other	O
,	O
LBH589	O
,	O
is	O
a	O
pan	O
HDAC	O
inhibitor	O
and	O
hydroxamic	O
acid	O
derivative	O
that	O
induces	O
apoptosis	O
of	O
multiple	O
myeloma	O
cells	O
resistant	O
to	O
conventional	O
therapies	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
recent	O
reports	O
on	O
targeting	O
the	O
aggresome	O
pathway	O
and	O
HDAC6	S-Protein
in	O
hematologic	O
malignancies	O
.	O

Interactions	O
between	O
the	O
quality	O
control	O
ubiquitin	S-Protein
ligase	O
CHIP	S-Protein
and	O
ubiquitin	S-Protein
conjugating	O
enzymes	O
.	O

BACKGROUND	O
:	O
Ubiquitin	S-Protein
(	O
E3	O
)	O
ligases	O
interact	O
with	O
specific	O
ubiquitin	S-Protein
conjugating	O
(	O
E2	O
)	O
enzymes	O
to	O
ubiquitinate	O
particular	O
substrate	O
proteins	O
.	O

As	O
the	O
combination	O
of	O
E2	O
and	O
E3	O
dictates	O
the	O
type	O
and	O
biological	O
consequence	O
of	O
ubiquitination	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
basis	O
of	O
specificity	O
in	O
E2	O
:	O
E3	O
interactions	O
.	O

The	O
E3	O
ligase	O
CHIP	S-Protein
interacts	O
with	O
Hsp70	O
and	O
Hsp90	O
and	O
ubiquitinates	O
client	O
proteins	O
that	O
are	O
chaperoned	O
by	O
these	O
heat	O
shock	O
proteins	O
.	O

CHIP	S-Protein
interacts	O
with	O
two	O
types	O
of	O
E2	O
enzymes	O
,	O
UbcH5	S-Protein
and	O
Ubc13	S-Protein
-	O
Uev1a	S-Protein
.	O

It	O
is	O
unclear	O
,	O
however	O
,	O
why	O
CHIP	S-Protein
binds	O
these	O
E2	O
enzymes	O
rather	O
than	O
others	O
,	O
and	O
whether	O
CHIP	S-Protein
interacts	O
preferentially	O
with	O
UbcH5	S-Protein
or	O
Ubc13	S-Protein
-	O
Uev1a	S-Protein
,	O
which	O
form	O
different	O
types	O
of	O
polyubiquitin	S-Protein
chains	O
.	O

RESULTS	O
:	O
The	O
2	O
.	O
9	O
A	O
crystal	O
structure	O
of	O
the	O
CHIP	S-Protein
U	O
-	O
box	O
domain	O
complexed	O
with	O
UbcH5a	S-Protein
shows	O
that	O
CHIP	S-Protein
binds	O
to	O
UbcH5	S-Protein
and	O
Ubc13	S-Protein
through	O
similar	O
specificity	O
determinants	O
,	O
including	O
a	O
key	O
S	O
-	O
P	O
-	O
A	O
motif	O
on	O
the	O
E2	O
enzymes	O
.	O

The	O
determinants	O
make	O
different	O
relative	O
contributions	O
to	O
the	O
overall	O
interactions	O
between	O
CHIP	S-Protein
and	O
the	O
two	O
E2	O
enzymes	O
.	O

CHIP	S-Protein
undergoes	O
auto	O
-	O
ubiquitination	O
by	O
UbcH5	S-Protein
but	O
not	O
by	O
Ubc13	S-Protein
-	O
Uev1a	S-Protein
.	O

Instead	O
,	O
CHIP	S-Protein
drives	O
the	O
formation	O
of	O
unanchored	O
polyubiquitin	S-Protein
by	O
Ubc13	S-Protein
-	O
Uev1a	S-Protein
.	O

CHIP	S-Protein
also	O
interacts	O
productively	O
with	O
the	O
class	O
III	O
E2	O
enzyme	O
Ube2e2	S-Protein
,	O
in	O
which	O
the	O
UbcH5	S-Protein
-	O
and	O
Ubc13	S-Protein
-	O
binding	O
specificity	O
determinants	O
are	O
highly	O
conserved	O
.	O

CONCLUSION	O
:	O
The	O
CHIP	S-Protein
:	O
UbcH5a	S-Protein
structure	O
emphasizes	O
the	O
importance	O
of	O
specificity	O
determinants	O
located	O
on	O
the	O
long	O
loops	O
and	O
central	O
helix	O
of	O
the	O
CHIP	S-Protein
U	O
-	O
box	O
,	O
and	O
on	O
the	O
N	O
-	O
terminal	O
helix	O
and	O
loops	O
L4	O
and	O
L7	O
of	O
its	O
cognate	O
E2	O
enzymes	O
.	O

The	O
S	O
-	O
P	O
-	O
A	O
motif	O
and	O
other	O
specificity	O
determinants	O
define	O
the	O
set	O
of	O
cognate	O
E2	O
enzymes	O
for	O
CHIP	S-Protein
,	O
which	O
likely	O
includes	O
several	O
Class	O
III	O
E2	O
enzymes	O
.	O

CHIP	S-Protein
'	O
s	O
interactions	O
with	O
UbcH5	S-Protein
,	O
Ube2e2	S-Protein
and	O
Ubc13	S-Protein
-	O
Uev1a	S-Protein
are	O
consistent	O
with	O
the	O
notion	O
that	O
Ubc13	S-Protein
-	O
Uev1a	S-Protein
may	O
work	O
sequentially	O
with	O
other	O
E2	O
enzymes	O
to	O
carry	O
out	O
K63	O
-	O
linked	O
polyubiquitination	O
of	O
CHIP	S-Protein
substrates	O
.	O

Regulation	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
self	O
-	O
ubiquitination	O
and	O
stability	O
by	O
a	O
PY	O
motif	O
located	O
within	O
its	O
HECT	O
-	O
domain	O
.	O

Ubiquitin	S-Protein
ligases	O
play	O
a	O
pivotal	O
role	O
in	O
substrate	O
recognition	O
and	O
ubiquitin	S-Protein
transfer	O
,	O
yet	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
their	O
catalytic	O
activity	O
.	O

Nedd4	B-Protein
(	I-Protein
neural	I-Protein
-	I-Protein
precursor	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
expressed	I-Protein
,	I-Protein
developmentally	I-Protein
down	I-Protein
-	I-Protein
regulated	I-Protein
4	I-Protein
)	I-Protein
-	I-Protein
2	E-Protein
is	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
composed	O
of	O
a	O
C2	O
domain	O
,	O
four	O
WW	O
domains	O
(	O
protein	O
-	O
protein	O
interaction	O
domains	O
containing	O
two	O
conserved	O
tryptophan	O
residues	O
)	O
that	O
bind	O
PY	O
motifs	O
(	O
L	O
/	O
PPXY	O
)	O
and	O
a	O
ubiquitin	S-Protein
ligase	O
HECT	O
(	O
homologous	O
with	O
E6	O
-	O
associated	O
protein	O
C	O
-	O
terminus	O
)	O
domain	O
.	O

In	O
the	O
present	O
paper	O
we	O
show	O
that	O
the	O
WW	O
domains	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
bind	O
(	O
weakly	O
)	O
to	O
a	O
PY	O
motif	O
(	O
LPXY	O
)	O
located	O
within	O
its	O
own	O
HECT	O
domain	O
and	O
inhibit	O
auto	O
-	O
ubiquitination	O
.	O

Pulse	O
-	O
chase	O
experiments	O
demonstrated	O
that	O
mutation	O
of	O
the	O
HECT	O
PY	O
-	O
motif	O
decreases	O
the	O
stability	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
,	O
suggesting	O
that	O
it	O
is	O
involved	O
in	O
stabilization	O
of	O
this	O
E3	O
ligase	O
.	O

Interestingly	O
,	O
the	O
HECT	O
PY	O
-	O
motif	O
mutation	O
does	O
not	O
affect	O
ubiquitination	O
or	O
down	O
-	O
regulation	O
of	O
a	O
known	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
substrate	O
,	O
ENaC	O
(	O
epithelial	O
sodium	O
channel	O
)	O
.	O

ENaC	O
ubiquitination	O
,	O
in	O
turn	O
,	O
appears	O
to	O
promote	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
self	O
-	O
ubiquitination	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
the	O
inter	O
-	O
or	O
intra	O
-	O
molecular	O
WW	O
-	O
domain	O
-	O
HECT	O
PY	O
-	O
motif	O
interaction	O
stabilizes	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
by	O
preventing	O
self	O
-	O
ubiquitination	O
.	O

Substrate	O
binding	O
disrupts	O
this	O
interaction	O
,	O
allowing	O
self	O
-	O
ubiquitination	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
and	O
subsequent	O
degradation	O
,	O
resulting	O
in	O
down	O
-	O
regulation	O
of	O
Nedd4	B-Protein
-	I-Protein
2	E-Protein
once	O
it	O
has	O
ubiquitinated	O
its	O
target	O
.	O

These	O
findings	O
also	O
point	O
to	O
a	O
novel	O
mechanism	O
employed	O
by	O
a	O
ubiquitin	S-Protein
ligase	O
to	O
regulate	O
itself	O
differentially	O
compared	O
with	O
substrate	O
ubiquitination	O
and	O
stability	O
.	O

Polyubiquitination	O
of	O
prolactin	B-Protein
receptor	E-Protein
stimulates	O
its	O
internalization	O
,	O
postinternalization	O
sorting	O
,	O
and	O
degradation	O
via	O
the	O
lysosomal	O
pathway	O
.	O

The	O
ubiquitination	O
of	O
the	O
receptor	O
that	O
mediates	O
signaling	O
induced	O
by	O
the	O
polypeptide	O
pituitary	O
hormone	O
prolactin	S-Protein
(	O
PRL	S-Protein
)	O
has	O
been	O
shown	O
to	O
lead	O
to	O
the	O
degradation	O
of	O
this	O
receptor	O
and	O
to	O
the	O
ensuing	O
negative	O
regulation	O
of	O
cellular	O
responses	O
to	O
PRL	S-Protein
.	O

However	O
,	O
the	O
mechanisms	O
of	O
PRL	B-Protein
receptor	E-Protein
(	O
PRLr	S-Protein
)	O
proteolysis	O
remain	O
largely	O
to	O
be	O
determined	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
PRLr	S-Protein
is	O
internalized	O
and	O
primarily	O
degraded	O
via	O
the	O
lysosomal	O
pathway	O
.	O

Ubiquitination	O
of	O
PRLr	S-Protein
is	O
essential	O
for	O
the	O
rapid	O
internalization	O
of	O
PRLr	S-Protein
,	O
which	O
proceeds	O
through	O
a	O
pathway	O
dependent	O
on	O
clathrin	O
and	O
the	O
assembly	O
polypeptide	O
2	O
(	O
AP2	O
)	O
adaptor	O
complexes	O
.	O

Recruitment	O
of	O
AP2	O
to	O
PRLr	S-Protein
is	O
stimulated	O
by	O
PRLr	S-Protein
ubiquitination	O
,	O
which	O
also	O
is	O
required	O
for	O
the	O
targeting	O
of	O
already	O
internalized	O
PRLr	O
to	O
the	O
lysosomal	O
compartment	O
.	O

While	O
mass	O
spectrometry	O
analysis	O
revealed	O
that	O
both	O
monoubiquitination	O
and	O
polyubiquitination	O
(	O
via	O
both	O
K48	O
-	O
and	O
K63	O
-	O
linked	O
chains	O
)	O
occur	O
on	O
PRLr	S-Protein
,	O
the	O
results	O
of	O
experiments	O
using	O
forced	O
expression	O
of	O
ubiquitin	S-Protein
mutants	O
indicate	O
that	O
PRLr	S-Protein
polyubiquitination	O
via	O
K63	O
-	O
linked	O
chains	O
is	O
important	O
for	O
efficient	O
interaction	O
of	O
PRLr	S-Protein
with	O
AP2	O
as	O
well	O
as	O
for	O
efficient	O
internalization	O
,	O
postinternalization	O
sorting	O
,	O
and	O
proteolytic	O
turnover	O
of	O
PRLr	S-Protein
.	O

We	O
discuss	O
how	O
specific	O
ubiquitination	O
may	O
regulate	O
early	O
and	O
late	O
stages	O
of	O
endocytosis	O
of	O
PRLr	S-Protein
and	O
of	O
related	O
receptors	O
to	O
contribute	O
to	O
the	O
negative	O
regulation	O
of	O
the	O
magnitude	O
and	O
duration	O
of	O
downstream	O
signaling	O
.	O

The	O
glycosylation	O
status	O
of	O
murine	O
[	O
corrected	O
]	O
postnatal	O
thymus	O
:	O
a	O
study	O
by	O
histochemistry	O
and	O
lectin	O
blotting	O
.	O

During	O
the	O
intrathymic	O
development	O
,	O
the	O
fate	O
of	O
the	O
thymocytes	O
depends	O
largely	O
on	O
variable	O
expression	O
of	O
CD4	S-Protein
/	O
CD8	O
markers	O
and	O
T	O
cell	O
receptor	O
protein	O
expressions	O
.	O

In	O
addition	O
,	O
changes	O
of	O
cell	O
surface	O
glycosylation	O
status	O
also	O
affect	O
the	O
thymocyte	O
maturation	O
.	O

In	O
this	O
study	O
the	O
glycosylation	O
alterations	O
in	O
thymic	O
tissues	O
from	O
1	O
,	O
9	O
,	O
13	O
and	O
16	O
days	O
old	O
mice	O
were	O
evaluated	O
by	O
histochemical	O
and	O
lectin	O
blotting	O
techniques	O
.	O

With	O
alcian	O
blue	O
(	O
AB	O
)	O
at	O
pH	O
5	O
.	O
7	O
/	O
periodic	O
acid	O
-	O
Schiff	O
(	O
PAS	O
)	O
stainings	O
,	O
it	O
was	O
shown	O
that	O
thymic	O
microenvironments	O
contained	O
carboxlylated	O
and	O
sulfated	O
glycosaminoglycans	O
(	O
GAGs	O
)	O
.	O

Strong	O
positivity	O
to	O
AB	O
at	O
pH	O
2	O
.	O
5	O
,	O
which	O
specific	O
for	O
sialomucins	O
,	O
was	O
seen	O
in	O
some	O
medullary	O
thymocytes	O
.	O

Similarly	O
,	O
it	O
was	O
shown	O
that	O
with	O
Maackia	O
amurensis	O
agglutinin	O
(	O
MAL	O
)	O
medullary	O
thymocytes	O
,	O
but	O
not	O
cortical	O
ones	O
,	O
contained	O
alpha	O
(	O
2	O
-	O
-	O
>	O
3	O
)	O
linked	O
sialic	O
acid	O
structures	O
.	O

On	O
the	O
other	O
hand	O
,	O
while	O
reaction	O
with	O
peanut	O
agglutinin	S-Protein
(	O
PNA	S-Protein
)	O
,	O
which	O
specific	O
for	O
core	O
disaccharide	O
galactose	O
beta	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
N	O
-	O
acetylgalactosamine	O
,	O
was	O
only	O
seen	O
in	O
cortical	O
thymocytes	O
,	O
reaction	O
with	O
Galanthus	O
nivalis	O
agglutinin	S-Protein
(	O
GNA	S-Protein
)	O
,	O
which	O
specific	O
for	O
terminal	O
mannose	O
residues	O
,	O
was	O
seen	O
in	O
both	O
cortex	O
and	O
medulla	O
.	O

However	O
,	O
Datura	O
stramonium	O
agglutinin	O
(	O
DSA	O
)	O
,	O
which	O
recognizes	O
galactose	O
beta	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
N	O
-	O
acetylglucosamine	O
,	O
was	O
not	O
only	O
cell	O
-	O
specific	O
,	O
but	O
it	O
was	O
bound	O
some	O
thymic	O
vessels	O
.	O

With	O
lectin	O
blotting	O
studies	O
,	O
five	O
glycoprotein	O
bands	O
of	O
molecular	O
weights	O
approximately	O
39	O
,	O
approximately	O
54	O
,	O
100	O
,	O
approximately	O
110	O
and	O
approximately	O
212	O
were	O
found	O
which	O
reacted	O
with	O
MAL	O
,	O
PNA	S-Protein
and	O
DSA	O
as	O
well	O
as	O
GNA	S-Protein
.	O

These	O
results	O
suggest	O
that	O
glycosylation	O
patterns	O
of	O
cell	O
surface	O
glycoconjugates	O
are	O
modified	O
during	O
thymocyte	O
selection	O
processes	O
of	O
postnatal	O
days	O
.	O

Chemical	O
and	O
structural	O
probing	O
of	O
the	O
N	O
-	O
terminal	O
residues	O
encoded	O
by	O
FMR1	S-Protein
exon	O
15	O
and	O
their	O
effect	O
on	O
downstream	O
arginine	O
methylation	O
.	O

Exon	O
15	O
of	O
the	O
fragile	O
X	O
mental	O
retardation	O
protein	O
gene	O
(	O
FMR1	S-Protein
)	O
is	O
alternatively	O
spliced	O
into	O
three	O
variants	O
.	O

The	O
amino	O
acids	O
encoded	O
by	O
the	O
5	O
'	O
end	O
of	O
the	O
exon	O
contain	O
several	O
regulatory	O
determinants	O
including	O
phosphorylation	O
sites	O
and	O
a	O
potential	O
conformational	O
switch	O
.	O

Residues	O
encoded	O
by	O
the	O
3	O
'	O
end	O
of	O
the	O
exon	O
specify	O
FMRP	O
'	O
s	O
RGG	O
box	O
,	O
an	O
RNA	O
binding	O
domain	O
that	O
interacts	O
with	O
G	O
-	O
quartet	O
motifs	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
exon	O
15	O
-	O
encoded	O
N	O
-	O
terminal	O
residues	O
influence	O
the	O
extent	O
of	O
arginine	O
methylation	O
,	O
independent	O
of	O
S	O
500	O
phosphorylation	O
.	O

In	O
the	O
present	O
study	O
we	O
focus	O
on	O
the	O
role	O
the	O
putative	O
conformational	O
switch	O
plays	O
in	O
arginine	O
methylation	O
.	O

Chemical	O
and	O
structural	O
probing	O
of	O
Ex15	O
alternatively	O
spliced	O
variant	O
proteins	O
and	O
several	O
mutants	O
leads	O
to	O
the	O
following	O
conclusions	O
:	O
Ex15c	O
resides	O
largely	O
in	O
a	O
conformation	O
that	O
is	O
refractory	O
toward	O
methylation	O
;	O
however	O
,	O
it	O
can	O
be	O
methylated	O
by	O
supplementing	O
extracts	O
with	O
recombinant	O
PRMT1	S-Protein
or	O
PRMT3	S-Protein
.	O

Protein	O
modeling	O
studies	O
reveal	O
that	O
the	O
RG	O
-	O
rich	O
region	O
is	O
part	O
of	O
a	O
three	O
to	O
four	O
strand	O
antiparallel	O
beta	O
-	O
sheet	O
,	O
which	O
in	O
other	O
RNA	O
binding	O
proteins	O
functions	O
as	O
a	O
platform	O
for	O
nucleic	O
acid	O
interactions	O
.	O

In	O
the	O
Ex15c	O
variant	O
the	O
first	O
strand	O
of	O
this	O
sheet	O
is	O
truncated	O
,	O
and	O
this	O
significantly	O
perturbs	O
the	O
side	O
-	O
chain	O
conformations	O
of	O
the	O
arginine	O
residues	O
in	O
the	O
RG	O
-	O
rich	O
region	O
.	O

Mutating	O
R	O
507	O
in	O
the	O
conformational	O
switch	O
to	O
K	O
also	O
truncates	O
the	O
first	O
strand	O
of	O
the	O
beta	O
-	O
sheet	O
,	O
and	O
corresponding	O
decreases	O
in	O
in	O
vitro	O
methylation	O
were	O
found	O
for	O
this	O
and	O
R	O
507	O
/	O
R	O
544	O
and	O
R	O
507	O
/	O
R	O
546	O
double	O
mutants	O
.	O

These	O
effects	O
are	O
not	O
due	O
to	O
the	O
loss	O
of	O
R	O
507	O
methylation	O
as	O
a	O
conformational	O
switch	O
-	O
containing	O
peptide	O
reacted	O
under	O
substrate	O
excess	O
and	O
in	O
methyl	O
donor	O
excess	O
was	O
not	O
significantly	O
methylated	O
.	O

Consistent	O
with	O
this	O
,	O
similar	O
changes	O
in	O
beta	O
-	O
sheet	O
structure	O
and	O
decreases	O
in	O
in	O
vitro	O
methylation	O
were	O
observed	O
with	O
a	O
W	O
513	O
-	O
K	O
mutant	O
.	O

These	O
data	O
support	O
a	O
novel	O
model	O
for	O
FMRP	O
arginine	O
methylation	O
and	O
a	O
role	O
for	O
conformational	O
switch	O
residues	O
in	O
arginine	O
modification	O
.	O

Oridonin	O
confers	O
protection	O
against	O
arsenic	O
-	O
induced	O
toxicity	O
through	O
activation	O
of	O
the	O
Nrf2	S-Protein
-	O
mediated	O
defensive	O
response	O
.	O

BACKGROUND	O
:	O
Groundwater	O
contaminated	O
with	O
arsenic	O
imposes	O
a	O
big	O
challenge	O
to	O
human	O
health	O
worldwide	O
.	O

Using	O
natural	O
compounds	O
to	O
subvert	O
the	O
detrimental	O
effects	O
of	O
arsenic	O
represents	O
an	O
attractive	O
strategy	O
.	O

The	O
transcription	O
factor	O
nuclear	B-Protein
factor	I-Protein
erythroid	I-Protein
2	I-Protein
-	I-Protein
related	I-Protein
factor	I-Protein
2	E-Protein
(	O
Nrf2	S-Protein
)	O
is	O
a	O
critical	O
regulator	O
of	O
the	O
cellular	O
antioxidant	O
response	O
and	O
xenobiotic	O
metabolism	O
.	O

Recently	O
,	O
activation	O
of	O
the	O
Nrf2	S-Protein
signaling	O
pathway	O
has	O
been	O
reported	O
to	O
confer	O
protection	O
against	O
arsenic	O
-	O
induced	O
toxicity	O
in	O
a	O
cell	O
culture	O
model	O
.	O

OBJECTIVES	O
:	O
The	O
goal	O
of	O
the	O
present	O
work	O
was	O
to	O
identify	O
a	O
potent	O
Nrf2	S-Protein
activator	O
from	O
plants	O
as	O
a	O
chemopreventive	O
compound	O
and	O
to	O
demonstrate	O
the	O
efficacy	O
of	O
the	O
compound	O
in	O
battling	O
arsenic	O
-	O
induced	O
toxicity	O
.	O

RESULTS	O
:	O
Oridonin	O
activated	O
the	O
Nrf2	S-Protein
signaling	O
pathway	O
at	O
a	O
low	O
subtoxic	O
dose	O
and	O
was	O
able	O
to	O
stabilize	O
Nrf2	S-Protein
by	O
blocking	O
Nrf2	S-Protein
ubiquitination	O
and	O
degradation	O
,	O
leading	O
to	O
accumulation	O
of	O
the	O
Nrf2	S-Protein
protein	O
and	O
activation	O
of	O
the	O
Nrf2	S-Protein
-	O
dependent	O
cytoprotective	O
response	O
.	O

Pretreatment	O
of	O
UROtsa	O
cells	O
with	O
1	O
.	O
4	O
muM	O
oridonin	O
significantly	O
enhanced	O
the	O
cellular	O
redox	O
capacity	O
,	O
reduced	O
formation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
and	O
improved	O
cell	O
survival	O
after	O
arsenic	O
challenge	O
.	O

CONCLUSIONS	O
:	O
We	O
identified	O
oridonin	O
as	O
representing	O
a	O
novel	O
class	O
of	O
Nrf2	S-Protein
activators	O
and	O
illustrated	O
the	O
mechanism	O
by	O
which	O
the	O
Nrf2	S-Protein
pathway	O
is	O
activated	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
the	O
feasibility	O
of	O
using	O
natural	O
compounds	O
targeting	O
Nrf2	S-Protein
as	O
a	O
therapeutic	O
approach	O
to	O
protect	O
humans	O
from	O
various	O
environmental	O
insults	O
that	O
may	O
occur	O
daily	O
.	O

beta	O
-	O
Hydroxylation	O
of	O
the	O
aspartyl	O
residue	O
in	O
the	O
phytotoxin	O
syringomycin	O
E	O
:	O
characterization	O
of	O
two	O
candidate	O
hydroxylases	O
AspH	S-Protein
and	O
SyrP	S-Protein
in	O
Pseudomonas	O
syringae	O
.	O

The	O
pseudomonal	O
phytotoxin	O
syringomycin	O
E	O
and	O
related	O
nonribosomal	O
peptides	O
contain	O
an	O
L	O
-	O
threo	O
-	O
beta	O
-	O
hydroxyaspartyl	O
residue	O
at	O
the	O
eighth	O
position	O
of	O
the	O
lipodepsipeptide	O
backbone	O
as	O
part	O
of	O
a	O
conserved	O
nonproteinogenic	O
tripeptide	O
motif	O
.	O

Informatic	O
analysis	O
of	O
the	O
P	O
.	O
syringae	O
genome	O
suggests	O
only	O
one	O
putative	O
non	O
-	O
heme	O
iron	O
hydroxylase	O
,	O
AspH	S-Protein
.	O

On	O
heterologous	O
expression	O
in	O
Escherichia	O
coli	O
AspH	S-Protein
shows	O
robust	O
catalytic	O
activity	O
with	O
free	O
L	O
-	O
Asp	O
and	O
L	O
-	O
Asp	O
thioesters	O
to	O
make	O
beta	O
-	O
OH	O
-	O
Asp	O
but	O
yields	O
the	O
erythro	O
diastereomer	O
rather	O
than	O
the	O
threo	O
configuration	O
that	O
is	O
found	O
in	O
syringomycin	O
.	O

Further	O
analysis	O
of	O
the	O
Syr	O
gene	O
cluster	O
indicated	O
that	O
SyrP	S-Protein
,	O
previously	O
annotated	O
as	O
the	O
gene	O
regulatory	O
protein	O
for	O
the	O
five	O
-	O
gene	O
Syr	O
cluster	O
,	O
is	O
actually	O
homologous	O
to	O
the	O
known	O
non	O
-	O
heme	O
mononuclear	O
iron	O
hydroxylase	O
TauD	S-Protein
.	O

Indeed	O
,	O
purified	O
SyrP	S-Protein
acts	O
on	O
Asp	O
tethered	O
as	O
the	O
protein	O
-	O
bound	O
S	O
-	O
pantetheinyl	O
thioester	O
on	O
the	O
eighth	O
module	O
of	O
the	O
SyrE	S-Protein
megasynthetase	O
.	O

The	O
hydroxylation	O
gives	O
the	O
anticipated	O
L	O
-	O
threo	O
-	O
3	O
-	O
OH	O
-	O
Asp	O
diastereomer	O
found	O
in	O
syringomycin	O
.	O

The	O
knockout	O
of	O
syrP	S-Protein
abolishes	O
the	O
production	O
of	O
the	O
mature	O
syringomycin	O
E	O
,	O
while	O
knockout	O
of	O
aspH	S-Protein
has	O
no	O
effect	O
on	O
syringomycin	O
production	O
.	O

A	O
critical	O
role	O
for	O
CHIP	S-Protein
in	O
the	O
aggresome	O
pathway	O
.	O

Recent	O
evidence	O
suggests	O
that	O
aggresome	O
formation	O
is	O
a	O
physiologic	O
stress	O
response	O
not	O
limited	O
to	O
misfolded	O
proteins	O
.	O

That	O
stress	O
response	O
,	O
termed	O
"	O
physiologic	O
aggresome	O
,	O
"	O
is	O
exemplified	O
by	O
aggresome	O
formation	O
of	O
inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	E-Protein
(	O
iNOS	S-Protein
)	O
,	O
an	O
important	O
host	O
defense	O
protein	O
.	O

CHIP	S-Protein
(	O
carboxy	B-Protein
terminus	I-Protein
of	I-Protein
Hsp70	I-Protein
-	I-Protein
interacting	I-Protein
protein	E-Protein
)	O
is	O
a	O
highly	O
conserved	O
protein	O
that	O
has	O
been	O
shown	O
to	O
mediate	O
substrate	O
ubiquitination	O
and	O
degradation	O
by	O
the	O
proteasome	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
CHIP	S-Protein
has	O
a	O
previously	O
unexpected	O
critical	O
role	O
in	O
the	O
aggresome	O
pathway	O
.	O

CHIP	S-Protein
interacts	O
with	O
iNOS	S-Protein
and	O
promotes	O
its	O
ubiquitination	O
and	O
degradation	O
by	O
the	O
proteasome	O
as	O
well	O
as	O
its	O
sequestration	O
to	O
the	O
aggresome	O
.	O

CHIP	S-Protein
-	O
mediated	O
iNOS	S-Protein
targeting	O
to	O
the	O
proteasome	O
sequentially	O
precedes	O
CHIP	S-Protein
-	O
mediated	O
iNOS	S-Protein
sequestration	O
to	O
the	O
aggresome	O
.	O

CHIP	S-Protein
is	O
required	O
for	O
iNOS	S-Protein
preaggresome	O
structures	O
to	O
form	O
a	O
mature	O
aggresome	O
.	O

Furthermore	O
,	O
CHIP	S-Protein
is	O
required	O
for	O
targeting	O
the	O
mutant	O
form	O
of	O
cystic	B-Protein
fibrosis	I-Protein
transconductance	I-Protein
regulator	E-Protein
(	O
CFTRDeltaF508	S-Protein
)	O
to	O
the	O
aggresome	O
.	O

Importantly	O
,	O
the	O
ubiquitin	S-Protein
ligase	O
function	O
of	O
CHIP	S-Protein
is	O
required	O
in	O
targeting	O
preaggresomal	O
structures	O
to	O
the	O
aggresome	O
by	O
promoting	O
an	O
iNOS	S-Protein
interaction	O
with	O
histone	B-Protein
deacetylase	I-Protein
6	E-Protein
,	O
which	O
serves	O
as	O
an	O
adaptor	O
between	O
ubiquitinated	O
proteins	O
and	O
the	O
dynein	O
motor	O
.	O

This	O
study	O
reveals	O
a	O
critical	O
role	O
for	O
CHIP	S-Protein
in	O
the	O
aggresome	O
pathway	O
.	O

AZGP1	S-Protein
autoantibody	O
predicts	O
survival	O
and	O
histone	S-Protein
deacetylase	O
inhibitors	O
increase	O
expression	O
in	O
lung	O
adenocarcinoma	O
.	O

INTRODUCTION	O
:	O
The	O
importance	O
of	O
alpha	B-Protein
-	I-Protein
2	I-Protein
-	I-Protein
glycoprotein	I-Protein
1	I-Protein
,	I-Protein
zinc	E-Protein
(	O
AZGP1	S-Protein
)	O
in	O
lung	O
adenocarcinoma	O
(	O
AD	O
)	O
remains	O
largely	O
unknown	O
.	O

Analysis	O
of	O
serum	O
autoantibodies	O
to	O
tumor	O
antigens	O
combined	O
with	O
gene	O
expression	O
profiling	O
of	O
primary	O
tumors	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
lung	O
carcinogenesis	O
and	O
identify	O
new	O
AD	O
biomarkers	O
.	O

METHODS	O
:	O
T7	O
phage	O
cDNA	O
libraries	O
were	O
used	O
to	O
identify	O
AZGP1	S-Protein
autoantibodies	O
in	O
the	O
serum	O
of	O
473	O
patients	O
(	O
192	O
ADs	O
,	O
192	O
matched	O
controls	O
,	O
and	O
89	O
additional	O
ADs	O
for	O
confirmation	O
of	O
findings	O
)	O
.	O

AZGP1	S-Protein
mRNA	O
expression	O
was	O
examined	O
in	O
86	O
ADs	O
and	O
10	O
control	O
lung	O
tissue	O
samples	O
using	O
oligonucleotide	O
microarrays	O
.	O

AZGP1	S-Protein
protein	O
expression	O
was	O
studied	O
in	O
230	O
tissue	O
samples	O
(	O
222	O
ADs	O
;	O
8	O
controls	O
)	O
with	O
immunohistochemistry	O
.	O

Kaplan	O
-	O
Meier	O
analyses	O
were	O
used	O
to	O
correlate	O
circulating	O
autoantibody	O
and	O
tissue	O
mRNA	O
production	O
with	O
survival	O
.	O

AD	O
cell	O
lines	O
A549	O
and	O
SKLU1	O
were	O
treated	O
with	O
5	O
-	O
aza	O
-	O
2	O
;	O
-	O
deoxycytidine	O
(	O
5	O
-	O
AZA	O
)	O
and	O
trichostatin	O
A	O
(	O
TSA	O
)	O
to	O
examine	O
the	O
role	O
of	O
promoter	O
methylation	O
and	O
histone	S-Protein
deacetylation	O
in	O
the	O
expression	O
of	O
AZGP1	S-Protein
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
quantify	O
the	O
effects	O
of	O
treatment	O
.	O

RESULTS	O
:	O
In	O
patients	O
with	O
AD	O
,	O
AZGP1	S-Protein
autoantibodies	O
were	O
observed	O
in	O
40	O
%	O
of	O
serum	O
samples	O
.	O

Autoantibody	O
production	O
correlated	O
with	O
improved	O
overall	O
5	O
-	O
year	O
survival	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
and	O
improved	O
survival	O
in	O
those	O
with	O
stage	O
I	O
to	O
II	O
disease	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

A	O
verification	O
analysis	O
was	O
performed	O
for	O
the	O
survival	O
benefit	O
and	O
found	O
similar	O
results	O
with	O
p	O
values	O
of	O
0	O
.	O
02	O
and	O
0	O
.	O
036	O
,	O
respectively	O
.	O

Although	O
abundant	O
mRNA	O
expression	O
was	O
found	O
in	O
a	O
subset	O
of	O
tumors	O
,	O
mRNA	O
expression	O
did	O
not	O
correlate	O
with	O
prognosis	O
.	O

In	O
normal	O
lung	O
,	O
AZGP1	S-Protein
mRNA	O
and	O
protein	O
expression	O
were	O
low	O
or	O
absent	O
,	O
whereas	O
in	O
AD	O
they	O
were	O
highly	O
expressed	O
in	O
31	O
.	O
3	O
%	O
and	O
42	O
.	O
8	O
%	O
of	O
samples	O
,	O
respectively	O
.	O

To	O
determine	O
whether	O
AZGP1	S-Protein
expression	O
in	O
this	O
subset	O
of	O
tumors	O
might	O
be	O
affected	O
by	O
epigenetic	O
mechanisms	O
,	O
low	O
AZGP1	S-Protein
-	O
expressing	O
A549	O
and	O
SKLU1	O
AD	O
cell	O
lines	O
were	O
treated	O
with	O
TSA	O
and	O
5	O
-	O
AZA	O
.	O

A	O
713	O
-	O
fold	O
and	O
169	O
-	O
fold	O
increase	O
in	O
mRNA	O
expression	O
were	O
noted	O
on	O
treatment	O
with	O
TSA	O
,	O
respectively	O
.	O

Treatment	O
with	O
5	O
-	O
AZA	O
had	O
minimal	O
effect	O
on	O
AZGP1	S-Protein
mRNA	O
expression	O
.	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
AZGP1	S-Protein
serum	O
autoantibody	O
may	O
be	O
used	O
as	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
AD	O
.	O

Furthermore	O
,	O
up	O
-	O
regulation	O
of	O
AZGP1	S-Protein
mRNA	O
in	O
AD	O
may	O
be	O
affected	O
by	O
chromatin	O
remodeling	O
by	O
means	O
of	O
histone	S-Protein
acetylation	O
.	O

A	O
phosphorylation	O
-	O
acetylation	O
switch	O
regulates	O
STAT1	S-Protein
signaling	O
.	O

Cytokines	O
such	O
as	O
interferons	O
(	O
IFNs	O
)	O
activate	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
via	O
phosphorylation	O
.	O

Histone	S-Protein
deacetylases	O
(	O
HDACs	O
)	O
and	O
the	O
histone	S-Protein
acetyltransferase	O
(	O
HAT	O
)	O
CBP	S-Protein
dynamically	O
regulate	O
STAT1	S-Protein
acetylation	O
.	O

Here	O
we	O
show	O
that	O
acetylation	O
of	O
STAT1	S-Protein
counteracts	O
IFN	O
-	O
induced	O
STAT1	S-Protein
phosphorylation	O
,	O
nuclear	O
translocation	O
,	O
DNA	O
binding	O
,	O
and	O
target	O
gene	O
expression	O
.	O

Biochemical	O
and	O
genetic	O
experiments	O
altering	O
the	O
HAT	O
/	O
HDAC	O
activity	O
ratio	O
and	O
STAT1	S-Protein
mutants	O
reveal	O
that	O
a	O
phospho	O
-	O
acetyl	O
switch	O
regulates	O
STAT1	S-Protein
signaling	O
via	O
CBP	S-Protein
,	O
HDAC3	S-Protein
,	O
and	O
the	O
T	B-Protein
-	I-Protein
cell	I-Protein
protein	I-Protein
tyrosine	I-Protein
phosphatase	E-Protein
(	O
TCP45	S-Protein
)	O
.	O

Strikingly	O
,	O
inhibition	O
of	O
STAT1	S-Protein
signaling	O
via	O
CBP	S-Protein
-	O
mediated	O
acetylation	O
is	O
distinct	O
from	O
the	O
functions	O
of	O
this	O
HAT	O
in	O
transcriptional	O
activation	O
.	O

STAT1	S-Protein
acetylation	O
induces	O
binding	O
of	O
TCP45	S-Protein
,	O
which	O
catalyzes	O
dephosphorylation	O
and	O
latency	O
of	O
STAT1	S-Protein
.	O

Our	O
results	O
provide	O
a	O
deeper	O
understanding	O
of	O
the	O
modulation	O
of	O
STAT1	S-Protein
activity	O
.	O

These	O
findings	O
reveal	O
a	O
new	O
layer	O
of	O
physiologically	O
relevant	O
STAT1	S-Protein
regulation	O
and	O
suggest	O
that	O
a	O
previously	O
unidentified	O
balance	O
between	O
phosphorylation	O
and	O
acetylation	O
affects	O
cytokine	O
signaling	O
.	O

Sem1p	S-Protein
and	O
Ubp6p	S-Protein
orchestrate	O
telomeric	O
silencing	O
by	O
modulating	O
histone	B-Protein
H2B	E-Protein
ubiquitination	O
and	O
H3	S-Protein
acetylation	O
.	O

Histone	S-Protein
covalent	O
modifications	O
and	O
26S	O
proteasome	O
-	O
mediated	O
proteolysis	O
modulate	O
many	O
regulatory	O
events	O
in	O
eukaryotes	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
heterochromatin	O
mediates	O
transcriptional	O
silencing	O
at	O
telomeres	O
,	O
HM	O
loci	O
and	O
rDNA	O
array	O
.	O

Here	O
,	O
we	O
show	O
that	O
proteasome	O
-	O
associated	O
Sem1p	S-Protein
and	O
its	O
interacting	O
partner	O
,	O
Ubp6p	S-Protein
(	O
a	O
deubiquitinating	O
enzyme	O
)	O
,	O
are	O
essential	O
to	O
maintain	O
telomeric	O
silencing	O
.	O

Simultaneous	O
deletion	O
of	O
SEM1	S-Protein
and	O
UBP6	S-Protein
induces	O
dramatic	O
silencing	O
defect	O
accompanied	O
by	O
significantly	O
increased	O
level	O
of	O
ubiquitinated	O
-	O
histone	B-Protein
H2B	E-Protein
and	O
markedly	O
reduced	O
levels	O
of	O
acetylated	O
-	O
lysine	O
14	O
and	O
23	O
on	O
histone	B-Protein
H3	E-Protein
at	O
the	O
telomeres	O
.	O

Further	O
,	O
the	O
loss	O
of	O
Sem1p	S-Protein
and	O
Ubp6p	S-Protein
triggers	O
relocation	O
of	O
silencing	O
factors	O
(	O
e	O
.	O
g	O
.	O
Sir	O
proteins	O
)	O
from	O
telomere	O
to	O
HM	O
loci	O
and	O
rDNA	O
array	O
.	O

Such	O
relocation	O
of	O
silencing	O
factors	O
enhances	O
gene	O
silencing	O
at	O
HM	O
loci	O
and	O
rDNA	O
array	O
,	O
but	O
diminishes	O
telomeric	O
silencing	O
.	O

Interestingly	O
,	O
both	O
Sem1p	S-Protein
and	O
Ubp6p	S-Protein
participate	O
in	O
the	O
proteolytic	O
function	O
of	O
the	O
proteasome	O
.	O

However	O
,	O
we	O
find	O
that	O
the	O
telomeric	O
silencing	O
is	O
not	O
influenced	O
by	O
proteolysis	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
Sem1p	S-Protein
and	O
Ubp6p	S-Protein
maintain	O
telomeric	O
heterochromatin	O
structure	O
(	O
and	O
hence	O
silencing	O
)	O
through	O
modulation	O
of	O
histone	S-Protein
covalent	O
modifications	O
and	O
association	O
of	O
silencing	O
factors	O
independently	O
of	O
the	O
proteolytic	O
function	O
of	O
the	O
proteasome	O
,	O
thus	O
offering	O
a	O
new	O
regulatory	O
mechanism	O
of	O
telomeric	O
silencing	O
.	O

Ubiquitination	O
of	O
mammalian	O
AP	O
endonuclease	O
(	O
APE1	S-Protein
)	O
regulated	O
by	O
the	O
p53	S-Protein
-	O
MDM2	S-Protein
signaling	O
pathway	O
.	O

APE1	S-Protein
/	O
Ref	B-Protein
-	I-Protein
1	E-Protein
is	O
an	O
essential	O
DNA	O
repair	O
/	O
gene	O
regulatory	O
protein	O
in	O
mammals	O
of	O
which	O
intracellular	O
level	O
significantly	O
affects	O
cellular	O
sensitivity	O
to	O
genotoxicants	O
.	O

The	O
apurinic	B-Protein
/	I-Protein
apyrimidinic	I-Protein
endonuclease	I-Protein
1	E-Protein
(	O
APE1	S-Protein
)	O
functions	O
are	O
altered	O
by	O
phosphorylation	O
and	O
acetylation	O
.	O

We	O
here	O
report	O
that	O
APE1	S-Protein
is	O
also	O
modified	O
by	O
ubiquitination	O
.	O

APE1	S-Protein
ubiquitination	O
occurred	O
specifically	O
at	O
Lys	O
residues	O
near	O
the	O
N	O
-	O
terminus	O
,	O
and	O
was	O
markedly	O
enhanced	O
by	O
mouse	B-Protein
double	I-Protein
minute	I-Protein
2	E-Protein
(	O
MDM2	S-Protein
)	O
,	O
the	O
major	O
intracellular	O
p53	S-Protein
inhibitor	O
.	O

Moreover	O
,	O
DNA	O
-	O
damaging	O
reagents	O
and	O
nutlin	O
-	O
3	O
,	O
an	O
inhibitor	O
of	O
MDM2	S-Protein
-	O
p53	S-Protein
interaction	O
,	O
increased	O
APE1	S-Protein
ubiquitination	O
in	O
the	O
presence	O
of	O
p53	S-Protein
.	O

Downmodulation	O
of	O
MDM2	S-Protein
increased	O
APE1	S-Protein
level	O
,	O
suggesting	O
that	O
MDM2	S-Protein
-	O
mediated	O
ubiquitination	O
can	O
be	O
a	O
signal	O
for	O
APE1	S-Protein
degradation	O
.	O

In	O
addition	O
,	O
unlike	O
the	O
wild	O
-	O
type	O
APE1	S-Protein
,	O
ubiquitin	S-Protein
-	O
APE1	S-Protein
fusion	O
proteins	O
were	O
predominantly	O
present	O
in	O
the	O
cytoplasm	O
.	O

Therefore	O
,	O
monoubiquitination	O
not	O
only	O
is	O
a	O
prerequisite	O
for	O
degradation	O
,	O
but	O
may	O
also	O
alter	O
the	O
APE1	S-Protein
activities	O
in	O
cells	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
regulation	O
of	O
APE1	S-Protein
through	O
ubiquitination	O
.	O

A	O
histone	S-Protein
map	O
of	O
human	O
chromosome	O
20q13	O
.	O
12	O
.	O

BACKGROUND	O
:	O
We	O
present	O
a	O
systematic	O
search	O
for	O
regulatory	O
elements	O
in	O
a	O
3	O
.	O
5	O
Mb	O
region	O
on	O
human	O
chromosome	O
20q13	O
.	O
12	O
,	O
a	O
region	O
associated	O
with	O
a	O
number	O
of	O
medical	O
conditions	O
such	O
as	O
type	O
II	O
diabetes	O
and	O
obesity	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
profiled	O
six	O
histone	S-Protein
modifications	O
alongside	O
RNA	O
polymerase	O
II	O
(	O
PolII	O
)	O
and	O
CTCF	S-Protein
in	O
two	O
cell	O
lines	O
,	O
HeLa	O
S3	O
and	O
NTERA	O
-	O
2	O
clone	O
D1	O
(	O
NT2	O
/	O
D1	O
)	O
,	O
by	O
chromatin	O
immunoprecipitation	O
using	O
an	O
in	O
-	O
house	O
spotted	O
DNA	O
array	O
,	O
constructed	O
with	O
1	O
.	O
8	O
kb	O
overlapping	O
plasmid	O
clones	O
.	O

In	O
both	O
cells	O
,	O
more	O
than	O
90	O
%	O
of	O
transcription	O
start	O
sites	O
(	O
TSSs	O
)	O
of	O
expressed	O
genes	O
showed	O
enrichments	O
with	O
PolII	O
,	O
di	O
-	O
methylated	O
lysine	O
4	O
of	O
histone	B-Protein
H3	E-Protein
(	O
H3K4me2	S-Protein
)	O
,	O
tri	O
-	O
methylated	O
lysine	O
4	O
of	O
histone	B-Protein
H3	E-Protein
(	O
H3K4me3	S-Protein
)	O
or	O
acetylated	O
H3	S-Protein
(	O
H3Ac	S-Protein
)	O
,	O
whereas	O
mono	O
-	O
methylated	O
lysine	O
4	O
of	O
histone	B-Protein
H3	E-Protein
(	O
H3K4me1	S-Protein
)	O
signals	O
did	O
not	O
correlate	O
with	O
expression	O
.	O

No	O
TSSs	O
were	O
enriched	O
with	O
tri	O
-	O
methylated	O
lysine	O
27	O
of	O
histone	B-Protein
H3	E-Protein
(	O
H3K27me3	S-Protein
)	O
in	O
HeLa	O
S3	O
,	O
while	O
eight	O
TSSs	O
(	O
4	O
expressed	O
)	O
showed	O
enrichments	O
in	O
NT2	O
/	O
D1	O
.	O

We	O
have	O
also	O
located	O
several	O
CTCF	S-Protein
binding	O
sites	O
that	O
are	O
potential	O
insulator	O
elements	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
In	O
summary	O
,	O
we	O
annotated	O
a	O
number	O
of	O
putative	O
regulatory	O
elements	O
in	O
20q13	O
.	O
12	O
and	O
went	O
on	O
to	O
verify	O
experimentally	O
a	O
subset	O
of	O
them	O
using	O
dual	O
luciferase	S-Protein
reporter	O
assays	O
.	O

Correlating	O
this	O
data	O
to	O
sequence	O
variation	O
can	O
aid	O
identification	O
of	O
disease	O
causing	O
variants	O
.	O

Untargeted	O
tail	O
acetylation	O
of	O
histones	S-Protein
in	O
chromatin	O
:	O
lessons	O
from	O
yeast	O
.	O

Dynamic	O
acetylation	O
of	O
lysine	O
residues	O
in	O
the	O
amino	O
-	O
terminal	O
tails	O
of	O
the	O
core	O
histones	S-Protein
is	O
functionally	O
important	O
for	O
the	O
regulation	O
of	O
diverse	O
DNA	O
-	O
dependent	O
processes	O
in	O
the	O
nucleus	O
,	O
including	O
replication	O
,	O
transcription	O
,	O
and	O
DNA	O
repair	O
.	O

The	O
targeted	O
and	O
untargeted	O
activities	O
of	O
histone	S-Protein
lysine	O
acetylases	O
(	O
KATs	O
)	O
and	O
deacetylases	O
(	O
HDACs	O
)	O
both	O
contribute	O
to	O
the	O
dynamics	O
of	O
chromatin	O
acetylation	O
.	O

While	O
the	O
mechanisms	O
and	O
functional	O
consequences	O
of	O
targeted	O
on	O
histone	S-Protein
acetylation	O
are	O
well	O
understood	O
,	O
relatively	O
little	O
is	O
known	O
about	O
untargeted	O
histone	S-Protein
acetylation	O
.	O

Here	O
,	O
we	O
review	O
the	O
current	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
untargeted	O
KAT	O
and	O
HDAC	O
activities	O
modulate	O
the	O
acetylation	O
state	O
of	O
nucleosomal	O
histones	S-Protein
,	O
focusing	O
on	O
results	O
obtained	O
for	O
H3	S-Protein
and	O
H4	S-Protein
in	O
budding	O
yeast	O
.	O

We	O
also	O
highlight	O
unresolved	O
problems	O
in	O
this	O
area	O
,	O
including	O
the	O
question	O
of	O
how	O
a	O
particular	O
steady	O
-	O
state	O
level	O
of	O
untargeted	O
acetylation	O
is	O
set	O
in	O
the	O
absence	O
of	O
cis	O
-	O
dependent	O
mechanisms	O
that	O
instruct	O
the	O
activity	O
of	O
KATs	O
and	O
HDACs	O
.	O

Hdm2	S-Protein
is	O
a	O
ubiquitin	S-Protein
ligase	O
of	O
Ku70	S-Protein
-	O
Akt	S-Protein
promotes	O
cell	O
survival	O
by	O
inhibiting	O
Hdm2	S-Protein
-	O
dependent	O
Ku70	S-Protein
destabilization	O
.	O

Earlier	O
,	O
we	O
have	O
reported	O
that	O
70	O
kDa	O
subunit	O
of	O
Ku	O
protein	O
heterodimer	O
(	O
Ku70	S-Protein
)	O
binds	O
and	O
inhibits	O
Bax	S-Protein
activity	O
in	O
the	O
cytosol	O
and	O
that	O
ubiquitin	S-Protein
(	O
Ub	S-Protein
)	O
-	O
dependent	O
proteolysis	O
of	O
cytosolic	O
Ku70	S-Protein
facilitates	O
Bax	S-Protein
-	O
mediated	O
apoptosis	O
.	O

We	O
found	O
that	O
Hdm2	S-Protein
(	O
human	O
homolog	O
of	O
murine	O
double	O
minute	O
)	O
has	O
an	O
ability	O
to	O
ubiquitinate	O
Ku70	S-Protein
and	O
that	O
Hdm2	S-Protein
overexpression	O
in	O
cultured	O
cells	O
causes	O
a	O
decrease	O
in	O
Ku70	S-Protein
expression	O
levels	O
.	O

An	O
interaction	O
between	O
Ku70	S-Protein
and	O
Hdm2	S-Protein
was	O
shown	O
by	O
means	O
of	O
immunoprecipitation	O
,	O
whereas	O
none	O
could	O
be	O
shown	O
between	O
80	O
kDa	O
subunit	O
of	O
Ku	O
protein	O
heterodimer	O
and	O
Hdm2	S-Protein
.	O

Vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	E-Protein
(	O
VEGF	S-Protein
)	O
is	O
known	O
to	O
inhibit	O
endothelial	O
cell	O
(	O
EC	O
)	O
apoptosis	O
through	O
an	O
Akt	O
-	O
mediated	O
survival	O
kinase	O
signal	O
;	O
however	O
,	O
the	O
mechanism	O
underlying	O
this	O
inhibition	O
of	O
apoptosis	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
found	O
that	O
VEGF	S-Protein
inhibited	O
cytosolic	O
Ku70	S-Protein
degradation	O
induced	O
by	O
apoptotic	O
stress	O
.	O

It	O
is	O
known	O
that	O
Akt	O
-	O
dependent	O
phosphorylation	O
of	O
Hdm2	S-Protein
causes	O
nuclear	O
translocation	O
of	O
Hdm2	S-Protein
followed	O
by	O
Hdm2	O
-	O
mediated	O
inactivation	O
of	O
p53	S-Protein
.	O

We	O
found	O
that	O
VEGF	S-Protein
stimulated	O
nuclear	O
translocation	O
of	O
Hdm2	S-Protein
in	O
EC	O
and	O
efficiently	O
inhibited	O
Ku70	S-Protein
degradation	O
.	O

We	O
also	O
found	O
that	O
constitutively	O
active	O
Akt	O
,	O
but	O
not	O
kinase	O
-	O
dead	O
Akt	O
,	O
inhibited	O
Ku70	S-Protein
degradation	O
in	O
the	O
cytosol	O
.	O

Furthermore	O
,	O
Ku70	S-Protein
knockdown	O
diminished	O
antiapoptotic	O
activity	O
of	O
Akt	O
.	O

Taken	O
together	O
,	O
we	O
propose	O
that	O
Hdm2	S-Protein
is	O
a	O
Ku70	S-Protein
Ub	S-Protein
ligase	O
and	O
that	O
Akt	O
inhibits	O
Bax	S-Protein
-	O
mediated	O
apoptosis	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
maintaining	O
Ku70	S-Protein
levels	O
through	O
the	O
promotion	O
of	O
Hdm2	S-Protein
nuclear	O
translocation	O
.	O

TRIM21	S-Protein
is	O
essential	O
to	O
sustain	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	E-Protein
activation	O
during	O
antiviral	O
response	O
.	O

Virus	O
infection	O
induces	O
host	O
antiviral	O
responses	O
including	O
induction	O
of	O
type	O
I	O
IFNs	O
.	O

Transcription	O
factor	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	E-Protein
(	O
IRF3	S-Protein
)	O
plays	O
an	O
essential	O
role	O
and	O
is	O
tightly	O
regulated	O
in	O
this	O
process	O
.	O

Herein	O
we	O
report	O
that	O
TRIM21	S-Protein
(	O
tripartite	B-Protein
motif	I-Protein
-	I-Protein
containing	I-Protein
21	E-Protein
)	O
is	O
significantly	O
induced	O
and	O
interacts	O
with	O
IRF3	S-Protein
upon	O
RNA	O
virus	O
infection	O
.	O

Ectopic	O
expression	O
or	O
knockdown	O
of	O
TRIM21	S-Protein
could	O
respectively	O
enhance	O
or	O
impair	O
IRF3	S-Protein
-	O
mediated	O
gene	O
expression	O
.	O

Mechanistically	O
,	O
TRIM21	S-Protein
interferes	O
with	O
the	O
interaction	O
between	O
Pin1	S-Protein
(	O
peptidyl	B-Protein
-	I-Protein
prolyl	I-Protein
cis	I-Protein
/	I-Protein
trans	I-Protein
isomerase	I-Protein
,	I-Protein
NIMA	I-Protein
-	I-Protein
interacting	I-Protein
1	E-Protein
)	O
and	O
IRF3	S-Protein
,	O
thus	O
preventing	O
IRF3	S-Protein
ubiquitination	O
and	O
degradation	O
.	O

A	O
conserved	O
motif	O
in	O
the	O
B	O
30	O
.	O
2	O
domain	O
of	O
TRIM21	S-Protein
is	O
critical	O
for	O
its	O
modulation	O
of	O
IRF3	S-Protein
function	O
,	O
while	O
the	O
RING	O
finger	O
is	O
dispensable	O
.	O

Host	O
antiviral	O
responses	O
are	O
significantly	O
boosted	O
or	O
crippled	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TRIM21	S-Protein
.	O

Our	O
results	O
identify	O
TRIM21	S-Protein
as	O
an	O
essential	O
modulator	O
of	O
IRF3	S-Protein
stability	O
and	O
demonstrate	O
that	O
it	O
positively	O
regulates	O
the	O
strength	O
and	O
duration	O
of	O
primary	O
antiviral	O
response	O
,	O
thus	O
further	O
strengthening	O
the	O
notion	O
that	O
the	O
TRIM	O
family	O
is	O
evolutionarily	O
integrated	O
with	O
innate	O
immunity	O
.	O

Phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	S-Protein
at	O
Ser468	O
controls	O
its	O
COMMD1	S-Protein
-	O
dependent	O
ubiquitination	O
and	O
target	O
gene	O
-	O
specific	O
proteasomal	O
elimination	O
.	O

The	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
transcription	O
factor	O
system	O
is	O
a	O
crucial	O
component	O
that	O
controls	O
several	O
important	O
biological	O
functions	O
,	O
thus	O
raising	O
the	O
need	O
for	O
mechanisms	O
that	O
ensure	O
the	O
correct	O
termination	O
of	O
its	O
activity	O
.	O

Here	O
,	O
we	O
identify	O
a	O
new	O
phosphorylation	O
/	O
ubiquitination	O
switch	O
in	O
the	O
NF	O
-	O
kappaB	O
network	O
that	O
controls	O
the	O
stability	O
of	O
the	O
transactivating	O
p65	S-Protein
subunit	O
.	O

Tumour	B-Protein
necrosis	I-Protein
factor	E-Protein
-	O
induced	O
phosphorylation	O
of	O
p65	S-Protein
at	O
Ser468	O
allows	O
binding	O
of	O
COMMD1	S-Protein
and	O
cullin	B-Protein
2	E-Protein
,	O
components	O
of	O
a	O
multimeric	O
ubiquitin	S-Protein
ligase	O
complex	O
mediating	O
p65	S-Protein
ubiquitination	O
.	O

Mutation	O
of	O
p65	S-Protein
at	O
Ser468	O
largely	O
prevents	O
p65	S-Protein
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

Inducible	O
p65	S-Protein
elimination	O
is	O
restricted	O
to	O
a	O
subset	O
of	O
NF	O
-	O
kappaB	O
target	O
genes	O
such	O
as	O
Icam1	S-Protein
.	O

Accordingly	O
,	O
chromatin	O
immunoprecipitation	O
experiments	O
reveal	O
the	O
selective	O
recruitment	O
of	O
Ser468	O
-	O
phosphorylated	O
p65	S-Protein
and	O
COMMD1	S-Protein
to	O
the	O
Icam1	S-Protein
promoter	O
.	O

Phosphorylation	O
of	O
p65	S-Protein
at	O
Ser468	O
leads	O
to	O
ubiquitin	S-Protein
/	O
proteasome	O
-	O
dependent	O
removal	O
of	O
chromatin	O
-	O
bound	O
p65	S-Protein
,	O
thus	O
contributing	O
to	O
the	O
selective	O
termination	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
.	O

PDCD5	S-Protein
interacts	O
with	O
Tip60	S-Protein
and	O
functions	O
as	O
a	O
cooperator	O
in	O
acetyltransferase	O
activity	O
and	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O

Tip60	S-Protein
is	O
a	O
histone	S-Protein
acetyltransferase	O
(	O
HAT	O
)	O
involved	O
in	O
the	O
acetyltransferase	O
activity	O
and	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O

Here	O
,	O
we	O
show	O
that	O
programmed	B-Protein
cell	I-Protein
death	I-Protein
5	E-Protein
(	O
PDCD5	S-Protein
)	O
,	O
a	O
human	O
apoptosis	O
-	O
related	O
protein	O
,	O
binds	O
to	O
Tip60	S-Protein
and	O
enhances	O
the	O
stability	O
of	O
Tip60	S-Protein
protein	O
in	O
unstressed	O
conditions	O
.	O

The	O
binding	O
amount	O
of	O
PDCD5	S-Protein
and	O
Tip60	S-Protein
is	O
significantly	O
increased	O
after	O
UV	O
irradiation	O
.	O

Further	O
,	O
PDCD5	S-Protein
enhances	O
HAT	O
activity	O
of	O
Tip60	S-Protein
and	O
Tip60	S-Protein
-	O
dependent	O
histone	S-Protein
acetylation	O
in	O
both	O
basal	O
and	O
UV	O
-	O
induced	O
levels	O
.	O

We	O
also	O
find	O
that	O
PDCD5	S-Protein
increases	O
Tip60	S-Protein
-	O
dependent	O
K120	O
acetylation	O
of	O
p53	S-Protein
and	O
participates	O
in	O
the	O
p53	S-Protein
-	O
dependent	O
expression	O
of	O
apoptosis	O
-	O
related	O
genes	O
,	O
such	O
as	O
Bax	S-Protein
.	O

Moreover	O
,	O
we	O
demonstrate	O
the	O
biological	O
significance	O
of	O
the	O
PDCD5	S-Protein
-	O
Tip60	S-Protein
interaction	O
;	O
that	O
is	O
,	O
they	O
function	O
in	O
cooperation	O
to	O
accelerate	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
and	O
knockdown	O
of	O
PDCD5	S-Protein
or	O
Tip60	S-Protein
impairs	O
their	O
apoptosis	O
-	O
accelerating	O
activity	O
,	O
mutually	O
.	O

Consistent	O
with	O
this	O
,	O
PDCD5	S-Protein
levels	O
increase	O
significantly	O
on	O
DNA	O
damage	O
in	O
U2OS	O
cells	O
,	O
as	O
does	O
Tip60	S-Protein
.	O

Together	O
,	O
our	O
findings	O
indicate	O
that	O
PDCD5	S-Protein
may	O
play	O
a	O
dual	O
role	O
in	O
the	O
Tip60	S-Protein
pathway	O
.	O

Specifically	O
,	O
under	O
normal	O
growth	O
conditions	O
,	O
PDCD5	S-Protein
contributes	O
to	O
maintaining	O
a	O
basal	O
pool	O
of	O
Tip60	S-Protein
and	O
its	O
HAT	O
activity	O
.	O

After	O
DNA	O
damage	O
,	O
PDCD5	S-Protein
functions	O
as	O
a	O
Tip60	S-Protein
coactivator	O
to	O
promote	O
apoptosis	O
.	O

MDM2	S-Protein
acts	O
downstream	O
of	O
p53	S-Protein
as	O
an	O
E3	O
ligase	O
to	O
promote	O
FOXO	O
ubiquitination	O
and	O
degradation	O
.	O

Members	O
of	O
the	O
FOXO	O
(	O
forkhead	O
O	O
)	O
class	O
of	O
transcription	O
factors	O
are	O
tumor	O
suppressors	O
that	O
also	O
control	O
aging	O
and	O
organismal	O
life	O
span	O
.	O

Mammalian	O
FOXO	O
degradation	O
is	O
proteasome	O
-	O
mediated	O
,	O
although	O
the	O
ubiquitin	S-Protein
E3	O
ligase	O
for	O
FOXO	O
factors	O
remains	O
to	O
be	O
defined	O
.	O

We	O
show	O
that	O
MDM2	S-Protein
binds	O
to	O
FOXO1	S-Protein
and	O
FOXO3A	S-Protein
and	O
promotes	O
their	O
ubiquitination	O
and	O
degradation	O
,	O
a	O
process	O
apparently	O
dependent	O
on	O
FOXO	O
phosphorylation	O
at	O
AKT	S-Protein
sites	O
and	O
the	O
E3	O
ligase	O
activity	O
of	O
MDM2	S-Protein
.	O

Binding	O
of	O
MDM2	S-Protein
to	O
FOXO	O
occurs	O
through	O
the	O
region	O
of	O
MDM2	S-Protein
that	O
directs	O
its	O
cellular	O
trafficking	O
and	O
the	O
forkhead	O
box	O
of	O
FOXO1	S-Protein
.	O

MDM2	S-Protein
promotes	O
the	O
ubiquitination	O
of	O
FOXO1	S-Protein
in	O
a	O
cell	O
-	O
free	O
system	O
,	O
and	O
its	O
knockdown	O
by	O
small	O
interfering	O
RNA	O
causes	O
accumulation	O
of	O
endogenous	O
FOXO3A	S-Protein
protein	O
in	O
cells	O
and	O
enhances	O
the	O
expression	O
of	O
FOXO	O
target	O
genes	O
.	O

In	O
cells	O
stably	O
expressing	O
a	O
temperature	O
-	O
sensitive	O
p53	S-Protein
mutant	O
,	O
activation	O
of	O
p53	S-Protein
by	O
shifting	O
to	O
permissive	O
temperatures	O
leads	O
to	O
MDM2	S-Protein
induction	O
and	O
degradation	O
of	O
endogenous	O
FOXO3A	S-Protein
.	O

These	O
data	O
suggest	O
that	O
MDM2	S-Protein
acts	O
as	O
an	O
ubiquitin	S-Protein
E3	O
ligase	O
,	O
downstream	O
of	O
p53	S-Protein
,	O
to	O
regulate	O
the	O
degradation	O
of	O
mammalian	O
FOXO	O
factors	O
.	O

Properties	O
of	O
Nat4	S-Protein
,	O
an	O
N	O
(	O
alpha	O
)	O
-	O
acetyltransferase	O
of	O
Saccharomyces	O
cerevisiae	O
that	O
modifies	O
N	O
termini	O
of	O
histones	B-Protein
H2A	E-Protein
and	O
H4	S-Protein
.	O

Nat4	S-Protein
,	O
also	O
designated	O
NatD	S-Protein
,	O
was	O
previously	O
shown	O
to	O
acetylate	O
the	O
N	O
termini	O
of	O
histones	B-Protein
H2A	E-Protein
and	O
H4	S-Protein
,	O
which	O
have	O
SGGKG	O
and	O
SGRGK	O
N	O
termini	O
(	O
O	O
.	O
K	O
.	O
Song	O
,	O
X	O
.	O
Wang	O
,	O
J	O
.	O
H	O
.	O
Waterborg	O
,	O
and	O
R	O
.	O
Sternglanz	O
,	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
278	O
:	O
38109	O
-	O
38112	O
,	O
2003	O
)	O
.	O

The	O
analysis	O
of	O
chimeric	O
proteins	O
with	O
various	O
N	O
-	O
terminal	O
segments	O
of	O
histone	B-Protein
H4	E-Protein
fused	O
to	O
iso	B-Protein
-	I-Protein
1	I-Protein
-	I-Protein
cytochrome	I-Protein
c	E-Protein
revealed	O
that	O
efficient	O
acetylation	O
by	O
NatD	S-Protein
required	O
at	O
least	O
30	O
to	O
50	O
amino	O
acid	O
residues	O
of	O
the	O
N	O
terminus	O
of	O
histone	B-Protein
H4	E-Protein
.	O

This	O
requirement	O
for	O
an	O
extended	O
N	O
terminus	O
is	O
in	O
marked	O
contrast	O
with	O
the	O
major	O
N	O
-	O
terminal	O
acetyl	O
transferases	O
(	O
NATs	O
)	O
,	O
i	O
.	O
e	O
.	O
,	O
NatA	S-Protein
,	O
NatB	S-Protein
,	O
and	O
NatC	S-Protein
,	O
which	O
require	O
as	O
few	O
as	O
two	O
specific	O
residues	O
and	O
usually	O
no	O
more	O
than	O
four	O
or	O
five	O
.	O

However	O
,	O
similar	O
to	O
the	O
other	O
NATs	O
,	O
NatD	S-Protein
is	O
associated	O
with	O
ribosomes	O
.	O

The	O
nat4	S-Protein
-	O
Delta	O
strain	O
showed	O
several	O
minor	O
phenotypes	O
,	O
including	O
sensitivity	O
to	O
3	O
-	O
aminotriazole	O
,	O
benomyl	O
,	O
and	O
thiabendazole	O
.	O

Moreover	O
,	O
these	O
nat4	S-Protein
-	O
Delta	O
phenotypes	O
were	O
enhanced	O
in	O
the	O
strain	O
containing	O
K5R	O
K8R	O
K12R	O
replacements	O
in	O
the	O
N	O
-	O
tail	O
of	O
histone	B-Protein
H4	E-Protein
,	O
suggesting	O
that	O
the	O
lack	O
of	O
N	O
-	O
terminal	O
serine	O
acetylation	O
is	O
synergistic	O
to	O
the	O
lack	O
of	O
acetylation	O
of	O
the	O
H4	S-Protein
N	O
-	O
tail	O
lysines	O
.	O

Thus	O
,	O
N	O
-	O
terminal	O
serine	O
acetylation	O
of	O
histone	B-Protein
H4	E-Protein
may	O
be	O
a	O
part	O
of	O
an	O
essential	O
charge	O
patch	O
first	O
described	O
for	O
the	O
histone	B-Protein
H2A	I-Protein
.	I-Protein
Z	E-Protein
variant	O
in	O
Tetrahymena	O
species	O
.	O

Ah	B-Protein
receptor	E-Protein
represses	O
acute	O
-	O
phase	O
response	O
gene	O
expression	O
without	O
binding	O
to	O
its	O
cognate	O
response	O
element	O
.	O

Repression	O
of	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
pathway	O
has	O
been	O
extensively	O
researched	O
because	O
of	O
its	O
pivotal	O
role	O
in	O
inflammation	O
.	O

We	O
investigated	O
the	O
potential	O
of	O
the	O
aryl	B-Protein
hydrocarbon	I-Protein
receptor	E-Protein
(	O
AHR	S-Protein
)	O
to	O
suppress	O
NF	O
-	O
kappaB	O
regulated	O
-	O
gene	O
expression	O
,	O
especially	O
acute	O
-	O
phase	O
genes	O
,	O
such	O
as	O
serum	B-Protein
amyloid	I-Protein
A	E-Protein
(	O
Saa	S-Protein
)	O
.	O

Using	O
AHR	S-Protein
mutants	O
,	O
it	O
was	O
determined	O
that	O
nuclear	O
translocation	O
and	O
heterodimerization	O
with	O
AHR	S-Protein
-	O
nuclear	O
translocator	O
are	O
essential	O
,	O
but	O
DNA	O
binding	O
is	O
not	O
involved	O
in	O
AHR	S-Protein
-	O
mediated	O
Saa	S-Protein
repression	O
.	O

A	O
number	O
of	O
AHR	S-Protein
ligands	O
were	O
capable	O
of	O
repressing	O
Saa3	S-Protein
expression	O
.	O

AHR	S-Protein
activation	O
leads	O
to	O
a	O
decrease	O
in	O
RELA	S-Protein
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
/	I-Protein
beta	E-Protein
recruitment	O
to	O
and	O
histone	S-Protein
acetylation	O
at	O
Saa3	S-Protein
gene	O
promoter	O
.	O

A	O
battery	O
of	O
acute	O
-	O
phase	O
genes	O
(	O
eg	O
C	B-Protein
-	I-Protein
reactive	I-Protein
protein	E-Protein
and	O
haptoglobin	S-Protein
)	O
induced	O
by	O
cytokine	O
exposure	O
was	O
repressed	O
by	O
AHR	S-Protein
activation	O
in	O
mouse	O
hepatocytes	O
.	O

Dietary	O
exposure	O
to	O
an	O
AHR	S-Protein
ligand	O
represses	O
cytokine	O
-	O
induced	O
acute	O
-	O
phase	O
response	O
in	O
the	O
liver	O
.	O

Use	O
of	O
a	O
human	O
liver	O
-	O
derived	O
cell	O
line	O
revealed	O
similar	O
repression	O
of	O
Saa	S-Protein
mRNA	O
levels	O
and	O
secreted	O
protein	O
.	O

Repression	O
of	O
AHR	S-Protein
expression	O
also	O
enhanced	O
Saa	O
induction	O
in	O
response	O
to	O
cytokines	O
,	O
suggesting	O
that	O
AHR	S-Protein
is	O
capable	O
of	O
constitutively	O
repressing	O
Saa	S-Protein
gene	O
expression	O
.	O

These	O
results	O
establish	O
a	O
role	O
for	O
AHR	S-Protein
in	O
inflammatory	O
signaling	O
within	O
the	O
liver	O
,	O
presenting	O
a	O
new	O
therapeutic	O
opportunity	O
,	O
and	O
signify	O
AHR	S-Protein
'	O
s	O
ability	O
to	O
function	O
in	O
a	O
DNA	O
-	O
independent	O
manner	O
.	O

Ubiquitin	S-Protein
-	O
like	O
protein	O
activation	O
by	O
E1	O
enzymes	O
:	O
the	O
apex	O
for	O
downstream	O
signalling	O
pathways	O
.	O

Attachment	O
of	O
ubiquitin	S-Protein
or	O
ubiquitin	S-Protein
-	O
like	O
proteins	O
(	O
known	O
as	O
UBLs	O
)	O
to	O
their	O
targets	O
through	O
multienzyme	O
cascades	O
is	O
a	O
central	O
mechanism	O
to	O
modulate	O
protein	O
functions	O
.	O

This	O
process	O
is	O
initiated	O
by	O
a	O
family	O
of	O
mechanistically	O
and	O
structurally	O
related	O
E1	O
(	O
or	O
activating	O
)	O
enzymes	O
.	O

These	O
activate	O
UBLs	O
through	O
carboxy	O
-	O
terminal	O
adenylation	O
and	O
thiol	O
transfer	O
,	O
and	O
coordinate	O
the	O
use	O
of	O
UBLs	O
in	O
specific	O
downstream	O
pathways	O
by	O
charging	O
cognate	O
E2	O
(	O
or	O
conjugating	O
)	O
enzymes	O
,	O
which	O
then	O
interact	O
with	O
the	O
downstream	O
ubiquitylation	O
machinery	O
to	O
coordinate	O
the	O
modification	O
of	O
the	O
target	O
.	O

A	O
broad	O
understanding	O
of	O
how	O
E1	O
enzymes	O
activate	O
UBLs	O
and	O
how	O
they	O
selectively	O
coordinate	O
UBLs	O
with	O
downstream	O
function	O
has	O
come	O
from	O
enzymatic	O
,	O
structural	O
and	O
genetic	O
studies	O
.	O

Histone	S-Protein
acetylations	O
mark	O
origins	O
of	O
polycistronic	O
transcription	O
in	O
Leishmania	O
major	O
.	O

BACKGROUND	O
:	O
Many	O
components	O
of	O
the	O
RNA	O
polymerase	O
II	O
transcription	O
machinery	O
have	O
been	O
identified	O
in	O
kinetoplastid	O
protozoa	O
,	O
but	O
they	O
diverge	O
substantially	O
from	O
other	O
eukaryotes	O
.	O

Furthermore	O
,	O
protein	O
-	O
coding	O
genes	O
in	O
these	O
organisms	O
lack	O
individual	O
transcriptional	O
regulation	O
,	O
since	O
they	O
are	O
transcribed	O
as	O
long	O
polycistronic	O
units	O
.	O

The	O
transcription	O
initiation	O
sites	O
are	O
assumed	O
to	O
lie	O
within	O
the	O
'	O
divergent	O
strand	O
-	O
switch	O
'	O
regions	O
at	O
the	O
junction	O
between	O
opposing	O
polycistronic	O
gene	O
clusters	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
Kinetoplastidae	O
initiate	O
transcription	O
is	O
unclear	O
,	O
and	O
promoter	O
sequences	O
are	O
undefined	O
.	O

RESULTS	O
:	O
The	O
chromosomal	O
location	O
of	O
TATA	O
-	O
binding	O
protein	O
(	O
TBP	O
or	O
TRF4	S-Protein
)	O
,	O
Small	O
Nuclear	O
Activating	O
Protein	O
complex	O
(	O
SNAP50	S-Protein
)	O
,	O
and	O
H3	B-Protein
histones	E-Protein
were	O
assessed	O
in	O
Leishmania	O
major	O
using	O
microarrays	O
hybridized	O
with	O
DNA	O
obtained	O
through	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
-	O
chip	O
)	O
.	O

The	O
TBP	O
and	O
SNAP50	S-Protein
binding	O
patterns	O
were	O
almost	O
identical	O
and	O
high	O
intensity	O
peaks	O
were	O
associated	O
with	O
tRNAs	O
and	O
snRNAs	O
.	O

Only	O
184	O
peaks	O
of	O
acetylated	O
H3	B-Protein
histone	E-Protein
were	O
found	O
in	O
the	O
entire	O
genome	O
,	O
with	O
substantially	O
higher	O
intensity	O
in	O
rapidly	O
-	O
dividing	O
cells	O
than	O
stationary	O
-	O
phase	O
.	O

The	O
majority	O
of	O
the	O
acetylated	O
H3	S-Protein
peaks	O
were	O
found	O
at	O
divergent	O
strand	O
-	O
switch	O
regions	O
,	O
but	O
some	O
occurred	O
at	O
chromosome	O
ends	O
and	O
within	O
polycistronic	O
gene	O
clusters	O
.	O

Almost	O
all	O
these	O
peaks	O
were	O
associated	O
with	O
lower	O
intensity	O
peaks	O
of	O
TBP	O
/	O
SNAP50	S-Protein
binding	O
a	O
few	O
kilobases	O
upstream	O
,	O
evidence	O
that	O
they	O
represent	O
transcription	O
initiation	O
sites	O
.	O

CONCLUSION	O
:	O
The	O
first	O
genome	O
-	O
wide	O
maps	O
of	O
DNA	O
-	O
binding	O
protein	O
occupancy	O
in	O
a	O
kinetoplastid	O
organism	O
suggest	O
that	O
H3	B-Protein
histones	E-Protein
at	O
the	O
origins	O
of	O
polycistronic	O
transcription	O
of	O
protein	O
-	O
coding	O
genes	O
are	O
acetylated	O
.	O

Global	O
regulation	O
of	O
transcription	O
initiation	O
may	O
be	O
achieved	O
by	O
modifying	O
the	O
acetylation	O
state	O
of	O
these	O
origins	O
.	O

Secretion	O
of	O
human	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
from	O
Saccharomyces	O
cerevisiae	O
using	O
synthetic	O
leader	O
sequences	O
.	O

We	O
have	O
investigated	O
different	O
leader	O
sequences	O
for	O
their	O
ability	O
to	O
direct	O
the	O
efficient	O
secretion	O
of	O
human	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
(	O
hEGF	S-Protein
)	O
from	O
Saccharomyces	O
cerevisiae	O
.	O

We	O
designed	O
a	O
consensus	O
signal	O
sequence	O
which	O
directs	O
secretion	O
of	O
hEGF	S-Protein
from	O
yeast	O
as	O
efficiently	O
as	O
the	O
yeast	O
invertase	O
signal	O
sequence	O
.	O

However	O
,	O
secretion	O
is	O
increased	O
over	O
fivefold	O
by	O
the	O
introduction	O
,	O
after	O
the	O
signal	O
sequence	O
,	O
of	O
a	O
synthetic	O
19	O
-	O
amino	O
acid	O
(	O
aa	O
)	O
pro	O
-	O
sequence	O
containing	O
a	O
cleavage	O
recognition	O
site	O
for	O
the	O
KEX2	S-Protein
protease	O
.	O

Even	O
in	O
the	O
absence	O
of	O
an	O
Asn	O
-	O
linked	O
glycosylation	O
site	O
,	O
secretion	O
of	O
hEGF	S-Protein
using	O
the	O
synthetic	O
prepro	O
-	O
leader	O
was	O
as	O
efficient	O
as	O
that	O
directed	O
by	O
the	O
alpha	O
-	O
factor	O
leader	O
.	O

The	O
role	O
of	O
the	O
KEX2	S-Protein
protease	O
cleavage	O
site	O
was	O
investigated	O
by	O
mutation	O
of	O
the	O
yeast	O
alpha	O
-	O
factor	O
KEX2	S-Protein
site	O
(	O
cleavage	O
after	O
Lys	O
-	O
Arg	O
)	O
.	O

Cleavage	O
was	O
obtained	O
with	O
the	O
following	O
order	O
of	O
efficiency	O
,	O
Lys	O
-	O
Arg	O
greater	O
than	O
Pro	O
-	O
Arg	O
greater	O
than	O
Asp	O
-	O
Arg	O
,	O
although	O
the	O
sequence	O
context	O
was	O
also	O
found	O
to	O
affect	O
efficiency	O
.	O

CYLD	S-Protein
:	O
a	O
tumor	O
suppressor	O
deubiquitinase	O
regulating	O
NF	O
-	O
kappaB	O
activation	O
and	O
diverse	O
biological	O
processes	O
.	O

Protein	O
ubiquitination	O
is	O
a	O
reversible	O
reaction	O
,	O
in	O
which	O
the	O
ubiquitin	S-Protein
chains	O
are	O
deconjugated	O
by	O
a	O
family	O
of	O
deubiquitinases	O
(	O
DUBs	O
)	O
.	O

The	O
presence	O
of	O
a	O
large	O
number	O
of	O
DUBs	O
suggests	O
that	O
they	O
likely	O
possess	O
certain	O
levels	O
of	O
substrate	O
selectivity	O
and	O
functional	O
specificity	O
.	O

Indeed	O
,	O
recent	O
studies	O
show	O
that	O
a	O
tumor	O
suppressor	O
DUB	O
,	O
cylindromatosis	S-Protein
(	O
CYLD	S-Protein
)	O
,	O
has	O
a	O
predominant	O
role	O
in	O
the	O
regulation	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
transcription	O
factor	O
that	O
promotes	O
cell	O
survival	O
and	O
oncogenesis	O
.	O

NF	O
-	O
kappaB	O
activation	O
involves	O
attachment	O
of	O
K63	O
-	O
linked	O
ubiquitin	S-Protein
chains	O
to	O
its	O
upstream	O
signaling	O
factors	O
,	O
which	O
is	O
thought	O
to	O
facilitate	O
protein	O
-	O
protein	O
interactions	O
in	O
the	O
assembly	O
of	O
signaling	O
complexes	O
.	O

By	O
deconjugating	O
these	O
K63	O
-	O
linked	O
ubiquitin	S-Protein
chains	O
,	O
CYLD	S-Protein
negatively	O
regulates	O
NF	O
-	O
kappaB	O
activation	O
,	O
which	O
may	O
contribute	O
to	O
its	O
tumor	O
suppressor	O
function	O
.	O

CYLD	S-Protein
also	O
regulates	O
diverse	O
physiological	O
processes	O
,	O
ranging	O
from	O
immune	O
response	O
and	O
inflammation	O
to	O
cell	O
cycle	O
progression	O
,	O
spermatogenesis	O
,	O
and	O
osteoclastogenesis	O
.	O

Interestingly	O
,	O
CYLD	S-Protein
itself	O
is	O
subject	O
to	O
different	O
mechanisms	O
of	O
regulation	O
.	O

LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
is	O
targeted	O
to	O
different	O
subcellular	O
compartments	O
by	O
ubiquitinylation	O
and	O
intrinsic	O
nuclear	O
localization	O
signals	O
.	O

PURPOSE	O
:	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
has	O
been	O
reported	O
to	O
influence	O
breast	O
cancer	O
survival	O
and	O
metastases	O
,	O
and	O
its	O
altered	O
expression	O
has	O
been	O
found	O
in	O
a	O
number	O
of	O
cancers	O
.	O

The	O
cellular	O
function	O
of	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
has	O
previously	O
been	O
related	O
to	O
its	O
subcellular	O
distribution	O
in	O
cell	O
lines	O
.	O

LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
contains	O
three	O
uncharacterized	O
nuclear	O
localization	O
signals	O
(	O
NLS	O
)	O
,	O
which	O
may	O
regulate	O
its	O
distribution	O
and	O
,	O
ultimately	O
,	O
function	O
in	O
cells	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Immunohistochemistry	O
of	O
a	O
human	O
prostate	O
tissue	O
microarray	O
composed	O
of	O
179	O
prostate	O
cancer	O
and	O
24	O
benign	O
samples	O
was	O
used	O
to	O
assess	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
distribution	O
.	O

Green	B-Protein
fluorescent	I-Protein
protein	E-Protein
-	O
NLS	O
fusion	O
proteins	O
and	O
deletion	O
constructs	O
were	O
used	O
to	O
show	O
the	O
ability	O
of	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
NLS	O
to	O
target	O
green	B-Protein
fluorescent	I-Protein
protein	E-Protein
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

Immunoprecipitation	O
and	O
Western	O
blotting	O
were	O
used	O
to	O
show	O
posttranslational	O
modification	O
of	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
NLS	O
regions	O
.	O

RESULTS	O
:	O
Using	O
a	O
prostate	O
tissue	O
microarray	O
,	O
significant	O
changes	O
in	O
the	O
distribution	O
of	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
were	O
observed	O
in	O
prostate	O
cancer	O
as	O
an	O
increased	O
cytoplasmic	O
distribution	O
in	O
tumors	O
compared	O
with	O
benign	O
tissue	O
.	O

These	O
differences	O
were	O
most	O
marked	O
in	O
high	O
grade	O
and	O
aggressive	O
prostate	O
cancers	O
and	O
were	O
associated	O
with	O
decreased	O
survival	O
.	O

The	O
COOH	O
-	O
terminal	O
extended	O
NLS	O
-	O
3	O
(	O
amino	O
acids	O
546	O
-	O
582	O
)	O
is	O
the	O
predominant	O
regulator	O
of	O
nuclear	O
localization	O
,	O
whereas	O
extended	O
NLS	O
-	O
1	O
(	O
amino	O
acids	O
78	O
-	O
130	O
)	O
regulates	O
its	O
nucleolar	O
localization	O
.	O

Within	O
the	O
extended	O
NLS	O
-	O
2	O
region	O
(	O
amino	O
acids	O
415	O
-	O
486	O
)	O
,	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
can	O
be	O
modified	O
by	O
ubiquitin	S-Protein
almost	O
exclusively	O
within	O
the	O
cytoplasm	O
.	O

CONCLUSIONS	O
:	O
Changes	O
in	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
subcellular	O
distribution	O
can	O
predict	O
Gleason	O
grade	O
and	O
survival	O
.	O

Two	O
lysine	O
-	O
rich	O
regions	O
(	O
NLS	O
-	O
1	O
and	O
NLS	O
-	O
3	O
)	O
can	O
target	O
LYRIC	S-Protein
/	O
AEG	B-Protein
-	I-Protein
1	E-Protein
to	O
subcellular	O
compartments	O
whereas	O
NLS	O
-	O
2	O
is	O
modified	O
by	O
ubiquitin	S-Protein
in	O
the	O
cytoplasm	O
.	O

Bile	O
acid	O
signaling	O
pathways	O
increase	O
stability	O
of	O
Small	B-Protein
Heterodimer	I-Protein
Partner	E-Protein
(	O
SHP	S-Protein
)	O
by	O
inhibiting	O
ubiquitin	S-Protein
-	O
proteasomal	O
degradation	O
.	O

Small	B-Protein
Heterodimer	I-Protein
Partner	E-Protein
(	O
SHP	S-Protein
)	O
inhibits	O
activities	O
of	O
numerous	O
transcription	O
factors	O
involved	O
in	O
diverse	O
biological	O
pathways	O
.	O

As	O
an	O
important	O
metabolic	O
regulator	O
,	O
SHP	S-Protein
plays	O
a	O
key	O
role	O
in	O
maintaining	O
cholesterol	O
and	O
bile	O
acid	O
homeostasis	O
by	O
inhibiting	O
cholesterol	O
conversion	O
to	O
bile	O
acids	O
.	O

While	O
SHP	S-Protein
gene	O
induction	O
by	O
increased	O
bile	O
acids	O
is	O
well	O
established	O
,	O
whether	O
SHP	S-Protein
activity	O
is	O
also	O
modulated	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
surprising	O
findings	O
that	O
SHP	S-Protein
is	O
a	O
rapidly	O
degraded	O
protein	O
via	O
the	O
ubiquitin	S-Protein
-	O
proteasomal	O
pathway	O
and	O
that	O
bile	O
acids	O
or	O
bile	O
acid	O
-	O
induced	O
intestinal	O
fibroblast	B-Protein
growth	I-Protein
factor	I-Protein
19	E-Protein
(	O
FGF19	S-Protein
)	O
increases	O
stability	O
of	O
hepatic	O
SHP	S-Protein
by	O
inhibiting	O
proteasomal	O
degradation	O
in	O
an	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
-	O
dependent	O
manner	O
.	O

SHP	S-Protein
was	O
ubiquitinated	O
at	O
Lys122	O
and	O
Lys123	O
,	O
and	O
mutation	O
of	O
these	O
sites	O
altered	O
its	O
stability	O
and	O
repression	O
activity	O
.	O

Tandem	O
mass	O
spectrometry	O
revealed	O
that	O
upon	O
bile	O
acid	O
treatment	O
,	O
SHP	S-Protein
was	O
phosphorylated	O
at	O
Ser26	O
,	O
within	O
an	O
ERK	O
motif	O
in	O
SHP	S-Protein
,	O
and	O
mutation	O
of	O
this	O
site	O
dramatically	O
abolished	O
SHP	S-Protein
stability	O
.	O

Surprisingly	O
,	O
SHP	S-Protein
stability	O
was	O
abnormally	O
elevated	O
in	O
ob	O
/	O
ob	O
mice	O
and	O
diet	O
-	O
induced	O
obese	O
mice	O
.	O

These	O
results	O
demonstrate	O
an	O
important	O
role	O
for	O
regulation	O
of	O
SHP	S-Protein
stability	O
in	O
bile	O
acid	O
signaling	O
in	O
normal	O
conditions	O
,	O
and	O
that	O
abnormal	O
stabilization	O
of	O
SHP	S-Protein
may	O
be	O
associated	O
with	O
metabolic	O
disorders	O
,	O
including	O
obesity	O
and	O
diabetes	O
.	O

Rapid	O
proteasomal	O
degradation	O
of	O
transcription	B-Protein
factor	I-Protein
IIB	E-Protein
in	O
accordance	O
with	O
F9	O
cell	O
differentiation	O
.	O

We	O
found	O
that	O
the	O
levels	O
of	O
all	O
general	O
transcription	O
factors	O
(	O
GTFs	O
)	O
for	O
RNA	O
polymerase	O
II	O
decreased	O
in	O
F9	O
cells	O
when	O
the	O
cells	O
were	O
subjected	O
to	O
a	O
differentiation	O
procedure	O
.	O

Different	O
from	O
other	O
GTFs	O
,	O
decrease	O
of	O
TFIIB	S-Protein
during	O
the	O
differentiation	O
was	O
suppressed	O
by	O
addition	O
of	O
a	O
proteasome	O
inhibitor	O
,	O
MG132	O
.	O

The	O
half	O
-	O
life	O
of	O
TFIIB	S-Protein
in	O
the	O
differentiated	O
cells	O
was	O
remarkably	O
reduced	O
compared	O
with	O
that	O
in	O
the	O
undifferentiated	O
cells	O
.	O

Moreover	O
,	O
it	O
was	O
demonstrated	O
that	O
TFIIB	S-Protein
is	O
a	O
poly	O
-	O
ubiquitinated	O
protein	O
.	O

Results	O
of	O
this	O
study	O
suggest	O
that	O
components	O
of	O
the	O
transcription	O
machinery	O
decreased	O
in	O
accordance	O
with	O
cell	O
differentiation	O
and	O
that	O
TFIIB	S-Protein
is	O
specifically	O
and	O
rapidly	O
degraded	O
by	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
.	O

Acetaldehyde	O
stimulates	O
FANCD2	S-Protein
monoubiquitination	O
,	O
H2AX	S-Protein
phosphorylation	O
,	O
and	O
BRCA1	S-Protein
phosphorylation	O
in	O
human	O
cells	O
in	O
vitro	O
:	O
implications	O
for	O
alcohol	O
-	O
related	O
carcinogenesis	O
.	O

According	O
to	O
a	O
recent	O
IARC	O
Working	O
Group	O
report	O
,	O
alcohol	O
consumption	O
is	O
causally	O
related	O
to	O
an	O
increased	O
risk	O
of	O
cancer	O
of	O
the	O
upper	O
aerodigestive	O
tract	O
,	O
liver	O
,	O
colorectum	O
,	O
and	O
female	O
breast	O
[	O
R	O
.	O
Baan	O
,	O
K	O
.	O
Straif	O
,	O
Y	O
.	O
Grosse	O
,	O
B	O
.	O
Secretan	O
,	O
F	O
.	O
El	O
Ghissassi	O
,	O
V	O
.	O
Bouvard	O
,	O
A	O
.	O
Altieri	O
,	O
V	O
.	O
Cogliano	O
,	O
Carcinogenicity	O
of	O
alcoholic	O
beverages	O
,	O
Lancet	O
Oncol	O
.	O
8	O
(	O
2007	O
)	O
292	O
-	O
293	O
]	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
acetaldehyde	O
(	O
AA	O
)	O
,	O
the	O
first	O
product	O
of	O
alcohol	O
metabolism	O
,	O
plays	O
a	O
very	O
important	O
role	O
in	O
alcohol	O
-	O
related	O
carcinogenesis	O
,	O
particularly	O
in	O
the	O
esophagus	O
.	O

We	O
previously	O
proposed	O
a	O
model	O
for	O
alcohol	O
-	O
related	O
carcinogenesis	O
in	O
which	O
AA	O
,	O
generated	O
from	O
alcohol	O
metabolism	O
,	O
reacts	O
in	O
cells	O
to	O
generate	O
DNA	O
lesions	O
that	O
form	O
interstrand	O
crosslinks	O
(	O
ICLs	O
)	O
[	O
J	O
.	O
A	O
.	O
Theruvathu	O
,	O
P	O
.	O
Jaruga	O
,	O
R	O
.	O
G	O
.	O
Nath	O
,	O
M	O
.	O
Dizdaroglu	O
,	O
P	O
.	O
J	O
.	O
Brooks	O
,	O
Polyamines	O
stimulate	O
the	O
formation	O
of	O
mutagenic	O
1	O
,	O
N2	O
-	O
propanodeoxyguanosine	O
adducts	O
from	O
acetaldehyde	O
,	O
Nucleic	O
Acids	O
Res	O
.	O
33	O
(	O
2005	O
)	O
3513	O
-	O
3520	O
]	O
.	O

Since	O
the	O
Fanconi	O
anemia	O
-	O
breast	O
cancer	O
associated	O
(	O
FANC	O
-	O
BRCA	O
)	O
DNA	O
damage	O
response	O
network	O
plays	O
a	O
crucial	O
role	O
in	O
protecting	O
cells	O
against	O
ICLs	O
,	O
in	O
the	O
present	O
work	O
we	O
tested	O
this	O
hypothesis	O
by	O
exposing	O
cells	O
to	O
AA	O
and	O
monitoring	O
activation	O
of	O
this	O
network	O
.	O

We	O
found	O
that	O
AA	O
exposure	O
results	O
in	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
FANCD2	S-Protein
monoubiquitination	O
,	O
which	O
is	O
dependent	O
upon	O
the	O
FANC	O
core	O
complex	O
.	O

AA	O
also	O
stimulated	O
BRCA1	S-Protein
phosphorylation	O
at	O
Ser1524	O
and	O
increased	O
the	O
level	O
of	O
gammaH2AX	S-Protein
,	O
with	O
both	O
modifications	O
occurring	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

However	O
,	O
AA	O
did	O
not	O
detectably	O
increase	O
the	O
levels	O
of	O
hyperphosphorylated	O
RPA34	S-Protein
,	O
a	O
marker	O
of	O
single	O
-	O
stranded	O
DNA	O
exposure	O
at	O
replication	O
forks	O
.	O

These	O
results	O
provide	O
the	O
initial	O
description	O
of	O
the	O
AA	O
-	O
DNA	O
damage	O
response	O
,	O
which	O
is	O
qualitatively	O
similar	O
to	O
the	O
cellular	O
response	O
to	O
mitomycin	O
C	O
,	O
a	O
known	O
DNA	O
crosslinking	O
agent	O
.	O

We	O
discuss	O
the	O
mechanistic	O
implications	O
of	O
these	O
results	O
,	O
as	O
well	O
as	O
their	O
possible	O
relationship	O
to	O
alcohol	O
-	O
related	O
carcinogenesis	O
in	O
different	O
human	O
tissues	O
.	O

Atg5	S-Protein
-	O
independent	O
sequestration	O
of	O
ubiquitinated	O
mycobacteria	O
.	O

Like	O
several	O
other	O
intracellular	O
pathogens	O
,	O
Mycobacterium	O
marinum	O
(	O
Mm	O
)	O
escapes	O
from	O
phagosomes	O
into	O
the	O
host	O
cytosol	O
where	O
it	O
can	O
polymerize	O
actin	O
,	O
leading	O
to	O
motility	O
that	O
promotes	O
spread	O
to	O
neighboring	O
cells	O
.	O

However	O
,	O
only	O
approximately	O
25	O
%	O
of	O
internalized	O
Mm	O
form	O
actin	O
tails	O
,	O
and	O
the	O
fate	O
of	O
the	O
remaining	O
bacteria	O
has	O
been	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
cytosolic	O
access	O
results	O
in	O
a	O
new	O
and	O
intricate	O
host	O
pathogen	O
interaction	O
:	O
host	O
macrophages	O
ubiquitinate	O
Mm	O
,	O
while	O
Mm	O
shed	O
their	O
ubiquitinated	O
cell	O
walls	O
.	O

Phagosomal	O
escape	O
and	O
ubiquitination	O
of	O
Mm	O
occurred	O
rapidly	O
,	O
prior	O
to	O
3	O
.	O
5	O
hours	O
post	O
infection	O
;	O
at	O
the	O
same	O
time	O
,	O
ubiquitinated	O
Mm	O
cell	O
wall	O
material	O
mixed	O
with	O
host	O
-	O
derived	O
dense	O
membrane	O
networks	O
appeared	O
in	O
close	O
proximity	O
to	O
cytosolic	O
bacteria	O
,	O
suggesting	O
cell	O
wall	O
shedding	O
and	O
association	O
with	O
remnants	O
of	O
the	O
lysed	O
phagosome	O
.	O

At	O
24	O
hours	O
post	O
-	O
infection	O
,	O
Mm	O
that	O
polymerized	O
actin	O
were	O
not	O
ubiquitinated	O
,	O
whereas	O
ubiquitinated	O
Mm	O
were	O
found	O
within	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
-	O
positive	O
vacuoles	O
resembling	O
lysosomes	O
.	O

Though	O
double	O
membranes	O
were	O
observed	O
which	O
sequestered	O
Mm	O
away	O
from	O
the	O
cytosol	O
,	O
targeting	O
of	O
Mm	O
to	O
the	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
-	O
positive	O
vacuoles	O
was	O
independent	O
of	O
classical	O
autophagy	O
,	O
as	O
demonstrated	O
by	O
absence	O
of	O
LC3	O
association	O
and	O
by	O
Atg5	S-Protein
-	O
independence	O
of	O
their	O
formation	O
.	O

Further	O
,	O
ubiquitination	O
and	O
LAMP	B-Protein
-	I-Protein
1	E-Protein
association	O
did	O
not	O
occur	O
with	O
mutant	O
avirulent	O
Mm	O
lacking	O
ESX	B-Protein
-	I-Protein
1	E-Protein
(	O
type	O
VII	O
)	O
secretion	O
,	O
which	O
fail	O
to	O
escape	O
the	O
primary	O
phagosome	O
;	O
apart	O
from	O
its	O
function	O
in	O
phagosome	O
escape	O
,	O
ESX	B-Protein
-	I-Protein
1	E-Protein
was	O
not	O
directly	O
required	O
for	O
Mm	O
ubiquitination	O
in	O
macrophages	O
or	O
in	O
vitro	O
.	O

These	O
data	O
suggest	O
that	O
virulent	O
Mm	O
follow	O
two	O
distinct	O
paths	O
in	O
the	O
cytosol	O
of	O
infected	O
host	O
cells	O
:	O
bacterial	O
ubiquitination	O
is	O
followed	O
by	O
sequestration	O
into	O
lysosome	O
-	O
like	O
organelles	O
via	O
an	O
autophagy	O
-	O
independent	O
pathway	O
,	O
while	O
cell	O
wall	O
shedding	O
may	O
allow	O
escape	O
from	O
this	O
fate	O
to	O
permit	O
continued	O
residence	O
in	O
the	O
cytosol	O
and	O
formation	O
of	O
actin	O
tails	O
.	O

CHIP	S-Protein
functions	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
of	O
Runx1	S-Protein
.	O

Runx1	S-Protein
is	O
a	O
key	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
hematopoietic	O
stem	O
cells	O
.	O

Improper	O
expression	O
and	O
mutations	O
in	O
Runx1	S-Protein
are	O
frequently	O
implicated	O
in	O
human	O
leukemia	O
.	O

Here	O
,	O
we	O
report	O
that	O
CHIP	S-Protein
,	O
the	O
carboxyl	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
,	O
also	O
named	O
Stub1	S-Protein
,	O
physically	O
interacts	O
with	O
Runx1	S-Protein
through	O
the	O
TPR	O
and	O
Charged	O
domains	O
in	O
the	O
nucleus	O
.	O

Over	O
-	O
expression	O
of	O
CHIP	S-Protein
directly	O
induced	O
Runx1	S-Protein
ubiquitination	O
and	O
degradation	O
through	O
the	O
ubiquitin	S-Protein
-	O
proteasome	O
pathway	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
CHIP	S-Protein
-	O
mediated	O
degradation	O
of	O
Runx1	S-Protein
is	O
independent	O
of	O
the	O
molecular	O
chaperone	O
Hsp70	O
/	O
90	O
.	O

Taken	O
together	O
,	O
we	O
propose	O
that	O
CHIP	S-Protein
serves	O
as	O
an	O
E3	O
ubiquitin	S-Protein
ligase	O
that	O
regulates	O
Runx1	S-Protein
protein	O
stability	O
via	O
an	O
ubiquitination	O
and	O
degradation	O
mechanism	O
that	O
is	O
independent	O
of	O
Hsp70	O
/	O
90	O
.	O

RIG	B-Protein
-	I-Protein
I	E-Protein
-	O
like	O
receptors	O
:	O
sensing	O
and	O
responding	O
to	O
RNA	O
virus	O
infection	O
.	O

Viral	O
and	O
microbial	O
pathogens	O
contain	O
specific	O
motifs	O
or	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
(	O
PAMPs	O
)	O
that	O
are	O
recognized	O
by	O
cell	O
surface	O
-	O
and	O
endosome	O
-	O
associated	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
.	O

RNA	O
virus	O
infection	O
is	O
also	O
detected	O
through	O
TLR	O
-	O
independent	O
mechanisms	O
.	O

Early	O
viral	O
replicative	O
intermediates	O
are	O
detected	O
by	O
two	O
recently	O
characterized	O
cystolic	O
viral	O
RNA	O
receptors	O
-	O
RIG	B-Protein
-	I-Protein
I	E-Protein
and	O
MDA	B-Protein
-	I-Protein
5	E-Protein
.	O

Both	O
are	O
DExDH	O
/	O
box	O
RNA	O
helicases	O
,	O
and	O
RIG	B-Protein
-	I-Protein
I	E-Protein
specifically	O
recognizes	O
5	O
'	O
-	O
triphosphate	O
containing	O
viral	O
RNA	O
and	O
transmits	O
signals	O
that	O
induce	O
type	O
I	O
interferon	O
-	O
mediated	O
host	O
immunity	O
against	O
virus	O
infection	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
focus	O
on	O
RIG	B-Protein
-	I-Protein
I	E-Protein
-	O
like	O
receptor	O
(	O
RLR	O
)	O
signal	O
transduction	O
and	O
the	O
regulatory	O
mechanisms	O
-	O
ubiquitination	O
,	O
deubiquitination	O
,	O
ISGylation	O
-	O
underlying	O
this	O
important	O
host	O
response	O
.	O

Arginine	O
methylation	O
analysis	O
of	O
the	O
splicing	O
-	O
associated	O
SR	O
protein	O
SFRS9	S-Protein
/	O
SRP30C	S-Protein
.	O

The	O
human	O
SFRS9	S-Protein
/	O
SRp30c	S-Protein
belongs	O
to	O
the	O
SR	O
family	O
of	O
splicing	O
regulators	O
.	O

Despite	O
evidence	O
that	O
members	O
of	O
this	O
protein	O
family	O
may	O
be	O
targeted	O
by	O
arginine	O
methylation	O
,	O
this	O
has	O
yet	O
to	O
be	O
experimentally	O
addressed	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
SFRS9	S-Protein
is	O
a	O
target	O
for	O
PRMT1	S-Protein
-	O
mediated	O
arginine	O
methylation	O
in	O
vitro	O
,	O
and	O
that	O
it	O
is	O
immunoprecipitated	O
from	O
HEK	O
-	O
293	O
lysates	O
by	O
antibodies	O
that	O
recognize	O
both	O
mono	O
-	O
and	O
dimethylated	O
arginines	O
.	O

We	O
further	O
observed	O
that	O
upon	O
treatment	O
with	O
the	O
methylation	O
inhibitor	O
Adox	O
,	O
the	O
fluorescent	O
EGFP	S-Protein
-	O
SFRS9	S-Protein
re	O
-	O
localizes	O
to	O
dot	O
-	O
like	O
structures	O
in	O
the	O
cell	O
nucleus	O
.	O

In	O
subsequent	O
confocal	O
analyses	O
,	O
we	O
found	O
that	O
EGFP	S-Protein
-	O
SFRS9	S-Protein
localizes	O
to	O
nucleoli	O
in	O
Adox	O
-	O
treated	O
cells	O
.	O

Our	O
findings	O
indicate	O
the	O
importance	O
of	O
arginine	O
methylation	O
for	O
the	O
subnuclear	O
localization	O
of	O
SFRS9	S-Protein
.	O

Multicenter	O
evaluation	O
of	O
an	O
investigational	O
prostate	O
cancer	O
methylation	O
assay	O
.	O

PURPOSE	O
:	O
Prostate	B-Protein
specific	I-Protein
antigen	E-Protein
tests	O
have	O
low	O
specificity	O
,	O
which	O
frequently	O
results	O
in	O
unnecessary	O
biopsy	O
and	O
typically	O
limits	O
screening	O
to	O
patients	O
with	O
prostate	B-Protein
specific	I-Protein
antigen	E-Protein
greater	O
than	O
4	O
.	O
0	O
ng	O
/	O
ml	O
.	O

We	O
evaluated	O
an	O
investigational	O
prostate	O
cancer	O
methylation	O
specific	O
polymerase	O
chain	O
reaction	O
assay	O
that	O
detects	O
aberrant	O
methylation	O
in	O
3	O
markers	O
(	O
GSTP1	S-Protein
,	O
RARbeta2	S-Protein
and	O
APC	S-Protein
)	O
that	O
indicate	O
the	O
presence	O
of	O
prostate	O
cancer	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
assay	O
was	O
evaluated	O
in	O
337	O
post	O
-	O
digital	O
rectal	O
examination	O
urine	O
samples	O
(	O
178	O
cancer	O
and	O
159	O
noncancer	O
)	O
collected	O
prospectively	O
at	O
a	O
total	O
of	O
9	O
clinical	O
sites	O
.	O

Samples	O
were	O
processed	O
wholly	O
or	O
after	O
division	O
into	O
equal	O
portions	O
.	O

Subject	O
prostate	B-Protein
specific	I-Protein
antigen	E-Protein
was	O
2	O
.	O
0	O
to	O
10	O
.	O
0	O
ng	O
/	O
ml	O
.	O

All	O
subjects	O
underwent	O
transrectal	O
ultrasound	O
guided	O
needle	O
biopsy	O
with	O
6	O
or	O
greater	O
cores	O
sampled	O
.	O

Detection	O
of	O
1	O
or	O
greater	O
markers	O
indicated	O
positivity	O
.	O

RESULTS	O
:	O
Methylation	O
specific	O
polymerase	O
chain	O
reaction	O
assay	O
performance	O
was	O
better	O
in	O
whole	O
than	O
in	O
divided	O
urine	O
cohorts	O
(	O
p	O
=	O
0	O
.	O
035	O
)	O
.	O

Assay	O
AUC	O
was	O
0	O
.	O
72	O
in	O
the	O
whole	O
urine	O
cohort	O
and	O
0	O
.	O
67	O
in	O
the	O
combined	O
population	O
.	O

These	O
values	O
were	O
higher	O
than	O
those	O
of	O
prostate	B-Protein
specific	I-Protein
antigen	E-Protein
alone	O
using	O
4	O
.	O
0	O
ng	O
/	O
ml	O
as	O
the	O
cutoff	O
(	O
p	O
=	O
0	O
.	O
00	O
and	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Moreover	O
,	O
the	O
assay	O
together	O
with	O
the	O
Prostate	O
Cancer	O
Prevention	O
Trial	O
risk	O
calculator	O
or	O
a	O
standard	O
nomogram	O
significantly	O
improved	O
AUC	O
in	O
the	O
whole	O
urine	O
cohort	O
and	O
the	O
combined	O
population	O
vs	O
predictive	O
algorithms	O
alone	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Assay	O
positive	O
predictive	O
value	O
was	O
54	O
%	O
in	O
whole	O
urine	O
cohort	O
with	O
prostate	B-Protein
specific	I-Protein
antigen	E-Protein
2	O
.	O
0	O
to	O
4	O
.	O
0	O
ng	O
/	O
ml	O
and	O
negative	O
predictive	O
value	O
was	O
87	O
%	O
with	O
prostate	B-Protein
specific	I-Protein
antigen	E-Protein
4	O
.	O
1	O
to	O
10	O
.	O
0	O
ng	O
/	O
ml	O
.	O

Assay	O
positive	O
predictive	O
value	O
was	O
higher	O
in	O
subjects	O
with	O
all	O
3	O
methylation	O
markers	O
positive	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
that	O
this	O
investigational	O
assay	O
used	O
in	O
conjunction	O
with	O
current	O
screening	O
algorithms	O
may	O
potentially	O
add	O
value	O
to	O
the	O
biopsy	O
decision	O
making	O
process	O
.	O

The	O
HECT	O
-	O
type	O
E3	O
ubiquitin	S-Protein
ligase	O
AIP2	S-Protein
inhibits	O
activation	O
-	O
induced	O
T	O
-	O
cell	O
death	O
by	O
catalyzing	O
EGR2	S-Protein
ubiquitination	O
.	O

E3	O
ubiquitin	S-Protein
ligases	O
,	O
which	O
target	O
specific	O
molecules	O
for	O
proteolytic	O
destruction	O
,	O
have	O
emerged	O
as	O
key	O
regulators	O
of	O
immune	O
functions	O
.	O

Several	O
E3	O
ubiquitin	S-Protein
ligases	O
,	O
including	O
c	B-Protein
-	I-Protein
Cbl	E-Protein
,	O
Cbl	B-Protein
-	I-Protein
b	E-Protein
,	O
GRAIL	S-Protein
,	O
Itch	S-Protein
,	O
and	O
Nedd4	S-Protein
,	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
T	O
-	O
cell	O
activation	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
HECT	O
-	O
type	O
E3	O
ligase	O
AIP2	S-Protein
positively	O
regulates	O
T	O
-	O
cell	O
activation	O
.	O

Ectopic	O
expression	O
of	O
AIP2	S-Protein
in	O
mouse	O
primary	O
T	O
cells	O
enhances	O
their	O
proliferation	O
and	O
interleukin	B-Protein
-	I-Protein
2	E-Protein
production	O
by	O
suppressing	O
the	O
apoptosis	O
of	O
T	O
cells	O
.	O

AIP2	S-Protein
interacts	O
with	O
and	O
promotes	O
ubiquitin	S-Protein
-	O
mediated	O
degradation	O
of	O
EGR2	S-Protein
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
that	O
has	O
been	O
found	O
to	O
regulate	O
Fas	B-Protein
ligand	E-Protein
(	O
FasL	S-Protein
)	O
expression	O
during	O
activation	O
-	O
induced	O
T	O
-	O
cell	O
death	O
.	O

Suppression	O
of	O
AIP2	S-Protein
expression	O
by	O
small	O
RNA	O
interference	O
upregulates	O
EGR2	S-Protein
,	O
inhibits	O
EGR2	S-Protein
ubiquitination	O
and	O
FasL	S-Protein
expression	O
,	O
and	O
enhances	O
the	O
apoptosis	O
of	O
T	O
cells	O
.	O

Therefore	O
,	O
AIP2	S-Protein
regulates	O
activation	O
-	O
induced	O
T	O
-	O
cell	O
death	O
by	O
suppressing	O
EGR2	S-Protein
-	O
mediated	O
FasL	S-Protein
expression	O
via	O
the	O
ubiquitin	S-Protein
pathway	O
.	O

Linking	O
cell	O
cycle	O
to	O
histone	S-Protein
modifications	O
:	O
SBF	O
and	O
H2B	S-Protein
monoubiquitination	O
machinery	O
and	O
cell	O
-	O
cycle	O
regulation	O
of	O
H3K79	S-Protein
dimethylation	O
.	O

To	O
identify	O
regulators	O
involved	O
in	O
determining	O
the	O
differential	O
pattern	O
of	O
H3K79	S-Protein
methylation	O
by	O
Dot1	S-Protein
,	O
we	O
screened	O
the	O
entire	O
yeast	O
gene	O
deletion	O
collection	O
by	O
GPS	O
for	O
genes	O
required	O
for	O
normal	O
levels	O
of	O
H3K79	S-Protein
di	O
-	O
but	O
not	O
trimethylation	O
.	O

We	O
identified	O
the	O
cell	O
cycle	O
-	O
regulated	O
SBF	O
protein	O
complex	O
required	O
for	O
H3K79	S-Protein
dimethylation	O
.	O

We	O
also	O
found	O
that	O
H3K79	S-Protein
di	O
-	O
and	O
trimethylation	O
are	O
mutually	O
exclusive	O
,	O
with	O
M	O
/	O
G1	O
cell	O
cycle	O
-	O
regulated	O
genes	O
significantly	O
enriched	O
for	O
H3K79	S-Protein
dimethylation	O
.	O

Since	O
H3K79	S-Protein
trimethylation	O
requires	O
prior	O
monoubiquitination	O
of	O
H2B	S-Protein
,	O
we	O
performed	O
genome	O
-	O
wide	O
profiling	O
of	O
H2BK123	S-Protein
monoubiquitination	O
and	O
showed	O
that	O
H2BK123	S-Protein
monoubiquitination	O
is	O
not	O
detected	O
on	O
cell	O
cycle	O
-	O
regulated	O
genes	O
and	O
sites	O
containing	O
H3K79me2	S-Protein
,	O
but	O
is	O
found	O
on	O
H3K79me3	S-Protein
-	O
containing	O
regions	O
.	O

A	O
screen	O
for	O
genes	O
responsible	O
for	O
the	O
establishment	O
/	O
removal	O
of	O
H3K79	S-Protein
dimethylation	O
resulted	O
in	O
identification	O
of	O
NRM1	S-Protein
and	O
WHI3	S-Protein
,	O
both	O
of	O
which	O
impact	O
the	O
transcription	O
by	O
the	O
SBF	O
and	O
MBF	O
protein	O
complexes	O
,	O
further	O
linking	O
the	O
regulation	O
of	O
methylation	O
status	O
of	O
H3K79	S-Protein
to	O
the	O
cell	O
cycle	O
.	O

Absence	O
of	O
ubiquitinated	O
inclusions	O
in	O
hypocretin	S-Protein
neurons	O
of	O
patients	O
with	O
narcolepsy	O
.	O

OBJECTIVES	O
:	O
The	O
cause	O
of	O
hypocretin	S-Protein
cell	O
loss	O
in	O
human	O
narcolepsy	O
-	O
cataplexy	O
is	O
unknown	O
but	O
has	O
been	O
suggested	O
to	O
be	O
neurodegenerative	O
in	O
nature	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
evaluated	O
the	O
remaining	O
hypocretin	S-Protein
cells	O
in	O
human	O
narcolepsy	O
brains	O
for	O
the	O
presence	O
of	O
aggregated	O
protein	O
inclusions	O
,	O
gliosis	O
,	O
and	O
inflammation	O
.	O

METHODS	O
:	O
Brains	O
were	O
examined	O
by	O
routine	O
histologic	O
methods	O
for	O
potential	O
comorbid	O
neurodegenerative	O
diseases	O
and	O
through	O
immunohistochemical	O
screening	O
for	O
protein	O
inclusions	O
in	O
the	O
hypothalamus	O
.	O

Hypothalamic	O
sections	O
of	O
4	O
subjects	O
with	O
narcolepsy	O
and	O
5	O
nonneurologic	O
controls	O
were	O
examined	O
immunohistochemically	O
with	O
antibodies	O
against	O
ubiquitin	S-Protein
(	O
a	O
marker	O
of	O
aggregated	O
protein	O
)	O
,	O
allograft	B-Protein
inflammatory	I-Protein
factor	I-Protein
1	E-Protein
(	O
AIF1	S-Protein
,	O
a	O
microglial	O
activation	O
marker	O
)	O
,	O
glial	B-Protein
fibrillary	I-Protein
acidic	I-Protein
protein	E-Protein
(	O
GFAP	S-Protein
,	O
a	O
reactive	O
astrocytic	O
marker	O
)	O
,	O
and	O
hypocretin	S-Protein
.	O

Hypothalami	O
of	O
subjects	O
with	O
narcolepsy	O
were	O
additionally	O
examined	O
for	O
the	O
presence	O
of	O
known	O
components	O
of	O
protein	O
aggregates	O
(	O
tau	S-Protein
,	O
alpha	B-Protein
-	I-Protein
synuclein	E-Protein
,	O
amyloid	B-Protein
beta	E-Protein
,	O
and	O
TDP	B-Protein
-	I-Protein
43	E-Protein
)	O
.	O

RESULTS	O
:	O
Hypocretin	S-Protein
cells	O
were	O
markedly	O
decreased	O
in	O
all	O
4	O
subjects	O
with	O
narcolepsy	O
.	O

Ubiquitinated	O
inclusions	O
were	O
not	O
observed	O
in	O
the	O
total	O
of	O
96	O
remaining	O
hypocretin	S-Protein
cells	O
in	O
these	O
subjects	O
.	O

Further	O
,	O
we	O
noted	O
that	O
even	O
in	O
patients	O
with	O
dementia	O
neuropathology	O
,	O
the	O
lateral	O
hypothalamic	O
hypocretin	S-Protein
area	O
was	O
spared	O
from	O
ubiquitinated	O
inclusions	O
.	O

AIF1	S-Protein
and	O
GFAP	S-Protein
staining	O
in	O
the	O
perifornical	O
area	O
was	O
unremarkable	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
hypocretin	S-Protein
cell	O
loss	O
does	O
not	O
involve	O
ubiquitinated	O
inclusions	O
,	O
the	O
hallmark	O
of	O
most	O
neurodegenerative	O
diseases	O
.	O

The	O
lack	O
of	O
increased	O
markers	O
of	O
inflammation	O
also	O
argues	O
against	O
a	O
progressive	O
and	O
continuous	O
neurodegenerative	O
process	O
.	O

Structural	O
basis	O
for	O
the	O
lack	O
of	O
E2	O
interaction	O
in	O
the	O
RING	O
domain	O
of	O
TRAF2	S-Protein
.	O

TRAF	O
proteins	O
are	O
intracellular	O
signal	O
transducers	O
for	O
a	O
number	O
of	O
immune	O
receptor	O
superfamilies	O
.	O

Specifically	O
,	O
TRAF2	S-Protein
interacts	O
with	O
members	O
of	O
the	O
TNF	O
receptor	O
superfamily	O
and	O
connects	O
the	O
receptors	O
to	O
downstream	O
signaling	O
proteins	O
.	O

It	O
has	O
been	O
assumed	O
that	O
TRAF2	S-Protein
is	O
a	O
ubiquitin	S-Protein
ligase	O
like	O
TRAF6	S-Protein
and	O
mediates	O
K63	O
-	O
linked	O
polyubiquitination	O
of	O
RIP1	S-Protein
,	O
a	O
kinase	O
pivotal	O
in	O
TNFalpha	S-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
RING	O
and	O
the	O
first	O
zinc	O
finger	O
domains	O
of	O
TRAF2	S-Protein
.	O

We	O
show	O
that	O
the	O
TRAF2	S-Protein
RING	O
structure	O
is	O
very	O
different	O
from	O
the	O
known	O
TRAF6	S-Protein
RING	O
structure	O
.	O

The	O
differences	O
are	O
multifaceted	O
,	O
including	O
amino	O
acid	O
differences	O
at	O
the	O
critical	O
Ubc13	S-Protein
-	O
interacting	O
site	O
,	O
local	O
conformational	O
differences	O
,	O
and	O
a	O
unique	O
nine	O
-	O
residue	O
insertion	O
between	O
the	O
RING	O
domain	O
and	O
the	O
first	O
zinc	O
finger	O
in	O
TRAF2	S-Protein
.	O

These	O
structural	O
differences	O
prevent	O
TRAF2	S-Protein
from	O
interacting	O
with	O
Ubc13	S-Protein
and	O
other	O
related	O
E2s	O
via	O
steric	O
clash	O
and	O
unfavorable	O
interfaces	O
.	O

Our	O
structural	O
observation	O
should	O
prompt	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
role	O
of	O
TRAF2	S-Protein
in	O
TNFalpha	S-Protein
signaling	O
and	O
may	O
indicate	O
that	O
TRAF2	S-Protein
-	O
associated	O
proteins	O
such	O
as	O
cIAPs	O
may	O
be	O
the	O
ubiquitin	S-Protein
ligases	O
for	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Changes	O
in	O
the	O
allelic	O
methylation	O
patterns	O
of	O
c	B-Protein
-	I-Protein
H	I-Protein
-	I-Protein
ras	I-Protein
-	I-Protein
1	E-Protein
,	O
insulin	S-Protein
and	O
retinoblastoma	S-Protein
genes	O
in	O
human	O
development	O
.	O

The	O
methylation	O
status	O
of	O
the	O
c	B-Protein
-	I-Protein
H	I-Protein
-	I-Protein
ras	I-Protein
-	I-Protein
1	E-Protein
,	O
insulin	S-Protein
and	O
retinoblastoma	S-Protein
genes	O
was	O
determined	O
in	O
human	O
sperm	O
,	O
hydatidiform	O
mole	O
,	O
fetal	O
tissues	O
,	O
adult	O
lymphocytes	O
and	O
adult	O
kidney	O
.	O

Individual	O
alleles	O
of	O
c	B-Protein
-	I-Protein
H	I-Protein
-	I-Protein
ras	I-Protein
-	I-Protein
1	E-Protein
and	O
insulin	S-Protein
were	O
distinguishable	O
due	O
to	O
presence	O
of	O
endogenous	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
polymorphisms	O
.	O

Both	O
alleles	O
of	O
the	O
latter	O
two	O
genes	O
were	O
extensively	O
methylated	O
in	O
sperm	O
compared	O
to	O
the	O
other	O
tissues	O
.	O

Several	O
sites	O
within	O
these	O
genes	O
were	O
less	O
methylated	O
in	O
fetal	O
tissues	O
and	O
the	O
two	O
alleles	O
were	O
differentially	O
methylated	O
in	O
some	O
cases	O
.	O

The	O
retinoblastoma	S-Protein
gene	O
was	O
highly	O
methylated	O
in	O
all	O
tissues	O
examined	O
,	O
with	O
the	O
exception	O
of	O
a	O
single	O
site	O
that	O
was	O
under	O
-	O
methylated	O
in	O
sperm	O
only	O
.	O

The	O
sperm	O
-	O
specific	O
methylation	O
patterns	O
in	O
all	O
three	O
genes	O
could	O
represent	O
imprinting	O
of	O
the	O
parental	O
chromosomes	O
.	O

Since	O
5	O
-	O
methylcytosine	O
is	O
inherently	O
mutagenic	O
,	O
it	O
is	O
possible	O
that	O
methylation	O
imprinting	O
could	O
alter	O
the	O
susceptibilities	O
of	O
human	O
genes	O
to	O
point	O
mutations	O
.	O

Screening	O
for	O
OST	O
deficiencies	O
in	O
unsolved	O
CDG	O
-	O
I	O
patients	O
.	O

Congenital	O
Disorders	O
of	O
Glycosylation	O
(	O
CDG	O
)	O
are	O
a	O
group	O
of	O
inherited	O
disorders	O
caused	O
by	O
deficiencies	O
in	O
glycosylation	O
.	O

Since	O
1980	O
,	O
14	O
CDG	O
type	O
I	O
(	O
CDG	O
-	O
I	O
)	O
defects	O
have	O
been	O
identified	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
all	O
affecting	O
the	O
assembly	O
of	O
the	O
oligosaccharide	O
precursor	O
.	O

However	O
,	O
the	O
number	O
of	O
unsolved	O
CDG	O
-	O
I	O
(	O
CDG	O
-	O
Ix	O
)	O
patients	O
displaying	O
protein	O
hypoglycosylation	O
in	O
combination	O
with	O
an	O
apparently	O
normal	O
assembly	O
of	O
the	O
oligosaccharide	O
precursor	O
is	O
currently	O
expanding	O
.	O

We	O
hypothesized	O
that	O
the	O
hypoglycosylation	O
observed	O
in	O
some	O
of	O
these	O
patients	O
could	O
be	O
caused	O
by	O
a	O
deficiency	O
in	O
the	O
transfer	O
of	O
the	O
oligosaccharide	O
precursor	O
onto	O
protein	O
,	O
a	O
reaction	O
catalyzed	O
by	O
the	O
oligosaccharyltransferase	O
(	O
OST	O
)	O
complex	O
.	O

For	O
this	O
purpose	O
,	O
the	O
different	O
subunits	O
of	O
the	O
OST	O
complex	O
were	O
screened	O
in	O
27	O
CDG	O
-	O
Ix	O
patients	O
for	O
whom	O
structural	O
analysis	O
of	O
the	O
lipid	O
-	O
linked	O
oligosaccharides	O
revealed	O
a	O
normal	O
level	O
and	O
intact	O
structure	O
of	O
the	O
oligosaccharide	O
precursor	O
.	O

Among	O
these	O
27	O
patients	O
,	O
one	O
was	O
identified	O
with	O
a	O
homozygous	O
missense	O
mutation	O
(	O
c	O
.	O
1121G	O
>	O
A	O
;	O
p	O
.	O
G374D	O
)	O
in	O
the	O
ribophorin	B-Protein
2	E-Protein
(	O
RPN2	S-Protein
)	O
subunit	O
of	O
the	O
OST	O
complex	O
.	O

The	O
pathogenic	O
nature	O
of	O
this	O
mutation	O
remains	O
unproven	O
due	O
to	O
the	O
complexity	O
of	O
tackling	O
a	O
possible	O
OST	O
defect	O
.	O

MdmX	S-Protein
is	O
a	O
substrate	O
for	O
the	O
deubiquitinating	O
enzyme	O
USP2a	S-Protein
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
ubiquitin	B-Protein
-	I-Protein
specific	I-Protein
protease	I-Protein
2a	E-Protein
(	O
USP2a	S-Protein
)	O
is	O
a	O
regulator	O
of	O
the	O
Mdm2	S-Protein
/	O
p53	S-Protein
pathway	O
.	O

USP2a	S-Protein
binds	O
to	O
Mdm2	S-Protein
and	O
can	O
deubiquitinate	O
Mdm2	S-Protein
without	O
reversing	O
Mdm2	S-Protein
-	O
mediated	O
p53	S-Protein
ubiquitination	O
.	O

Overexpression	O
of	O
USP2a	S-Protein
causes	O
accumulation	O
of	O
Mdm2	S-Protein
and	O
promotes	O
p53	S-Protein
degradation	O
.	O

We	O
now	O
show	O
that	O
MdmX	S-Protein
is	O
also	O
a	O
substrate	O
for	O
USP2a	S-Protein
.	O

MdmX	O
associates	O
with	O
USP2a	S-Protein
independently	O
of	O
Mdm2	S-Protein
.	O

Ectopic	O
expression	O
of	O
wild	O
-	O
type	O
USP2a	S-Protein
but	O
not	O
a	O
catalytic	O
mutant	O
prevents	O
Mdm2	S-Protein
-	O
mediated	O
degradation	O
of	O
MdmX	S-Protein
.	O

This	O
correlates	O
with	O
the	O
ability	O
of	O
wild	O
-	O
type	O
USP2a	S-Protein
to	O
deubiquitinate	O
MdmX	S-Protein
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
USP2a	S-Protein
in	O
NTERA	O
-	O
2	O
testicular	O
embryonal	O
carcinoma	O
cells	O
and	O
MCF7	O
breast	O
cancer	O
cells	O
causes	O
destabilization	O
of	O
MdmX	S-Protein
and	O
results	O
in	O
a	O
decrease	O
in	O
MdmX	S-Protein
protein	O
levels	O
,	O
showing	O
that	O
endogenous	O
USP2a	S-Protein
participates	O
in	O
the	O
regulation	O
of	O
MdmX	S-Protein
stability	O
.	O

The	O
therapeutic	O
drug	O
,	O
cisplatin	O
decreases	O
MdmX	S-Protein
protein	O
expression	O
.	O

USP2a	S-Protein
mRNA	O
and	O
protein	O
levels	O
were	O
also	O
reduced	O
after	O
cisplatin	O
exposure	O
.	O

The	O
magnitude	O
and	O
time	O
course	O
of	O
USP2a	S-Protein
downregulation	O
suggests	O
that	O
the	O
reduction	O
in	O
USP2a	S-Protein
levels	O
could	O
contribute	O
to	O
the	O
decrease	O
in	O
MdmX	S-Protein
expression	O
following	O
treatment	O
with	O
cisplatin	O
.	O

Knockdown	O
of	O
USP2a	S-Protein
increases	O
the	O
sensitivity	O
of	O
NTERA	O
-	O
2	O
cells	O
to	O
cisplatin	O
,	O
raising	O
the	O
possibility	O
that	O
suppression	O
of	O
USP2a	S-Protein
in	O
combination	O
with	O
cisplatin	O
may	O
be	O
an	O
approach	O
for	O
cancer	O
therapy	O
.	O

Prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	E-Protein
and	O
CRTAP	S-Protein
are	O
mutually	O
stabilizing	O
in	O
the	O
endoplasmic	O
reticulum	O
collagen	O
prolyl	O
3	O
-	O
hydroxylation	O
complex	O
.	O

Null	O
mutations	O
in	O
cartilage	B-Protein
-	I-Protein
associated	I-Protein
protein	E-Protein
(	O
CRTAP	S-Protein
)	O
and	O
prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	E-Protein
(	O
P3H1	S-Protein
/	O
LEPRE1	S-Protein
)	O
cause	O
types	O
VII	O
and	O
VIII	O
OI	O
,	O
respectively	O
,	O
two	O
novel	O
recessive	O
forms	O
of	O
osteogenesis	O
imperfecta	O
(	O
OI	O
)	O
with	O
severe	O
to	O
lethal	O
bone	O
dysplasia	O
and	O
overmodification	O
of	O
the	O
type	O
I	O
collagen	O
helical	O
region	O
.	O

CRTAP	S-Protein
and	O
P3H1	S-Protein
form	O
a	O
complex	O
with	O
cyclophilin	B-Protein
B	E-Protein
(	O
CyPB	S-Protein
)	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
which	O
3	O
-	O
hydroxylates	O
the	O
Pro986	O
residue	O
of	O
alpha1	B-Protein
(	I-Protein
I	I-Protein
)	E-Protein
and	O
alpha1	B-Protein
(	I-Protein
II	I-Protein
)	I-Protein
collagen	E-Protein
chains	O
.	O

We	O
investigated	O
the	O
interaction	O
of	O
complex	O
components	O
in	O
fibroblasts	O
from	O
types	O
VII	O
and	O
VIII	O
OI	O
patients	O
.	O

Both	O
CRTAP	S-Protein
and	O
P3H1	S-Protein
are	O
absent	O
or	O
reduced	O
on	O
western	O
blots	O
and	O
by	O
immunofluorescence	O
microscopy	O
in	O
cells	O
containing	O
null	O
mutations	O
in	O
either	O
gene	O
.	O

Levels	O
of	O
LEPRE1	S-Protein
or	O
CRTAP	S-Protein
transcripts	O
,	O
however	O
,	O
are	O
normal	O
in	O
CRTAP	S-Protein
-	O
or	O
LEPRE1	S-Protein
-	O
null	O
cells	O
,	O
respectively	O
.	O

Stable	O
transfection	O
of	O
a	O
CRTAP	S-Protein
or	O
LEPRE1	S-Protein
expression	O
construct	O
into	O
cells	O
with	O
null	O
mutations	O
for	O
the	O
transfected	O
cDNA	O
restored	O
both	O
CRTAP	S-Protein
and	O
P3H1	S-Protein
protein	O
levels	O
.	O

Normalization	O
of	O
collagen	O
helical	O
modification	O
in	O
transfected	O
CRTAP	S-Protein
-	O
null	O
cells	O
demonstrated	O
that	O
the	O
restored	O
proteins	O
functioned	O
effectively	O
as	O
a	O
complex	O
.	O

These	O
data	O
indicate	O
that	O
CRTAP	S-Protein
and	O
P3H1	S-Protein
are	O
mutually	O
stabilized	O
in	O
the	O
collagen	O
prolyl	O
3	O
-	O
hydroxylation	O
complex	O
.	O

CyPB	S-Protein
levels	O
were	O
unaffected	O
by	O
mutations	O
in	O
either	O
CRTAP	S-Protein
or	O
LEPRE1	S-Protein
.	O

Proteasomal	O
inhibitors	O
partially	O
rescue	O
P3H1	S-Protein
protein	O
in	O
CRTAP	S-Protein
-	O
null	O
cells	O
.	O

In	O
LEPRE1	S-Protein
-	O
null	O
cells	O
,	O
secretion	O
of	O
CRTAP	S-Protein
is	O
increased	O
compared	O
with	O
control	O
cells	O
and	O
accounts	O
for	O
15	O
-	O
20	O
%	O
of	O
the	O
decreased	O
CRTAP	S-Protein
detected	O
in	O
cells	O
.	O

Thus	O
,	O
mutual	O
stabilization	O
of	O
P3H1	S-Protein
and	O
CRTAP	S-Protein
in	O
the	O
ER	O
collagen	O
modification	O
complex	O
is	O
an	O
underlying	O
mechanism	O
for	O
the	O
overlapping	O
phenotype	O
of	O
types	O
VII	O
and	O
VIII	O
OI	O
.	O

GDP	B-Protein
-	I-Protein
mannose	I-Protein
pyrophosphorylase	E-Protein
is	O
essential	O
in	O
the	O
bloodstream	O
form	O
of	O
Trypanosoma	O
brucei	O
.	O

A	O
putative	O
GDP	B-Protein
-	I-Protein
Man	I-Protein
PP	E-Protein
(	O
guanidine	B-Protein
diphosphomannose	I-Protein
pyrophosphorylase	E-Protein
)	O
gene	O
from	O
Trypanosoma	O
brucei	O
(	O
TbGDP	B-Protein
-	I-Protein
Man	I-Protein
PP	E-Protein
)	O
was	O
identified	O
in	O
the	O
genome	O
and	O
subsequently	O
cloned	O
,	O
sequenced	O
and	O
recombinantly	O
expressed	O
,	O
and	O
shown	O
to	O
be	O
a	O
catalytically	O
active	O
dimer	O
.	O

Kinetic	O
analysis	O
revealed	O
a	O
Vmax	O
of	O
0	O
.	O
34	O
mumol	O
/	O
min	O
per	O
mg	O
of	O
protein	O
and	O
Km	O
values	O
of	O
67	O
muM	O
and	O
12	O
muM	O
for	O
GTP	O
and	O
mannose	O
1	O
-	O
phosphate	O
respectively	O
.	O

Further	O
kinetic	O
studies	O
showed	O
GDP	O
-	O
Man	O
was	O
a	O
potent	O
product	O
feedback	O
inhibitor	O
.	O

RNAi	O
(	O
RNA	O
interference	O
)	O
of	O
the	O
cytosolic	O
TbGDP	B-Protein
-	I-Protein
Man	I-Protein
PP	E-Protein
showed	O
that	O
mRNA	O
levels	O
were	O
reduced	O
to	O
~	O
20	O
%	O
of	O
wild	O
-	O
type	O
levels	O
,	O
causing	O
the	O
cells	O
to	O
die	O
after	O
3	O
-	O
4	O
days	O
,	O
demonstrating	O
that	O
TbGDP	B-Protein
-	I-Protein
Man	I-Protein
PP	E-Protein
is	O
essential	O
in	O
the	O
bloodstream	O
form	O
of	O
T	O
.	O
brucei	O
and	O
thus	O
a	O
potential	O
drug	O
target	O
.	O

The	O
RNAi	O
-	O
induced	O
parasites	O
have	O
a	O
greatly	O
reduced	O
capability	O
to	O
form	O
GDP	O
-	O
Man	O
,	O
leading	O
ultimately	O
to	O
a	O
reduction	O
in	O
their	O
ability	O
to	O
synthesize	O
their	O
essential	O
GPI	O
(	O
glycosylphosphatidylinositol	O
)	O
anchors	O
.	O

The	O
RNAi	O
-	O
induced	O
parasites	O
also	O
showed	O
aberrant	O
N	O
-	O
glycosylation	O
of	O
their	O
major	O
cell	O
-	O
surface	O
glycoprotein	O
,	O
variant	O
surface	O
glycoprotein	O
,	O
with	O
loss	O
of	O
the	O
high	O
-	O
mannose	O
Man9GlcNAc2	O
N	O
-	O
glycosylation	O
at	O
Asn428	O
and	O
formation	O
of	O
complex	O
N	O
-	O
glycans	O
at	O
Asn263	O
.	O

Regulation	O
of	O
virus	O
-	O
triggered	O
signaling	O
by	O
OTUB1	S-Protein
-	O
and	O
OTUB2	S-Protein
-	O
mediated	O
deubiquitination	O
of	O
TRAF3	S-Protein
and	O
TRAF6	S-Protein
.	O

Ubiquitination	O
and	O
deubiquitination	O
have	O
emerged	O
as	O
critical	O
post	O
-	O
translational	O
regulatory	O
mechanisms	O
for	O
activation	O
or	O
attenuation	O
of	O
the	O
virus	O
-	O
triggered	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
(	O
2	O
)	O
induction	O
pathways	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
two	O
deubiquitinating	O
enzymes	O
,	O
OTUB1	S-Protein
and	O
OTUB2	S-Protein
,	O
as	O
negative	O
regulators	O
of	O
virus	O
-	O
triggered	O
type	O
I	O
IFN	O
induction	O
.	O

Overexpression	O
of	O
OTUB1	S-Protein
and	O
OTUB2	S-Protein
inhibited	O
virus	O
-	O
induced	O
activation	O
of	O
IRF3	S-Protein
and	O
NF	O
-	O
kappaB	O
,	O
transcription	O
of	O
the	O
IFNB1	S-Protein
gene	O
as	O
well	O
as	O
cellular	O
antiviral	O
response	O
,	O
whereas	O
knockdown	O
of	O
OTUB1	S-Protein
and	O
OTUB2	S-Protein
had	O
opposite	O
effects	O
.	O

Coimmunoprecipitations	O
indicated	O
OTUB1	S-Protein
and	O
-	B-Protein
2	E-Protein
interacted	O
with	O
TRAF3	S-Protein
and	O
TRAF6	S-Protein
,	O
two	O
E3	O
ubiquitin	S-Protein
ligases	O
required	O
for	O
virus	O
-	O
triggered	O
IRF3	S-Protein
and	O
NF	O
-	O
kappaB	O
activation	O
,	O
respectively	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
OTUB1	S-Protein
and	O
OTUB2	S-Protein
mediated	O
virus	O
-	O
triggered	O
deubiquitination	O
of	O
TRAF3	S-Protein
and	O
-	B-Protein
6	E-Protein
.	O

These	O
findings	O
suggest	O
that	O
OTUB1	S-Protein
and	O
OTUB2	S-Protein
negatively	O
regulate	O
virus	O
-	O
triggered	O
type	O
I	O
IFN	O
induction	O
and	O
cellular	O
antiviral	O
response	O
by	O
deubiquitinating	O
TRAF3	S-Protein
and	O
-	B-Protein
6	E-Protein
.	O

Fbxo45	S-Protein
,	O
a	O
novel	O
ubiquitin	S-Protein
ligase	O
,	O
regulates	O
synaptic	O
activity	O
.	O

Neurons	O
communicate	O
with	O
each	O
other	O
through	O
synapses	O
.	O

To	O
establish	O
the	O
precise	O
yet	O
flexible	O
connections	O
that	O
make	O
up	O
neural	O
networks	O
in	O
the	O
brain	O
,	O
continuous	O
synaptic	O
modulation	O
is	O
required	O
.	O

The	O
ubiquitin	S-Protein
-	O
proteasome	O
system	O
of	O
protein	O
degradation	O
is	O
one	O
of	O
the	O
critical	O
mechanisms	O
that	O
underlie	O
this	O
process	O
,	O
playing	O
crucial	O
roles	O
in	O
the	O
regulation	O
of	O
synaptic	O
structure	O
and	O
function	O
.	O

We	O
identified	O
a	O
novel	O
ubiquitin	S-Protein
ligase	O
,	O
Fbxo45	S-Protein
,	O
that	O
functions	O
at	O
synapses	O
.	O

Fbxo45	S-Protein
is	O
evolutionarily	O
conserved	O
and	O
selectively	O
expressed	O
in	O
the	O
nervous	O
system	O
.	O

We	O
demonstrated	O
that	O
the	O
knockdown	O
of	O
Fbxo45	S-Protein
in	O
primary	O
cultured	O
hippocampal	O
neurons	O
resulted	O
in	O
a	O
greater	O
frequency	O
of	O
miniature	O
excitatory	O
postsynaptic	O
currents	O
.	O

We	O
also	O
found	O
that	O
Fbxo45	S-Protein
induces	O
the	O
degradation	O
of	O
a	O
synaptic	O
vesicle	O
-	O
priming	O
factor	O
,	O
Munc13	B-Protein
-	I-Protein
1	E-Protein
.	O

We	O
propose	O
that	O
Fbxo45	S-Protein
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
neurotransmission	O
by	O
modulating	O
Munc13	B-Protein
-	I-Protein
1	E-Protein
at	O
the	O
synapse	O
.	O

The	O
19S	O
proteasomal	O
lid	O
subunit	O
POH1	S-Protein
enhances	O
the	O
transcriptional	O
activation	O
by	O
Mitf	S-Protein
in	O
osteoclasts	O
.	O

The	O
microphthalmia	B-Protein
-	I-Protein
associated	I-Protein
transcription	I-Protein
factor	E-Protein
(	O
Mitf	S-Protein
)	O
regulates	O
gene	O
expression	O
required	O
for	O
osteoclast	O
differentiation	O
.	O

Genes	O
regulated	O
by	O
Mitf	S-Protein
have	O
been	O
previously	O
identified	O
.	O

However	O
,	O
proteins	O
that	O
interact	O
and	O
regulate	O
Mitf	S-Protein
'	O
s	O
activity	O
in	O
osteoclasts	O
are	O
not	O
well	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
POH1	S-Protein
,	O
a	O
subunit	O
of	O
the	O
19S	O
proteasome	O
lid	O
is	O
a	O
regulator	O
of	O
Mitf	S-Protein
.	O

We	O
show	O
that	O
POH1	S-Protein
and	O
Mitf	S-Protein
interact	O
in	O
osteoclasts	O
and	O
that	O
this	O
interaction	O
is	O
dependent	O
on	O
RANKL	S-Protein
signaling	O
.	O

Overexpression	O
of	O
POH1	S-Protein
increased	O
Mitf	S-Protein
'	O
s	O
activation	O
of	O
5XGal4	O
-	O
TK	O
and	O
Acp5	S-Protein
promoters	O
.	O

The	O
amino	O
terminus	O
of	O
POH1	S-Protein
mediates	O
the	O
binding	O
to	O
Mitf	S-Protein
and	O
is	O
sufficient	O
to	O
increase	O
Mitf	S-Protein
'	O
s	O
transcriptional	O
activity	O
.	O

Finally	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
JAMM	O
motif	O
of	O
POH1	S-Protein
reduced	O
Mitf	S-Protein
activation	O
of	O
promoters	O
.	O

In	O
summary	O
,	O
our	O
results	O
identify	O
a	O
novel	O
mechanism	O
of	O
Mitf	S-Protein
regulation	O
in	O
osteoclasts	O
by	O
POH1	S-Protein
.	O

Mutations	O
in	O
Cullin	B-Protein
4B	E-Protein
result	O
in	O
a	O
human	O
syndrome	O
associated	O
with	O
increased	O
camptothecin	O
-	O
induced	O
topoisomerase	B-Protein
I	E-Protein
-	O
dependent	O
DNA	O
breaks	O
.	O

CUL4A	S-Protein
and	O
B	S-Protein
encode	O
subunits	O
of	O
E3	O
-	O
ubiquitin	S-Protein
ligases	O
implicated	O
in	O
diverse	O
processes	O
including	O
nucleotide	O
excision	O
repair	O
,	O
regulating	O
gene	O
expression	O
and	O
controlling	O
DNA	O
replication	O
fork	O
licensing	O
.	O

But	O
,	O
the	O
functional	O
distinction	O
between	O
CUL4A	S-Protein
and	O
CUL4B	S-Protein
,	O
if	O
any	O
,	O
is	O
unclear	O
.	O

Recently	O
,	O
mutations	O
in	O
CUL4B	S-Protein
were	O
identified	O
in	O
humans	O
associated	O
with	O
mental	O
retardation	O
,	O
relative	O
macrocephaly	O
,	O
tremor	O
and	O
a	O
peripheral	O
neuropathy	O
.	O

Cells	O
from	O
these	O
patients	O
offer	O
a	O
unique	O
system	O
to	O
help	O
define	O
at	O
the	O
molecular	O
level	O
the	O
consequences	O
of	O
defective	O
CUL4B	S-Protein
specifically	O
.	O

We	O
show	O
that	O
these	O
patient	O
-	O
derived	O
cells	O
exhibit	O
sensitivity	O
to	O
camptothecin	O
(	O
CPT	O
)	O
,	O
impaired	O
CPT	O
-	O
induced	O
topoisomerase	B-Protein
I	E-Protein
(	O
Topo	B-Protein
I	E-Protein
)	O
degradation	O
and	O
ubiquitination	O
,	O
thereby	O
suggesting	O
Topo	B-Protein
I	E-Protein
to	O
be	O
a	O
novel	O
Cul4	O
-	O
dependent	O
substrate	O
.	O

Consistent	O
with	O
this	O
,	O
we	O
also	O
find	O
that	O
these	O
cells	O
exhibit	O
increased	O
levels	O
of	O
CPT	O
-	O
induced	O
DNA	O
breaks	O
.	O

Furthermore	O
,	O
over	O
-	O
expression	O
of	O
known	O
CUL4	O
-	O
dependent	O
substrates	O
including	O
Cdt1	S-Protein
and	O
p21	S-Protein
appear	O
to	O
be	O
a	O
feature	O
of	O
these	O
patient	O
-	O
derived	O
cells	O
.	O

Collectively	O
,	O
our	O
findings	O
highlight	O
the	O
interplay	O
between	O
CUL4A	S-Protein
and	O
CUL4B	S-Protein
and	O
provide	O
insight	O
into	O
the	O
pathogenesis	O
of	O
CUL4B	S-Protein
-	O
deficiency	O
in	O
humans	O
.	O

Normal	O
shear	O
stress	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
modulate	O
migration	O
of	O
endothelial	O
cells	O
through	O
histone	B-Protein
deacetylase	I-Protein
6	E-Protein
activation	O
and	O
tubulin	O
acetylation	O
.	O

Endothelial	O
cells	O
(	O
ECs	O
)	O
line	O
the	O
innermost	O
of	O
the	O
blood	O
vessel	O
wall	O
and	O
are	O
constantly	O
subjected	O
to	O
shear	O
stress	O
imposed	O
by	O
blood	O
flow	O
.	O

ECs	O
were	O
also	O
influenced	O
by	O
the	O
neighboring	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
.	O

The	O
bidirectional	O
communication	O
between	O
ECs	O
and	O
VSMCs	O
modulates	O
vascular	O
homeostasis	O
.	O

In	O
this	O
study	O
,	O
the	O
involvement	O
of	O
histone	B-Protein
deacetylase	I-Protein
6	E-Protein
(	O
HDAC6	S-Protein
)	O
in	O
modulating	O
migration	O
of	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
by	O
the	O
normal	O
level	O
of	O
laminar	O
shear	O
stress	O
(	O
NSS	O
)	O
was	O
investigated	O
.	O

ECs	O
was	O
either	O
cultured	O
alone	O
or	O
co	O
-	O
cultured	O
with	O
VSMCs	O
under	O
static	O
conditions	O
or	O
subjected	O
to	O
NSS	O
of	O
15	O
dyne	O
/	O
cm2	O
by	O
using	O
a	O
parallel	O
-	O
plate	O
co	O
-	O
culture	O
flow	O
chamber	O
system	O
.	O

It	O
was	O
demonstrated	O
that	O
both	O
NSS	O
and	O
VSMCs	O
could	O
increase	O
EC	O
migration	O
.	O

The	O
migration	O
level	O
of	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
under	O
NSS	O
was	O
not	O
higher	O
than	O
that	O
under	O
the	O
static	O
condition	O
.	O

The	O
process	O
of	O
EC	O
migration	O
regulated	O
by	O
VSMCs	O
and	O
NSS	O
was	O
associated	O
with	O
the	O
increased	O
expression	O
of	O
HDAC6	S-Protein
and	O
low	O
level	O
of	O
acetylated	O
tubulin	O
.	O

The	O
increase	O
in	O
HDAC6	S-Protein
expression	O
was	O
accompanied	O
by	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
acetylation	O
of	O
tubulin	O
in	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
.	O

Inhibition	O
of	O
the	O
HDAC6	S-Protein
by	O
siRNA	O
or	O
tributyrin	O
,	O
an	O
inhibitor	O
of	O
HDACs	O
,	O
induced	O
a	O
parallel	O
alteration	O
in	O
the	O
migration	O
and	O
the	O
acetylated	O
tubulin	O
of	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
.	O

It	O
was	O
observed	O
by	O
immunofluorescence	O
staining	O
that	O
the	O
acetylated	O
tubulin	O
was	O
distributed	O
mostly	O
around	O
the	O
cell	O
nucleus	O
in	O
ECs	O
co	O
-	O
cultured	O
with	O
VSMCs	O
.	O

The	O
results	O
suggest	O
that	O
the	O
NSS	O
may	O
display	O
a	O
protective	O
function	O
on	O
the	O
vascular	O
homeostasis	O
by	O
modulating	O
EC	O
migration	O
to	O
a	O
normal	O
level	O
in	O
a	O
VSMC	O
-	O
dependent	O
manner	O
.	O

This	O
modulation	O
process	O
involves	O
the	O
down	O
-	O
regulation	O
of	O
acetylated	O
tubulin	O
which	O
results	O
from	O
increased	O
HDAC6	S-Protein
activity	O
in	O
ECs	O
.	O

Tonic	O
ubiquitylation	O
controls	O
T	O
-	O
cell	O
receptor	O
:	O
CD3	O
complex	O
expression	O
during	O
T	O
-	O
cell	O
development	O
.	O

Expression	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
:	O
CD3	O
complex	O
is	O
tightly	O
regulated	O
during	O
T	O
-	O
cell	O
development	O
.	O

The	O
mechanism	O
and	O
physiological	O
role	O
of	O
this	O
regulation	O
are	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
TCR	O
:	O
CD3	O
complex	O
is	O
constitutively	O
ubiquitylated	O
in	O
immature	O
double	O
positive	O
(	O
DP	O
)	O
thymocytes	O
,	O
but	O
not	O
mature	O
single	O
positive	O
(	O
SP	O
)	O
thymocytes	O
or	O
splenic	O
T	O
cells	O
.	O

This	O
steady	O
state	O
,	O
tonic	O
CD3	O
monoubiquitylation	O
is	O
mediated	O
by	O
the	O
CD3varepsilon	O
proline	O
-	O
rich	O
sequence	O
,	O
Lck	S-Protein
,	O
c	B-Protein
-	I-Protein
Cbl	E-Protein
,	O
and	O
SLAP	S-Protein
,	O
which	O
collectively	O
trigger	O
the	O
dynamin	O
-	O
dependent	O
downmodulation	O
,	O
lysosomal	O
sequestration	O
and	O
degradation	O
of	O
surface	O
TCR	O
:	O
CD3	O
complexes	O
.	O

Blocking	O
this	O
tonic	O
ubiquitylation	O
by	O
mutating	O
all	O
the	O
lysines	O
in	O
the	O
CD3	O
cytoplasmic	O
tails	O
significantly	O
upregulates	O
TCR	O
levels	O
on	O
DP	O
thymocytes	O
.	O

Mimicking	O
monoubiquitylation	O
by	O
expression	O
of	O
a	O
CD3zeta	S-Protein
-	O
monoubiquitin	S-Protein
(	O
monoUb	S-Protein
)	O
fusion	O
molecule	O
significantly	O
reduces	O
TCR	O
levels	O
on	O
immature	O
thymocytes	O
.	O

Moreover	O
,	O
modulating	O
CD3	O
ubiquitylation	O
alters	O
immunological	O
synapse	O
(	O
IS	O
)	O
formation	O
and	O
Erk	O
phosphorylation	O
,	O
thereby	O
shifting	O
the	O
signalling	O
threshold	O
for	O
positive	O
and	O
negative	O
selection	O
,	O
and	O
regulatory	O
T	O
-	O
cell	O
development	O
.	O

Thus	O
,	O
tonic	O
TCR	O
:	O
CD3	O
ubiquitylation	O
results	O
in	O
precise	O
regulation	O
of	O
TCR	O
expression	O
on	O
immature	O
T	O
cells	O
,	O
which	O
is	O
required	O
to	O
maintain	O
the	O
fidelity	O
of	O
T	O
-	O
cell	O
development	O
.	O

RNF8	S-Protein
-	O
dependent	O
histone	S-Protein
modifications	O
regulate	O
nucleosome	O
removal	O
during	O
spermatogenesis	O
.	O

During	O
spermatogenesis	O
,	O
global	O
nucleosome	O
removal	O
occurs	O
where	O
histones	S-Protein
are	O
initially	O
replaced	O
by	O
transition	O
proteins	O
and	O
subsequently	O
by	O
protamines	O
.	O

This	O
chromatin	O
reorganization	O
is	O
thought	O
to	O
facilitate	O
the	O
compaction	O
of	O
the	O
paternal	O
genome	O
into	O
the	O
sperm	O
head	O
and	O
to	O
protect	O
the	O
DNA	O
from	O
damaging	O
agents	O
.	O

Histone	S-Protein
ubiquitination	O
has	O
been	O
suggested	O
to	O
be	O
important	O
for	O
sex	O
chromosome	O
inactivation	O
during	O
meiotic	O
prophase	O
and	O
nucleosome	O
removal	O
at	O
postmeiotic	O
stages	O
.	O

However	O
,	O
the	O
mechanisms	O
regulating	O
these	O
ubiquitin	S-Protein
-	O
mediated	O
processes	O
are	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	O
of	O
the	O
ubiquitin	S-Protein
ligase	O
RNF8	S-Protein
during	O
spermatogenesis	O
and	O
find	O
that	O
RNF8	S-Protein
-	O
deficient	O
mice	O
are	O
proficient	O
in	O
meiotic	O
sex	O
chromosome	O
inactivation	O
(	O
MSCI	O
)	O
but	O
deficient	O
in	O
global	O
nucleosome	O
removal	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
RNF8	S-Protein
-	O
dependent	O
histone	S-Protein
ubiquitination	O
induces	O
H4K16	S-Protein
acetylation	O
,	O
which	O
may	O
be	O
an	O
initial	O
step	O
in	O
nucleosome	O
removal	O
.	O

Thus	O
,	O
our	O
results	O
show	O
that	O
RNF8	S-Protein
plays	O
an	O
important	O
role	O
during	O
spermatogenesis	O
through	O
histone	S-Protein
ubiquitination	O
,	O
resulting	O
in	O
trans	O
-	O
histone	S-Protein
acetylation	O
and	O
global	O
nucleosome	O
removal	O
.	O

Predicted	O
functions	O
of	O
MdmX	S-Protein
in	O
fine	O
-	O
tuning	O
the	O
response	O
of	O
p53	S-Protein
to	O
DNA	O
damage	O
.	O

Tumor	O
suppressor	O
protein	O
p53	S-Protein
is	O
regulated	O
by	O
two	O
structurally	O
homologous	O
proteins	O
,	O
Mdm2	S-Protein
and	O
MdmX	S-Protein
.	O

In	O
contrast	O
to	O
Mdm2	S-Protein
,	O
MdmX	S-Protein
lacks	O
ubiquitin	S-Protein
ligase	O
activity	O
.	O

Although	O
the	O
essential	O
interactions	O
of	O
MdmX	S-Protein
are	O
known	O
,	O
it	O
is	O
not	O
clear	O
how	O
they	O
function	O
to	O
regulate	O
p53	S-Protein
.	O

The	O
regulation	O
of	O
tumor	O
suppressor	O
p53	S-Protein
by	O
Mdm2	S-Protein
and	O
MdmX	S-Protein
in	O
response	O
to	O
DNA	O
damage	O
was	O
investigated	O
by	O
mathematical	O
modeling	O
of	O
a	O
simplified	O
network	O
.	O

The	O
simplified	O
network	O
model	O
was	O
derived	O
from	O
a	O
detailed	O
molecular	O
interaction	O
map	O
(	O
MIM	O
)	O
that	O
exhibited	O
four	O
coherent	O
DNA	O
damage	O
response	O
pathways	O
.	O

The	O
results	O
suggest	O
that	O
MdmX	S-Protein
may	O
amplify	O
or	O
stabilize	O
DNA	O
damage	O
-	O
induced	O
p53	S-Protein
responses	O
via	O
non	O
-	O
enzymatic	O
interactions	O
.	O

Transient	O
effects	O
of	O
MdmX	S-Protein
are	O
mediated	O
by	O
reservoirs	O
of	O
p53ratioMdmX	S-Protein
and	O
Mdm2ratioMdmX	S-Protein
heterodimers	O
,	O
with	O
MdmX	S-Protein
buffering	O
the	O
concentrations	O
of	O
p53	S-Protein
and	O
/	O
or	O
Mdm2	S-Protein
.	O

A	O
survey	O
of	O
kinetic	O
parameter	O
space	O
disclosed	O
regions	O
of	O
switch	O
-	O
like	O
behavior	O
stemming	O
from	O
such	O
reservoir	O
-	O
based	O
transients	O
.	O

During	O
an	O
early	O
response	O
to	O
DNA	O
damage	O
,	O
MdmX	S-Protein
positively	O
or	O
negatively	O
regulated	O
p53	S-Protein
activity	O
,	O
depending	O
on	O
the	O
level	O
of	O
Mdm2	S-Protein
;	O
this	O
led	O
to	O
amplification	O
of	O
p53	S-Protein
activity	O
and	O
switch	O
-	O
like	O
response	O
.	O

During	O
a	O
late	O
response	O
to	O
DNA	O
damage	O
,	O
MdmX	S-Protein
could	O
dampen	O
oscillations	O
of	O
p53	S-Protein
activity	O
.	O

A	O
possible	O
role	O
of	O
MdmX	S-Protein
may	O
be	O
to	O
dampen	O
such	O
oscillations	O
that	O
otherwise	O
could	O
produce	O
erratic	O
cell	O
behavior	O
.	O

Our	O
study	O
suggests	O
how	O
MdmX	S-Protein
may	O
participate	O
in	O
the	O
response	O
of	O
p53	S-Protein
to	O
DNA	O
damage	O
either	O
by	O
increasing	O
dependency	O
of	O
p53	S-Protein
on	O
Mdm2	S-Protein
or	O
by	O
dampening	O
oscillations	O
of	O
p53	S-Protein
activity	O
and	O
presents	O
a	O
model	O
for	O
experimental	O
investigation	O
.	O

Glioma	B-Protein
pathogenesis	I-Protein
-	I-Protein
related	I-Protein
1	I-Protein
-	I-Protein
like	I-Protein
1	E-Protein
is	O
testis	O
enriched	O
,	O
dynamically	O
modified	O
,	O
and	O
redistributed	O
during	O
male	O
germ	O
cell	O
maturation	O
and	O
has	O
a	O
potential	O
role	O
in	O
sperm	O
-	O
oocyte	O
binding	O
.	O

The	O
glioma	B-Protein
pathogenesis	I-Protein
-	I-Protein
related	I-Protein
1	E-Protein
(	O
GLIPR1	S-Protein
)	O
family	O
consists	O
of	O
three	O
genes	O
[	O
GLIPR1	S-Protein
,	O
GLIPR1	B-Protein
-	I-Protein
like	I-Protein
1	E-Protein
(	O
GLIPR1L1	S-Protein
)	O
,	O
and	O
GLIPR1	B-Protein
-	I-Protein
like	I-Protein
2	E-Protein
(	O
GLIPR1L2	S-Protein
)	O
]	O
and	O
forms	O
a	O
distinct	O
subgroup	O
within	O
the	O
cysteine	O
-	O
rich	O
secretory	O
protein	O
(	O
CRISP	O
)	O
,	O
antigen	O
5	O
,	O
and	O
pathogenesis	O
-	O
related	O
1	O
(	O
CAP	O
)	O
superfamily	O
.	O

CAP	O
superfamily	O
proteins	O
are	O
found	O
in	O
phyla	O
ranging	O
from	O
plants	O
to	O
humans	O
and	O
,	O
based	O
largely	O
on	O
expression	O
and	O
limited	O
functional	O
studies	O
,	O
are	O
hypothesized	O
to	O
have	O
roles	O
in	O
carcinogenesis	O
,	O
immunity	O
,	O
cell	O
adhesion	O
,	O
and	O
male	O
fertility	O
.	O

Specifically	O
data	O
from	O
a	O
number	O
of	O
systems	O
suggests	O
that	O
sequences	O
within	O
the	O
C	O
-	O
terminal	O
CAP	O
domain	O
of	O
CAP	O
proteins	O
have	O
the	O
ability	O
to	O
promote	O
cell	O
-	O
cell	O
adhesion	O
.	O

Herein	O
we	O
cloned	O
mouse	O
Glipr1l1	S-Protein
and	O
have	O
shown	O
it	O
has	O
a	O
testis	O
-	O
enriched	O
expression	O
profile	O
.	O

GLIPR1L1	S-Protein
is	O
posttranslationally	O
modified	O
by	O
N	O
-	O
linked	O
glycosylation	O
during	O
spermatogenesis	O
and	O
ultimately	O
becomes	O
localized	O
to	O
the	O
connecting	O
piece	O
of	O
elongated	O
spermatids	O
and	O
sperm	O
.	O

After	O
sperm	O
capacitation	O
,	O
however	O
,	O
GLIPR1L1	S-Protein
is	O
also	O
localized	O
to	O
the	O
anterior	O
regions	O
of	O
the	O
sperm	O
head	O
.	O

Zona	O
pellucida	O
binding	O
assays	O
indicate	O
that	O
GLIPR1L1	S-Protein
has	O
a	O
role	O
in	O
the	O
binding	O
of	O
sperm	O
to	O
the	O
zona	O
pellucida	O
surrounding	O
the	O
oocyte	O
.	O

These	O
data	O
suggest	O
that	O
,	O
along	O
with	O
other	O
members	O
of	O
the	O
CAP	O
superfamily	O
and	O
several	O
other	O
proteins	O
,	O
GLIPR1L1	S-Protein
is	O
involved	O
in	O
the	O
binding	O
of	O
sperm	O
to	O
the	O
oocyte	O
complex	O
.	O

Collectively	O
these	O
data	O
further	O
strengthen	O
the	O
role	O
of	O
CAP	O
domain	O
-	O
containing	O
proteins	O
in	O
cellular	O
adhesion	O
and	O
propose	O
a	O
mechanism	O
whereby	O
CAP	O
proteins	O
show	O
overlapping	O
functional	O
significance	O
during	O
fertilization	O
.	O

UTX	S-Protein
mediates	O
demethylation	O
of	O
H3K27me3	S-Protein
at	O
muscle	O
-	O
specific	O
genes	O
during	O
myogenesis	O
.	O

Polycomb	O
(	O
PcG	O
)	O
and	O
Trithorax	O
(	O
TrxG	O
)	O
group	O
proteins	O
act	O
antagonistically	O
to	O
establish	O
tissue	O
-	O
specific	O
patterns	O
of	O
gene	O
expression	O
.	O

The	O
PcG	O
protein	O
Ezh2	S-Protein
facilitates	O
repression	O
by	O
catalysing	O
histone	B-Protein
H3	E-Protein
-	O
Lys27	O
trimethylation	O
(	O
H3K27me3	S-Protein
)	O
.	O

For	O
expression	O
,	O
H3K27me3	S-Protein
marks	O
are	O
removed	O
and	O
replaced	O
by	O
TrxG	O
protein	O
catalysed	O
histone	O
H3	S-Protein
-	O
Lys4	O
trimethylation	O
(	O
H3K4me3	S-Protein
)	O
.	O

Although	O
H3K27	S-Protein
demethylases	O
have	O
been	O
identified	O
,	O
the	O
mechanism	O
by	O
which	O
these	O
enzymes	O
are	O
targeted	O
to	O
specific	O
genomic	O
regions	O
to	O
remove	O
H3K27me3	S-Protein
marks	O
has	O
not	O
been	O
established	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
two	O
-	O
step	O
mechanism	O
for	O
UTX	S-Protein
-	O
mediated	O
demethylation	O
at	O
muscle	O
-	O
specific	O
genes	O
during	O
myogenesis	O
.	O

Although	O
the	O
transactivator	O
Six4	S-Protein
initially	O
recruits	O
UTX	S-Protein
to	O
the	O
regulatory	O
region	O
of	O
muscle	O
genes	O
,	O
the	O
resulting	O
loss	O
of	O
H3K27me3	S-Protein
marks	O
is	O
limited	O
to	O
the	O
region	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

Removal	O
of	O
the	O
repressive	O
H3K27me3	S-Protein
mark	O
within	O
the	O
coding	O
region	O
then	O
requires	O
RNA	O
Polymerase	O
II	O
(	O
Pol	O
II	O
)	O
elongation	O
.	O

Interestingly	O
,	O
blocking	O
Pol	O
II	O
elongation	O
on	O
transcribed	O
genes	O
leads	O
to	O
increased	O
H3K27me3	S-Protein
within	O
the	O
coding	O
region	O
,	O
and	O
formation	O
of	O
bivalent	O
(	O
H3K27me3	S-Protein
/	O
H3K4me3	S-Protein
)	O
chromatin	O
domains	O
.	O

Thus	O
,	O
removal	O
of	O
repressive	O
H3K27me3	S-Protein
marks	O
by	O
UTX	S-Protein
occurs	O
through	O
targeted	O
recruitment	O
followed	O
by	O
spreading	O
across	O
the	O
gene	O
.	O

Protein	O
-	O
protein	O
interactions	O
involving	O
IKKgamma	S-Protein
(	O
NEMO	S-Protein
)	O
that	O
promote	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Inhibitor	B-Protein
of	I-Protein
kappaB	I-Protein
kinase	I-Protein
(	I-Protein
IKK	I-Protein
)	I-Protein
gamma	E-Protein
(	O
IKKgamma	S-Protein
)	O
,	O
also	O
referred	O
to	O
as	O
nuclear	B-Protein
factor	I-Protein
kappaB	I-Protein
(	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
)	I-Protein
essential	I-Protein
modulator	E-Protein
(	O
NEMO	S-Protein
)	O
,	O
is	O
an	O
important	O
regulatory	O
component	O
of	O
the	O
IKK	O
complex	O
.	O

The	O
IKK	O
complex	O
is	O
a	O
signalosome	O
that	O
catalyzes	O
the	O
inducible	O
phosphorylation	O
of	O
IkappaB	O
proteins	O
,	O
which	O
is	O
a	O
key	O
step	O
that	O
leads	O
to	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
exact	O
functions	O
of	O
IKKgamma	S-Protein
(	O
NEMO	S-Protein
)	O
as	O
part	O
of	O
the	O
IKK	O
complex	O
have	O
not	O
yet	O
been	O
fully	O
elucidated	O
.	O

This	O
mini	O
-	O
review	O
covers	O
16	O
proteins	O
that	O
have	O
been	O
reported	O
to	O
bind	O
to	O
IKKgamma	S-Protein
and	O
lead	O
to	O
the	O
enhancement	O
of	O
the	O
activities	O
of	O
the	O
IKK	O
complex	O
,	O
thus	O
resulting	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
major	O
mechanisms	O
by	O
which	O
these	O
interactions	O
are	O
mediated	O
involve	O
the	O
recognition	O
of	O
ubiquitinated	O
upstream	O
signaling	O
components	O
by	O
IKKgamma	S-Protein
or	O
the	O
modification	O
of	O
IKKgamma	S-Protein
itself	O
by	O
ubiquitination	O
.	O

Additional	O
mechanisms	O
include	O
the	O
sumoylation	O
or	O
phosphorylation	O
of	O
IKKgamma	S-Protein
and	O
the	O
modification	O
of	O
the	O
tertiary	O
or	O
quaternary	O
structure	O
of	O
IKKgamma	S-Protein
.	O

Extended	O
ischemia	O
prevents	O
HIF1alpha	S-Protein
degradation	O
at	O
reoxygenation	O
by	O
impairing	O
prolyl	O
-	O
hydroxylation	O
:	O
role	O
of	O
Krebs	O
cycle	O
metabolites	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
heterodimeric	O
transcription	O
factor	O
that	O
activates	O
the	O
cellular	O
response	O
to	O
hypoxia	O
.	O

The	O
HIF1alpha	S-Protein
subunit	O
is	O
constantly	O
synthesized	O
and	O
degraded	O
under	O
normoxia	O
,	O
but	O
degradation	O
is	O
rapidly	O
inhibited	O
when	O
oxygen	O
levels	O
drop	O
.	O

Oxygen	O
-	O
dependent	O
hydroxylation	O
by	O
prolyl	O
-	O
4	O
-	O
hydroxylases	O
(	O
PHD	O
)	O
mediates	O
HIF1alpha	S-Protein
proteasome	O
degradation	O
.	O

Brain	O
ischemia	O
limits	O
the	O
availability	O
not	O
only	O
of	O
oxygen	O
but	O
also	O
of	O
glucose	O
.	O

We	O
hypothesized	O
that	O
this	O
circumstance	O
could	O
have	O
a	O
modulating	O
effect	O
on	O
HIF	O
.	O

We	O
assessed	O
the	O
separate	O
involvement	O
of	O
oxygen	O
and	O
glucose	O
in	O
HIF1alpha	S-Protein
regulation	O
in	O
differentiated	O
neuroblastoma	O
cells	O
subjected	O
to	O
ischemia	O
.	O

We	O
report	O
higher	O
transcriptional	O
activity	O
and	O
HIF1alpha	S-Protein
expression	O
under	O
oxygen	O
deprivation	O
in	O
the	O
presence	O
of	O
glucose	O
(	O
OD	O
)	O
,	O
than	O
in	O
its	O
absence	O
(	O
oxygen	O
and	O
glucose	O
deprivation	O
,	O
OGD	O
)	O
.	O

Unexpectedly	O
,	O
HIF1alpha	S-Protein
was	O
not	O
degraded	O
at	O
reoxygenation	O
after	O
an	O
episode	O
of	O
OGD	O
.	O

This	O
was	O
not	O
due	O
to	O
impairment	O
of	O
proteasome	O
function	O
,	O
but	O
was	O
associated	O
with	O
lower	O
HIF1alpha	S-Protein
hydroxylation	O
.	O

Krebs	O
cycle	O
metabolites	O
fumarate	O
and	O
succinate	O
are	O
known	O
inhibitors	O
of	O
PHD	O
,	O
while	O
alpha	O
-	O
ketoglutarate	O
is	O
a	O
co	O
-	O
substrate	O
of	O
the	O
reaction	O
.	O

Lack	O
of	O
HIF1alpha	S-Protein
degradation	O
in	O
the	O
presence	O
of	O
oxygen	O
was	O
accompanied	O
by	O
a	O
very	O
low	O
alpha	O
-	O
ketoglutarate	O
/	O
fumarate	O
ratio	O
.	O

Furthermore	O
,	O
treatment	O
with	O
a	O
fumarate	O
analogue	O
prevented	O
HIF1alpha	O
degradation	O
under	O
normoxia	O
.	O

In	O
all	O
,	O
our	O
data	O
suggest	O
that	O
postischemic	O
metabolic	O
alterations	O
in	O
Krebs	O
cycle	O
metabolites	O
impair	O
HIF1alpha	O
degradation	O
in	O
the	O
presence	O
of	O
oxygen	O
by	O
decreasing	O
its	O
hydroxylation	O
,	O
and	O
highlight	O
the	O
involvement	O
of	O
metabolic	O
pathways	O
in	O
HIF1alpha	S-Protein
regulation	O
besides	O
the	O
well	O
known	O
effects	O
of	O
oxygen	O
.	O

Regulated	O
degradation	O
of	O
spindle	O
assembly	O
factors	O
by	O
the	O
anaphase	O
-	O
promoting	O
complex	O
.	O

The	O
ubiquitin	S-Protein
ligase	O
anaphase	O
-	O
promoting	O
complex	O
(	O
APC	O
/	O
C	O
)	O
is	O
essential	O
for	O
cell	O
division	O
in	O
all	O
eukaryotes	O
.	O

Loss	O
of	O
APC	O
/	O
C	O
activity	O
arrests	O
cells	O
at	O
metaphase	O
and	O
results	O
in	O
severe	O
aberrations	O
of	O
the	O
mitotic	O
spindle	O
,	O
but	O
how	O
the	O
APC	O
/	O
C	O
regulates	O
spindle	O
formation	O
is	O
not	O
understood	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
APC	O
/	O
C	O
promotes	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
four	O
proteins	O
required	O
for	O
Ran	S-Protein
-	O
dependent	O
spindle	O
assembly	O
:	O
Bard1	S-Protein
,	O
Hmmr	S-Protein
,	O
HURP	S-Protein
,	O
and	O
NuSAP	S-Protein
.	O

Among	O
these	O
substrates	O
,	O
HURP	S-Protein
and	O
NuSAP	S-Protein
can	O
be	O
degraded	O
during	O
spindle	O
formation	O
when	O
the	O
spindle	O
checkpoint	O
is	O
active	O
.	O

Their	O
degradation	O
requires	O
additional	O
layers	O
of	O
regulation	O
,	O
and	O
both	O
SAFs	O
are	O
only	O
degraded	O
after	O
being	O
released	O
from	O
their	O
inhibitor	O
importin	O
beta	O
by	O
Ran	S-Protein
(	O
GTP	O
)	O
.	O

Our	O
findings	O
reveal	O
a	O
tightly	O
regulated	O
mechanism	O
by	O
which	O
the	O
APC	O
/	O
C	O
and	O
the	O
GTPase	O
Ran	S-Protein
control	O
the	O
abundance	O
of	O
active	O
spindle	O
assembly	O
factors	O
to	O
achieve	O
the	O
accurate	O
formation	O
of	O
the	O
mitotic	O
spindle	O
.	O

A	O
novel	O
antioxidant	O
role	O
for	O
hemoglobin	O
.	O

The	O
comproportionation	O
of	O
ferrylhemoglobin	O
with	O
oxyhemoglobin	O
.	O

Ferrylhemoglobin	O
(	O
X	O
-	O
FeIV	O
-	O
OH	O
,	O
where	O
X	O
denotes	O
an	O
amino	O
acid	O
residue	O
in	O
the	O
globin	O
moiety	O
)	O
has	O
long	O
been	O
suspected	O
as	O
a	O
cytotoxic	O
agent	O
produced	O
by	O
the	O
interaction	O
of	O
oxyhemoglobin	O
(	O
X	O
-	O
FeIIO2	O
)	O
or	O
methemoglobin	O
(	O
X	O
-	O
FeIII	O
)	O
with	O
H2O2	O
in	O
red	O
blood	O
cells	O
.	O

To	O
date	O
,	O
however	O
,	O
technical	O
difficulties	O
have	O
prevented	O
the	O
identification	O
and	O
quantification	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
.	O

Oxyhemoglobin	O
exposed	O
to	O
a	O
continuous	O
flux	O
of	O
H2O2	O
(	O
generated	O
at	O
a	O
rate	O
of	O
120	O
microM	O
/	O
min	O
during	O
the	O
glucose	B-Protein
oxidase	E-Protein
-	O
catalyzed	O
oxidation	O
of	O
glucose	O
)	O
was	O
oxidized	O
to	O
(	O
a	O
)	O
X	O
-	O
FeIV	O
-	O
OH	O
when	O
[	O
X	O
-	O
FeIIO2	O
]	O
less	O
than	O
75	O
microM	O
and	O
(	O
b	O
)	O
X	O
-	O
FeIII	O
when	O
[	O
X	O
-	O
FeIIO2	O
]	O
greater	O
than	O
75	O
microM	O
(	O
the	O
production	O
of	O
X	O
-	O
FeIII	O
proceeded	O
with	O
intermediate	O
formation	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
)	O
.	O

The	O
reduction	O
of	O
the	O
X	O
-	O
FeIV	O
-	O
OH	O
to	O
X	O
-	O
FeIII	O
could	O
be	O
explained	O
by	O
either	O
of	O
two	O
alternative	O
mechanisms	O
:	O
a	O
O2	O
(	O
-	O
)	O
-	O
mediated	O
X	O
-	O
FeIV	O
-	O
OH	O
-	O
-	O
-	O
X	O
-	O
FeIII	O
transition	O
or	O
a	O
comproportionation	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
and	O
X	O
-	O
FeIIO2	O
to	O
yield	O
X	O
-	O
FeIII	O
(	O
a	O
process	O
mediated	O
by	O
a	O
tyrosine	O
moiety	O
in	O
the	O
hemoprotein	O
)	O
.	O

The	O
low	O
rate	O
of	O
X	O
-	O
FeIIO2	O
autoxidation	O
plus	O
the	O
negligible	O
decrease	O
in	O
the	O
rate	O
of	O
X	O
-	O
FeIII	O
formation	O
in	O
the	O
presence	O
of	O
either	O
native	O
or	O
heat	O
-	O
denatured	O
superoxide	O
dismutase	O
or	O
apoenzyme	O
(	O
1	O
microM	O
)	O
suggested	O
that	O
O2	O
-	O
does	O
not	O
contribute	O
to	O
the	O
reduction	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
.	O

Moreover	O
,	O
the	O
dependence	O
of	O
X	O
-	O
FeIII	O
formation	O
on	O
X	O
-	O
FeIIO2	O
concentration	O
,	O
together	O
with	O
the	O
results	O
of	O
O2	O
uptake	O
and	O
H2O2	O
consumption	O
measurements	O
,	O
provide	O
experimental	O
evidence	O
to	O
support	O
the	O
comproportionation	O
reaction	O
.	O

Comproportionation	O
is	O
apparently	O
catalyzed	O
by	O
intermolecular	O
electron	O
transfer	O
between	O
tyrosine	O
residues	O
,	O
since	O
the	O
reaction	O
did	O
not	O
occur	O
when	O
tyrosine	O
residues	O
were	O
blocked	O
by	O
acetylation	O
.	O

Intact	O
red	O
blood	O
cells	O
exposed	O
to	O
the	O
same	O
flow	O
rate	O
of	O
H2O2	O
presented	O
a	O
spectral	O
profile	O
which	O
could	O
be	O
explained	O
as	O
a	O
transition	O
from	O
X	O
-	O
FeIIO2	O
to	O
X	O
-	O
FeIII	O
.	O

The	O
intermediate	O
production	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
was	O
detected	O
by	O
adding	O
Na2S	O
(	O
2	O
mM	O
)	O
,	O
which	O
revealed	O
a	O
spectral	O
profile	O
identical	O
with	O
that	O
obtained	O
with	O
purified	O
X	O
-	O
FeIV	O
-	O
OH	O
.	O

Measurements	O
of	O
concentrations	O
and	O
relative	O
rate	O
constants	O
for	O
the	O
reaction	O
of	O
various	O
intracellular	O
reductants	O
(	O
glutathione	O
,	O
NAD	O
(	O
P	O
)	O
H	O
,	O
uric	O
acid	O
,	O
ascorbic	O
acid	O
)	O
with	O
X	O
-	O
FeIV	O
-	O
OH	O
revealed	O
that	O
comproportionation	O
of	O
X	O
-	O
FeIV	O
-	O
OH	O
with	O
X	O
-	O
FeIIO2	O
is	O
the	O
favored	O
reaction	O
.	O

Our	O
results	O
provide	O
(	O
to	O
our	O
knowledge	O
)	O
the	O
first	O
definitive	O
evidence	O
for	O
X	O
-	O
FeIV	O
-	O
OH	O
in	O
intact	O
red	O
blood	O
cells	O
.	O

The	O
rapid	O
comproportionation	O
reaction	O
between	O
X	O
-	O
FeIV	O
-	O
OH	O
and	O
X	O
-	O
FeIIO2	O
(	O
to	O
produce	O
X	O
-	O
FeIII	O
)	O
explains	O
why	O
X	O
-	O
FeIV	O
-	O
OH	O
has	O
been	O
elusive	O
to	O
date	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Expression	O
and	O
characterization	O
of	O
human	O
factor	B-Protein
IX	E-Protein
and	O
factor	B-Protein
IX	E-Protein
-	O
factor	B-Protein
X	E-Protein
chimeras	O
in	O
mouse	O
C127	O
cells	O
.	O

Human	O
blood	O
clotting	O
factor	B-Protein
IX	E-Protein
,	O
and	O
two	O
chimeric	O
molecules	O
of	O
factor	B-Protein
IX	E-Protein
,	O
in	O
which	O
the	O
first	O
epidermal	O
growth	O
factor	O
-	O
like	O
domain	O
or	O
both	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
have	O
been	O
replaced	O
by	O
that	O
of	O
human	O
factor	B-Protein
X	E-Protein
,	O
have	O
been	O
expressed	O
in	O
mouse	O
C127	O
cells	O
.	O

The	O
recombinants	O
have	O
been	O
purified	O
using	O
a	O
metal	O
ion	O
-	O
dependent	O
monoclonal	O
antibody	O
specific	O
for	O
residues	O
1	O
-	O
42	O
of	O
human	O
factor	B-Protein
IX	E-Protein
.	O

All	O
recombinant	O
molecules	O
are	O
activated	O
normally	O
by	O
human	O
factor	B-Protein
XIa	E-Protein
in	O
the	O
presence	O
of	O
calcium	O
ion	O
.	O

Activation	O
of	O
the	O
factor	B-Protein
IX	E-Protein
recombinants	O
by	O
factor	B-Protein
VIIa	E-Protein
-	O
tissue	B-Protein
factor	E-Protein
appears	O
to	O
be	O
normal	O
for	O
the	O
epidermal	O
growth	O
factor	O
-	O
1	O
exchange	O
but	O
considerably	O
reduced	O
for	O
the	O
construction	O
containing	O
both	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
of	O
factor	B-Protein
X	E-Protein
.	O

The	O
analysis	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
residues	O
reveals	O
that	O
all	O
of	O
the	O
purified	O
recombinants	O
are	O
almost	O
fully	O
carboxylated	O
.	O

The	O
extent	O
of	O
aspartic	O
acid	O
hydroxylation	O
at	O
residue	O
64	O
is	O
60	O
%	O
for	O
all	O
recombinants	O
.	O

The	O
chimeric	O
molecule	O
with	O
both	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
from	O
factor	B-Protein
X	E-Protein
has	O
about	O
4	O
%	O
normal	O
activity	O
in	O
the	O
activated	O
partial	O
thromboplastin	S-Protein
time	O
assay	O
.	O

In	O
contrast	O
,	O
the	O
construct	O
containing	O
the	O
first	O
epidermal	O
growth	O
factor	O
-	O
like	O
domain	O
of	O
factor	B-Protein
X	E-Protein
shows	O
essentially	O
normal	O
clotting	O
activity	O
.	O

Thus	O
,	O
it	O
is	O
unlikely	O
that	O
this	O
domain	O
is	O
involved	O
in	O
a	O
unique	O
interaction	O
with	O
factor	B-Protein
VIII	E-Protein
.	O

Release	O
of	O
[	O
hydroxyproline3	O
]	O
-	O
kinins	S-Protein
by	O
tissue	O
kallikreins	O
of	O
pig	O
,	O
rat	O
and	O
man	O
.	O

To	O
determine	O
the	O
susceptibility	O
of	O
kininogens	S-Protein
containing	O
the	O
recently	O
described	O
[	O
Hyp3	O
]	O
-	O
bradykinin	S-Protein
moiety	O
to	O
cleavage	O
by	O
tissue	O
kallikreins	O
,	O
we	O
have	O
studied	O
the	O
release	O
of	O
[	O
Hyp3	O
]	O
-	O
kinins	S-Protein
from	O
heat	O
inactivated	O
human	O
plasma	O
by	O
purified	O
tissue	O
kallikreins	O
.	O

Kallikreins	O
from	O
man	O
and	O
pig	O
were	O
employed	O
and	O
compared	O
with	O
purified	O
rat	O
urinary	O
kallikrein	O
which	O
is	O
known	O
to	O
have	O
a	O
different	O
cleavage	O
specificity	O
.	O

Kinins	O
released	O
were	O
separated	O
by	O
a	O
modified	O
reversed	O
phase	O
HPLC	O
method	O
and	O
quantitated	O
by	O
bioassay	O
and	O
radioimmunoassay	O
.	O

Human	O
urinary	O
kallikrein	O
and	O
hog	O
tissue	O
kallikreins	O
released	O
85	O
-	O
90	O
%	O
of	O
the	O
total	O
kinins	S-Protein
as	O
Lys	O
-	O
bradykinin	S-Protein
and	O
10	O
-	O
15	O
%	O
as	O
[	O
Hyp3	O
]	O
-	O
Lys	O
-	O
bradykinin	S-Protein
.	O

In	O
contrast	O
,	O
rat	O
urinary	O
kallikrein	O
released	O
77	O
%	O
as	O
bradykinin	S-Protein
,	O
22	O
%	O
as	O
[	O
Hyp3	O
]	O
-	O
bradykinin	S-Protein
and	O
negligible	O
amounts	O
of	O
[	O
Hyp3	O
]	O
-	O
Lys	O
-	O
bradykinin	S-Protein
from	O
the	O
identical	O
substrate	O
source	O
indicating	O
that	O
rat	O
tissue	O
kallikreins	O
prefer	O
the	O
Lys	O
-	O
Arg	O
-	O
bond	O
within	O
both	O
unhydroxylated	O
and	O
hydroxylated	O
kininogens	S-Protein
.	O

Therefore	O
,	O
hydroxylation	O
of	O
human	O
kininogens	S-Protein
apparently	O
does	O
not	O
affect	O
their	O
ability	O
to	O
serve	O
as	O
substrates	O
for	O
tissue	O
kallikreins	O
with	O
different	O
cleavage	O
specificities	O
.	O

Processing	O
of	O
the	O
gp55	S-Protein
-	O
116	S-Protein
envelope	O
glycoprotein	O
complex	O
(	O
gB	S-Protein
)	O
of	O
human	O
cytomegalovirus	O
.	O

The	O
processing	O
pathway	O
of	O
the	O
major	O
envelope	O
glycoprotein	O
complex	O
,	O
gp55	S-Protein
-	O
116	S-Protein
(	O
gB	S-Protein
)	O
,	O
of	O
human	O
cytomegalovirus	O
was	O
studied	O
using	O
inhibitors	O
of	O
glycosylation	O
and	O
endoglycosidases	O
.	O

The	O
results	O
of	O
these	O
studies	O
indicated	O
that	O
the	O
mature	O
gp55	S-Protein
-	O
116	S-Protein
is	O
synthesized	O
by	O
the	O
addition	O
of	O
both	O
simple	O
and	O
complex	O
N	O
-	O
linked	O
sugars	O
to	O
a	O
nonglycosylated	O
precursor	O
of	O
estimated	O
Mr	O
105	O
,	O
000	O
.	O

In	O
a	O
rapid	O
processing	O
step	O
,	O
the	O
Mr	O
105	O
,	O
000	O
precursor	O
is	O
glycosylated	O
to	O
a	O
protein	O
of	O
Mr	O
150	O
,	O
000	O
(	O
gp150	S-Protein
)	O
which	O
contains	O
only	O
endoglycosidase	B-Protein
H	E-Protein
-	O
sensitive	O
sugar	O
linkages	O
.	O

The	O
gp150	S-Protein
is	O
then	O
processed	O
relatively	O
slowly	O
to	O
a	O
Mr	O
165	O
,	O
000	O
to	O
170	O
,	O
000	O
species	O
(	O
gp165	B-Protein
-	I-Protein
170	E-Protein
)	O
,	O
which	O
is	O
then	O
cleaved	O
to	O
yield	O
the	O
mature	O
gp55	S-Protein
-	O
116	S-Protein
.	O

Monensin	O
prevented	O
the	O
final	O
processing	O
steps	O
of	O
the	O
gp150	S-Protein
,	O
including	O
cleavage	O
,	O
suggesting	O
that	O
transport	O
through	O
the	O
Golgi	O
apparatus	O
is	O
required	O
for	O
complete	O
processing	O
.	O

Digestion	O
of	O
the	O
intracellular	O
forms	O
of	O
this	O
complex	O
as	O
well	O
as	O
the	O
virion	O
forms	O
confirmed	O
the	O
above	O
findings	O
and	O
indicated	O
that	O
the	O
mature	O
virion	O
form	O
of	O
gp55	S-Protein
contains	O
8	O
,	O
000	O
daltons	O
of	O
N	O
-	O
linked	O
sugars	O
.	O

The	O
virion	O
gp116	S-Protein
contains	O
some	O
52	O
,	O
000	O
to	O
57	O
,	O
000	O
daltons	O
of	O
N	O
-	O
linked	O
carbohydrates	O
and	O
approximately	O
5	O
,	O
000	O
daltons	O
of	O
O	O
-	O
linked	O
sugars	O
.	O

Microthrombomodulin	S-Protein
.	O

Residues	O
310	O
-	O
486	O
from	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
precursor	O
homology	O
domain	O
of	O
thrombomodulin	S-Protein
will	O
accelerate	O
protein	O
C	O
activation	O
.	O

Thrombomodulin	S-Protein
is	O
the	O
endothelial	O
cell	O
cofactor	O
for	O
thrombin	O
-	O
catalyzed	O
activation	O
of	O
protein	B-Protein
C	E-Protein
.	O

Recently	O
,	O
we	O
isolated	O
a	O
10	O
-	O
kDa	O
thrombin	S-Protein
binding	O
fragment	O
,	O
CB3	O
,	O
from	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
precursor	O
homology	O
domain	O
(	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
(	O
EGF	S-Protein
)	O
-	O
like	O
regions	O
)	O
of	O
thrombomodulin	S-Protein
(	O
Kurasawa	O
,	O
S	O
.	O
,	O
Stearns	O
,	O
D	O
.	O
J	O
.	O
,	O
Jackson	O
,	O
K	O
.	O
W	O
.	O
,	O
and	O
Esmon	O
,	O
C	O
.	O
T	O
.	O
(	O
1988	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
263	O
,	O
5993	O
-	O
5996	O
)	O
.	O

The	O
CB3	O
fragment	O
did	O
not	O
,	O
however	O
,	O
support	O
protein	B-Protein
C	E-Protein
activation	O
.	O

A	O
29	O
-	O
kDa	O
fragment	O
,	O
called	O
CB23	O
,	O
has	O
now	O
been	O
isolated	O
and	O
corresponds	O
to	O
residues	O
310	O
-	O
486	O
in	O
the	O
EGF	S-Protein
-	O
like	O
region	O
of	O
thrombomodulin	S-Protein
.	O

The	O
CB23	O
fragment	O
bound	O
thrombin	S-Protein
and	O
accelerated	O
thrombin	S-Protein
-	O
catalyzed	O
protein	B-Protein
C	E-Protein
activation	O
.	O

With	O
two	O
separate	O
preparations	O
of	O
CB23	O
,	O
the	O
Km	O
for	O
protein	B-Protein
C	E-Protein
was	O
1	O
.	O
6	O
and	O
1	O
.	O
9	O
microM	O
and	O
the	O
Kd	O
for	O
thrombin	S-Protein
was	O
8	O
.	O
9	O
and	O
13	O
.	O
2	O
nM	O
.	O

The	O
carboxyl	O
terminus	O
of	O
CB23	O
and	O
CB3	O
was	O
identified	O
by	O
isolation	O
and	O
sequence	O
analysis	O
of	O
a	O
tryptic	O
peptide	O
from	O
CB3	O
.	O

The	O
sequence	O
of	O
this	O
peptide	O
corresponded	O
to	O
Asn457	O
-	O
Ser486	O
,	O
indicating	O
that	O
the	O
carboxyl	O
terminus	O
of	O
these	O
fragments	O
is	O
6	O
residues	O
beyond	O
the	O
sixth	O
EGF	S-Protein
-	O
like	O
region	O
of	O
thrombomodulin	S-Protein
.	O

In	O
addition	O
,	O
although	O
CB3	O
cannot	O
accelerate	O
protein	B-Protein
C	E-Protein
activation	O
,	O
CB3	O
did	O
inhibit	O
the	O
rate	O
of	O
thrombin	S-Protein
-	O
catalyzed	O
fibrinopeptide	O
release	O
from	O
fibrinogen	O
.	O

Thus	O
,	O
like	O
native	O
thrombomodulin	S-Protein
,	O
CB3	O
will	O
alter	O
thrombin	S-Protein
'	O
s	O
substrate	O
specificity	O
,	O
but	O
protein	B-Protein
C	E-Protein
activation	O
requires	O
additional	O
information	O
all	O
of	O
which	O
can	O
be	O
provided	O
by	O
other	O
regions	O
of	O
the	O
EGF	S-Protein
-	O
like	O
domain	O
.	O

Clonal	O
analysis	O
of	O
the	O
glycosylation	O
of	O
immunoglobulin	O
G	O
secreted	O
by	O
murine	O
hybridomas	O
.	O

A	O
panel	O
of	O
10	O
hybridomas	O
was	O
assembled	O
to	O
assess	O
the	O
influence	O
of	O
various	O
genetic	O
and	O
biological	O
factors	O
upon	O
glycosylation	O
of	O
secreted	O
monoclonal	O
IgG	O
.	O

After	O
exhaustive	O
Pronase	O
digestion	O
of	O
IgG	O
,	O
glycopeptides	O
were	O
characterized	O
chromatographically	O
by	O
apparent	O
size	O
,	O
charge	O
,	O
and	O
concanavalin	B-Protein
A	E-Protein
(	O
Con	B-Protein
A	E-Protein
)	O
-	O
Sepharose	O
and	O
Lens	O
culinaris	O
(	O
LcH	O
)	O
-	O
agarose	O
affinity	O
.	O

Six	O
glycosylation	O
phenotypes	O
were	O
found	O
to	O
be	O
common	O
among	O
all	O
clones	O
studied	O
.	O

Despite	O
this	O
phenotypic	O
heterogeneity	O
in	O
glycosylation	O
of	O
IgG	O
,	O
considerable	O
similarity	O
exists	O
between	O
different	O
clones	O
.	O

In	O
particular	O
,	O
virtually	O
all	O
IgG	O
glycopeptides	O
bear	O
a	O
core	O
fucose	O
residue	O
.	O

Second	O
,	O
the	O
majority	O
of	O
the	O
glycosylation	O
repertoire	O
is	O
comprised	O
of	O
two	O
phenotypes	O
,	O
characterized	O
by	O
glycopeptides	O
which	O
differ	O
in	O
affinity	O
for	O
Con	B-Protein
A	E-Protein
-	O
Sepharose	O
.	O

Of	O
these	O
,	O
the	O
predominantly	O
expressed	O
phenotype	O
is	O
the	O
same	O
for	O
all	O
clones	O
.	O

The	O
carbohydrate	O
structure	O
derived	O
from	O
this	O
phenotype	O
,	O
elucidated	O
by	O
500	O
-	O
MHz	O
1H	O
NMR	O
spectroscopy	O
,	O
is	O
(	O
Formula	O
:	O
see	O
text	O
)	O
.	O

Significant	O
variability	O
between	O
different	O
hybridomas	O
exists	O
in	O
the	O
relative	O
expression	O
of	O
the	O
two	O
major	O
phenotypes	O
.	O

Other	O
differences	O
between	O
clones	O
may	O
reflect	O
the	O
expression	O
of	O
an	O
additional	O
site	O
which	O
is	O
glycosylated	O
differently	O
.	O

However	O
,	O
there	O
is	O
no	O
apparent	O
correlation	O
of	O
phenotype	O
with	O
either	O
the	O
hybridoma	O
'	O
s	O
parentage	O
or	O
the	O
serologically	O
defined	O
polypeptide	O
structure	O
of	O
the	O
IgG	O
which	O
it	O
secretes	O
.	O

In	O
addition	O
to	O
clonal	O
variability	O
,	O
other	O
sources	O
of	O
variability	O
in	O
phenotypic	O
expression	O
were	O
identified	O
.	O

A	O
generational	O
variability	O
is	O
apparent	O
upon	O
continuous	O
culturing	O
of	O
the	O
same	O
hybridoma	O
.	O

Also	O
,	O
differences	O
in	O
culture	O
medium	O
pH	O
or	O
proliferative	O
state	O
of	O
the	O
cells	O
may	O
have	O
a	O
modest	O
influence	O
upon	O
the	O
glycosylation	O
phenotype	O
.	O

Specific	O
immune	O
responses	O
restored	O
by	O
alteration	O
in	O
carbohydrate	O
chains	O
of	O
surface	O
molecules	O
on	O
antigen	O
-	O
presenting	O
cells	O
.	O

Two	O
class	O
I	O
major	O
histocompatibility	O
(	O
MHC	O
)	O
mutant	O
mouse	O
strains	O
,	O
H	O
-	O
2bm14	O
and	O
H	O
-	O
2bm6	O
,	O
differ	O
from	O
the	O
strain	O
of	O
origin	O
C57BL	O
/	O
6	O
(	O
B6	O
,	O
H	O
-	O
2b	O
)	O
in	O
one	O
and	O
two	O
amino	O
acids	O
of	O
the	O
H	B-Protein
-	I-Protein
2Db	E-Protein
and	O
H	B-Protein
-	I-Protein
2Kb	E-Protein
molecule	O
,	O
respectively	O
.	O

The	O
bm14	O
Db	O
mutation	O
results	O
in	O
specific	O
failure	O
of	O
female	O
bm14	O
mice	O
to	O
generate	O
a	O
cytotoxic	O
T	O
lymphocyte	O
(	O
Tc	O
)	O
response	O
to	O
the	O
male	O
-	O
specific	O
antigen	O
H	B-Protein
-	I-Protein
Y	E-Protein
.	O

The	O
allospecific	O
Tc	O
response	O
of	O
CD8	S-Protein
+	O
B6T	O
cells	O
against	O
bm6	O
Kb	O
mutant	O
spleen	O
cells	O
,	O
in	O
contrast	O
to	O
that	O
against	O
other	O
Kb	O
mutants	O
,	O
is	O
absolutely	O
CD4	S-Protein
+	O
T	O
helper	O
cell	O
dependent	O
.	O

Purified	O
CD8	S-Protein
+	O
T	O
cells	O
completely	O
fail	O
to	O
respond	O
.	O

We	O
now	O
report	O
that	O
the	O
inability	O
to	O
mount	O
these	O
specific	O
immune	O
responses	O
is	O
restored	O
by	O
the	O
use	O
of	O
dendritic	O
cells	O
(	O
DC	O
)	O
as	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
)	O
.	O

Comparison	O
of	O
MHC	O
expression	O
on	O
various	O
types	O
of	O
APC	O
by	O
cytofluorimetry	O
and	O
quantitative	O
immunoprecipitation	O
showed	O
very	O
high	O
expression	O
of	O
class	O
I	O
and	O
class	O
II	O
MHC	O
molecules	O
on	O
DC	O
.	O

Strikingly	O
,	O
examination	O
of	O
class	O
I	O
and	O
class	O
II	O
molecules	O
by	O
isoelectric	O
focusing	O
revealed	O
qualitative	O
differences	O
as	O
well	O
.	O

We	O
show	O
that	O
the	O
surface	O
MHC	O
class	O
I	O
molecules	O
of	O
DC	O
are	O
present	O
in	O
greater	O
quantity	O
and	O
carry	O
on	O
average	O
fewer	O
sialic	O
acids	O
than	O
the	O
same	O
molecules	O
isolated	O
from	O
other	O
APC	O
types	O
such	O
as	O
spleen	O
cells	O
,	O
lipopolysaccharide	O
blasts	O
or	O
concanavalin	B-Protein
A	E-Protein
blasts	O
.	O

That	O
sialic	O
acids	O
on	O
cell	O
surface	O
molecules	O
,	O
including	O
MHC	O
,	O
may	O
play	O
a	O
role	O
in	O
antigen	O
presentation	O
is	O
suggested	O
by	O
our	O
finding	O
that	O
removal	O
of	O
sialic	O
acids	O
,	O
by	O
neuraminidase	O
,	O
can	O
restore	O
specific	O
responses	O
to	O
nonresponder	O
APC	O
as	O
well	O
.	O

Effects	O
of	O
histone	S-Protein
acetylation	O
on	O
nucleosome	O
properties	O
as	O
evaluated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
hydroxylapatite	O
dissociation	O
chromatography	O
.	O

The	O
release	O
of	O
acetylated	O
histones	S-Protein
from	O
chick	O
oviduct	O
chromatin	O
was	O
analyzed	O
by	O
hydroxylapatite	O
column	O
chromatography	O
.	O

By	O
raising	O
of	O
the	O
NaCl	O
concentration	O
,	O
acetylated	O
histones	S-Protein
were	O
eluted	O
from	O
hydroxylapatite	O
-	O
bound	O
chromatin	O
depending	O
on	O
their	O
release	O
from	O
nucleosomal	O
DNA	O
.	O

Electrophoresis	O
on	O
acid	O
-	O
urea	O
gel	O
showed	O
that	O
hyperacetylated	O
forms	O
of	O
histone	B-Protein
H4	E-Protein
were	O
eluted	O
at	O
a	O
lower	O
NaCl	O
concentration	O
than	O
non	O
-	O
acetylated	O
or	O
hypoacetylated	O
H4	S-Protein
,	O
suggesting	O
that	O
hyperacetylated	O
H4	S-Protein
has	O
decreased	O
stability	O
in	O
nucleosomes	O
.	O

However	O
,	O
under	O
milder	O
ionic	O
conditions	O
which	O
do	O
not	O
induce	O
dissociation	O
between	O
histones	S-Protein
and	O
DNA	O
,	O
polyacrylamide	O
gel	O
electrophoresis	O
of	O
purified	O
nucleosome	O
cores	O
showed	O
no	O
evidence	O
for	O
their	O
unfolding	O
or	O
for	O
increased	O
accessibility	O
by	O
high	B-Protein
mobility	I-Protein
group	I-Protein
protein	I-Protein
-	I-Protein
17	E-Protein
.	O

beta	O
-	O
Hydroxyasparagine	O
in	O
domains	O
homologous	O
to	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
precursor	O
in	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
S	E-Protein
.	O

Vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
S	E-Protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
blood	O
coagulation	O
.	O

It	O
is	O
a	O
75	O
-	O
kDa	O
single	O
chain	O
protein	O
with	O
an	O
NH2	O
-	O
terminal	O
gamma	O
-	O
carboxyglutamic	O
acid	O
-	O
containing	O
domain	O
followed	O
by	O
a	O
thrombin	S-Protein
-	O
sensitive	O
region	O
and	O
four	O
domains	O
arranged	O
in	O
tandem	O
,	O
each	O
of	O
which	O
is	O
homologous	O
to	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	E-Protein
(	O
EGF	S-Protein
)	O
precursor	O
.	O

The	O
NH2	O
-	O
terminal	O
EGF	O
-	O
like	O
domain	O
contains	O
beta	O
-	O
hydroxyaspartic	O
acid	O
,	O
which	O
has	O
been	O
identified	O
in	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
.	O

The	O
following	O
EGF	O
-	O
like	O
repeat	O
has	O
a	O
very	O
pronounced	O
sequence	O
homology	O
(	O
10	O
consecutive	O
residues	O
identical	O
)	O
to	O
one	O
of	O
the	O
EGF	O
-	O
like	O
units	O
in	O
the	O
EGF	S-Protein
precursor	O
.	O

We	O
now	O
show	O
that	O
,	O
in	O
protein	B-Protein
S	E-Protein
,	O
this	O
EGF	O
-	O
like	O
repeat	O
has	O
one	O
beta	O
-	O
hydroxyasparagine	O
residue	O
formed	O
by	O
hydroxylation	O
of	O
asparagine	O
.	O

The	O
two	O
COOH	O
-	O
terminal	O
EGF	O
-	O
like	O
repeats	O
also	O
contain	O
beta	O
-	O
hydroxyasparagine	O
,	O
an	O
amino	O
acid	O
not	O
previously	O
found	O
in	O
proteins	O
.	O

Sequence	O
comparisons	O
have	O
enabled	O
us	O
to	O
identify	O
a	O
consensus	O
sequence	O
that	O
seems	O
to	O
be	O
required	O
by	O
the	O
hydroxylase	O
(	O
s	O
)	O
.	O

Comparison	O
of	O
the	O
immune	O
response	O
to	O
variant	O
influenza	O
type	O
B	O
hemagglutinins	S-Protein
expressed	O
in	O
vaccinia	O
virus	O
.	O

To	O
compare	O
the	O
immune	O
response	O
induced	O
by	O
influenza	O
hemagglutinin	S-Protein
(	O
HA	S-Protein
)	O
variants	O
differing	O
by	O
a	O
single	O
amino	O
acid	O
,	O
the	O
genes	O
for	O
each	O
HA	S-Protein
variant	O
were	O
cloned	O
and	O
expressed	O
in	O
vaccinia	O
virus	O
.	O

These	O
variant	O
HA	S-Protein
genes	O
have	O
been	O
previously	O
described	O
as	O
being	O
present	O
exclusively	O
in	O
either	O
egg	O
-	O
derived	O
or	O
MDCK	O
cell	O
-	O
derived	O
subpopulations	O
of	O
influenza	O
B	O
/	O
England	O
/	O
222	O
/	O
82	O
virus	O
.	O

By	O
using	O
this	O
approach	O
we	O
were	O
able	O
to	O
vaccinate	O
animals	O
with	O
homogeneous	O
preparations	O
of	O
these	O
viral	O
antigens	O
and	O
thus	O
circumvent	O
the	O
problem	O
of	O
heterogeneity	O
within	O
RNA	O
virus	O
stocks	O
.	O

Immunization	O
and	O
challenge	O
experiments	O
in	O
mice	O
indicated	O
that	O
even	O
though	O
vaccination	O
with	O
the	O
recombinant	O
vaccinia	O
viruses	O
induced	O
different	O
levels	O
of	O
cross	O
-	O
reactive	O
neutralizing	O
antibodies	O
,	O
mice	O
vaccinated	O
with	O
either	O
recombinant	O
vaccinia	O
virus	O
were	O
protected	O
from	O
infection	O
with	O
either	O
subpopulation	O
of	O
influenza	O
virus	O
.	O

Results	O
with	O
this	O
model	O
system	O
support	O
the	O
view	O
that	O
influenza	O
vaccines	O
prepared	O
with	O
egg	O
-	O
derived	O
virus	O
should	O
be	O
protective	O
against	O
microvariants	O
of	O
virus	O
that	O
grow	O
preferentially	O
in	O
MDCK	O
and	O
possibly	O
other	O
mammalian	O
cells	O
.	O

Biosynthesis	O
of	O
type	O
I	O
procollagen	O
.	O

Characterization	O
of	O
the	O
distribution	O
of	O
chain	O
sizes	O
and	O
extent	O
of	O
hydroxylation	O
of	O
polysome	O
-	O
associated	O
pro	O
-	O
alpha	O
-	O
chains	O
.	O

[	O
3H	O
]	O
Proline	O
-	O
labeled	O
nascent	O
procollagen	O
chains	O
were	O
isolated	O
from	O
chick	O
tendon	O
polysome	O
preparations	O
as	O
peptidyl	O
-	O
tRNA	O
complexes	O
by	O
ion	O
exchange	O
chromatography	O
.	O

Proline	O
hydroxylation	O
of	O
the	O
nascent	O
chains	O
was	O
at	O
least	O
40	O
%	O
complete	O
,	O
based	O
on	O
radioactive	O
hydroxyproline	O
/	O
proline	O
ratios	O
.	O

These	O
data	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
hydroxylation	O
of	O
procollagen	O
proline	O
residues	O
does	O
occur	O
on	O
nascent	O
chains	O
.	O

The	O
electrophoretic	O
profiles	O
of	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
nascent	O
chains	O
and	O
of	O
unlabeled	O
nascent	O
chains	O
visualized	O
by	O
Western	O
blotting	O
with	O
35S	O
-	O
labeled	O
monoclonal	O
antibodies	O
to	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	E-Protein
N	O
-	O
propeptide	O
or	O
the	O
C	O
-	O
propeptides	O
indicate	O
that	O
there	O
are	O
pauses	O
in	O
the	O
translation	O
of	O
procollagen	O
alpha	O
-	O
chains	O
in	O
the	O
intact	O
cells	O
.	O

Approximately	O
25	O
%	O
of	O
the	O
radioactivity	O
associated	O
with	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
polysomes	O
was	O
in	O
fully	O
elongated	O
but	O
underhydroxylated	O
(	O
relative	O
to	O
secreted	O
procollagen	O
)	O
pro	O
-	O
alpha	O
-	O
chains	O
.	O

The	O
association	O
of	O
these	O
completely	O
elongated	O
but	O
only	O
partially	O
modified	O
procollagen	O
chains	O
with	O
the	O
polysome	O
complex	O
may	O
facilitate	O
the	O
carboxyl	O
-	O
terminal	O
interactions	O
which	O
lead	O
to	O
triple	O
helix	O
formation	O
.	O

A	O
comparison	O
of	O
accessibility	O
of	O
ribosomal	O
proteins	O
on	O
free	O
and	O
membrane	O
-	O
bound	O
ribosomes	O
:	O
the	O
ribosomal	O
proteins	O
potentially	O
involved	O
in	O
ribosome	O
-	O
membrane	O
binding	O
.	O

The	O
relative	O
accessibility	O
of	O
rat	O
liver	O
ribosomal	O
proteins	O
to	O
reductive	O
methylation	O
was	O
examined	O
using	O
membrane	O
-	O
bound	O
and	O
free	O
ribosomes	O
.	O

Comparisons	O
indicated	O
that	O
12	O
-	O
13	O
large	O
ribosomal	O
proteins	O
are	O
masked	O
by	O
ribosomal	O
association	O
with	O
membranes	O
.	O

These	O
consisted	O
of	O
L8	S-Protein
,	O
L10	S-Protein
,	O
L17	S-Protein
,	O
L26	S-Protein
-	O
28	S-Protein
,	O
L31	S-Protein
and	O
L36	S-Protein
,	O
and	O
probably	O
also	O
include	O
L4	S-Protein
,	O
L5	S-Protein
,	O
L7	S-Protein
and	O
L29	S-Protein
.	O

These	O
proteins	O
seem	O
to	O
surround	O
a	O
region	O
centered	O
about	O
L3	S-Protein
and	O
may	O
partly	O
define	O
a	O
ribosomal	O
channel	O
through	O
which	O
the	O
nascent	O
peptide	O
emerges	O
.	O

Approx	O
.	O
10	O
-	O
20	O
%	O
of	O
the	O
large	O
ribosomal	O
subunit	O
surface	O
area	O
is	O
shielded	O
by	O
the	O
membrane	O
.	O

The	O
prolonged	O
stimulatory	O
effect	O
of	O
ACTH	S-Protein
on	O
11	O
beta	O
-	O
hydroxylation	O
,	O
and	O
its	O
contribution	O
to	O
the	O
steroidogenic	O
potency	O
of	O
adrenocortical	O
cells	O
.	O

The	O
mechanism	O
of	O
the	O
prolonged	O
stimulatory	O
influence	O
of	O
corticotropin	S-Protein
(	O
ACTH	S-Protein
)	O
on	O
the	O
capacity	O
of	O
adrenocortical	O
cells	O
to	O
produce	O
cortisol	O
in	O
response	O
to	O
ACTH	S-Protein
and	O
more	O
specifically	O
the	O
role	O
of	O
11	O
beta	O
-	O
hydroxylation	O
,	O
was	O
studied	O
on	O
guinea	O
-	O
pig	O
adrenocortical	O
cells	O
dispersed	O
from	O
control	O
and	O
ACTH	S-Protein
-	O
treated	O
animals	O
.	O

As	O
a	O
result	O
of	O
the	O
previous	O
in	O
vivo	O
exposure	O
to	O
ACTH	S-Protein
,	O
the	O
net	O
maximal	O
production	O
of	O
glucocorticoids	O
in	O
response	O
to	O
ACTH	S-Protein
(	O
by	O
10	O
(	O
5	O
)	O
cells	O
and	O
2	O
h	O
incubation	O
)	O
increased	O
from	O
660	O
+	O
/	O
-	O
33	O
.	O
9	O
ng	O
(	O
control	O
group	O
)	O
to	O
1105	O
+	O
/	O
-	O
117	O
.	O
9	O
ng	O
for	O
cells	O
from	O
ACTH	S-Protein
-	O
treated	O
animals	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
whereas	O
the	O
apparent	O
affinity	O
of	O
the	O
steroidogenic	O
response	O
remained	O
unchanged	O
.	O

In	O
addition	O
there	O
occurred	O
an	O
increased	O
conversion	O
of	O
exogenous	O
pregnenolone	O
into	O
cortisol	O
by	O
cells	O
from	O
ACTH	S-Protein
-	O
treated	O
animals	O
,	O
indicating	O
a	O
prolonged	O
stimulatory	O
influence	O
of	O
ACTH	S-Protein
on	O
the	O
post	O
-	O
pregnenolone	O
pathway	O
of	O
cortisol	O
biosynthesis	O
.	O

The	O
activity	O
of	O
11	O
beta	O
-	O
hydroxylation	O
step	O
was	O
therefore	O
examined	O
by	O
incubating	O
the	O
adrenocortical	O
cells	O
from	O
control	O
and	O
ACTH	S-Protein
-	O
treated	O
animals	O
in	O
the	O
presence	O
of	O
increasing	O
amounts	O
of	O
11	O
-	O
deoxycortisol	O
.	O

The	O
maximal	O
capacity	O
of	O
11	O
-	O
deoxycortisol	O
conversion	O
into	O
cortisol	O
was	O
increased	O
as	O
a	O
result	O
of	O
the	O
in	O
vivo	O
exposure	O
to	O
ACTH	S-Protein
,	O
averaging	O
3423	O
+	O
/	O
-	O
211	O
ng	O
cortisol	O
formed	O
from	O
5	O
micrograms	O
11	O
-	O
deoxycortisol	O
by	O
10	O
(	O
5	O
)	O
cells	O
from	O
ACTH	S-Protein
-	O
treated	O
animals	O
vs	O
2074	O
+	O
/	O
-	O
185	O
ng	O
for	O
cells	O
from	O
control	O
guinea	O
-	O
pigs	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
the	O
conversion	O
of	O
lower	O
amounts	O
of	O
11	O
-	O
deoxycortisol	O
into	O
cortisol	O
,	O
reproducing	O
quantitatively	O
the	O
maximal	O
effect	O
of	O
ACTH	S-Protein
on	O
cortisol	O
biosynthesis	O
,	O
was	O
only	O
barely	O
increased	O
in	O
cells	O
from	O
ACTH	S-Protein
-	O
treated	O
animals	O
(	O
P	O
greater	O
than	O
0	O
.	O
05	O
)	O
.	O

Therefore	O
it	O
was	O
concluded	O
that	O
ACTH	S-Protein
increases	O
in	O
a	O
lasting	O
way	O
not	O
only	O
the	O
overall	O
steroidogenic	O
capacity	O
of	O
adrenocortical	O
cells	O
but	O
also	O
the	O
maximal	O
efficiency	O
of	O
11	O
beta	O
-	O
hydroxylation	O
.	O

Since	O
the	O
latter	O
effect	O
cannot	O
account	O
quantitatively	O
for	O
the	O
magnitude	O
of	O
the	O
lasting	O
effect	O
of	O
ACTH	S-Protein
on	O
the	O
maximal	O
capacity	O
of	O
adrenocortical	O
cells	O
to	O
produce	O
cortisol	O
in	O
response	O
to	O
ACTH	S-Protein
,	O
it	O
appears	O
that	O
the	O
prolonged	O
influence	O
of	O
ACTH	S-Protein
on	O
cortisol	O
biosynthesis	O
should	O
also	O
involve	O
a	O
stimulatory	O
influence	O
of	O
the	O
peptide	O
on	O
earlier	O
step	O
(	O
s	O
)	O
of	O
steroidogenesis	O
.	O

Pyridine	O
borane	O
as	O
a	O
reducing	O
agent	O
for	O
proteins	O
.	O

Pyridine	O
borane	O
has	O
been	O
reported	O
as	O
a	O
superior	O
reagent	O
over	O
a	O
wide	O
pH	O
range	O
,	O
5	O
-	O
9	O
,	O
for	O
the	O
reductive	O
methylation	O
of	O
amino	O
groups	O
of	O
proteins	O
with	O
formaldehyde	O
[	O
J	O
.	O
C	O
.	O
Cabacungan	O
,	O
A	O
.	O
I	O
.	O
Ahmed	O
,	O
and	O
R	O
.	O
E	O
.	O
Feeney	O
(	O
1982	O
)	O
Anal	O
.	O
Biochem	O
.	O
124	O
,	O
272	O
-	O
278	O
]	O
.	O

It	O
has	O
also	O
been	O
reported	O
to	O
reduce	O
tryptophan	O
to	O
dihydrotryptophan	O
and	O
to	O
inactivate	O
lysozyme	S-Protein
in	O
trifluoroacetic	O
acid	O
[	O
M	O
.	O
Kurata	O
,	O
Y	O
.	O
Kikugawa	O
,	O
T	O
.	O
Kuwae	O
,	O
I	O
.	O
Koyama	O
,	O
and	O
T	O
.	O
Takagi	O
(	O
1980	O
)	O
Chem	O
.	O
Pharm	O
.	O
Bull	O
28	O
,	O
2274	O
-	O
2275	O
]	O
.	O

In	O
the	O
present	O
study	O
the	O
specificity	O
of	O
pyridine	O
borane	O
for	O
the	O
two	O
different	O
modifications	O
under	O
different	O
reaction	O
conditions	O
has	O
been	O
demonstrated	O
,	O
and	O
extended	O
to	O
the	O
application	O
to	O
the	O
synthesis	O
of	O
protein	O
containing	O
reductively	O
attached	O
carbohydrates	O
.	O

In	O
the	O
acid	O
reduction	O
,	O
pyridine	O
borane	O
selectively	O
reduced	O
all	O
six	O
tryptophans	O
in	O
lysozyme	S-Protein
to	O
dihydrotryptophan	O
while	O
all	O
other	O
amino	O
acids	O
remained	O
intact	O
.	O

On	O
similar	O
treatment	O
no	O
cleavage	O
of	O
the	O
carbohydrate	O
moiety	O
from	O
chicken	O
ovomucoid	S-Protein
,	O
and	O
no	O
losses	O
of	O
activity	O
of	O
ovomucoid	S-Protein
or	O
ribonuclease	O
,	O
two	O
proteins	O
devoid	O
of	O
tryptophan	O
,	O
were	O
observed	O
.	O

Nearly	O
complete	O
methylation	O
of	O
the	O
lysines	O
of	O
lysozyme	S-Protein
,	O
chicken	O
ovomucoid	S-Protein
,	O
and	O
ribonuclease	O
was	O
achieved	O
with	O
formaldehyde	O
at	O
pH	O
7	O
.	O
0	O
after	O
2	O
h	O
at	O
room	O
temperature	O
,	O
with	O
the	O
retention	O
of	O
full	O
activity	O
of	O
the	O
protein	O
without	O
any	O
destruction	O
of	O
tryptophan	O
.	O

The	O
same	O
chemistry	O
was	O
applied	O
to	O
covalently	O
attach	O
glucose	O
and	O
lactose	O
to	O
bovine	O
serum	B-Protein
albumin	E-Protein
.	O

Parameters	O
,	O
including	O
pH	O
,	O
temperature	O
,	O
and	O
methanol	O
,	O
that	O
affect	O
the	O
reactions	O
were	O
investigated	O
.	O

Incremental	O
additions	O
of	O
pyridine	O
borane	O
during	O
the	O
course	O
of	O
the	O
reactions	O
increased	O
the	O
rate	O
of	O
modification	O
.	O

The	O
covalent	O
attachment	O
of	O
sugar	O
to	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
lysine	O
was	O
demonstrated	O
by	O
the	O
synthesis	O
of	O
N	O
-	O
alpha	O
-	O
acetylglucitollysine	O
and	O
comparison	O
with	O
acid	O
hydrolysates	O
of	O
the	O
bovine	O
serum	B-Protein
albumin	E-Protein
-	O
sugar	O
derivatives	O
.	O

Arylamine	O
N	O
-	O
acetyltransferase	O
and	O
arylalkylamine	B-Protein
N	I-Protein
-	I-Protein
acetyltransferase	E-Protein
in	O
the	O
mammalian	O
pineal	O
gland	O
.	O

Amine	O
N	O
-	O
acetylation	O
in	O
the	O
pineal	O
gland	O
is	O
of	O
special	O
importance	O
because	O
it	O
is	O
the	O
first	O
step	O
in	O
the	O
synthesis	O
of	O
melatonin	O
from	O
serotonin	O
.	O

In	O
the	O
present	O
study	O
the	O
N	O
-	O
acetylation	O
of	O
arylamines	O
and	O
arylalkylamines	O
by	O
homogenates	O
of	O
rat	O
and	O
sheep	O
pineal	O
glands	O
was	O
investigated	O
.	O

The	O
arylamines	O
studied	O
were	O
p	O
-	O
phenetidine	O
and	O
aniline	O
;	O
the	O
arylalkylamines	O
studied	O
were	O
tryptamine	O
,	O
serotonin	O
,	O
5	O
-	O
methoxytryptamine	O
,	O
6	O
-	O
fluorotryptamine	O
,	O
and	O
phenylethylamine	O
.	O

These	O
amines	O
were	O
acetylated	O
by	O
pineal	O
homogenates	O
of	O
both	O
species	O
,	O
although	O
marked	O
interspecies	O
differences	O
in	O
apparent	O
Km	O
and	O
Vmax	O
values	O
were	O
found	O
.	O

A	O
series	O
of	O
observations	O
in	O
both	O
species	O
indicate	O
that	O
aromatic	O
amine	O
N	O
-	O
acetylation	O
is	O
catalyzed	O
by	O
two	O
distinct	O
enzymes	O
;	O
one	O
preferentially	O
acetylates	O
arylamines	O
and	O
the	O
other	O
preferentially	O
acetylates	O
arylalkylamines	O
.	O

First	O
,	O
isoproterenol	O
treatment	O
of	O
the	O
rat	O
increased	O
arylalkylamine	O
N	O
-	O
acetylation	O
100	O
-	O
fold	O
without	O
increasing	O
arylamine	O
N	O
-	O
acetylation	O
.	O

Second	O
,	O
cycloheximide	O
treatment	O
in	O
sheep	O
reduced	O
arylalkylamine	O
N	O
-	O
acetylation	O
at	O
night	O
to	O
one	O
-	O
tenth	O
control	O
values	O
,	O
without	O
altering	O
arylamine	O
N	O
-	O
acetylation	O
.	O

Third	O
,	O
arylamine	O
N	O
-	O
acetyltransferase	O
and	O
arylalkylamine	B-Protein
N	I-Protein
-	I-Protein
acetyltransferase	E-Protein
inactivated	O
at	O
different	O
rates	O
at	O
4	O
degrees	O
C	O
.	O

Fourth	O
,	O
the	O
two	O
enzymes	O
were	O
resolved	O
by	O
size	O
exclusion	O
chromatography	O
.	O

These	O
results	O
clearly	O
establish	O
that	O
the	O
pineal	O
gland	O
contains	O
an	O
arylamine	O
N	O
-	O
acetyltransferase	O
and	O
a	O
second	O
,	O
independently	O
regulated	O
arylalkylamine	B-Protein
N	I-Protein
-	I-Protein
acetyltransferase	E-Protein
which	O
appears	O
to	O
be	O
primarily	O
responsible	O
for	O
the	O
physiological	O
conversion	O
of	O
serotonin	O
to	O
melatonin	O
via	O
the	O
intermediate	O
N	O
-	O
acetylserotonin	O
.	O

Undermethylation	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
albumin	S-Protein
gene	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
albumin	S-Protein
production	O
by	O
rat	O
hepatoma	O
cells	O
in	O
culture	O
.	O

We	O
have	O
measured	O
methylation	O
of	O
the	O
albumin	S-Protein
gene	O
in	O
clones	O
of	O
rat	O
hepatoma	O
cells	O
that	O
vary	O
quantitatively	O
in	O
their	O
rates	O
of	O
synthesis	O
of	O
albumin	S-Protein
and	O
in	O
variant	O
and	O
hybrid	O
cells	O
that	O
produce	O
no	O
albumin	S-Protein
.	O

Although	O
the	O
albumin	S-Protein
gene	O
is	O
undermethylated	O
for	O
its	O
entire	O
length	O
in	O
rat	O
liver	O
,	O
only	O
the	O
5	O
'	O
end	O
is	O
ever	O
undermethylated	O
in	O
hepatoma	O
cells	O
.	O

Moreover	O
,	O
undermethylation	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
appears	O
to	O
be	O
necessary	O
for	O
stable	O
expression	O
of	O
the	O
albumin	S-Protein
gene	O
in	O
hepatoma	O
cells	O
.	O

Since	O
undermethylation	O
of	O
this	O
region	O
is	O
found	O
in	O
some	O
variant	O
cells	O
that	O
fail	O
to	O
produce	O
albumin	S-Protein
,	O
it	O
is	O
not	O
a	O
sufficient	O
condition	O
for	O
albumin	S-Protein
gene	O
expression	O
.	O

Despite	O
the	O
excellent	O
correlation	O
between	O
undermethylation	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
albumin	S-Protein
gene	O
and	O
its	O
stable	O
expression	O
,	O
the	O
results	O
argue	O
against	O
the	O
possibility	O
that	O
the	O
methylated	O
state	O
of	O
such	O
genes	O
during	O
development	O
determines	O
whether	O
they	O
will	O
or	O
will	O
not	O
be	O
expressed	O
.	O

Hydroxylated	O
aromatic	O
inhibitors	O
of	O
HIV	O
-	O
1	O
integrase	S-Protein
.	O

Efficient	O
replication	O
of	O
HIV	O
-	O
1	O
requires	O
integration	O
of	O
a	O
DNA	O
copy	O
of	O
the	O
viral	O
genome	O
into	O
a	O
chromosome	O
of	O
the	O
host	O
cell	O
.	O

Integration	O
is	O
catalyzed	O
by	O
the	O
viral	O
integrase	S-Protein
,	O
and	O
we	O
have	O
previously	O
reported	O
that	O
phenolic	O
moieties	O
in	O
compounds	O
such	O
as	O
flavones	O
,	O
caffeic	O
acid	O
phenethyl	O
ester	O
(	O
CAPE	O
,	O
2	O
)	O
,	O
and	O
curcumin	O
confer	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
1	O
integrase	S-Protein
.	O

We	O
now	O
extend	O
these	O
findings	O
by	O
performing	O
a	O
comprehensive	O
structure	O
-	O
activity	O
relationship	O
using	O
CAPE	O
analogues	O
.	O

Approximately	O
30	O
compounds	O
have	O
been	O
prepared	O
as	O
HIV	O
integrase	S-Protein
inhibitors	O
based	O
on	O
the	O
structural	O
lead	O
provided	O
by	O
CAPE	O
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
exhibit	O
an	O
IC50	O
value	O
of	O
7	O
microM	O
in	O
our	O
integration	O
assay	O
.	O

These	O
analogues	O
were	O
designed	O
to	O
examine	O
specific	O
features	O
of	O
the	O
parent	O
CAPE	O
structure	O
which	O
may	O
be	O
important	O
for	O
activity	O
.	O

Among	O
the	O
features	O
examined	O
for	O
their	O
effects	O
on	O
inhibitory	O
potency	O
were	O
ring	O
substitution	O
,	O
side	O
chain	O
length	O
and	O
composition	O
,	O
and	O
phenyl	O
ring	O
conformational	O
orientation	O
.	O

In	O
an	O
assay	O
which	O
measured	O
the	O
combined	O
effect	O
of	O
two	O
sequential	O
steps	O
,	O
dinucleotide	O
cleavage	O
and	O
strand	O
transfer	O
,	O
several	O
analogues	O
have	O
IC50	O
values	O
for	O
3	O
'	O
-	O
processing	O
and	O
strand	O
transfer	O
lower	O
than	O
those	O
of	O
CAPE	O
.	O

Inhibition	O
of	O
strand	O
transfer	O
was	O
assayed	O
using	O
both	O
blunt	O
-	O
ended	O
and	O
"	O
precleaved	O
"	O
DNA	O
substrates	O
.	O

Disintegration	O
using	O
an	O
integrase	S-Protein
mutant	O
lacking	O
the	O
N	O
-	O
terminal	O
zinc	O
finger	O
and	O
C	O
-	O
terminal	O
DNA	O
-	O
binding	O
domains	O
was	O
also	O
inhibited	O
by	O
these	O
analogues	O
,	O
suggesting	O
that	O
the	O
binding	O
site	O
for	O
these	O
compounds	O
resides	O
in	O
the	O
central	O
catalytic	O
core	O
.	O

Several	O
CAPE	O
analogues	O
were	O
also	O
tested	O
for	O
selective	O
activity	O
against	O
transformed	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
development	O
of	O
novel	O
antiviral	O
agents	O
for	O
the	O
treatment	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
can	O
be	O
based	O
upon	O
inhibition	O
of	O
HIV	O
-	O
1	O
integrase	S-Protein
.	O

Effect	O
of	O
modification	O
of	O
carbohydrate	O
side	O
chains	O
on	O
the	O
reactivity	O
of	O
antibodies	O
with	O
core	O
-	O
protein	O
epitopes	O
of	O
the	O
MUC1	S-Protein
gene	O
product	O
.	O

The	O
product	O
of	O
the	O
MUC1	S-Protein
gene	O
,	O
the	O
polymorphic	B-Protein
epithelial	I-Protein
mucin	E-Protein
(	O
PEM	S-Protein
)	O
,	O
contains	O
a	O
large	O
domain	O
consisting	O
of	O
tandem	O
repeats	O
of	O
20	O
amino	O
acids	O
.	O

Each	O
repeat	O
contains	O
five	O
potential	O
sites	O
for	O
O	O
-	O
glycosylation	O
,	O
suggesting	O
that	O
this	O
region	O
forms	O
a	O
scaffold	O
for	O
the	O
attachment	O
of	O
the	O
O	O
-	O
linked	O
carbohydrate	O
which	O
makes	O
up	O
more	O
than	O
50	O
%	O
of	O
the	O
molecule	O
.	O

A	O
number	O
of	O
monoclonal	O
antibodies	O
have	O
been	O
shown	O
to	O
recognize	O
core	O
-	O
protein	O
epitopes	O
within	O
the	O
tandem	O
repeat	O
domain	O
.	O

One	O
such	O
antibody	O
,	O
SM3	O
,	O
reacts	O
with	O
the	O
mucin	O
expressed	O
by	O
breast	O
carcinomas	O
but	O
shows	O
little	O
or	O
no	O
reaction	O
with	O
normal	O
resting	O
or	O
lactating	O
breast	O
.	O

Using	O
primary	O
mammary	O
epithelial	O
cells	O
(	O
HuME	O
)	O
,	O
an	O
immortalized	O
cell	O
line	O
derived	O
from	O
HuME	O
(	O
MTSV1	O
-	O
7	O
)	O
and	O
a	O
breast	O
carcinoma	O
cell	O
line	O
(	O
BT20	O
)	O
the	O
influence	O
of	O
the	O
carbohydrate	O
side	O
chains	O
on	O
the	O
binding	O
of	O
antibodies	O
to	O
core	O
-	O
protein	O
epitopes	O
has	O
been	O
investigated	O
.	O

We	O
unequivocally	O
show	O
that	O
the	O
masking	O
of	O
the	O
SM3	O
epitopes	O
in	O
normal	O
breast	O
epithelial	O
cells	O
is	O
due	O
to	O
the	O
carbohydrate	O
side	O
chains	O
.	O

In	O
addition	O
we	O
demonstrate	O
that	O
the	O
binding	O
of	O
two	O
other	O
antibodies	O
(	O
HMFG1	O
,	O
HMFG2	O
)	O
to	O
core	O
-	O
protein	O
epitopes	O
is	O
influenced	O
by	O
the	O
carbohydrate	O
side	O
chains	O
.	O

The	O
binding	O
of	O
HMFG	O
-	O
1	O
is	O
particularly	O
affected	O
by	O
sialic	O
acid	O
whereas	O
the	O
binding	O
of	O
HMFG2	O
is	O
influenced	O
by	O
the	O
length	O
of	O
the	O
oligosaccharide	O
side	O
chains	O
.	O

Furthermore	O
,	O
inhibited	O
elongation	O
of	O
O	O
-	O
linked	O
carbohydrate	O
side	O
chains	O
does	O
not	O
seem	O
to	O
interfere	O
with	O
the	O
cell	O
trafficking	O
of	O
the	O
mucin	O
to	O
the	O
cell	O
surface	O
.	O

Fusing	O
the	O
carboxy	O
-	O
terminal	O
peptide	O
of	O
the	O
chorionic	B-Protein
gonadotropin	I-Protein
(	I-Protein
CG	I-Protein
)	I-Protein
beta	I-Protein
-	I-Protein
subunit	E-Protein
to	O
the	O
common	O
alpha	O
-	O
subunit	O
:	O
retention	O
of	O
O	O
-	O
linked	O
glycosylation	O
and	O
enhanced	O
in	O
vivo	O
bioactivity	O
of	O
chimeric	O
human	O
CG	O
.	O

The	O
hCG	B-Protein
beta	I-Protein
-	I-Protein
subunit	E-Protein
contains	O
a	O
carboxy	O
-	O
terminal	O
extension	O
bearing	O
four	O
serine	O
-	O
linked	O
oligosaccharides	O
[	O
carboxy	O
-	O
terminal	O
peptide	O
(	O
CTP	O
)	O
]	O
,	O
which	O
is	O
important	O
for	O
maintaining	O
its	O
longer	O
half	O
-	O
life	O
compared	O
with	O
the	O
other	O
glycoprotein	O
hormones	O
.	O

Previously	O
,	O
we	O
enhanced	O
the	O
in	O
vivo	O
half	O
-	O
life	O
of	O
FSH	O
by	O
fusing	O
the	O
CTP	O
to	O
the	O
carboxy	O
end	O
of	O
FSH	B-Protein
beta	E-Protein
coding	O
sequence	O
.	O

The	O
alpha	O
-	O
subunit	O
is	O
common	O
to	O
the	O
glycoprotein	O
family	O
.	O

We	O
constructed	O
alpha	O
-	O
subunit	O
CTP	O
chimeras	O
,	O
since	O
such	O
analogs	O
with	O
the	O
appropriate	O
O	O
-	O
linked	O
glycosylation	O
and	O
conformation	O
would	O
increase	O
the	O
in	O
vivo	O
stability	O
of	O
the	O
entire	O
glycoprotein	O
hormone	O
family	O
.	O

Two	O
chimeras	O
were	O
constructed	O
using	O
overlapping	O
polymerase	O
chain	O
reaction	O
mutagenesis	O
:	O
a	O
variant	O
with	O
CTP	O
at	O
the	O
carboxy	O
end	O
and	O
another	O
analog	O
with	O
the	O
CTP	O
at	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
subunit	O
,	O
between	O
amino	O
acids	O
3	O
and	O
4	O
.	O

The	O
latter	O
design	O
was	O
based	O
on	O
models	O
showing	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
alpha	O
is	O
not	O
involved	O
in	O
assembly	O
with	O
the	O
beta	O
-	O
subunit	O
,	O
nor	O
is	O
it	O
essential	O
for	O
receptor	O
binding	O
and	O
signal	O
transduction	O
.	O

These	O
chimeras	O
were	O
cotransfected	O
with	O
the	O
hCG	B-Protein
beta	E-Protein
gene	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
chimeras	O
were	O
secreted	O
and	O
combined	O
efficiently	O
with	O
the	O
CG	B-Protein
beta	I-Protein
-	I-Protein
subunit	E-Protein
,	O
comparable	O
to	O
the	O
wild	O
type	O
alpha	O
-	O
subunit	O
.	O

CG	O
dimers	O
containing	O
the	O
alpha	O
-	O
subunit	O
chimera	O
with	O
CTP	O
at	O
the	O
carboxy	O
end	O
of	O
the	O
subunit	O
had	O
a	O
much	O
lower	O
binding	O
affinity	O
for	O
the	O
hLH	B-Protein
-	I-Protein
hCG	I-Protein
receptor	E-Protein
in	O
vitro	O
,	O
whereas	O
the	O
binding	O
of	O
the	O
dimer	O
containing	O
the	O
CTP	O
at	O
the	O
amino	O
-	O
terminal	O
end	O
of	O
the	O
subunit	O
was	O
similar	O
to	O
wild	O
type	O
hCG	O
.	O

Furthermore	O
,	O
the	O
in	O
vivo	O
activity	O
of	O
this	O
analog	O
was	O
enhanced	O
significantly	O
.	O

Moreover	O
,	O
regardless	O
of	O
the	O
two	O
insertion	O
points	O
in	O
the	O
alpha	O
-	O
subunit	O
,	O
the	O
CTP	O
sequence	O
was	O
O	O
-	O
glycosylated	O
.	O

These	O
data	O
suggest	O
that	O
the	O
entire	O
signal	O
for	O
O	O
-	O
glycosylation	O
is	O
primarily	O
contained	O
within	O
the	O
CTP	O
sequence	O
and	O
is	O
not	O
dependent	O
on	O
the	O
flanking	O
regions	O
of	O
the	O
recipient	O
protein	O
.	O

The	O
transfer	O
of	O
CTP	O
to	O
the	O
alpha	O
-	O
subunit	O
of	O
hCG	O
results	O
in	O
an	O
agonist	O
with	O
prolonged	O
biological	O
action	O
in	O
vivo	O
.	O

These	O
data	O
further	O
support	O
the	O
rationale	O
for	O
using	O
the	O
CTP	O
as	O
a	O
general	O
target	O
to	O
increase	O
the	O
potency	O
of	O
bioactive	O
glycoproteins	O
.	O

Glycosylation	O
of	O
IgG	O
during	O
potentially	O
arthritogenic	O
lentiviral	O
infections	O
.	O

Agalactosyl	O
IgG	O
[	O
Gal	O
(	O
0	O
)	O
]	O
was	O
first	O
discovered	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

However	O
,	O
the	O
proportion	O
of	O
this	O
glycoform	O
is	O
also	O
raised	O
in	O
tuberculosis	O
and	O
leprosy	O
.	O

This	O
has	O
helped	O
reinforce	O
the	O
suggestion	O
that	O
RA	O
may	O
be	O
triggered	O
by	O
a	O
mycobacterium	O
-	O
like	O
slow	O
bacterial	O
infection	O
.	O

On	O
the	O
other	O
hand	O
,	O
arthritis	O
can	O
occur	O
in	O
mycobacterial	O
diseases	O
,	O
so	O
raised	O
Gal	O
(	O
0	O
)	O
could	O
be	O
associated	O
with	O
a	O
tendency	O
to	O
arthritis	O
,	O
rather	O
than	O
with	O
a	O
particular	O
type	O
of	O
infection	O
.	O

Therefore	O
,	O
we	O
wished	O
to	O
find	O
out	O
whether	O
the	O
percentage	O
of	O
Gal	O
(	O
0	O
)	O
[	O
%	O
Gal	O
(	O
0	O
)	O
]	O
is	O
increased	O
in	O
sheep	O
and	O
goats	O
following	O
infection	O
with	O
maedi	O
visna	O
virus	O
or	O
caprine	O
arthritis	O
encephalitis	O
virus	O
(	O
CAEV	O
)	O
,	O
both	O
of	O
which	O
can	O
lead	O
to	O
inflammatory	O
synovitis	O
.	O

We	O
found	O
that	O
the	O
normal	O
level	O
of	O
Gal	O
(	O
0	O
)	O
in	O
these	O
species	O
is	O
much	O
lower	O
than	O
in	O
humans	O
.	O

Goats	O
infected	O
with	O
CAEV	O
or	O
Mycobacterium	O
paratuberculosis	O
(	O
used	O
as	O
a	O
control	O
mycobacterial	O
infection	O
)	O
had	O
a	O
significant	O
increase	O
in	O
%	O
Gal	O
(	O
0	O
)	O
,	O
though	O
it	O
was	O
still	O
below	O
the	O
level	O
seen	O
in	O
normal	O
humans	O
.	O

Studies	O
by	O
Western	O
blot	O
confirmed	O
the	O
presence	O
of	O
terminal	O
N	O
-	O
acetylglucosamine	O
on	O
heavy	O
chains	O
,	O
and	O
percentages	O
of	O
Gal	O
(	O
0	O
)	O
comparable	O
to	O
those	O
seen	O
in	O
human	O
RA	O
could	O
be	O
generated	O
by	O
exposing	O
goat	O
IgG	O
to	O
streptococcal	O
beta	B-Protein
-	I-Protein
galactosidase	E-Protein
.	O

The	O
rise	O
in	O
%	O
Gal	O
(	O
0	O
)	O
was	O
greatest	O
in	O
members	O
of	O
infected	O
herds	O
that	O
were	O
just	O
starting	O
to	O
manifest	O
arthritis	O
,	O
and	O
tended	O
to	O
be	O
lower	O
in	O
those	O
in	O
which	O
severe	O
carpitis	O
had	O
developed	O
at	O
the	O
time	O
of	O
bleeding	O
,	O
implying	O
the	O
possibility	O
that	O
raise	O
%	O
Gal	O
(	O
0	O
)	O
may	O
be	O
an	O
early	O
or	O
predisposing	O
event	O
for	O
the	O
development	O
of	O
arthritis	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
effects	O
of	O
variable	O
glycosylation	O
on	O
the	O
functional	O
activities	O
of	O
ribonuclease	O
,	O
plasminogen	S-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	E-Protein
.	O

The	O
relatively	O
large	O
size	O
and	O
dynamics	O
of	O
oligosaccharides	O
can	O
result	O
in	O
substantial	O
shielding	O
of	O
functionally	O
important	O
areas	O
of	O
proteins	O
to	O
which	O
they	O
are	O
attached	O
,	O
modulate	O
the	O
interactions	O
of	O
glycoconjugates	O
with	O
other	O
molecules	O
and	O
affect	O
the	O
rate	O
of	O
processes	O
which	O
involve	O
conformational	O
changes	O
.	O

This	O
review	O
focuses	O
on	O
the	O
occupancy	O
of	O
N	O
-	O
linked	O
glycosylation	O
sites	O
on	O
three	O
enzymes	O
,	O
ribonuclease	O
,	O
plasminogen	S-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	E-Protein
.	O

Each	O
of	O
these	O
proteins	O
occurs	O
naturally	O
as	O
two	O
populations	O
of	O
molecules	O
,	O
distinguished	O
from	O
each	O
other	O
only	O
by	O
the	O
presence	O
or	O
absence	O
of	O
an	O
oligosaccharide	O
at	O
one	O
glycosylation	O
site	O
.	O

The	O
presence	O
of	O
an	O
oligomannose	O
sugar	O
on	O
ribonuclease	O
(	O
at	O
Asn	O
-	O
34	O
)	O
alters	O
its	O
overall	O
dynamics	O
,	O
increases	O
its	O
stability	O
towards	O
proteinases	O
and	O
decreases	O
its	O
functional	O
activity	O
towards	O
double	O
-	O
stranded	O
RNA	O
.	O

The	O
N	O
-	O
linked	O
sugar	O
on	O
plasminogen	S-Protein
(	O
at	O
Asn	O
-	O
288	O
)	O
within	O
kringle	O
3	O
reduces	O
the	O
rate	O
of	O
the	O
beta	O
-	O
to	O
alpha	O
-	O
conformational	O
change	O
,	O
modulates	O
the	O
transport	O
of	O
plasminogen	S-Protein
into	O
the	O
extravascular	O
compartment	O
,	O
decreases	O
plasminogen	S-Protein
binding	O
to	O
U937	O
cells	O
and	O
downregulates	O
the	O
activation	O
of	O
plasminogen	S-Protein
by	O
both	O
urokinase	S-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	E-Protein
.	O

Additionally	O
,	O
in	O
fibrinolysis	O
,	O
within	O
a	O
ternary	O
complex	O
of	O
fibrin	O
,	O
plasminogen	S-Protein
and	O
tissue	B-Protein
plasminogen	I-Protein
activator	E-Protein
,	O
the	O
N	O
-	O
linked	O
sugar	O
of	O
plasminogen	S-Protein
hinders	O
the	O
initial	O
interaction	O
with	O
tissue	B-Protein
plasminogen	I-Protein
activator	E-Protein
(	O
i	O
.	O
e	O
.	O
,	O
it	O
alters	O
Km	O
)	O
.	O

The	O
presence	O
of	O
an	O
N	O
-	O
linked	O
glycan	O
(	O
at	O
Asn	O
-	O
184	O
)	O
in	O
the	O
kringle	O
2	O
domain	O
of	O
tissue	B-Protein
plasminogen	I-Protein
activator	E-Protein
hinders	O
the	O
rearrangement	O
of	O
this	O
ternary	O
complex	O
,	O
decreasing	O
the	O
turnover	O
rate	O
(	O
Kcat	O
)	O
.	O

Production	O
of	O
vampire	O
bat	O
plasminogen	S-Protein
activator	O
DSPA	B-Protein
alpha	I-Protein
1	E-Protein
in	O
CHO	O
and	O
insect	O
cells	O
.	O

Salivary	O
plasminogen	S-Protein
activator	O
from	O
the	O
vampire	O
bat	O
Desmodus	O
rotundus	O
(	O
DSPA	B-Protein
alpha	I-Protein
1	E-Protein
)	O
is	O
a	O
promising	O
new	O
thrombolytic	O
agent	O
.	O

Continuous	O
growth	O
of	O
a	O
stably	O
transfected	O
,	O
methotrexate	O
amplified	O
,	O
dhfr	O
-	O
CHO	O
cell	O
line	O
yields	O
up	O
to	O
60	O
mg	O
l	O
-	O
1	O
of	O
DSPA	B-Protein
alpha	I-Protein
1	E-Protein
.	O

Utilizing	O
an	O
engineered	O
baculovirus	O
10	O
mg	O
l	O
-	O
1	O
were	O
produced	O
in	O
batches	O
of	O
Sf9	O
insect	O
cells	O
.	O

Recombinant	O
DSPA	B-Protein
alpha	I-Protein
1	E-Protein
is	O
purified	O
from	O
both	O
sources	O
using	O
a	O
one	O
-	O
step	O
purification	O
protocol	O
.	O

Although	O
differences	O
in	O
glycosylation	O
were	O
detected	O
,	O
enzymatic	O
activity	O
and	O
fibrin	O
cofactor	O
dependency	O
are	O
unaffected	O
when	O
DSPA	B-Protein
alpha	I-Protein
1	E-Protein
derived	O
from	O
the	O
two	O
expression	O
systems	O
is	O
compared	O
.	O

Glycosylation	O
of	O
CD4	S-Protein
and	O
Thy	B-Protein
-	I-Protein
1	E-Protein
.	O

The	O
site	O
-	O
specific	O
glycosylation	O
of	O
soluble	O
recombinant	O
variants	O
of	O
human	O
and	O
rat	O
CD4	S-Protein
(	O
sCD4	S-Protein
)	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
has	O
been	O
characterized	O
.	O

The	O
presence	O
of	O
identical	O
oligosaccharides	O
at	O
the	O
conserved	O
glycosylation	O
site	O
in	O
domain	O
3	O
of	O
rat	O
and	O
human	O
sCD4	S-Protein
and	O
the	O
greater	O
abundance	O
of	O
oligomannose	O
and	O
hybrid	O
type	O
glycans	O
at	O
the	O
non	O
-	O
conserved	O
glycosylation	O
site	O
of	O
rat	O
sCD4	S-Protein
clearly	O
indicate	O
that	O
the	O
protein	O
structure	O
influences	O
oligosaccharide	O
processing	O
.	O

Comparisons	O
of	O
rat	O
sCD4	S-Protein
glycopeptides	O
with	O
mutant	O
molecules	O
with	O
only	O
single	O
glycosylation	O
sites	O
and	O
with	O
a	O
truncated	O
form	O
containing	O
only	O
the	O
two	O
NH2	O
-	O
terminal	O
domains	O
,	O
indicate	O
that	O
independent	O
processing	O
occurs	O
at	O
each	O
glycosylation	O
site	O
and	O
that	O
domain	O
interactions	O
can	O
also	O
affect	O
oligosaccharide	O
processing	O
.	O

These	O
and	O
other	O
analyses	O
of	O
sCD2	S-Protein
expressed	O
in	O
CHO	O
cells	O
and	O
Thy	B-Protein
-	I-Protein
1	E-Protein
purified	O
from	O
various	O
tissues	O
suggest	O
that	O
the	O
diversity	O
of	O
oligosaccharide	O
structures	O
on	O
a	O
protein	O
is	O
regulated	O
by	O
the	O
location	O
of	O
the	O
glycosylation	O
sites	O
and	O
the	O
nature	O
of	O
the	O
target	O
protein	O
,	O
cell	O
and	O
tissue	O
.	O

The	O
functional	O
significance	O
of	O
this	O
control	O
remains	O
to	O
be	O
determined	O
.	O

Protein	O
carboxyl	O
methylation	O
in	O
Saccharomyces	O
cerevisiae	O
:	O
evidence	O
for	O
STE14	S-Protein
-	O
dependent	O
and	O
STE14	S-Protein
-	O
independent	O
pathways	O
.	O

We	O
incubated	O
yeast	O
cells	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
with	O
the	O
methyl	O
donor	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
and	O
then	O
fractionated	O
their	O
cellular	O
components	O
by	O
gel	O
electrophoresis	O
in	O
sodium	O
dodecyl	O
sulfate	O
.	O

By	O
analyzing	O
gel	O
slices	O
for	O
[	O
3H	O
]	O
methyl	O
esters	O
by	O
a	O
vapor	O
-	O
phase	O
diffusion	O
assay	O
,	O
we	O
detect	O
major	O
methyl	O
-	O
esterified	O
species	O
that	O
migrate	O
at	O
apparent	O
polypeptide	O
sizes	O
of	O
24	O
and	O
22	O
kDa	O
and	O
minor	O
species	O
of	O
49	O
,	O
38	O
,	O
35	O
,	O
33	O
,	O
31	O
,	O
and	O
26	O
kDa	O
.	O

Incubation	O
of	O
extracts	O
from	O
labeled	O
cells	O
with	O
ribonuclease	B-Protein
A	E-Protein
or	O
proteinase	B-Protein
K	E-Protein
revealed	O
that	O
the	O
24	O
-	O
and	O
22	O
-	O
kDa	O
species	O
represent	O
methyl	O
-	O
esterified	O
RNAs	O
,	O
whereas	O
the	O
other	O
species	O
are	O
methyl	O
-	O
esterified	O
polypeptides	O
.	O

The	O
38	O
-	O
,	O
33	O
-	O
,	O
31	O
-	O
,	O
and	O
26	O
-	O
kDa	O
polypeptides	O
were	O
not	O
methyl	O
-	O
esterified	O
in	O
an	O
isogenic	O
yeast	O
strain	O
lacking	O
the	O
STE14	S-Protein
gene	O
encoding	O
a	O
C	O
-	O
terminal	O
isoprenylcysteine	O
methyltransferase	O
,	O
suggesting	O
that	O
they	O
are	O
substrates	O
for	O
the	O
STE14	S-Protein
methyltransferase	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
amount	O
of	O
the	O
methylated	O
49	O
-	O
kDa	O
polypeptide	O
is	O
reduced	O
in	O
the	O
ste14	S-Protein
mutant	O
,	O
indicating	O
that	O
at	O
least	O
two	O
methylated	O
polypeptides	O
are	O
present	O
-	O
-	O
one	O
a	O
substrate	O
of	O
the	O
STE14	S-Protein
methyltransferase	O
and	O
one	O
a	O
substrate	O
of	O
a	O
STE14	S-Protein
-	O
independent	O
methyltransferase	O
.	O

The	O
35	O
-	O
kDa	O
polypeptide	O
also	O
appears	O
to	O
be	O
methylated	O
by	O
a	O
STE14	S-Protein
-	O
independent	O
methyltransferase	O
.	O

When	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
little	O
or	O
no	O
methylation	O
of	O
the	O
STE14	S-Protein
-	O
dependent	O
species	O
was	O
detected	O
while	O
the	O
methylation	O
of	O
the	O
STE14	S-Protein
-	O
independent	O
substrates	O
was	O
unaffected	O
.	O

Pulse	O
-	O
chase	O
studies	O
revealed	O
significant	O
turnover	O
of	O
all	O
of	O
the	O
methylated	O
species	O
in	O
a	O
4	O
-	O
h	O
period	O
,	O
with	O
the	O
exception	O
of	O
the	O
38	O
-	O
kDa	O
polypeptide	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Reconstitution	O
of	O
the	O
folding	O
pathway	O
of	O
collagen	O
in	O
a	O
cell	O
-	O
free	O
system	O
:	O
formation	O
of	O
correctly	O
aligned	O
and	O
hydroxylated	O
triple	O
helices	O
.	O

We	O
describe	O
here	O
a	O
cell	O
-	O
free	O
system	O
which	O
will	O
carry	O
out	O
the	O
initial	O
stages	O
in	O
the	O
synthesis	O
,	O
post	O
-	O
translational	O
modification	O
and	O
assembly	O
of	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	E-Protein
.	O

The	O
mRNA	O
coding	O
for	O
bovine	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	E-Protein
was	O
synthesized	O
in	O
vitro	O
and	O
translated	O
in	O
a	O
rabbit	O
reticulocyte	O
lysate	O
to	O
yield	O
a	O
protein	O
that	O
was	O
collagenase	O
sensitive	O
and	O
could	O
be	O
immunoprecipitated	O
with	O
antibodies	O
raised	O
to	O
purified	O
avian	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	E-Protein
.	O

When	O
type	B-Protein
-	I-Protein
X	I-Protein
collagen	E-Protein
was	O
synthesized	O
in	O
the	O
absence	O
of	O
added	O
microsomes	O
or	O
in	O
the	O
presence	O
of	O
canine	O
pancreas	O
microsomes	O
,	O
the	O
translation	O
products	O
showed	O
partial	O
resistance	O
to	O
digestion	O
with	O
pepsin	O
but	O
were	O
completely	O
degraded	O
with	O
a	O
mixture	O
of	O
chymotrypsin	O
and	O
trypsin	O
,	O
suggesting	O
that	O
only	O
incorrectly	O
aligned	O
non	O
-	O
native	O
collagen	O
molecules	O
were	O
synthesized	O
under	O
these	O
conditions	O
.	O

When	O
the	O
protein	O
was	O
synthesized	O
in	O
the	O
presence	O
of	O
microsomes	O
derived	O
from	O
avian	O
fibroblasts	O
or	O
a	O
human	O
fibrosarcoma	O
cell	O
line	O
,	O
the	O
translocated	O
product	O
migrated	O
as	O
a	O
diffuse	O
band	O
characteristic	O
of	O
hydroxylated	O
collagen	O
.	O

The	O
synthesized	O
polypeptides	O
were	O
also	O
resistant	O
to	O
both	O
pepsin	O
and	O
trypsin	O
/	O
chymotrypsin	O
digestion	O
,	O
demonstrating	O
the	O
formation	O
of	O
correctly	O
aligned	O
native	O
collagen	O
.	O

Furthermore	O
,	O
the	O
collagen	O
polypeptides	O
assembled	O
into	O
higher	O
-	O
order	O
structures	O
,	O
possibly	O
trimers	O
,	O
which	O
were	O
stabilized	O
by	O
interchain	O
disulphide	O
bonds	O
.	O

The	O
collagen	O
helix	O
synthesized	O
in	O
vitro	O
had	O
a	O
melting	O
temperature	O
of	O
41	O
degrees	O
C	O
which	O
is	O
comparable	O
with	O
the	O
protein	O
synthesized	O
in	O
vivo	O
,	O
further	O
demonstrating	O
that	O
the	O
polypeptides	O
were	O
hydroxylated	O
and	O
that	O
the	O
triple	O
helix	O
formed	O
was	O
correctly	O
aligned	O
.	O

Structural	O
requirements	O
for	O
the	O
binding	O
of	O
modified	O
proteins	O
to	O
the	O
scavenger	O
receptor	O
of	O
macrophages	O
.	O

Oxidized	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
and	O
certain	O
chemically	O
modified	O
LDL	O
are	O
recognized	O
by	O
the	O
scavenger	O
receptor	O
of	O
macrophages	O
.	O

All	O
of	O
these	O
modifications	O
involve	O
charge	O
-	O
neutralizing	O
derivatization	O
of	O
lysine	O
amino	O
groups	O
.	O

However	O
,	O
it	O
remains	O
controversial	O
whether	O
recognition	O
of	O
modified	O
LDL	O
by	O
this	O
receptor	O
is	O
due	O
to	O
the	O
modification	O
per	O
se	O
,	O
or	O
to	O
other	O
factors	O
such	O
as	O
a	O
conformational	O
change	O
of	O
apoB	S-Protein
.	O

In	O
this	O
study	O
,	O
LDL	O
and	O
other	O
proteins	O
including	O
bovine	O
serum	B-Protein
albumin	E-Protein
,	O
human	O
high	O
density	O
lipoprotein	O
,	O
and	O
murine	O
IgG	O
were	O
derivatized	O
with	O
oxidation	O
products	O
generated	O
from	O
arachidonic	O
acid	O
by	O
thermal	O
autoxidation	O
.	O

Modified	O
proteins	O
had	O
increased	O
negative	O
charge	O
,	O
and	O
showed	O
a	O
more	O
than	O
10	O
-	O
fold	O
enhancement	O
of	O
degradation	O
by	O
mouse	O
peritoneal	O
macrophages	O
via	O
the	O
scavenger	O
receptor	O
pathway	O
.	O

Modification	O
was	O
prevented	O
by	O
blocking	O
lysine	O
residues	O
of	O
the	O
proteins	O
by	O
prior	O
reductive	O
methylation	O
.	O

Amino	O
acid	O
analysis	O
revealed	O
dose	O
-	O
dependent	O
modification	O
of	O
lysine	O
residues	O
with	O
no	O
significant	O
effects	O
on	O
any	O
other	O
amino	O
acid	O
.	O

Fab	O
fragments	O
of	O
monoclonal	O
antibodies	O
specific	O
for	O
adducts	O
of	O
oxidation	O
products	O
with	O
lysine	O
prevented	O
the	O
uptake	O
of	O
oxidation	O
product	O
-	O
modified	O
LDL	O
and	O
oxidized	O
LDL	O
by	O
macrophages	O
.	O

Chromatography	O
of	O
oxidation	O
product	O
-	O
modified	O
LDL	O
over	O
Sepharose	O
CL	O
-	O
4B	O
showed	O
that	O
uptake	O
by	O
macrophages	O
did	O
not	O
require	O
LDL	O
aggregation	O
.	O

These	O
results	O
suggest	O
that	O
a	O
relatively	O
simple	O
domain	O
consisting	O
of	O
a	O
cluster	O
of	O
suitably	O
derivatized	O
lysine	O
residues	O
is	O
sufficient	O
for	O
recognition	O
by	O
the	O
scavenger	O
receptor	O
of	O
macrophages	O
.	O

Adenosine	O
stimulation	O
of	O
AMP	O
deaminase	O
activity	O
in	O
adult	O
rat	O
cardiac	O
myocytes	O
.	O

Using	O
an	O
in	O
situ	O
assay	O
for	O
analyzing	O
AMP	O
deaminase	O
activity	O
in	O
isolated	O
adult	O
rat	O
ventricular	O
myocytes	O
,	O
we	O
have	O
shown	O
that	O
IMP	O
production	O
is	O
stimulated	O
approximately	O
twofold	O
in	O
cardiac	O
cells	O
incubated	O
with	O
10	O
microM	O
adenosine	O
.	O

This	O
effect	O
of	O
adenosine	O
was	O
not	O
blocked	O
by	O
the	O
adenosine	B-Protein
A1	I-Protein
-	I-Protein
receptor	E-Protein
antagonist	O
8	O
-	O
cyclophenyl	O
-	O
1	O
,	O
3	O
-	O
dipropylaxanthine	O
(	O
0	O
.	O
01	O
-	O
1	O
microM	O
)	O
except	O
at	O
a	O
concentration	O
(	O
100	O
microM	O
)	O
that	O
may	O
inhibit	O
adenosine	O
transport	O
.	O

Similarly	O
,	O
in	O
situ	O
AMP	O
deaminase	O
activity	O
was	O
not	O
enhanced	O
by	O
treatment	O
with	O
the	O
specific	O
adenosine	B-Protein
A1	I-Protein
-	I-Protein
receptor	E-Protein
agonists	O
N6	O
-	O
phenylisopropyl	O
adenosine	O
or	O
cyclopentyladenosine	O
,	O
nor	O
was	O
it	O
sensitive	O
to	O
prior	O
treatment	O
of	O
cells	O
with	O
pertussis	O
toxin	O
.	O

The	O
nucleoside	O
transport	O
blockers	O
S	O
-	O
4	O
-	O
nitrobenzyl	O
-	O
6	O
-	O
thioinosine	O
,	O
dipyridamole	O
,	O
and	O
papaverine	O
inhibited	O
adenosine	O
-	O
induced	O
increases	O
in	O
IMP	O
production	O
by	O
75	O
-	O
85	O
%	O
,	O
suggesting	O
an	O
intracellular	O
site	O
of	O
action	O
.	O

Modulation	O
of	O
enzyme	O
activity	O
via	O
the	O
transmethylation	O
pathway	O
could	O
not	O
be	O
implicated	O
since	O
incubation	O
of	O
cardiac	O
cells	O
under	O
conditions	O
known	O
to	O
elevate	O
intracellular	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
homocysteine	O
had	O
no	O
demonstrable	O
effect	O
on	O
AMP	O
deaminase	O
.	O

Furthermore	O
,	O
a	O
direct	O
allosteric	O
effect	O
of	O
adenosine	O
on	O
the	O
partially	O
purified	O
rat	O
cardiac	O
enzyme	O
was	O
not	O
observed	O
.	O

The	O
results	O
indicate	O
that	O
intracellular	O
adenosine	O
modulates	O
rat	O
cardiac	O
AMP	O
deaminase	O
by	O
an	O
unknown	O
mechanism	O
.	O

Purification	O
and	O
characterization	O
of	O
Saccharomyces	O
cerevisiae	O
DNA	B-Protein
damage	I-Protein
-	I-Protein
responsive	I-Protein
protein	I-Protein
48	E-Protein
(	O
DDRP	B-Protein
48	E-Protein
)	O
.	O

A	O
yeast	O
protein	O
was	O
purified	O
from	O
wild	O
type	O
Saccharomyces	O
cerevisiae	O
(	O
S	O
.	O
cerevisiae	O
)	O
to	O
near	O
homogeneity	O
using	O
an	O
ethanolamine	O
affinity	O
chromatography	O
procedure	O
.	O

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequencing	O
and	O
the	O
amino	O
acid	O
composition	O
analyses	O
identified	O
this	O
protein	O
as	O
the	O
product	O
of	O
the	O
second	O
open	O
reading	O
frame	O
of	O
S	O
.	O
cerevisiae	O
DNA	B-Protein
Damage	I-Protein
-	I-Protein
responsive	I-Protein
gene	I-Protein
48	E-Protein
(	O
DDR48	S-Protein
)	O
(	O
Treger	O
,	O
J	O
.	O
M	O
.	O
,	O
and	O
McEntee	O
,	O
K	O
.	O
(	O
1990	O
)	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
10	O
,	O
3174	O
-	O
3184	O
)	O
The	O
first	O
methionine	O
residue	O
encoded	O
by	O
the	O
translation	O
starting	O
codon	O
was	O
not	O
present	O
in	O
the	O
mature	O
protein	O
which	O
is	O
designated	O
as	O
DDRP	B-Protein
48	E-Protein
.	O

DDRP	B-Protein
48	E-Protein
was	O
found	O
to	O
be	O
a	O
negatively	O
charged	O
and	O
highly	O
hydrophilic	O
glycoprotein	O
.	O

The	O
glycosidase	O
cleavage	O
analyses	O
suggested	O
that	O
DDRP	B-Protein
48	E-Protein
was	O
mainly	O
N	O
-	O
link	O
-	O
glycosylated	O
.	O

The	O
apparent	O
molecular	O
mass	O
of	O
DDRP	B-Protein
48	E-Protein
was	O
estimated	O
to	O
be	O
approximately	O
65	O
kilodaltons	O
.	O

DDRP	B-Protein
48	E-Protein
was	O
found	O
able	O
to	O
hydrolyze	O
ATP	O
and	O
GTP	O
yielding	O
PPi	O
.	O

The	O
Km	O
values	O
for	O
ATP	O
and	O
GTP	O
are	O
0	O
.	O
29	O
mM	O
and	O
0	O
.	O
58	O
mM	O
,	O
respectively	O
.	O

The	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
DDRP	B-Protein
48	E-Protein
was	O
expressed	O
to	O
various	O
concentrations	O
in	O
different	O
S	O
.	O
cerevisiae	O
strains	O
.	O

Increased	O
DDRP	S-Protein
48	O
abundance	O
was	O
observed	O
after	O
yeast	O
cells	O
carrying	O
the	O
wild	B-Protein
type	I-Protein
RAD	I-Protein
52	I-Protein
gene	E-Protein
were	O
exposed	O
to	O
either	O
ethylmethane	O
sulfonate	O
or	O
heat	O
shock	O
treatments	O
.	O

After	O
similar	O
DNA	O
-	O
damaging	O
treatments	O
,	O
however	O
,	O
no	O
significant	O
inductions	O
of	O
DDRP	B-Protein
48	E-Protein
were	O
found	O
in	O
a	O
rad	O
52	O
mutant	O
strain	O
.	O

These	O
observations	O
are	O
consistent	O
with	O
the	O
predictions	O
resulting	O
from	O
previous	O
studies	O
on	O
transcriptional	O
regulation	O
of	O
the	O
DDR	B-Protein
48	E-Protein
gene	O
(	O
Maga	O
,	O
J	O
.	O
A	O
.	O
,	O
McClanahan	O
,	O
T	O
.	O
A	O
.	O
,	O
and	O
McEntee	O
,	O
K	O
.	O
(	O
1986	O
)	O
Mol	O
.	O
&	O
Gen	O
.	O
Genet	O
.	O
205	O
,	O
276	O
-	O
284	O
;	O
McClanahan	O
,	O
T	O
.	O
,	O
and	O
McEntee	O
,	O
K	O
.	O
(	O
1986	O
)	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
6	O
,	O
90	O
-	O
96	O
)	O
.	O

Control	O
of	O
IgG	O
/	O
Fc	S-Protein
glycosylation	O
:	O
a	O
comparison	O
of	O
oligosaccharides	O
from	O
chimeric	O
human	O
/	O
mouse	O
and	O
mouse	O
subclass	O
immunoglobulin	O
Gs	O
.	O

Oligosaccharide	O
profiles	O
were	O
obtained	O
for	O
chimeric	O
mouse	O
-	O
human	O
antibodies	O
corresponding	O
to	O
each	O
of	O
the	O
human	O
IgG	O
subclasses	O
1	O
-	O
4	O
,	O
and	O
mouse	O
IgG2b	O
antibodies	O
each	O
expressed	O
in	O
the	O
mouse	O
J558L	O
cell	O
line	O
.	O

These	O
antibodies	O
have	O
specificity	O
for	O
the	O
NIP	O
hapten	O
and	O
form	O
a	O
matched	O
set	O
of	O
IgGs	O
.	O

An	O
IgG4	O
chimeric	O
antibody	O
(	O
B72	O
.	O
3	O
)	O
produced	O
in	O
the	O
chinese	O
hamster	O
ovary	O
(	O
CHO	O
-	O
K1	O
)	O
cell	O
line	O
was	O
also	O
analysed	O
for	O
carbohydrate	O
.	O

Additionally	O
aglycosylated	O
mutants	O
of	O
this	O
IgG4	O
(	O
B72	O
.	O
3	O
)	O
and	O
anti	O
-	O
NIP	O
mouse	O
IgG2b	O
were	O
analysed	O
.	O

The	O
total	O
lack	O
of	O
carbohydrate	O
found	O
in	O
the	O
aglycosylated	O
site	O
-	O
directed	O
mutants	O
human	O
chimeric	O
IgG4	O
B72	O
.	O
3	O
(	O
Asn	O
297	O
-	O
-	O
>	O
Gln	O
)	O
and	O
mouse	O
IgG2b	O
(	O
Asn	O
297	O
-	O
-	O
>	O
Ala	O
)	O
demonstrates	O
that	O
there	O
are	O
no	O
N	O
-	O
glycosylation	O
sites	O
other	O
than	O
Asn	O
297	O
.	O

Therefore	O
glycosylation	O
profiles	O
for	O
all	O
the	O
IgGs	O
analysed	O
reflect	O
carbohydrate	O
attached	O
to	O
this	O
site	O
.	O

Factors	O
such	O
as	O
cell	O
type	O
(	O
A	O
)	O
,	O
template	O
direction	O
by	O
the	O
IgG	O
heavy	O
chains	O
(	O
B	O
)	O
and	O
culture	O
conditions	O
(	O
C	O
)	O
are	O
shown	O
to	O
influence	O
IgG	O
glycosylation	O
profiles	O
.	O

(	O
A	O
)	O
The	O
anti	O
-	O
NIP	O
IgG	O
antibodies	O
expressed	O
by	O
the	O
J558L	O
cell	O
line	O
may	O
have	O
one	O
or	O
two	O
Gal	O
(	O
alpha	O
1	O
-	O
-	O
>	O
3	O
)	O
Gal	O
residues	O
per	O
oligosaccharide	O
unit	O
,	O
indicative	O
of	O
the	O
presence	O
of	O
(	O
alpha	O
1	O
-	O
-	O
>	O
3	O
)	O
galactosyl	O
transferase	O
in	O
the	O
J558L	O
mouse	O
cell	O
line	O
.	O

(	O
B	O
)	O
The	O
galactosylation	O
profiles	O
obtained	O
for	O
the	O
IgG	O
heavy	O
chains	O
,	O
in	O
particular	O
the	O
preference	O
for	O
galactosylation	O
of	O
the	O
Man	O
(	O
alpha	O
1	O
-	O
-	O
>	O
6	O
)	O
arm	O
rather	O
than	O
the	O
Man	O
(	O
alpha	O
1	O
-	O
-	O
>	O
3	O
)	O
arm	O
,	O
contrary	O
to	O
the	O
beta	O
-	O
galactosyltransferase	O
specificity	O
,	O
suggest	O
that	O
the	O
polypeptide	O
chain	O
may	O
act	O
as	O
a	O
template	O
to	O
influence	O
the	O
extent	O
of	O
galactosylation	O
and	O
hence	O
the	O
proportions	O
of	O
each	O
oligosaccharide	O
incorporated	O
.	O

The	O
IgG2	O
antibody	O
does	O
not	O
display	O
this	O
galactosylation	O
preference	O
.	O

(	O
C	O
)	O
The	O
extent	O
of	O
galactosylation	O
appears	O
to	O
be	O
influenced	O
by	O
the	O
growth	O
conditions	O
,	O
with	O
the	O
highest	O
levels	O
of	O
galactosylation	O
being	O
found	O
for	O
IgG	O
produced	O
by	O
cells	O
grown	O
in	O
still	O
cultures	O
,	O
rather	O
than	O
cells	O
grown	O
as	O
ascites	O
or	O
in	O
hollow	O
fibre	O
bioreactors	O
.	O

It	O
is	O
concluded	O
that	O
though	O
the	O
profile	O
of	O
glycosylation	O
is	O
controlled	O
predominantly	O
by	O
the	O
glycosylation	O
activity	O
of	O
the	O
cell	O
in	O
which	O
the	O
IgG	O
is	O
expressed	O
,	O
differences	O
between	O
the	O
IgG	O
heavy	O
chain	O
templates	O
of	O
the	O
various	O
subclasses	O
and	O
culture	O
conditions	O
can	O
also	O
influence	O
glycosylation	O
.	O

Regulation	O
of	O
CD44	S-Protein
binding	O
to	O
hyaluronan	O
by	O
glycosylation	O
of	O
variably	O
spliced	O
exons	O
.	O

The	O
hyaluronan	O
(	O
HA	O
)	O
-	O
binding	O
function	O
(	O
lectin	O
function	O
)	O
of	O
the	O
leukocyte	O
homing	O
receptor	O
,	O
CD44	S-Protein
,	O
is	O
tightly	O
regulated	O
.	O

Herein	O
we	O
address	O
possible	O
mechanisms	O
that	O
regulate	O
CD44	S-Protein
isoform	O
-	O
specific	O
HA	O
binding	O
.	O

Binding	O
studies	O
with	O
melanoma	O
transfectants	O
expressing	O
CD44H	S-Protein
,	O
CD44E	S-Protein
,	O
or	O
with	O
soluble	O
immunoglobulin	O
fusions	O
of	O
CD44H	S-Protein
and	O
CD44E	S-Protein
(	O
CD44H	S-Protein
-	O
Rg	O
,	O
CD44E	S-Protein
-	O
Rg	O
)	O
showed	O
that	O
although	O
both	O
CD44	S-Protein
isoforms	O
can	O
bind	O
HA	O
,	O
CD44H	S-Protein
binds	O
HA	O
more	O
efficiently	O
than	O
CD44E	S-Protein
.	O

Using	O
CD44	S-Protein
-	O
Rg	O
fusion	O
proteins	O
we	O
show	O
that	O
the	O
variably	O
spliced	O
exons	O
in	O
CD44E	S-Protein
,	O
V8	O
-	O
V10	O
,	O
specifically	O
reduce	O
the	O
lectin	O
function	O
of	O
CD44	S-Protein
,	O
while	O
replacement	O
of	O
V8	O
-	O
V10	O
by	O
an	O
ICAM	B-Protein
-	I-Protein
1	E-Protein
immunoglobulin	O
domain	O
restores	O
binding	O
to	O
a	O
level	O
comparable	O
to	O
that	O
of	O
CD44H	S-Protein
.	O

Conversely	O
,	O
CD44	S-Protein
bound	O
HA	O
very	O
weakly	O
when	O
exons	O
V8	O
-	O
V10	O
were	O
replaced	O
with	O
a	O
CD34	S-Protein
mucin	O
domain	O
,	O
which	O
is	O
heavily	O
modified	O
by	O
O	O
-	O
linked	O
glycans	O
.	O

Production	O
of	O
CD44E	S-Protein
-	O
Rg	O
or	O
incubation	O
of	O
CD44E	S-Protein
-	O
expressing	O
transfectants	O
in	O
the	O
presence	O
of	O
an	O
O	O
-	O
linked	O
glycosylation	O
inhibitor	O
restored	O
HA	O
binding	O
to	O
CD44H	S-Protein
-	O
Rg	O
and	O
to	O
cell	O
surface	O
CD44H	O
levels	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
differential	O
splicing	O
provides	O
a	O
regulatory	O
mechanism	O
for	O
CD44	S-Protein
lectin	O
function	O
and	O
that	O
this	O
effect	O
is	O
due	O
in	O
part	O
to	O
O	O
-	O
linked	O
carbohydrate	O
moieties	O
which	O
are	O
added	O
to	O
the	O
Ser	O
/	O
Thr	O
rich	O
regions	O
encoded	O
by	O
the	O
variably	O
spliced	O
CD44	S-Protein
exons	O
.	O

Alternative	O
splicing	O
resulting	O
in	O
changes	O
in	O
protein	O
glycosylation	O
provide	O
a	O
novel	O
mechanism	O
for	O
the	O
regulation	O
of	O
lectin	O
activity	O
.	O

Recombinant	O
fish	O
neurotrophin	B-Protein
-	I-Protein
6	E-Protein
is	O
a	O
heparin	O
-	O
binding	O
glycoprotein	O
:	O
implications	O
for	O
a	O
role	O
in	O
axonal	O
guidance	O
.	O

Neurotrophin	B-Protein
-	I-Protein
6	E-Protein
(	O
NT	B-Protein
-	I-Protein
6	E-Protein
)	O
was	O
identified	O
in	O
the	O
teleost	O
fish	O
Xiphophorus	O
as	O
a	O
new	O
member	O
of	O
the	O
neurotrophin	O
gene	O
family	O
.	O

NT	B-Protein
-	I-Protein
6	E-Protein
binds	O
specifically	O
the	O
glycosaminoglycan	O
heparin	O
.	O

In	O
this	O
study	O
NT	B-Protein
-	I-Protein
6	E-Protein
was	O
expressed	O
in	O
a	O
stably	O
transfected	O
mammalian	O
cell	O
line	O
,	O
and	O
in	O
insect	O
cells	O
via	O
a	O
recombinant	O
baculovirus	O
.	O

It	O
was	O
purified	O
to	O
homogeneity	O
and	O
characterized	O
by	O
MS	O
and	O
N	O
-	O
terminal	O
sequencing	O
.	O

NT	B-Protein
-	I-Protein
6	E-Protein
from	O
both	O
expression	O
systems	O
was	O
proteolytically	O
processed	O
at	O
one	O
of	O
two	O
protease	O
cleavage	O
motifs	O
and	O
was	O
found	O
to	O
be	O
glycosylated	O
.	O

It	O
supported	O
the	O
survival	O
of	O
embryonic	O
chick	O
sensory	O
neurons	O
;	O
half	O
-	O
maximal	O
survival	O
was	O
observed	O
at	O
100	O
ng	O
/	O
ml	O
.	O

Furthermore	O
,	O
NT	B-Protein
-	I-Protein
6	E-Protein
elicited	O
neurite	O
outgrowth	O
in	O
explanted	O
embryonic	O
dorsal	O
root	O
ganglia	O
.	O

Addition	O
of	O
heparin	O
into	O
the	O
medium	O
did	O
not	O
potentiate	O
the	O
activity	O
of	O
NT	B-Protein
-	I-Protein
6	E-Protein
in	O
survival	O
assays	O
.	O

However	O
,	O
when	O
a	O
sensory	O
ganglion	O
explant	O
was	O
cultured	O
in	O
a	O
collagen	O
gel	O
matrix	O
assay	O
adjacent	O
to	O
a	O
heparin	O
bead	O
coated	O
with	O
NT	B-Protein
-	I-Protein
6	E-Protein
,	O
neurite	O
outgrowth	O
directed	O
towards	O
the	O
bead	O
was	O
observed	O
.	O

This	O
indicated	O
that	O
NT	B-Protein
-	I-Protein
6	E-Protein
was	O
slowly	O
released	O
from	O
the	O
heparin	O
bead	O
generating	O
a	O
concentration	O
gradient	O
of	O
NT	B-Protein
-	I-Protein
6	E-Protein
instrumental	O
for	O
axonal	O
guidance	O
in	O
vitro	O
.	O

Thus	O
the	O
interaction	O
of	O
NT	B-Protein
-	I-Protein
6	E-Protein
with	O
heparin	O
might	O
not	O
be	O
required	O
for	O
the	O
activation	O
of	O
the	O
cellular	O
receptor	O
for	O
NT	B-Protein
-	I-Protein
6	E-Protein
on	O
responsive	O
cells	O
but	O
rather	O
may	O
serve	O
to	O
control	O
,	O
in	O
vivo	O
,	O
the	O
distribution	O
of	O
NT	B-Protein
-	I-Protein
6	E-Protein
.	O

Study	O
of	O
biochemical	O
substrate	O
and	O
role	O
of	O
metalloproteinases	O
in	O
fascia	O
transversalis	O
from	O
hernial	O
processes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
fascia	O
transversalis	O
(	O
FT	O
)	O
from	O
patients	O
with	O
direct	O
and	O
indirect	O
hernia	O
in	O
an	O
attempt	O
to	O
identify	O
possible	O
differences	O
between	O
each	O
type	O
of	O
hernia	O
.	O

FT	O
samples	O
were	O
obtained	O
from	O
36	O
patients	O
presenting	O
inguinal	O
hernia	O
(	O
23	O
indirect	O
hernia	O
and	O
13	O
direct	O
hernia	O
)	O
who	O
underwent	O
surgery	O
.	O

We	O
have	O
analysed	O
the	O
ultrastructure	O
of	O
the	O
fascia	O
surrounding	O
the	O
hernial	O
lesions	O
,	O
the	O
proline	O
and	O
lysine	O
hydroxylation	O
in	O
the	O
tissue	O
,	O
the	O
type	O
I	O
-	O
type	B-Protein
III	I-Protein
collagen	E-Protein
ratio	O
and	O
the	O
presence	O
of	O
metalloproteinases	O
.	O

We	O
have	O
not	O
detected	O
ultrastructural	O
differences	O
in	O
the	O
collagen	O
fibrils	O
from	O
FT	O
in	O
direct	O
and	O
indirect	O
hernias	O
.	O

However	O
,	O
the	O
interfibrillar	O
matrix	O
was	O
more	O
abundant	O
in	O
direct	O
hernias	O
,	O
showing	O
abundant	O
electron	O
-	O
dense	O
particles	O
.	O

No	O
differences	O
in	O
proline	O
hydroxylation	O
were	O
observed	O
between	O
each	O
type	O
of	O
hernia	O
.	O

A	O
small	O
decrease	O
in	O
lysine	O
hydroxylation	O
was	O
detected	O
in	O
patients	O
with	O
direct	O
hernia	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
showed	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
type	O
I	O
-	O
type	B-Protein
III	I-Protein
collagen	E-Protein
absorbance	O
ratios	O
.	O

Immunohistochemistry	O
revealed	O
no	O
differences	O
in	O
the	O
expression	O
of	O
matrix	B-Protein
metalloproteinase	I-Protein
-	I-Protein
1	E-Protein
.	O

FT	O
from	O
patients	O
presenting	O
direct	O
hernia	O
showed	O
a	O
very	O
strong	O
staining	O
vs	O
.	O
metalloproteinase	B-Protein
-	I-Protein
2	E-Protein
when	O
compared	O
with	O
that	O
observed	O
in	O
indirect	O
hernia	O
.	O

Porcine	O
submaxillary	B-Protein
mucin	E-Protein
forms	O
disulfide	O
-	O
linked	O
multimers	O
through	O
its	O
amino	O
-	O
terminal	O
D	O
-	O
domains	O
.	O

COS	O
-	O
7	O
cells	O
expressing	O
1	O
,	O
360	O
residues	O
from	O
the	O
amino	O
terminus	O
of	O
porcine	O
submaxillary	B-Protein
mucin	E-Protein
were	O
used	O
to	O
determine	O
whether	O
this	O
region	O
,	O
containing	O
the	O
D1	O
,	O
D2	O
,	O
and	O
D3	O
domains	O
,	O
is	O
involved	O
in	O
forming	O
mucin	O
multimers	O
.	O

Analysis	O
of	O
the	O
proteins	O
immunoprecipitated	O
from	O
the	O
medium	O
of	O
transfected	O
cells	O
by	O
reducing	O
SDS	O
-	O
gel	O
electrophoresis	O
showed	O
a	O
single	O
N	O
-	O
glycosylated	O
protein	O
with	O
no	O
indication	O
of	O
proteolytically	O
processed	O
forms	O
.	O

Without	O
prior	O
reduction	O
,	O
only	O
two	O
proteins	O
,	O
corresponding	O
to	O
monomeric	O
and	O
disulfide	O
-	O
linked	O
trimeric	O
species	O
,	O
were	O
observed	O
.	O

The	O
expressed	O
protein	O
devoid	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
also	O
formed	O
trimers	O
,	O
but	O
was	O
secreted	O
from	O
cells	O
in	O
significantly	O
less	O
amounts	O
than	O
glycosylated	O
trimers	O
.	O

Pulse	O
-	O
chase	O
studies	O
showed	O
that	O
the	O
disulfide	O
-	O
linked	O
trimers	O
were	O
assembled	O
inside	O
the	O
cells	O
no	O
earlier	O
than	O
30	O
min	O
after	O
protein	O
synthesis	O
commenced	O
and	O
after	O
the	O
intracellular	O
precursors	O
were	O
N	O
-	O
glycosylated	O
.	O

Trimer	O
formation	O
was	O
inhibited	O
in	O
cells	O
treated	O
with	O
brefeldin	O
A	O
,	O
monensin	O
,	O
chloroquine	O
,	O
or	O
bafilomycin	O
A1	O
,	O
although	O
only	O
brefeldin	O
A	O
prevented	O
the	O
secretion	O
of	O
the	O
protein	O
.	O

These	O
results	O
suggest	O
that	O
trimerization	O
takes	O
place	O
in	O
compartments	O
of	O
the	O
Golgi	O
complex	O
in	O
which	O
the	O
vacuolar	O
H	O
+	O
-	O
ATPase	O
maintains	O
an	O
acidic	O
pH	O
.	O

Coexpression	O
in	O
the	O
same	O
cells	O
of	O
the	O
amino	O
-	O
terminal	O
region	O
and	O
the	O
disulfide	O
-	O
rich	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
mucin	O
showed	O
that	O
these	O
structures	O
were	O
not	O
disulfide	O
-	O
linked	O
with	O
one	O
another	O
.	O

Cells	O
expressing	O
a	O
DNA	O
construct	O
encoding	O
a	O
fusion	O
protein	O
between	O
the	O
amino	O
-	O
and	O
carboxyl	O
-	O
terminal	O
regions	O
of	O
the	O
mucin	O
secreted	O
disulfide	O
-	O
linked	O
dimeric	O
and	O
high	O
molecular	O
weight	O
multimeric	O
species	O
of	O
the	O
recombinant	O
mucin	O
.	O

The	O
presence	O
of	O
monensin	O
in	O
the	O
medium	O
was	O
without	O
effect	O
on	O
dimerization	O
,	O
but	O
inhibited	O
the	O
formation	O
of	O
disulfide	O
-	O
linked	O
multimers	O
.	O

These	O
studies	O
suggest	O
that	O
disulfide	O
-	O
linked	O
dimers	O
of	O
mucin	O
are	O
subsequently	O
assembled	O
into	O
disulfide	O
-	O
linked	O
multimers	O
by	O
the	O
amino	O
-	O
terminal	O
regions	O
.	O

They	O
also	O
suggest	O
that	O
the	O
porcine	O
mucin	O
forms	O
branched	O
disulfide	O
-	O
linked	O
multimers	O
.	O

This	O
ability	O
of	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
mucin	O
to	O
aid	O
in	O
the	O
assembly	O
of	O
multimers	O
is	O
consistent	O
with	O
its	O
amino	O
acid	O
identities	O
to	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
human	O
von	B-Protein
Willebrand	I-Protein
factor	E-Protein
,	O
which	O
also	O
serves	O
to	O
form	O
disulfide	O
-	O
linked	O
multimers	O
of	O
this	O
protein	O
.	O

A	O
link	O
between	O
secretion	O
and	O
pre	O
-	O
mRNA	O
processing	O
defects	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
the	O
identification	O
of	O
a	O
novel	O
splicing	O
gene	O
,	O
RSE1	S-Protein
.	O

Secretory	O
proteins	O
in	O
eukaryotic	O
cells	O
are	O
transported	O
to	O
the	O
cell	O
surface	O
via	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
the	O
Golgi	O
apparatus	O
by	O
membrane	O
-	O
bounded	O
vesicles	O
.	O

We	O
screened	O
a	O
collection	O
of	O
temperature	O
-	O
sensitive	O
mutants	O
of	O
Saccharomyces	O
cerevisiae	O
for	O
defects	O
in	O
ER	O
-	O
to	O
-	O
Golgi	O
transport	O
.	O

Two	O
of	O
the	O
genes	O
identified	O
in	O
this	O
screen	O
were	O
PRP2	S-Protein
,	O
which	O
encodes	O
a	O
known	O
pre	O
-	O
mRNA	O
splicing	O
factor	O
,	O
and	O
RSE1	S-Protein
,	O
a	O
novel	O
gene	O
that	O
we	O
show	O
to	O
be	O
important	O
for	O
pre	O
-	O
mRNA	O
splicing	O
.	O

Both	O
prp2	S-Protein
-	O
13	O
and	O
rse1	S-Protein
-	O
1	O
mutants	O
accumulate	O
the	O
ER	O
forms	O
of	O
invertase	O
and	O
the	O
vacuolar	O
protease	O
CPY	S-Protein
at	O
restrictive	O
temperature	O
.	O

The	O
secretion	O
defect	O
in	O
each	O
mutant	O
can	O
be	O
suppressed	O
by	O
increasing	O
the	O
amount	O
of	O
SAR1	S-Protein
,	O
which	O
encodes	O
a	O
small	O
GTPase	O
essential	O
for	O
COPII	O
vesicle	O
formation	O
from	O
the	O
ER	O
,	O
or	O
by	O
deleting	O
the	O
intron	O
from	O
the	O
SAR1	S-Protein
gene	O
.	O

These	O
data	O
indicate	O
that	O
a	O
failure	O
to	O
splice	O
SAR1	S-Protein
pre	O
-	O
mRNA	O
is	O
the	O
specific	O
cause	O
of	O
the	O
secretion	O
defects	O
in	O
prp2	S-Protein
-	O
13	O
and	O
rse1	S-Protein
-	O
1	O
.	O

Moreover	O
,	O
these	O
data	O
imply	O
that	O
Sar1p	S-Protein
is	O
a	O
limiting	O
component	O
of	O
the	O
ER	O
-	O
to	O
-	O
Golgi	O
transport	O
machinery	O
and	O
suggest	O
a	O
way	O
that	O
secretory	O
pathway	O
function	O
might	O
be	O
coordinated	O
with	O
the	O
amount	O
of	O
gene	O
expression	O
in	O
a	O
cell	O
.	O

Comparative	O
methylation	O
analysis	O
of	O
murine	O
transgenes	O
that	O
undergo	O
or	O
escape	O
X	O
-	O
chromosome	O
inactivation	O
.	O

We	O
analyzed	O
an	O
X	O
-	O
linked	O
metallothionein	O
-	O
vasopressin	S-Protein
(	O
MTVP	S-Protein
)	O
fusion	O
transgene	O
that	O
undergoes	O
X	O
-	O
chromosome	O
inactivation	O
(	O
X	O
inactivation	O
)	O
and	O
an	O
X	O
-	O
linked	O
transferrin	S-Protein
(	O
TFN	S-Protein
)	O
transgene	O
that	O
escapes	O
X	O
inactivation	O
with	O
respect	O
to	O
methylation	O
in	O
the	O
5	O
'	O
regulatory	O
regions	O
.	O

The	O
MTVP	S-Protein
transgene	O
promoter	O
region	O
is	O
unmethylated	O
when	O
the	O
transgene	O
is	O
on	O
the	O
active	O
X	O
chromosome	O
and	O
methylated	O
when	O
on	O
the	O
inactive	O
X	O
chromosome	O
.	O

Interestingly	O
,	O
the	O
MTVP	S-Protein
transgene	O
is	O
not	O
detectably	O
transcribed	O
from	O
the	O
male	O
X	O
chromosome	O
,	O
although	O
it	O
is	O
unmethylated	O
,	O
consistent	O
with	O
its	O
availability	O
for	O
transcription	O
.	O

The	O
TFN	S-Protein
transgene	O
promoter	O
region	O
is	O
hypomethylated	O
on	O
both	O
the	O
active	O
and	O
inactive	O
X	O
chromosomes	O
,	O
consistent	O
with	O
its	O
expression	O
from	O
both	O
chromosomes	O
.	O

The	O
TFN	S-Protein
and	O
MTVP	S-Protein
transgenes	O
have	O
been	O
mapped	O
to	O
chromosomal	O
regions	O
D	O
and	O
C	O
,	O
respectively	O
,	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

These	O
observations	O
are	O
discussed	O
in	O
the	O
context	O
of	O
our	O
understanding	O
of	O
the	O
role	O
of	O
DNA	O
methylation	O
in	O
the	O
spread	O
and	O
maintenance	O
of	O
X	O
-	O
chromosome	O
inactivation	O
.	O
